<SEC-DOCUMENT>0001193125-16-520317.txt : 20160329
<SEC-HEADER>0001193125-16-520317.hdr.sgml : 20160329
<ACCEPTANCE-DATETIME>20160329060634
ACCESSION NUMBER:		0001193125-16-520317
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160329
DATE AS OF CHANGE:		20160329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vascular Biogenics Ltd.
		CENTRAL INDEX KEY:			0001603207
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36581
		FILM NUMBER:		161533528

	BUSINESS ADDRESS:	
		STREET 1:		6 JONATHAN NETANYAHU ST.
		CITY:			OR YEHUDA
		STATE:			L3
		ZIP:			60376
		BUSINESS PHONE:		972-3-6346450

	MAIL ADDRESS:	
		STREET 1:		6 JONATHAN NETANYAHU ST.
		CITY:			OR YEHUDA
		STATE:			L3
		ZIP:			60376
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>d160947d20f.htm
<DESCRIPTION>20-F
<TEXT>
<HTML><HEAD>
<TITLE>20-F</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 20-F
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(Mark One) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>REGISTRATION STATEMENT PURSUANT TO SECTION&nbsp;12(b) OR (g)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2015 </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>SHELL COMPANY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Date of event requiring this shell company report: Not applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number
001-36581 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Vascular Biogenics Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s name into English) </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Israel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Jurisdiction of
incorporation or organization) </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>6 Jonathan Netanyahu St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Or Yehuda </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Israel 60376
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dror Harats, Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>6 Jonathan Netanyahu St. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Or Yehuda </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Israel 60376
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +972 3 634 6450 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered or to be registered pursuant to Section&nbsp;12(b) of the Act. </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:56.15pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:135.30pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Name of Each Exchange on which Registered</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Ordinary Shares, par value NIS 0.01 each</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered or to be registered pursuant to Section&nbsp;12(g) of the Act. None </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities for which there is a reporting obligation pursuant to Section&nbsp;15(d) of the Act. None </B></P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate the number of
outstanding shares of each of the issuer&#146;s classes of capital or common stock as of the close of the period covered by the annual report. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>As of
December&nbsp;31, 2015, the Registrant had 22,470,321 Ordinary Shares outstanding. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this report is an annual report or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or
15(d) of the Securities Exchange Act of 1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a
non-accelerated filer. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Large accelerated filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Accelerated&nbsp;filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Non-accelerated filer&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this
filing: </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">U.S.&nbsp;GAAP&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">International Financing Reporting Standards as issued</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">by the International Accounting Standards Board&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Other&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If &#147;Other&#148; has been checked in response to the previous question, indicate by check mark which financial statement
item the registrant has elected to follow. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Item&nbsp;17&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;18&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_1"><B>PART I</B></A><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_2">Item&nbsp;1. Identity of Directors, Senior Management and Advisers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_3">Item&nbsp;2. Offer Statistics and Expected Timetable</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_4">Item&nbsp;3. Key Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_5">Item&nbsp;4. Information on the Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_6">Item&nbsp;4A. Unresolved Staff Comments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_7">Item&nbsp;5. Operating and Financial Review and Prospects</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_8">Item&nbsp;6. Directors, Senior Management and Employees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_9">Item&nbsp;7. Major Shareholders and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_10">Item&nbsp;8. Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_11">Item&nbsp;9. The Offer and Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_12">Item&nbsp;10. Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_13">Item&nbsp;11. Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_14">Item&nbsp;12. Description of Securities Other Than Equity Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc160947_15">PART II</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_16">Item&nbsp;13. Defaults, Dividend Arrearages and Delinquencies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_17">Item&nbsp;14. Material Modifications to the Rights of Security Holders and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_18">Item&nbsp;15. Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_19">Item&nbsp;16. [Reserved]</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_20">Item&nbsp;16A. Audit committee financial expert</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_21">Item&nbsp;16B. Code of Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_22">Item&nbsp;16C. Principal Accountant Fees and Services</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_23">Item&nbsp;16D. Exemptions from the Listing Standards for Audit Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_24">Item&nbsp;16E. Purchase of Equity Securities by the Issuer and Affiliated Purchasers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_25">Item&nbsp;16F. Change in Registrant&#146;s Certifying Accountant</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_26">Item&nbsp;16G. Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_27">Item&nbsp;16H. Mine Safety Disclosure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc160947_28">PART III</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>F-1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_29">Item&nbsp;17. Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_30">Item&nbsp;18. Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc160947_31">Item&nbsp;19. Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In this Annual Report on Form 20-F (&#147;Annual Report&#148;), unless the context indicates otherwise, references to &#147;NIS&#148; are
to the legal currency of Israel, &#147;U.S. dollars,&#148; &#147;$&#148; or &#147;dollars&#148; are to United States dollars, and the terms &#147;we,&#148; &#147;us,&#148; &#147;our company,&#148; &#147;our,&#148; and &#147;Vascular Biogenics&#148;
refer to Vascular Biogenics Ltd. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This Annual Report contains forward-looking statements that relate to future events or our future financial performance, which express the
current beliefs and expectations of our management. Such statements involve a number of known and unknown risks, uncertainties and other factors that could cause our actual future results, performance or achievements to differ materially from any
future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by words such as, but not limited to,
&#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;targets,&#148; &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; and similar expressions or
phrases. We have based these forward-looking statements largely on our management&#146;s current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and
financial needs. Forward-looking statements include, but are not limited to, statements about: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initiation, timing, progress and results of our pre-clinical and clinical trials, and our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations about the availability of data from our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to advance product candidates into, and successfully complete, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans for future trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture our product candidates in sufficient quantities for clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing or likelihood of regulatory filings and approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the commercialization of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential advantages of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the pricing and reimbursement of our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop and commercialize additional product candidates based on our platform technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our business strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the implementation of our business model, strategic plans for our business, product candidates and technology; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope and duration of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of our expenses, future revenues, capital requirements and our needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborations and the benefits of such collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain our level of grant funding or obtain additional grant funding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>All forward-looking statements involve risks, assumptions and uncertainties. You should not rely upon forward-looking statements as
predictors of future events. The occurrence of the events described, and the achievement of the expected results, depend on many events, some or all of which are not predictable or within </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
our control. Actual results may differ materially from expected results. See the sections &#147;Item 3. Key Information&#151;D. Risk Factors,&#148; &#147;Item 5. Operating and Financial Review
and Prospectus&#148; and elsewhere in this Annual Report for a more complete discussion of these risks, assumptions and uncertainties and for other risks and uncertainties. These risks, assumptions and uncertainties are not necessarily all of the
important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>All of the forward-looking statements we have included in this Annual Report are based on information available to us on the date of this
Annual Report. We undertake no obligation, and specifically decline any obligation, to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks,
uncertainties and assumptions, the forward-looking events discussed in this Annual Report might not occur. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The audited financial
statements for the years ended December&nbsp;31, 2015, 2014 and 2013 in this Annual Report have been prepared in accordance with the international financial reporting standards (&#147;IFRS&#148;) as issued by the international accounting standards
board (&#147;IASB&#148;). </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc160947_1"></A>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_2"></A>Item&nbsp;1. Identity of Directors, Senior Management and Advisers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_3"></A>Item&nbsp;2. Offer Statistics and Expected Timetable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_4"></A>Item&nbsp;3. Key Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. Selected Financial Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table summarizes our financial data. We have derived the summary statements of operations data for the years ended December&nbsp;31, 2015, 2014, and 2013 and the balance sheet data as of December&nbsp;31, 2015 and 2014 from our audited financial
statements included elsewhere in this Annual Report. The balance sheet data as of December&nbsp;31, 2013 and 2012 and the statement of operations data for the year ended December&nbsp;31, 2012 is derived from audited financial statements not
included in this Annual Report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary of our financial data set forth below should be read together with our financial statements
and the related notes, as well as the section entitled &#147;Item 5. Operating and Financial Review and Prospects,&#148; included elsewhere in this Annual Report. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>(in&nbsp;thousands,<BR>except share<BR>and per-share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,804</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value of convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive Loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per ordinary share, basic and diluted (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average ordinary shares outstanding, basic and diluted (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,309,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Includes a one-time expense related to the IPO grant of options to our Chief Executive Officer of $2.2 million. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of financial position data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="13" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term bank deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity (capital deficiency)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Capitalization and Indebtedness </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C. Reasons for the Offer and
Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D.
Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider carefully the risks and uncertainties described below, together with all of the other information
in this Annual Report, including the financial statements and the related notes included elsewhere in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are
unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future
prospects could be materially and adversely affected. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company, and we have not yet generated any revenue. We have incurred losses in each year since our inception in
2000, including net losses of $14.9 million, $17.4 million and $17.4&nbsp;million for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. As of December&nbsp;31, 2015, we had an accumulated deficit of $142.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have devoted most of our financial resources to research and development, including our clinical and pre-clinical development activities. To date, we have
financed our operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through grants from governmental agencies. The amount of our future net losses will depend, in part, on the rate of our future
expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations or additional grants. We have not completed pivotal clinical trials for any product candidate and it will be several years, if ever, before we
have a product candidate ready for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenues will depend upon the size of any markets in which our product candidates have received approval, and our
ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product candidates in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase
substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and pre-clinical and clinical development of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand the scope of our current clinical trials for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate additional pre-clinical, clinical or other studies for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">further develop the manufacturing process for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change or add additional manufacturers or suppliers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek to identify and validate additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or in-license other product candidates and technologies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make milestone or other payments under any in-license or other intellectual property related agreements, including our agreement with Tel Hashomer&#151;Medical Research, Infrastructure and Services Ltd. and our license
from Crucell Holland B.V., or Crucell, and any other licensing arrangements we may enter into the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, protect and expand our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attract and retain skilled personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create additional infrastructure to support our operations as a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience any delays or encounter issues with any of the above. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net losses we incur may fluctuate
significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could
be below the expectations of securities analysts or investors, which could cause our share price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have never generated any revenue from
product sales and may never be profitable. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic
collaboration partners, to successfully complete the development of, obtain the regulatory approvals of, and commercialize our product candidates. We do not anticipate generating revenues from product sales for the foreseeable future, if ever. Our
ability to generate future revenues from product sales depends heavily on our success in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing research and pre-clinical and clinical development of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a sustainable, scalable, reproducible, and transferable manufacturing process for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining supply and manufacturing relationships with third parties that can provide products and services adequate, in amount and quality, to support clinical development and the market demand for
our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing any product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing and
distribution infrastructure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of any product candidates that receive regulatory approval as viable treatment options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implementing additional internal systems and infrastructure, as needed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying and validating new product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if one or more of our product candidates is
approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or
the EMA, or other regulatory agencies, domestic or foreign, to perform clinical and other studies in addition to those that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary
capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently advancing VB-111
for rGBM, ovarian cancer and thyroid cancer. We intend to advance this current clinical product candidate through clinical development and other product candidates through pre-clinical and clinical development. Developing pharmaceutical products is
expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates in clinical trials. For instance, in order to complete our Phase 3
trial of VB-111, we will need to obtain additional funding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, our cash and cash equivalents and short-term bank deposits were
$37.1 million. As of December&nbsp;31, 2015, we estimate that our existing cash, cash equivalents and short-term bank deposits will be sufficient to fund our operations for approximately 30 months. However, our operating plan may change as a result
of many factors currently unknown to us, and we may need to seek additional funds sooner than planned through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other
collaborations, strategic alliances and licensing arrangements or a combination of these approaches. In any event, we will require additional capital to obtain regulatory approval for our product candidates, and to commercialize any that receive
regulatory approval. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are
favorable or if we have specific strategic considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities,
which may compromise our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any
financing may adversely affect the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares to
decline. The sale of additional equity or convertible securities would dilute all of our shareholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive
covenants such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our
business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may be required to significantly
curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates, and we may be unable to expand our operations or otherwise capitalize on our business opportunities, as desired.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have received and may continue to receive Israeli governmental grants to assist in the funding of our research and development activities. If we
lose our funding from these research and development grants, we may encounter difficulties in the funding of future research and development projects and implementing technological improvements, which would harm our operating results. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2015 we had received an aggregate of $18.1 million in the form of grants from the Israeli Office of the Chief Scientist, or OCS. The
requirements and restrictions for such grants are found in the Israel Encouragement of Research and Development in Industries, or the Research Law. Under the Research Law, royalties of 3% to 3.5% on the revenues derived from sales of products or
services developed in whole or in part </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using these OCS grants are payable to the Israeli government. We developed both of our platform technologies, at least in part, with funds from these grants, and accordingly we would be obligated
to pay these royalties on sales of any of our product candidates that achieve regulatory approval. The maximum aggregate royalties paid generally cannot exceed 100% of the grants made to us, plus annual interest equal to the 12-month LIBOR
applicable to dollar deposits, as published on the first business day of each calendar year. As of December&nbsp;31, 2015, the balance of the principal and interest in respect of our commitments for future payments to the OCS totaled approximately
$21.7 million. As of December&nbsp;31, 2015, we had not paid any royalties to the OCS. As part of funding our current and planned product development activities, we submitted follow-up grant application totaling between $1.0 million and $3.0 million
for 2016 in connection with our oncology program. We do not intend to submit any further application in support of the development of VB-201/Lecinoxoid project. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These grants have funded some of our personnel, development activities with subcontractors and other research and development costs and expenses. However, if
these awards are not funded in their entirety or if new grants are not awarded in the future, due to, for example, OCS budget constraints or governmental policy decisions, our ability to fund future research and development and implement
technological improvements would be impaired, which would negatively impact our ability to develop our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Israeli government
grants we have received for research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may
be required to refund grants previously received together with interest and penalties. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development efforts have been financed, in
part, through the grants that we have received from the OCS. We, therefore, must comply with the requirements of the Research Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Research
Law, we are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do
receive approval to manufacture products developed with government grants outside of Israel, the royalty rate may be increased and we may be required to pay up to 300% of the grant amounts plus interest, depending on the manufacturing volume that is
performed outside of Israel. This restriction may impair our ability to outsource manufacturing or engage in our own manufacturing operations for those products or technologies. See &#147;Item 5. Operating and Financial Review and
Prospects&#151;Financial Overview&#151;Research and Development Expenses&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, under the Research Law, we are
prohibited from transferring, including by way of license, the OCS-financed technologies and related intellectual property rights and know-how outside of the State of Israel, except under limited circumstances and only with the approval of the OCS
Research Committee. We may not receive the required approvals for any proposed transfer and, even if received, we may be required to pay the OCS a portion of the consideration that we receive upon any sale of such technology to a non-Israeli entity
up to 600% of the grant amounts plus interest. The scope of the support received, the royalties that we have already paid to the OCS, the amount of time that has elapsed between the date on which the know-how or the related intellectual property
rights were transferred and the date on which the OCS grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to the OCS. Approval of the transfer of technology
to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay
royalties. No assurance can be made that approval to any such transfer, if requested, will be granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These restrictions may impair our ability to sell
our technology assets or to perform or outsource manufacturing outside of Israel, engage in change of control transactions or otherwise transfer our know-how outside of Israel and may require us to obtain the approval of the OCS for certain actions
and transactions and pay additional royalties and other amounts to the OCS. In addition, any change of control and any change of ownership of our ordinary shares that would make a non-Israeli citizen or resident an &#147;interested party,&#148; as
defined in the Research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Law, requires prior written notice to the OCS, and our failure to comply with this requirement could result in criminal liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These restrictions will continue to apply even after we have repaid the full amount of royalties on the grants. For the years ended December&nbsp;31, 2015,
2014 and, 2013, we recorded grants totaling $1.9 million, $1.6 million, and $0.6 million from the OCS, respectively. The grants represented 14%, 12.7%, and 4% respectively, of our gross research and development expenditures for the years ended
December&nbsp;31, 2015, 2014 and, 2013. If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and may become subject to criminal charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery and Development of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We currently depend heavily on the future success of our lead product candidate, VB-111. Any failure to successfully develop, obtain regulatory approval for
and commercialize VB-111 for rGBM, independently or in cooperation with a third party collaborator, or the experience of significant delays in doing so, would compromise our ability to generate revenue and become profitable. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our efforts and financial resources in the development of VB-111 for rGBM, for which we are conducting our Phase 3
pivotal trial, and VB-201 for psoriasis and ulcerative colitis for which we have recently completed Phase 2 clinical trials in which it did not meet its primary endpoints. Our ability to generate product revenue from our product candidate depends
heavily on the successful development and commercialization of our products, which, in turn, depends on several factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to continue and support the lecinoxoids platform technology in light of the negative results in psoriasis and ulcerative colitis, or otherwise out-license or collaborate with third party partner to further
develop the platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to continue and support the VTS platform technology and its lead candidate VB-111 in light of the negative results in the clinical development of the VB-201 in psoriasis and ulcerative colitis;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully completing our ongoing and future trials of VB-111 for rGBM; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to raise additional funding sufficient to conduct other future clinical trials, especially as we might suffer from the loss of trust from the investors and financial institutions community due to the
negative results of the VB-201 in psoriasis and ulcerative colitis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrating that VB-111 for rGBM is safe and effective at a sufficient level of statistical or clinical significance and otherwise obtaining marketing approvals from regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing successful manufacturing arrangements with third-party manufacturers that are compliant with current good manufacturing practices, or cGMP, and which will ensure the development of a large scale
manufacturing process and adequate facilities or being able to conduct such manufacturing ourselves; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing a facility as a second source for the manufacture of commercial quantities of VB-111, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing successful sales and marketing arrangements for VB-111, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining an acceptable safety and efficacy profile for VB-111; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of coverage and reimbursement to patients from healthcare payors for VB- 111, if approved; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other risks described in these &#147;Risk Factors.&#148; </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our product candidates are based on novel
technologies, which makes it difficult to predict the time and cost of product candidate development and potential regulatory approval. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
concentrated our product research and development efforts on our two distinct platform technologies, and our future success depends on the successful development of these technologies. We could experience
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development problems in the future related to our technologies, which could cause significant delays or unanticipated costs, and we may not be able to solve such development problems. We may also
experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, if we decide to do so, which may prevent us from completing our clinical trials or commercializing
our products on a timely or profitable basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the clinical trial requirements of the FDA, the EMA and other regulatory agencies
and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process
for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the FDA may not be indicative of what the EMA or other
regulatory agencies may require for approval, and vice versa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing pharmaceutical products have changed frequently and may
continue to change in the future. Also, before a clinical trial can begin at an institution funded by the U.S. National Institutes of Health, or the NIH, that institution&#146;s institutional review board, or IRB, and its Institutional Biosafety
Committee will have to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of pharmaceutical products conducted by others may cause the FDA or other regulatory bodies to change
the requirements for approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These regulatory agencies and review committees and the new requirements and guidelines
they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of
these treatment candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory groups, and comply with applicable requirements and guidelines.
If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market
could impair our ability to generate product revenue and to become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may find it difficult to enroll patients in our clinical trials, and
patients could discontinue their participation in our clinical trials, which could delay or prevent clinical trials of our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials
depends on the speed at which we can recruit patients to participate in testing our product candidates. We have experienced delays in some of our clinical trials, and we may experience similar delays in the future. If patients are unwilling to
participate in our clinical trials because of negative publicity from adverse events in the biotechnology or pharmaceutical industries or for other reasons, including competitive clinical trials for similar patient populations, the timeline for
recruiting patients, conducting trials and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our
technology or termination of the clinical trials altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to identify, recruit and enroll a sufficient number of patients, or those
with required or desired characteristics to achieve diversity in a trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">design of the trial protocol; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">size of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eligibility criteria for the trial in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">perceived risks and benefits of the product candidate under study; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proximity and availability of clinical trial sites for prospective patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of competing therapies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">efforts to facilitate timely enrollment in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient referral practices of physicians; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to monitor patients adequately during and after treatment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, VB-111 for rGBM is intended
for a rare disorder with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing
patients may prove costly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to seek initial marketing approval in Europe in addition to the United States. We may not be able to initiate or
continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the EMA or other foreign regulatory agencies. Our ability to successfully initiate, enroll and complete a
clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in establishing or managing relationships with contract research organizations, or CROs, and physicians; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different standards for the conduct of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to locate qualified local consultants, physicians and partners; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or
planned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, patients enrolled in our clinical trials may discontinue their participation at any time during the trial as a
result of a number of factors, including withdrawing their consent or experiencing adverse clinical events, which may or may not be judged related to our product candidates under evaluation. The discontinuation of patients in any one of our trials
may cause us to delay or abandon our clinical trial, or cause the results from that trial not to be positive or sufficient to support a filing for regulatory approval of the applicable product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory
authorities. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently in Phase 3 clinical trial for VB-111 for rGBM and Phase 2 clinical trials for VB-111 for rGBM, ovarian cancer and
thyroid cancer. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical
testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of
testing. Events that may prevent successful or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching a consensus with regulatory agencies on trial design; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in obtaining required IRB approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in recruiting suitable patients to participate in our clinical trials including in particular for those trials for rare diseases such as rGBM; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial operations or trial sites; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to perform in accordance with the FDA&#146;s good clinical practices, or GCP, or applicable regulatory requirements in other countries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in having patients complete participation in a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trial sites or patients dropping out of a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements and guidance that require amending or submitting new clinical trial protocols. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete pre-clinical and clinical development could result in additional costs to us or impair our ability to generate revenue
from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also
shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product
candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fail to obtain, or be delayed in obtaining, marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">need to change the way the product is administered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy, or REMS, or modified REMS; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to the addition of labeling statements, such as warnings or contraindications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be sued; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">experience damage to our reputation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining
market acceptance of our product candidates and impair our ability to commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Side effects may occur following treatment
with our product candidates, which could make it more difficult for our product candidates to receive regulatory approval. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with our product
candidates may cause side effects or adverse events. In addition, since our product candidates are in some cases administered in combination with other therapies, patients or clinical trial participants may experience side effects or other adverse
events that are unrelated to our product candidate, but may still impact the success of our clinical trials. Additionally, our product candidates could potentially cause other adverse events that have not yet been predicted. The inclusion of
critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be using or the severity of the medical condition treated. The experience of side effects and adverse events in our clinical trials could make it more difficult to achieve regulatory approval of
our product candidates or, if approved, could negatively impact the market acceptance of such products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Success in early clinical trials may not be
indicative of results obtained in later trials. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of
companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Data obtained from pre-clinical and clinical
activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the
period of product development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Although we have reached agreement with the FDA on the SPA relating to our pivotal Phase 3 clinical trial of VB-111 for
rGBM, the agency&#146;s concurrence does not guarantee any particular outcome with respect to regulatory review of the pivotal trial or with respect to regulatory approval of VB-111. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA normally requires two pivotal clinical trials to approve a biologic or drug product. The FDA typically does not consider a single clinical trial to be
adequate to serve as a pivotal trial unless it is, among other things, well-controlled and demonstrates a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with potentially serious outcome, and a
confirmatory trial would be practically or ethically impossible. Although we have reached agreement with the FDA on an SPA under which we agreed with the FDA that, if successful, our pivotal Phase 3 clinical trial will be sufficient for approval,
and even if we believe that the data from the pivotal Phase 3 clinical trial are supportive, an SPA is not a guarantee of approval, and we cannot be certain that the design of, or data collected from, the pivotal Phase 3 clinical trial will be
adequate to demonstrate the safety, purity and potency of VB-111 for the potential treatment of rGBM, or will otherwise be sufficient to support FDA or any foreign regulatory approvals. Indeed, while the FDA has accepted our planned safety database,
the agency has stated that the adequacy of such database will depend on the magnitude of the clinical benefit and the adverse event profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, an
SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA is entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if we fail to comply with the agreed upon trial
protocol. In addition, an SPA may be changed on written agreement of both parties, and the FDA retains significant latitude and discretion in interpreting the terms of an SPA and the data and results of clinical trials conducted under an SPA.
Therefore, significant uncertainty remains regarding the clinical development of, and regulatory approval process for, VB-111 for rGBM, and it is possible that we might never receive any regulatory approvals for VB-111. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The results from our clinical trials may not be sufficiently robust to support the submission for marketing approval for our product candidates. Before we
submit our product candidates for marketing approval, the FDA and the EMA may require us to conduct additional clinical trials, or evaluate subjects for an additional follow-up period. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that, even if we achieve favorable results in our clinical trials, the FDA may require us to conduct additional clinical trials, possibly
involving a larger sample size or a different clinical trial design, particularly if the FDA does not find the results from our completed clinical trials to be sufficiently persuasive to support a Biologics License Application, or BLA, or a New Drug
Application, or NDA. For example, because the dose we used in our Phase 2 trial was limited by our production capacity, the dose of VB-111 that we intend to use in our Phase 3 pivotal trial may not be the maximum efficacious dose. If the FDA
requires data on higher doses of <FONT STYLE="white-space:nowrap">VB-111,</FONT> this will likely delay development or prevent approval of VB-111 for rGBM. The FDA may also require that we conduct a longer follow-up period of subjects treated with
our product candidates prior to accepting our BLA or NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that the FDA or the EMA may not consider the results of our clinical trials to
be sufficient for approval of our product candidates for their target indications. If the FDA or the EMA requires additional studies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for any reason, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition, it is possible that
the FDA and the EMA may have divergent opinions on the elements necessary for a successful BLA or NDA and Marketing Authorization Application, which is the equivalent of a BLA, respectively, which may cause us to alter our development, regulatory or
commercialization strategies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even if we complete the necessary pre-clinical studies and clinical trials, we cannot predict when or if we will obtain
regulatory approval to commercialize a product candidate or the approval may be for a more narrow indication than we expect. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot commercialize a
product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes
in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience
delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory
agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims
that are necessary or desirable for the successful commercialization of our treatment candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A fast track designation by the FDA may not actually
lead to a faster development or regulatory review or approval process. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a drug is intended for the treatment of a serious or life-threatening
disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. If fast track designation is obtained, the FDA may initiate review
of sections of a new drug application, or NDA, before the application is complete. This &#147;rolling review&#148; is available if the applicant provides, and the FDA approves, a schedule for submission of the individual sections of the application.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received fast track designation from the FDA for VB-111 for prolongation of survival in patients with glioblastoma that has recurred following
treatment with temozolomide, a chemotherapeutic agent commonly used to treat newly diagnosed glioblastoma, and radiation. We may seek fast track designation for other product candidates and other indications. Even though we have received fast track
designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our
clinical development program. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the expedited review procedures or that we will ultimately obtain regulatory approval of VB-111. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even though we have obtained orphan drug designation for VB-111 for treatment of malignant glioma in the United States and glioma in Europe, we may not be
able to obtain orphan drug exclusivity for this drug or for any of our other product candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some jurisdictions,
including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or
condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. For VB-111, we have obtained orphan drug designation from the FDA for the treatment of malignant glioma and the EMA for
the treatment of glioma, and we may seek orphan drug designation for other drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if a product with an orphan drug designation
subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which precludes the EMA or the FDA from approving another marketing application for the same drug for the same use or indication for that time period. The applicable period is seven years in the
United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer
justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the
rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from
competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior
in that it is shown to be safer, more effective or makes a major contribution to patient care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Even if we obtain regulatory approval for a product
candidate, our products will remain subject to regulatory scrutiny. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority
may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved
BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to
the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other
regulatory authorities for compliance with cGMP, and adherence to commitments made in the BLA or NDA as the case may be. If we or a regulatory agency discover previously unknown problems with a product such as adverse events of unanticipated
severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from
the market or suspension of manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable regulatory requirements following approval of any of our product
candidates, a regulatory agency may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue a warning letter asserting that we are in violation of the law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek an injunction or impose civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend or withdraw regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspend any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to approve a pending BLA or NDA or supplements to a BLA or NDA submitted by us for other indications or new drug products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seize our product; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refuse to allow us to enter into supply contracts, including government contracts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any government
investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize
our product candidates and generate revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have only limited experience in regulatory affairs and intend to rely on consultants and other third
parties for regulatory matters, which may affect our ability or the time we require to obtain necessary regulatory approvals. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited
experience in filing and prosecuting the applications necessary to gain regulatory approvals for drug and biologics candidates. Moreover, the product candidates that are likely to result from our development programs are based on new technologies
that have not been extensively tested in humans. The regulatory requirements governing these types of product candidates may be less well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory
process in connection with obtaining regulatory approvals of any products that we develop. We intend to rely on independent consultants for purposes of our regulatory compliance and product development and approvals in the United States and
elsewhere. Any failure by our consultants to properly advise us regarding, or properly perform tasks related to, regulatory compliance requirements could compromise our ability to develop and seek regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In addition to the level of commercial success of our product candidates, if approved, our future prospects are also dependent on our ability to
successfully develop a pipeline of additional product candidates, and we may not be successful in our efforts in using our platform technologies to identify or discover additional product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our two platform technologies. Our
research programs may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates
may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program or programs. Research programs to identify new product
candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We
expect to rely on third parties to conduct some or all aspects of our product manufacturing, protocol development, research and pre-clinical and clinical testing, and these third parties may not perform satisfactorily. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to independently conduct all aspects of our product manufacturing, protocol development, research and pre-clinical and clinical testing. We
currently rely, and expect to continue to rely, on third parties with respect to these items. In addition, we may pursue further clinical development of VB-111 for thyroid cancer or other indications with a strategic partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product
development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and
study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our Investigational New Drug, or IND, enabling studies and clinical trials are conducted in
accordance with the study plan and protocols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or
conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the pre-clinical studies and clinical trials required to support future IND
submissions and approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the
product candidates ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future
products. Some of these events could be the basis for FDA action, including injunction, recall, seizure or total or partial suspension of production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We and our contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities
on which we rely may not continue to meet regulatory requirements and have limited capacity. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have relationships with a limited number of
suppliers for the manufacturing of our product candidates. Each supplier may require licenses to manufacture components of our product candidates or to utilize certain processes for the manufacture of our product candidates. If such components or
licenses are not owned by the supplier or in the public domain, we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product
candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing
processes and procedures (including record keeping) and the implementation and operation of systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the
introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support
of a BLA or NDA, as applicable, on a timely basis and must adhere to the FDA&#146;s good laboratory practices, or GLP, and cGMP regulations enforced by the FDA through its facilities inspection program. Our contract manufacturer for VB-111 has not
produced a commercially approved product based on viral vectors and therefore has not yet obtained the requisite FDA approvals to do so. Our facilities and controls and the facilities and controls of some or all of our third-party contractors must
pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or
inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated controls for compliance with the regulations applicable to the activities being conducted. If these facilities
do not pass a pre-approval plant inspection, FDA approval of the products will not be granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory authorities also may, at any time following
approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or our product specifications or if a violation of
applicable regulations, including a failure to comply with the product specifications, occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming
for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose
regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative
manufacturer would need to be qualified through a BLA or NDA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors could
cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our
suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to rely on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner,
it may harm our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to rely on CROs and clinical trial sites to ensure our clinical trials are conducted properly and on time. While
we will have agreements governing their activities, we will have limited influence over their actual performance. We will control only some aspects of our CROs&#146; activities. Nevertheless, we will be responsible for ensuring that each of our
clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific requirements and standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our CROs are required to comply with the FDA&#146;s GCPs for conducting, recording and reporting the results of IND-enabling studies and clinical
trials to assure that the data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA enforces these GCPs through periodic inspections of study
sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our future clinical trials may be deemed unreliable and the FDA may require us to perform additional
clinical trials before approving any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with GCPs. In addition, our future clinical trials will require a sufficient number of test subjects to
evaluate the safety and effectiveness of our product candidates. Recruitment may be challenging in the event of rare diseases and may require the performance of trials in a significant number of sites which may be harder to monitor. Accordingly, if
our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CROs are not our employees, and we are therefore unable to directly monitor whether or not they devote sufficient time and resources to our clinical and
nonclinical programs. These CROs may also have relationships with other commercial entities, including parties developing potentially competitive products, for whom they may also be conducting clinical trials or other drug development activities
that could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical protocols or regulatory requirements, or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our
product candidates. As a result, the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute our product candidates for any clinical trials that we may conduct. Any performance
failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, if approved, producing additional losses and depriving us of potential product revenue.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor will discover them or that our trade secrets will be misappropriated or disclosed. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to manufacture our
product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our technology, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by
entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to
beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite these contractual provisions, the need to
share trade secrets and other confidential information increases the risk that such trade secrets become known by potential competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, discovery by a third party of our trade secrets or other unauthorized use or disclosure would impair our intellectual property rights and
protections in our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our collaborators, advisors, employees and
consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order to secure our
intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. Despite our efforts to protect our trade secrets,
our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at
the time of publication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our development of VB-111 for the treatment of rGBM relies upon the continued availability of bevacizumab for the treatment
of rGBM, and any interruption in availability or supply of bevacizumab, or negative results concerning the use of bevacizumab in rGBM or otherwise, may cause delays in our ongoing Phase 3 clinical trial or, if approved, adversely affect commercial
utilization of VB-111. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ongoing Phase 3 trial of VB-111 for the treatment of rGBM is designed for use of VB-111 in combination with bevacizumab.
Any shortage in supply of bevacizumab or any change in its availability for use in patients with rGBM would delay enrollment or completion of our Phase 3 trial, or if approved, adversely affect commercial utilization of VB-111. We have no control
over the availability of bevacizumab, which is a sole source product and which may encounter manufacturing or other problems that adversely affect its availability. While bevacizumab is the standard of care treatment for rGBM in the United States,
cost and other factors have adversely impacted its availability elsewhere, and may similarly adversely impact the availability of VB-111 to be investigated or used in combination with bevacizumab. Clinical trials of bevacizumab in rGBM have achieved
mixed results, and any negative future clinical results for bevacizumab in rGBM may undermine the reliability of our current Phase 3 trial design and require that we revise our development program and conduct additional trials, or prevent us from
obtaining approval for VB-111 for use in combination with bevacizumab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We intend to rely on third-party manufacturers to produce commercial quantities of any of our product candidates that receives regulatory approval, but we
have not entered into binding agreements with any such manufacturers to support commercialization. Additionally, these manufacturers do not have experience producing our product candidates at commercial levels and may not achieve the necessary
regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to support commercialization. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
not yet secured manufacturing capabilities for commercial quantities of our product candidates or established facilities in the desired locations to support commercialization of our product candidates. Although we intend to rely on third-party
manufacturers for commercialization, we have only entered into agreements with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such manufacturers to assist in the scaling up of the manufacturing process of VB-111. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization
activities on commercially reasonable terms, which agreements will further be required to comply with the restrictions imposed under the Research Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
may encounter technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. Although we currently have process development and small-scale manufacturing
capabilities for VB-111 internally, we do not have the capacity to manufacture our product candidates on a commercial scale. In addition, our product candidates are novel, and no manufacturer currently has the experience or ability to produce our
product candidates at commercial levels. If we are unable to engage manufacturing partners to produce our product candidates on a larger scale on reasonable terms, our commercialization efforts will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we timely develop a manufacturing process and successfully transfer it to the third- party manufacturers of our product candidates, if such
third-party manufacturers are unable to produce the necessary quantities of our product candidates, or in compliance with cGMP or with pertinent regulatory requirements, and within our planned time frame and cost parameters, the development and
sales of our product candidates, if approved, may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any significant disruption in our supplier relationships could harm our
business. We source key materials from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There are a small number of suppliers for certain key materials that
are used to manufacture our product candidates. Such suppliers may not sell these key materials to our manufacturers at the times we need them or on commercially reasonable terms. We do not have any control over the process or timing of the
acquisition of these key materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these key materials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any of our product candidates
that obtain regulatory approval, we may be unable to generate any revenue. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no experience selling and marketing our product candidates or any
other products. To successfully commercialize any products that may result from our development programs and obtain regulatory approval, we will need to develop these capabilities, either on our own or with others. We may seek to enter into
collaborations with other entities to utilize their marketing and distribution capabilities, but we may be unable to do so on favorable terms, if at all. If any future collaborative partners do not commit sufficient resources to commercialize our
future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We will be competing with many companies that currently have
extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies or
successfully commercialize any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face intense competition and rapid technological change and the possibility that our
competitors may develop therapies that are more advanced or effective than ours, which could impair our ability to successfully commercialize our product candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are engaged in pharmaceutical development, which is a rapidly changing field. We have competitors both in the United States and internationally, including
major multinational pharmaceutical companies, biotechnology companies and universities and other research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our potential competitors
have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Competition may increase further as a result of advances in the commercial
applicability of technologies and greater </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
availability of capital for investment in these industries. Our potential competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or
less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than us. Additionally, technologies developed by others may render our potential
product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In particular, VB-111
may face competition from currently approved drugs and drug candidates under development by others to treat rGBM. In May 2009, the FDA granted accelerated approval to Avastin (bevacizumab), which is an angiogenesis inhibitor, to treat patients with
rGBM at progression after standard first-line therapy. In addition to bevacizumab, a number of companies are conducting late-stage clinical trials to test targeted drugs focused on angiogenesis inhibition for the treatment of ovarian cancer,
including, among others, Amgen&#146;s trebananib, Boehringer Ingelheim&#146;s nintedanib and GlaxoSmithKline&#146;s Votrient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are successful
in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars. In the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated
approval pathway for biological products that are demonstrated to be &#147;highly similar,&#148; or biosimilar, to or &#147;interchangeable&#148; with an FDA-approved biological product. This pathway could allow competitors to reference data from
biological products already approved after 12 years from the time of approval. In Europe, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for
biosimilar approvals issued over the past few years. In Europe, a competitor may reference data from biological products already approved, but will not be able to market a biosimilar until ten years after the time of approval. This 10-year period
will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies.
In addition, companies may be developing biosimilars in other countries that could compete with our products. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to
competition from such biosimilars, with the attendant competitive pressure and consequences. Expiration or successful challenge of our applicable patent rights could also trigger competition from other products, assuming any relevant exclusivity
period has expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, although VB-111 has been granted orphan drug status by the FDA and EMA for a specified indication, there are limitations
to the exclusivity. In the United States, the exclusivity period for orphan drugs is seven years, while pediatric exclusivity adds six months to any existing patents or exclusivity periods. In Europe, orphan drugs may be able to obtain 10 years of
marketing exclusivity and up to an additional two years on the basis of qualifying pediatric studies. However, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria. Additionally, a
marketing authorization holder may lose its orphan exclusivity if it consents to a second orphan drug application or cannot supply enough drug. Orphan drug exclusivity also can be lost when a second applicant demonstrates its drug is
&#147;clinically superior&#148; to the original orphan drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, as a result of the expiration or successful challenge of our patent rights, we
could face more litigation with respect to the validity or scope of patents relating to other parties&#146; products. The availability of other parties&#146; products could limit the demand, and the price we are able to charge, for any products that
we may develop and commercialize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since some of our product candidates are aimed for rare diseases, loss of exclusivity or competition as described above
may be very significant in light of the limited size of the relevant market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The commercial success of any current or future product candidate, if
approved, will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we
obtain the requisite regulatory approvals, the commercial success of our product candidates will depend in part on the medical community, patients, and third-party payors accepting our product candidates as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical community.
If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of these product candidates, if approved for commercial sale, will
depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential efficacy and potential advantages over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#146;s approved labeling; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects resulting from the procedure by which our product candidates are administered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support and timing of market introduction of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicity concerning our products or competing products and treatments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficient third-party insurance coverage or reimbursement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a potential product displays a favorable
efficacy and safety profile in pre-clinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the
product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by conventional technologies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A variety of risks associated with international operations could hurt our business. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved for commercialization, it is our current intention to market them on a worldwide basis, either alone or in
collaboration with others. In addition, we conduct development activities in various jurisdictions throughout the world. We expect that we will be subject to additional risks related to engaging in international operations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different regulatory requirements for approval of drugs and biologics in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States and Israel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or
maintain adequate coverage and reimbursement for any of our product candidates that are approved could limit our ability to market those products and compromise our ability to generate revenue. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our
product candidates will depend substantially, both in the U.S. and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations,
or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize
our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions
about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine
will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no
body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not
been approved for reimbursement in certain European countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intended use of a drug product by a physician can also affect pricing. For example,
CMS could initiate a National Coverage Determination administrative procedure, by which the agency determines which uses of a therapeutic product would and would not be reimbursable under Medicare. This determination process can be lengthy, thereby
creating a long period during which the future reimbursement for a particular product may be uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, international
operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries is likely to put pressure on the
pricing and usage of any of our product candidates that are approved for marketing. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of
medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. Additional foreign price controls or other changes in
pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be
insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors, in the United
States and abroad, to cap or reduce healthcare costs, resulting in legislation and reforms such as the Patient Protection and Affordable Care Act of 2010, may cause such organizations to limit both coverage and level of reimbursement for new
products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has
become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The prescription for or promotion of
off-label uses of our products by physicians could adversely affect our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approval of our products is limited to those specific
diseases and indications for which our products have been deemed safe and effective by the FDA or similar authorities in other jurisdictions. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, any new indication for an approved product also requires regulatory approval. If we produce an approved therapeutic product, we will rely on physicians to prescribe and administer it as
we have directed and for the indications described on the labeling. It is not, however, uncommon for physicians to prescribe medication for unapproved, or &#147;off-label,&#148; uses or in a manner that is inconsistent with the manufacturer&#146;s
directions. To the extent such off-label uses and departures from our administration directions become pervasive and produce results such as reduced efficacy or other adverse effects, the reputation of our products in the marketplace may suffer. In
addition, off-label uses may cause a decline in our revenue or potential revenue, to the extent that there is a difference between the prices of our product for different indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, while physicians may choose to prescribe our drugs for off-label uses, our ability to promote the products is limited to those indications that
are specifically approved by the FDA or other regulators. Although regulatory authorities generally do not regulate the behavior of physicians, they do restrict communications by companies with respect to off-label use. If our promotional activities
fail to comply with these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, failure to follow FDA rules and guidelines relating to promotion and advertising can result in the
FDA&#146;s refusal to approve a product, the suspension or withdrawal of an approved product from the market, product recalls, fines, disgorgement of money, operating restrictions, injunctions or criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Due to the small target patient populations for some of our product candidates, we face uncertainty related to pricing and reimbursement for these product
candidates. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our target patient populations for our initial product candidates are relatively small, as a result of which the pricing and
reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be
adversely affected. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our future
success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
highly dependent on principal members of our executive team listed under &#147;Management&#148; in this prospectus, including Prof. Dror Harats, our chief executive officer, the loss of whose services may adversely impact the achievement of our
objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#147;at will&#148; employees. Recruiting and retaining other qualified
employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result,
competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals
with similar skill sets. In addition, failure to succeed in pre-clinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive, key
employee, consultant or advisor may impede the progress of our research, development and commercialization objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our collaborations with outside
scientists and consultants may be subject to restriction and change. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We work with medical experts, chemists, biologists and other scientists at
academic and other institutions, and consultants who assist us in our research, development and regulatory efforts, including the members of our scientific advisory board. In addition, these scientists and consultants have provided, and we expect
that they will continue to provide, valuable advice regarding our programs and regulatory approval processes. These scientists and consultants are not our employees and may have other commitments that would limit their future availability to us. If
a conflict of interest arises between their work for us and their work for another entity, we may lose their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services. In addition, we are limited in our ability to prevent them from establishing competing businesses or developing competing products. For example, if a key scientist acting as a principal
investigator in any of our clinical trials identifies a potential product or compound that is more scientifically interesting to his or her professional interests, his or her availability to remain involved in our clinical trials could be restricted
or eliminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2016, we had 27 employees. As we mature and undertake the activities required to advance our product candidates into later
stage clinical development and to operate as a public company, we expect to expand our full-time employee base and to hire more consultants and contractors. Our management may need to divert a disproportionate amount of its attention away from our
day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development
of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate or grow revenue could be compromised, and we may not be able to implement our
business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance
with regulatory standards and requirements and insider trading. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, principal
investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators,
comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions
are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our
product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging
product liability claims. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval
exposes us to the risk of product liability claims. Product liability claims might be brought against us by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. There is a risk that our product candidates may induce
adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs due to related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates, if approved for commercial sale; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our ability to obtain product liability insurance coverage. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We carry combined public and
products liability (including human clinical trials extension) insurance of $5.0&nbsp;million per occurrence and $5.0 million aggregate limit. We believe our product liability insurance coverage is sufficient in light of our current clinical
programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for any product candidates, we intend to expand our
insurance coverage to include the sale of commercial products, but we may not be able to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action
lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage,
could materially and adversely affect our financial position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with the diseases targeted by some of our product candidates are often already in
severe and advanced stages of disease and have both known and unknown significant pre- existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may
be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval
to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidate, the investigation into the circumstance may be
time-consuming or inconclusive. These investigations may harm our reputation, delay our regulatory approval process, limit the type of regulatory approvals our product candidates receive or maintain, and compromise the market acceptance of any of
our product candidates that receive regulatory approval. As a result of these factors, a product liability claim, even if successfully defended, could hurt our business and impair our ability to generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If our existing manufacturing facility is damaged or destroyed, or production at this facility is otherwise interrupted, our business and prospects would
be negatively affected. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have a single, small-scale manufacturing facility in Israel. If our existing manufacturing facility, or the
equipment in it, is damaged or destroyed, we likely would not be able to quickly or inexpensively replace our manufacturing capacity and possibly would not be able to replace it at all. Any new facility needed to replace our existing manufacturing
facility would need to comply with the necessary regulatory requirements, and be tailored to our manufacturing requirements and processes. We would need FDA approval before using any product candidates manufactured at a new facility in clinical
trials or selling any products that are ultimately approved. Such an event could delay our clinical trials or, if any of our product candidates are approved by the FDA, reduce or eliminate our product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on the success of our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials,
including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated
with civil or criminal fines and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due
to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply
with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If our shipping capabilities become unavailable due to an accident, an act of terrorism, a labor
strike or other similar event, our supply, production and distribution processes could be disrupted. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of our raw materials for the manufacturing
of VB-111, and VB-111 itself, must be transported at a temperature controlled cold chain at temperatures varying between -4 degrees Celsius to -70 degrees Celsius (25&nbsp;to -94 degrees Fahrenheit) to ensure their quality and vitality. Not all
shipping or distribution channels are equipped to transport at these temperatures. If any of our shipping or distribution channels become inaccessible because of a serious accident, an act of terrorism, a labor strike or other similar event, we may
experience disruptions in our continued supply of raw materials, delays in our production process or a reduction in our ability to distribute our therapeutics to our customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product
candidates that may be more profitable or for which there is a greater likelihood of success. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited resources, we may forego or
delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities. Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We will continue to incur significant increased costs as a result of operating as a public company, and our management will continue to be required to
devote substantial time to new compliance initiatives. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we will continue to incur significant legal, accounting and other
expenses. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange Commission, or SEC, and The NASDAQ Global Market have imposed various requirements on public companies. Recent legislation
permits smaller &#147;emerging growth companies&#148; to implement many of these requirements over a longer period and up to five years from the pricing of our offering. We intend to take advantage of this new legislation but cannot guarantee that
we will not be required to implement these requirements sooner than </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
budgeted or planned and thereby incur unexpected expenses. Shareholder activism, the current political environment and the current high level of government intervention and regulatory reform may
lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need
to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect
these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage. While compliance
with these additional requirements will result in increased costs to us, we cannot accurately predict or estimate at this time the amount of additional costs we may incur as a public company under both U.S. and Israeli laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are subject to foreign currency exchange risk, and fluctuations between the U.S. dollar and the NIS, the Euro and other non-U.S. currencies may
negatively affect our earnings and results of operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We operate in a number of different currencies. While the dollar is our functional and
reporting currency and investments in our share capital have been denominated in dollars, our financial results may be adversely affected by fluctuations in currency exchange rates as a significant portion of our operating expenses, including our
salary-related and manufacturing expenses are denominated in the NIS, and a significant portion of our clinical trials and manufacturing expenses are denominated in euros. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation
rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar- denominated
results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, the average exchange rate of the dollar against
the NIS increased in 2015 and 2014 and decreased in 2013. Market volatility and currency fluctuations may limit our ability to cost- effectively hedge against our foreign currency exposure and, in addition, our ability to hedge our exposure to
currency fluctuations in certain emerging markets may be limited. Hedging strategies may not eliminate our exposure to foreign exchange rate fluctuations and may involve costs and risks of their own, such as devotion of management time, external
costs to implement the strategies and potential accounting implications. Foreign currency fluctuations, independent of the performance of our underlying business, could lead to materially adverse results or could lead to positive results that are
not repeated in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We depend on our license agreement with Crucell and if we cannot meet requirements under such license agreement, we could lose the rights to our products,
which could have a material adverse effect on our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VB-111 incorporates an adenoviral vector as the delivery vehicle based on our rights under
a license agreement with Crucell. If we fail to meet our obligations under this license agreement, including various diligence, milestone payment, royalty and other obligations, Crucell has the right to terminate our license, and upon the effective
date of such termination, our right to use the licensed technology would terminate. We may enter into additional agreements in the future with Crucell that may impose similar obligations on us. While we would expect to exercise all rights and
remedies available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights under the patents and other technology licensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at
all. Any uncured, material breach under the license agreement could result in our loss of rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product candidates since there
are currently no significant similar alternatives on the market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If we are unable to obtain or protect intellectual property rights related to our product candidates, we may
not be able to obtain exclusivity for our product candidates or prevent others from developing similar competitive products. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely upon a
combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and
scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance
that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue
and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in the patent claims being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents
and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition
from third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue, if the
breadth or strength of our patent protection is threatened, or if our patent portfolio fails to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates and
threaten our ability to commercialize future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, applications will issue as patents, the breadth of any
such issued patent claims or whether any issued claims will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of
rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection
could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any
patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of
the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available,
but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. This risk is
material in light of the length of the development process of our products and lifespan of our current patent portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection
afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements
of our product candidate discovery and development processes that involve proprietary know- how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary
technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by
maintaining physical security of our premises and physical and electronic security of our information technology systems. Security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may
otherwise become known or be independently discovered by competitors. Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to
our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information
will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse
effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently
discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that
we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a
result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our
technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of
litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes
review proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in
which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of
third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or
patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently
pending patent applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these
patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of
any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of
competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we
obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would
involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and
attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be successful in obtaining or maintaining necessary rights to pharmaceutical product components and
processes for our development pipeline through acquisitions and in- licenses. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Presently we have rights to the intellectual property, through licenses
from Crucell and under patents that we own, to develop our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend
in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to
acquire or in-license any compositions, methods of use, processes or other third- party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive
area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to
their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or
acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may enter into
license agreements with third parties, and if we fail to comply with our obligations in such agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our
licensors, we could lose license rights that are important to our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may need to obtain licenses from third parties to advance our research
or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant
time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or
other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the
intellectual property. In some cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners.
Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding
intellectual property subject to a licensing agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have
licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time-consuming and unsuccessful. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors. To counter infringement or
unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable or is
not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our
patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interference proceedings
provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related
technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may
fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in
countries where the laws may not protect those rights as fully as in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of
hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the trading price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or
defense of our issued patents. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The
Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The U.S. PTO is currently developing regulations and
procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, were enacted March&nbsp;16, 2013. However, it is not
clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be
subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former
employers. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our key employees and personnel are or were previously employed at universities, medical institutions or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we try to ensure that our employees, consultants and independent
contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed
intellectual property, including trade secrets or other proprietary information, of any of our employee&#146;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management and other employees. Furthermore, universities or medical institutions who employ some of our key employees and personnel in parallel to their engagement by us may claim that
intellectual property developed by such person is owned by the respective academic or medical institution under the respective institution intellectual property policy or applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and
adversely affect our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant portion of our intellectual property has been developed by our employees in the course of their
employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the term and as part of the scope of his or her employment with a company are regarded as &#147;service inventions,&#148; which
belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli
Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his inventions. Recent decisions by the Committee (which have been upheld by the
Israeli Supreme Court on appeal) have created uncertainty in this area, as it held that employees may be entitled to remuneration for their service inventions despite having specifically waived any such rights. Further, the Committee has not yet
determined the method for calculating this remuneration nor the criteria or circumstances under which an employee&#146;s waiver of his right to remuneration will be disregarded. We generally enter into assignment-of-invention agreements with our
employees pursuant to which such individuals assign to us all rights to any inventions created in the scope of their employment or engagement with us. Although our employees have agreed to assign to us service invention rights, we may face claims
demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current or former employees, or be forced to litigate such claims, which could
negatively affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other
intellectual property. We may have to in the future, ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against
these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use,
valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications will be due to be paid to the U.S. PTO
and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. There are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss
of patent rights in the relevant jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates,
the defendant may contend that the patent covering our product candidate is invalid, unenforceable or fails to cover the product candidate or the infringing product. In patent litigation in the United States, defendants commonly allege that asserted
patent claims are invalid and unenforceable. Grounds for a validity challenge could be an alleged failure to meet one or more of several statutory requirements, including lack of novelty, obviousness, lack of written description, indefiniteness and
non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties
may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions, such
as opposition proceedings. Such proceedings could result in revocation, amendments to our patent claims or statements being made on the record such that our claims may no longer be construed to cover our product candidates. The outcome following
legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during
prosecution. If a defendant were to prevail on a legal assertion of invalidity, unenforceability or non-infringement, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be
public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of
our ordinary shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing
patents in the biotechnology industry involve both technological and legal complexity, and is therefore is costly, time- consuming and inherently uncertain. In addition, the United&nbsp;States has recently enacted and is currently implementing
wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in some situations. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the
U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have not yet registered trademarks for a commercial trade name for our product candidates and failure to secure such registrations could adversely
affect our business. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet registered trademarks for a commercial trade name for our product candidates. During trademark registration
proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the U.S. PTO and in comparable agencies in many foreign jurisdictions,
third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such
proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a
review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify
under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may not be able to protect our
intellectual property rights throughout the world. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the
world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect
intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or
importing products made using our inventions in and into the United States or other jurisdictions. Potential competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and
further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, if approved, and our patents or
other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant
problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other
intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights
generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted
narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Under applicable employment laws, we may not be able to enforce covenants not to compete. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally enter into non-competition agreements with our employees. These agreements prohibit our employees, if they cease working for us, from competing
directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors
from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that
the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the protection of a company&#146;s trade secrets or other intellectual
property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The market price of our ordinary shares may be highly volatile, and you may not be able to resell your shares at the purchase price. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An active trading market for our ordinary shares may not be available. You may not be able to sell your shares quickly or at the market price if trading in our
ordinary shares is not active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our ordinary shares has been and is likely to remain volatile. Our share price could be subject to
wide fluctuations in response to a variety of factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results or delays in pre-clinical studies or clinical trials, and resulting changes in our clinical development programs; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reports of adverse events in other similar products or clinical trials of such products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain additional funding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay in filing an IND or BLA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA&#146;s review of that IND or BLA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to develop successfully and commercialize our product candidates for the proposed indications and future product candidates for other indications or new candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to maintain our licensing arrangements or enter into strategic collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to scale up our manufacturing capabilities (including in Israel), inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions, including by the OCS under the Research Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products, services or technologies by our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed financial projections we may provide to the public; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the financial expectations of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant lawsuits, including patent or shareholder litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our ordinary shares by us or our shareholders in the future; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our ordinary shares. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in general, and
biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively
affect the market price of our ordinary shares, regardless of our actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>There has been limited trading volume for our ordinary
shares. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even though our ordinary shares have been listed on the NASDAQ Global Market, there has been limited liquidity in the market for the ordinary
shares, which could make it more difficult for holders to sell their ordinary shares. There can be no assurance that an active trading market for our ordinary shares will be sustained. In addition, the stock market generally has experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our
actual operating performance. The market price and liquidity of the market for our ordinary shares that will prevail in the market may be higher or lower than the price you pay and may be significantly affected by numerous factors, some of which are
beyond our control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our principal shareholders and management own a significant percentage of our shares and will be able to exert
significant control over matters subject to shareholder approval. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, our executive officers, directors, five percent
shareholders and their affiliates beneficially owned approximately 61.2% of our voting shares. Therefore, these shareholders have the ability to control us through their ownership positions. These shareholders may be able to determine all matters
requiring shareholder approval. For example, these shareholders, if they were to act together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major
corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our ordinary shares that you may believe are in your best interest as one of our shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; and a &#147;foreign private issuer,&#148; and we cannot be certain if the reduced reporting requirements
applicable to emerging growth companies and foreign private issuers will make our ordinary shares less attractive to investors. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements
that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes- Oxley Act of 2002, or the Sarbanes-Oxley Act,
reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our ordinary shares
held by non-affiliates exceeds $700.0 million as of any June&nbsp;30 before that time or if we have total annual gross revenue of $1.0 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth
company as of the following December&nbsp;31 or, if we issue more than $1.0&nbsp;billion in non-convertible debt during any three-year period before that time, we would cease to be an emerging growth company immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, as a foreign private issuer, we are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the
Securities Exchange Act of 1934, or the Exchange Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, we will not be required to
issue quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed as that required of U.S. domestic reporting companies.
We will also have four months after the end of each fiscal year to file our annual reports with the SEC and will not be required to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore, our officers,
directors and principal shareholders will be exempt from the requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained in Section&nbsp;16 of the Exchange Act. These exemptions and
leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic reporting companies. See &#147;Item 16G. Corporate Governance&#148; for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our ordinary shares less attractive because we may rely on these reduced requirements. If some investors find our
ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private
companies. We are electing to not take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as a result, we will comply with new or revised accounting standards on
the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to not take advantage of the extended transition period for complying with new or
revised accounting standards is irrevocable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our ordinary shares are subject to substantial dilution in their book value. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, options and warrants to purchase 3,554,179 ordinary shares at a weighted average exercise price of $4.69 per share were
outstanding. The exercise of any of these options and warrants would result in additional dilution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of a substantial number of our ordinary
shares in the public market could cause our share price to fall. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our existing shareholders sell, indicate an intention to sell or the market
perceives that they intend to sell, substantial amounts of our ordinary shares in the public market, the market price of our ordinary shares could decline significantly. As of December&nbsp;31, 2015, we had outstanding a total of 22,470,321 ordinary
shares. Substantially all of the shares are available for sale in the public market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, 12,248,009 ordinary shares are held by
directors, executive officers and other affiliates and are subject to Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition, as of March 1, 2016, an aggregate of 3,984,514 ordinary shares that are either subject to outstanding options, reserved for future issuance under our 2014 Plan or subject to outstanding warrants will or may become eligible for sale in the
public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act. In addition, our investor rights agreement entitles certain shareholders who previously held preferred shares
prior to our initial public offering to certain registration rights. As of March&nbsp;1, 2016, these holders collectively held an aggregate of 9,043,261 ordinary shares entitled to such registration rights. If these additional ordinary shares are
sold, or if it is perceived that they will be sold, in the public market, the market price of our ordinary shares could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales and
issuances of our ordinary shares or rights to purchase ordinary shares, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity
securities, our shareholders may experience substantial dilution. We may sell ordinary shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell
ordinary shares, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing shareholders, and new
investors could gain rights superior to our existing shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Employee Share Ownership and Option Plan (2014), or the 2014 Plan, our
management is authorized to grant share options and other equity-based awards to our employees, directors and consultants. Currently, we plan to register the increased number of shares available for issuance under the 2014 Plan each year. If our
board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our shareholders may experience additional dilution, which could cause our share price to fall. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We could be subject to securities class action litigation. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk
is especially relevant for us because pharmaceutical companies have experienced significant share price volatility in recent years. For example, the price of our ordinary shares, which reached its high record of $17.02 per share at the close of the
trading on January&nbsp;27, 2015, decreased as low as $2.8 per share at the close of the trading on February&nbsp;1, 2016 a drop of about 84%. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s
attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not intend to pay dividends on our ordinary shares, so any returns will be limited to
the value of our shares. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our share capital. We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to shareholders will therefore be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited to the appreciation of their shares. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes. Furthermore, our
payment of dividends (out of tax- exempt income) may retroactively subject us to certain Israeli corporate income taxes, to which we would not otherwise be subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If equity research analysts do not publish research reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares,
the price of our ordinary shares could decline. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our ordinary shares relies in part on the research and reports that equity
research analysts publish about us and our business. The price of our ordinary shares could decline if we do not obtain research analyst coverage, or one or more securities analysts downgrade our ordinary shares or if those analysts issue other
unfavorable commentary or cease publishing reports about us or our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Incorporation and Operations in Israel </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We are a &#147;foreign private issuer&#148; and intend to follow certain home country corporate governance practices, and our shareholders may not have the
same protections afforded to shareholders of companies that are subject to all NASDAQ corporate governance requirements. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a foreign private issuer,
we are permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required under the NASDAQ Stock Market for domestic U.S. issuers. For instance, we intend to follow home country practice in
Israel with regard to the quorum requirement for shareholder meetings. As permitted under the Israeli Companies Law, 5759-1999, or the Companies Law, our articles of association provide that the quorum for any meeting of shareholders shall be the
presence of at least two shareholders present in person, by proxy or by a voting instrument, who hold at least 25% of the voting power of our shares instead of the 33 1/3% of the issued share capital requirement. We may in the future elect to follow
home country practices in Israel (and consequently avoid the requirements that would otherwise apply to a U.S. company listed on The NASDAQ Global Market) with regard to other matters, as well, such as the formation of compensation, nominating and
governance committees, separate executive sessions of independent directors and non-management directors and the requirement to obtain shareholder approval for certain dilutive events (such as for the establishment or amendment of certain
equity-based compensation plans, issuances that will result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the stock
or assets of another company). Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on The NASDAQ Global Market may provide less protection to you than what is accorded to
investors under the NASDAQ Stock Market rules applicable to domestic U.S. issuers. See &#147;Item 16G. Corporate Governance&#148; for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy
statements, including the requirement for an emerging growth company to disclose the compensation of the chief executive officer and other two highest compensated executive officers on an individual, rather than aggregate, basis. A recent amendment
to regulations under the Israeli Companies Law will require us to disclose, at the latest, in the notice for our 2015 annual meeting of shareholders, the annual compensation of our five most highly compensated officers on an individual, rather than
aggregate, basis. However, this disclosure will not be as extensive as that required of a U.S. domestic issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We would lose our foreign private issuer
status if a majority of our directors or executive officers are U.S. citizens or residents and we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. Although we have elected to comply with certain U.S.
regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic reporting company may be significantly higher. If we are
not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic reporting company forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer.
We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic reporting companies. Such conversion and modifications will involve additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential political, economic and military instability in the State of Israel, where the majority of our senior management and our research and development
facilities are located, may adversely affect our results of operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under Israeli law and our offices and operations are
located in the State of Israel. In addition, our key employees, officers and all but three of our directors are residents of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business. Since the State of
Israel was established in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any hostilities involving Israel
or the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic or financial condition of Israel, could affect adversely our operations. Since October 2000, there have been
increasing occurrences of terrorist violence. Ongoing and revived hostilities or other Israeli political or economic factors could harm our operations, product development and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Israel has entered into various agreements with Egypt, Jordan and the Palestinian Authority, there has been an increase in unrest and terrorist
activity, which began in October 2000 and has continued with varying levels of severity. The establishment in 2006 of a government in the Palestinian Authority by representatives of the Hamas militant group has created additional unrest and
uncertainty in the region. In 2006, a conflict between Israel and the Hezbollah in Lebanon resulted in thousands of rockets being fired from Lebanon up to 50 miles into Israel. Starting in December 2008, for approximately three weeks, Israel engaged
in an armed conflict with Hamas in the Gaza Strip, which involved missile strikes against civilian targets in various parts of Israel and negatively affected business conditions in Israel. In November 2012, for approximately one week, Israel
experienced a similar armed conflict, resulting in hundreds of rockets being fired from the Gaza Strip and disrupting most day-to-day civilian activity in southern Israel. Beginning in July 2014, for approximately seven weeks, Israel experienced
additional armed conflict between Israel and Hamas, which included rocket strikes against civilian targets in various parts of Israel. If renewed, these hostilities may negatively affect business conditions in Israel. In addition, Israel faces
threats from more distant neighbors, in particular, Iran. Our insurance policies do not cover us for the damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of
law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. In
the event that hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies and products, our operations may be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, since the end of 2010, numerous acts of protest and civil unrest have taken place in several countries in the Middle East and North Africa, many
of which involved significant violence. The civil unrest in Egypt, which borders Israel, resulted in the resignation of its president Hosni Mubarak, and to significant changes to the country&#146;s government. In Syria, also bordering Israel, a
civil war is continuing to take place. The ultimate effect of these developments on the political and security situation in the Middle East and on Israel&#146;s position within the region is not clear at this time. Such instability may lead to
deterioration in the political and trade relationships that exist between the State of Israel and certain other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Popular uprisings in various
countries in the Middle East and North Africa are affecting the political stability of those countries. Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and these countries.
Several countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or
political instability in the region continues or increases. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or significant downturns in the economic or financial condition
of Israel, could adversely affect our operations and product development and adversely affect our share price. Similarly, Israeli companies are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited in conducting business with entities from several countries. For instance, in 2008, the Israeli legislature passed a law forbidding any investments in entities that transact business with
Iran. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our operations may be disrupted by the obligations of personnel to perform military service. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2016, we had 27 employees, all of whom were based in Israel. Some of our employees may be called upon to perform up to 36 days (and in
some cases more) of annual military reserve duty until they reach the age of 40 (and in some cases, up to 45 or older) and, in emergency circumstances, could be called to immediate and unlimited active duty. In the event of severe unrest or other
conflict, individuals could be required to serve in the military for extended periods of time. Since September 2000, in response to increased tension and hostilities, there have been occasional call-ups of military reservists, including in
connection with the 2006 conflict in Lebanon, and the December 2008 and November 2012 conflicts with Hamas, and it is possible that there will be additional call-ups in the future. Our operations could be disrupted by the absence of a significant
number of our employees related to military service or the absence for extended periods of one or more of our key employees for military service. Such disruption could materially adversely affect our business and results of operations. Additionally,
the absence of a significant number of the employees of our Israeli suppliers and contractors related to military service or the absence for extended periods of one or more of their key employees for military service may disrupt their operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The tax benefits that are available to us if and when we generate taxable income require us to meet various conditions and may be prevented or reduced
in the future, which could increase our costs and taxes. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when we generate taxable income, we would be eligible for certain tax benefits
provided to &#147;Benefited Enterprises&#148; under the Israeli Law for the Encouragement of Capital Investments, 1959, as amended, or the Investment Law. In order to remain eligible for the tax benefits for &#147;Benefited Enterprises&#148; we must
continue to meet certain conditions stipulated in the Investment Law and its regulations, as amended. In addition, we informed the Israeli Tax Authority of our choice of 2012 as a &#147;Benefited Enterprise&#148; election year, all under the
Investment Law. The benefits available to us under this tax regulation are subject to the fulfillment of conditions stipulated in the regulation. Further, in the future these tax benefits may be reduced or discontinued. If these tax benefits are
reduced, cancelled or discontinued, our Israeli taxable income would be subject to regular Israeli corporate tax rates. The standard corporate tax rate for Israeli companies is 25% for 2015 and thereafter. Additionally, if we increase our activities
outside of Israel through acquisitions, for example, our expanded activities might not be eligible for inclusion in future Israeli tax benefit programs. See &#147;Item 10E. Taxation&#151;Israeli Tax Considerations and Government Programs&#151;Law
for the Encouragement of Capital Investments, 5719-1959.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>It may be difficult to enforce a U.S. judgment against us, our officers and directors
and the Israeli experts named in this prospectus in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on our officers and directors and these experts. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in Israel, and our corporate headquarters and substantially all of our operations are located in Israel. All of our executive officers and
all but two of our directors, and the Israeli experts named in this prospectus, are located in Israel. The majority of our assets and the assets of these persons are located outside the United States. Therefore, it may be difficult for an investor,
or any other person or entity, to enforce a U.S. court judgment based upon the civil liability provisions of the U.S. federal securities laws against us or any of these persons in a U.S. or Israeli court, or to effect service of process upon these
persons in the United States. Additionally, it may be difficult for an investor, or any other person or entity, to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an
alleged violation of U.S. securities laws against us or our officers and directors on the grounds that Israel is not the most appropriate forum in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel addressing the matters described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some
respects from the rights and responsibilities of shareholders of U.S. corporations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since we are incorporated under Israeli law, the rights and
responsibilities of our shareholders are governed by our articles of association and Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders of U.S. corporations. In
particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power in the
company, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment to the company&#146;s articles of association, an increase of the company&#146;s authorized share capital, a merger of
the company and approval of related party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who
knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of an officer of the company has a duty to act in fairness towards the company with regard to such vote or appointment.
However, Israeli law does not define the substance of this duty of fairness. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to
impose additional obligations and liabilities on our shareholders that are not typically imposed on shareholders of U.S. corporations. See &#147;Item 6. Directors, Senior Management and Employees&#151;Approval of Related Party Transactions Under
Israeli Law&#151;Shareholders&#146; Duties.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions of Israeli law and our amended and restated articles of association could make it more
difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our shareholders. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such
types of transactions. For example, a tender offer for all of a company&#146;s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion
of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless at least 98% of the company&#146;s outstanding shares are tendered. Furthermore, the shareholders, including
those who indicated their acceptance of the tender offer (unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights), may, at any time within six months following the completion of the
tender offer, petition an Israeli court to alter the consideration for the acquisition. See &#147;Item 10B. Memorandum and Articles of Association&#151;Acquisitions under Israeli Law&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not have
a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax
deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares
of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the
shares has occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain U.S. shareholders may be subject to adverse tax consequences if we are characterized as &#147;Controlled Foreign
Corporation.&#148; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each &#147;Ten Percent Shareholder&#148; in a non-U.S. corporation that is classified as a &#147;controlled foreign
corporation,&#148; or a CFC, for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#146;s pro rata share of the CFC&#146;s &#147;Subpart F income&#148; and
investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. A non-U.S. corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all
classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#147;Ten Percent Shareholder&#148; is a U.S. person (as defined by the U.S. Internal Revenue Code of 1986, as amended), who owns or is
considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely
certain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that we were a CFC for the taxable year ended December&nbsp;31, 2014 or that we are currently a CFC. It is possible, however,
that a shareholder treated as a U.S. person for U.S. federal income tax purposes will acquire, directly or indirectly, enough shares to be treated as a Ten Percent Shareholder after application of the constructive ownership rules and, together with
any other Ten Percent Shareholders of our company, cause us to be treated as a CFC for U.S. federal income tax purposes. We believe that certain of our shareholders are Ten Percent Shareholders for U.S. federal income tax purposes. Holders should
consult their own tax advisors with respect to the potential adverse U.S. federal income tax consequences of becoming a Ten Percent Shareholder in a CFC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We expect to be classified as a passive foreign investment company, and our U.S. shareholders may suffer adverse tax consequences as a result. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets
that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive
income includes dividends, interest, and gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or
business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the
preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of share sales. See &#147;Item 10E. Taxation&#151;Certain
Material U.S. Federal Income Tax Considerations&#151;Passive Foreign Investment Company Considerations.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since PFIC status depends on the
composition of our income and the composition and value of our assets (which, assuming we are not a CFC for the year being tested, may be determined in large part by reference to the market value of our ordinary shares, which may be volatile) from
time to time, there can be no assurance that we will not be considered a PFIC for any taxable year. However, because we had no revenue-producing operations, we believe that we were a PFIC for our 2015 taxable year. In addition, unless and until we
generate sufficient revenue from active licensing and other non-passive sources and otherwise satisfy the asset test above, we expect to be treated as a PFIC in future taxable years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_5"></A>Item&nbsp;4. Information on the Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal name of our company is
Vascular Biogenics Ltd. and we conduct business under the name VBL Therapeutics. We were incorporated in Israel on January&nbsp;27, 2000 as a company limited by shares under the name Medicard Ltd. In January 2003, we changed our name to Vascular
Biogenics Ltd. Our registered and principal office is located at 6 Jonathan Netanyahu St., Or Yehuda, Israel 60376. Our service agent in the United&nbsp;States is located at c/o CT Corporation System, 111 8th Avenue, New York, New York 10011 and our
telephone number is 972-3-6346450. Throughout this prospectus, we refer to various trademarks, service marks and trade names that we use in our business. The &#147;Vascular Biogenics&#148; design logo, &#147;VBL Therapeutics,&#148; &#147;Vascular
Targeting System,&#148; &#147;VTS,&#148; &#147;Lecinoxoids,&#148; &#147;VB-111,&#148; &#147;VB-201,&#148; the &#147;GLOBE&#148; design logo and other trademarks or service marks of Vascular Biogenics Ltd. appearing in this prospectus are the
property of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Vascular Biogenics Ltd. We have several other registered trademarks, service marks and pending applications relating to our products. Although we have omitted the &#147;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> &#147; and &#147;&#153;&#148; trademark designations for such marks in this prospectus, all rights to such trademarks are nevertheless reserved. Other trademarks and service marks appearing in
this prospectus are the property of their respective holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. Thus, we may take advantage of certain
exemptions from various reporting requirements that are applicable to public companies generally. For example, we have elected not to have our independent registered public accounting firm provide an attestation report on the effectiveness of our
internal control over financial reporting, as would otherwise be required by Section&nbsp;404(b) of the Sarbanes-Oxley Act, or SOX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will cease to be
an &#147;emerging growth company&#148; upon the earliest of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">December&nbsp;31, 2019, which is the last day of the fiscal year in which the fifth anniversary of our initial public offering in the United States has occurred; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of the fiscal year in which our annual gross revenues are $1.0 billion or more; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of any fiscal year in which the market value of our ordinary shares held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JOBS Act also provides that an &#147;emerging growth company&#148; can utilize the extended transition period provided in Section&nbsp;7(a)(2)(B) of the
Securities Act, for complying with new or revised accounting standards. However, we have chosen to &#147;opt out&#148; of such extended transition period, and, as a result, we will comply with new or revised accounting standards on the relevant
dates on which adoption of such standards is required for companies that are not &#147;emerging growth companies.&#148; Section&nbsp;107 of the JOBS Act provides that our decision to opt out of the extended transition period for complying with new
or revised accounting standards is irrevocable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Expenditures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a discussion of our capital expenditures, see &#147;Item 5. Operating and Financial Review and Prospects&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. Our program is based on our proprietary Vascular Targeting System, or VTS, platform technology, which utilizes genetically
targeted therapy to destroy newly formed, or angiogenic, blood vessels, and which we believe will allow us to develop product candidates for multiple oncology indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that we are developing for solid tumor indications, with an advanced
program for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. We have obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following treatment
with standard chemotherapy and radiation. We have also received orphan drug designation in both the United States and Europe. In September 2015, we reported complete results from our Phase 2 trial of VB-111 in rGBM, demonstrating a
statistically-significant benefit in overall survival and favorable response rate in patients treated with VB-111 in combination with bevacizumab. Our pivotal Phase 3 GLOBE study in rGBM began in August 2015 and is comparing a combination of VB-111
and bevacizumab to bevacizumab alone. The study is being conducted under a special protocol assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA, with full endorsement by the&nbsp;Canadian Brain Tumor Consortium (CBTC)
and is planned to recruit approximately 252&nbsp;patients in the US, Canada and Israel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have been conducting a program targeting anti-inflammatory diseases, based on the use of our Lecinoxoid
platform technology. Lecinoxoids are a novel class of small molecules we developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201,
is a Phase 2-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase 2 sub-study in psoriatic patients with cardiovascular risk. Due to business limitations associated with the heavy burden of developing medications
for cardiovascular diseases, we chose to test it in psoriasis and ulcerative colitis; however, as we reported in February 2015, VB-201 failed to meet the primary endpoint in Phase 2 clinical trials for psoriasis and for ulcerative colitis. As a
result, we have terminated our development of VB-201 in those indications. Nevertheless, based on recent pre-clinical studies, we believe that VB-201 and some second generation molecules such as VB-703 may be applicable for NASH and renal fibrosis.
Since the company intends to focus substantially all of our efforts and resources on advancing our oncology program, we will seek to monetize our Lecinoxoid assets via strategic deals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing our lead oncology product candidate, VB-111, for solid tumor indications, with current clinical programs in rGBM, thyroid cancer and ovarian
cancer. In interim analyses of data from our ongoing open-label Phase 2 clinical trial of VB-111 in rGBM, we observed dose-dependent attenuation of tumor growth and an increase in median overall survival, which is the time interval from initiation
of treatment to the patient&#146;s death. The U.S. Food and Drug Administration, or FDA, has granted VB-111 fast track designation for prolongation of survival in patients with glioblastoma that has recurred following treatment with temozolomide, a
chemotherapeutic agent commonly used to treat newly diagnosed glioblastoma, and radiation. On July&nbsp;1, 2014, the FDA concurred with the design and planned analyses of our Phase 3 pivotal trial of VB-111 in rGBM pursuant to an SPA. At the time,
commencement of the trial was subject to our providing the agency with more information regarding our potency release assay for the trial. We developed this assay and submitted initial information to the FDA on May&nbsp;26, 2014. On February&nbsp;5,
2015 the FDA has found our data satisfactory and removed the partial hold. We began our Phase 3 pivotal trial of VB-111 in rGBM in August 2015. According to the study protocol, an interim analysis will take place when 91 mortality events will occur
in the trial. The timing of the interim analysis, which depends both on enrollment and on VB-111 activity, is expected in the first half of 2017. Full data will be available when 151 events will occur in the trial. Based on interactions with the
FDA, we believe the current trial, if successful, will support a Biologics License Application (BLA) in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VB-111 is also being studied in a Phase 2
trial for recurrent platinum-resistant Ovarian Cancer and in a Phase 2 study in recurrent, iodine-resistant differentiated Thyroid Cancer. An interim analysis of the ovarian cancer study showed evidence of clinical benefit, and the Thyroid Cancer
study met its primary endpoint of 6 month Progression Free Survival (PFS) with disease stabilization and safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, we had
studied VB-111 in over 170 patients and have observed it to be well-tolerated. In December 2015, we have been granted a US composition of matter patents that provides intellectual property protection for VB-111 in the US until October 2033 before
any patent term extension. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is
to become a leading biopharmaceutical company focused on discovering, developing and commercializing innovative therapeutics that leverage our proprietary VTS platform technology for oncology indications. We intend to achieve this goal by pursuing
the following strategies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Pursue regulatory approval for our lead oncology compound, VB-111, for rGBM </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced a
Phase 3 pivotal trial of VB-111 for rGBM in August 2015, under our SPA with the FDA, and estimate that we will receive interim data in the first half of 2017. We have secured funding for the GLOBE trial trough a follow-on offering of $15M on
November 2015. We expect to complete the trial in the beginning of 2018. The timing of this data will depend on overall survival of the patients in the trial and patient recruitment. If we receive positive data from the trial, we expect to submit a
BLA to the FDA during 2018, seeking approval of VB-111 for the treatment of rGBM in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Expand indications for VB-111 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe VB-111 has the potential for applications in other
solid tumors in addition to rGBM. We are therefore conducting clinical trials in both ovarian and thyroid cancer. We intend to continue development of VB-111 for platinum-resistant ovarian cancer. For development of VB-111 for thyroid cancer and
additional cancer indications we will seek to establish collaboration with strategic partner(s). We may also pursue expansion of the treatment indication of VB-111 in glioblastoma beyond recurrent cases to include newly diagnosed cases if clinical
data support such expansion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Selectively enter into licensing and collaboration arrangements to supplement our internal development capabilities </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we advance our pipeline of anti-cancer product candidates, we will evaluate opportunities to selectively form collaborative alliances for our non-oncology
assets to expand our capabilities and accelerate the development and commercialization of our oncology products. We engage in conversations with third parties to evaluate such potential collaborations on an ongoing basis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B>Expand our manufacturing capacity to support clinical trials and commercialization of VB-111 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
currently manufacture clinical quantities of VB-111 at our facility in Israel and through a third party in the United States. Subject to obtaining additional financing, we intend to construct a large-scale manufacturing facility that would enable us
to manufacture commercial quantities of VB-111, if it receives regulatory approval, and potentially other product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates
and Technology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the status of pipeline: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g160947g71z06.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our VTS Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our innovative, proprietary VTS platform
technology enables systemic administration of gene therapy to either destroy or promote angiogenic blood vessels. VTS is both tissue- and condition-specific, allowing for targeted and limited gene expression in endothelial cells, the thin layer of
cells that lines the interior surface of blood vessels undergoing angiogenesis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our VTS platform technology comprises three components, a viral vector, a
promoter and a transgene: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Viral vector&#151;a modified virus that is used as a delivery vehicle to distribute the promoter and the transgene throughout
the body. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Promoter&#151;our proprietary, genetically modified promoter, called PPE-1-3X, that specifically targets the endothelial cells of angiogenic
blood vessels. When present in these cells, the promoter initiates the expression of the transgene. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Transgene&#151;a genetic sequence designed to yield
a specific biologic effect, the expression of which is directed by PPE-1-3X. The particular transgene will vary depending on the therapeutic objectives of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the gene therapy has reached the angiogenic blood vessels, the PPE-1-3X promoter activates expression of the transgene to produce a desired RNA or
protein in the endothelial cells of those vessels. For oncology applications, the transgene selected is designed to destroy angiogenic blood vessels that feed solid tumors. For other potential applications, such as the treatment of ischemia, a
different transgene can be selected that is designed to promote the development of angiogenic blood vessels instead of their destruction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VB-111
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We designed VB-111 to address oncology indications, specifically solid tumors, by selectively targeting the blood vessels required for tumor
growth and encouraging the programmed cell-death process, or apoptosis, of cells in those blood vessels. VB-111 is administered intravenously. PPE-1-3X is activated specifically in angiogenic endothelial cells and regulates a transgene consisting of
a combination of two gene sequences known as Fas and TNFR1. When expressed, the transgene produces a unique pro-apoptotic protein, the Fas-TNFR1 chimera, that interacts with a native inflammatory molecule, Tumor Necrosis Factor, or TNF- alpha, and
results in the destruction of newly formed or immature blood vessels. When activated by PPE-1-3X, specifically in angiogenic endothelial cells, this combination enables VB-111 to reduce tumor growth in a highly targeted manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our preclinical studies suggest that there seems to be an immune inflammatory response to the presence of the viral vector and the Fas-TNFR1
chimera that may contribute to the efficacy of VB-111. Further support for a potential role of the immune system as part of VB-111&#146;s mechanism of action comes from a recent observation that patients who developed fever as a response to VB-111
administration, at least once along the treatment course, had a survival benefit over those who did not experience post-dosing fever. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VB-111&#146;s mechanism of action is illustrated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g160947g45z76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism retains
activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. We believe that this mode of action makes VB-111 less susceptible to resistance and, therefore, potentially applicable for a broader
patient population than current therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have conducted pre-clinical studies in animal models of lung cancer, colon cancer, thyroid cancer, rGBM and
melanoma. Based on those studies, and clinical results to date, we believe that VB-111 has anti-angiogenic activity that may hold clinical promise and may be suitable for treatment of rGBM and other solid tumors. We also decided to focus on rGBM as
our first indication because we expect the rapid kinetics of this disease will enable us to accumulate clinical data in a short time and, therefore, may facilitate development of VB-111 for this and other indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VB-111 Clinical Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initially studied
VB-111 in a Phase 1 &#147;all comers&#148; trial involving patients with multiple types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma and lung cancer. In that trial, VB-111 was
well-tolerated and showed a dose- dependent extension in median overall survival across a range of tumor types. Based on these results, we decided to proceed with the development of VB-111 for the lead indication of rGBM, as well as to investigate
VB-111 as a monotherapy for the treatment of thyroid cancer and, in combination with chemotherapy, for ovarian cancer. We have an open IND for VB-111 with the Office of Cellular, Tissue, and Gene Therapeutics within FDA&#146;s Center for Biologics
Evaluation and Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glioblastoma is a brain cancer that affects approximately 10,000 newly diagnosed people each year in the United&nbsp;States. It
is a devastating, rapidly progressing tumor, with a median time from diagnosis to the patient&#146;s death of 12 to 15 months. In recurrent glioblastoma, treatment consists of both symptomatic and palliative therapies. However, with currently
available therapies, glioblastoma typically remains fatal within a very short period of time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted an open-label Phase 2 trial in rGBM, which was originally initiated as an adaptive Phase 1/2 trial.
The trial was intended to evaluate the safety and efficacy of VB-111, both by itself and in combination with bevacizumab, an anti-angiogenesis agent approved by the FDA for use in rGBM. In this trial, patients were initially dosed with VB-111 alone.
After disease progression on VB-111 alone, they receive either bevacizumab alone as standard of care, or, in a second cohort, a combination of VB-111 and bevacizumab. Disease progression was defined as a worsening of the patient&#146;s cancer with
an increase of at least 25% in the overall mass of measurable tumors, the appearance of new tumors, the worsening of non-measurable tumors since beginning of treatment, a need for an increased dose of corticosteroids or clinical deterioration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2015, we reported full Phase 2 data on VB-111 in combination with Bevacizumab (Avastin&#153;) in rGBM. Trial results include 46 patients
with rGBM treated with VB-111; upon disease progression, 23&nbsp;patients were treated with VB-111 in combination with Avastin &#153; , and 22 received Avastin &#153; alone. One patient, who achieved a complete response, is still stable on VB-111
alone at 22&nbsp;months and was included in the continuous exposure cohort. The median number of bi-monthly VB-111 doses was four for the continuous exposure cohort versus one in the limited exposure cohort (average of 4.6 vs. 2.2, respectively).
Continuous exposure to VB-111 demonstrated significant improvement in overall survival, with median overall survival of 15&nbsp;months, compared to eight months in patients on limited VB-111 exposure (p=0.048), meeting the primary endpoint of the
trial. VB-111 also demonstrated a statistically significant improvement over the historical Avastin&#153; arm from the BELOB trial, which looked at efficacy of Avastin&#153; , lomustine or a combination of both agents, and reported a median overall
survival of eight months for Avastin&#153; in 50&nbsp;patients with rGBM (p=0.005). Comparison of VB-111 data to historical control data of Avastin from 4 trials demonstrated that the 12 months overall survival in the Avastin pooled data (n=233) was
28% compared to 57% in the VB-111 continuous exposure cohort (p=0.007). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Two complete responses and five partial responses were seen in the VB-111
continuous exposure cohort (n=24), compared to only two partial responses in VB-111 limited exposure cohort (n=22). VB-111 was found to be well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trial data also suggest that VB-111 may induce an immuno-therapeutic effect. Of the 46 patients who received VB-111, 25 patients experienced a fever
post-dosing of VB-111 at least once, while 21 patients did not. Patients with fevers demonstrated increased overall survival of 16 months, compared to patients without fevers, who had a median overall survival of 8.5 months (p=0.03). This
correlation between clinical efficacy and fever suggests that VB-111 may induce an immune response in patients and supports a role of the immune system as part of VB-111&#146;s mechanism of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 62 patients with rGBM, the most frequent toxicity was self-limited fever, starting several hours post therapy and usually resolving within 24 hours and
controlled with anti-pyretics. There were 22 adverse events classified as grade 3 or higher, of which 7 were considered possibly related to VB-111 including asthenia, pyrexia, brain edema, depressed consciousness, pulmonary embolism, or PE (in a
patient with PE prior to enrollment in the trial) and hypertension. Safety results were reviewed five times by the trial Data and Safety Monitoring Board, as well as by the FDA, without safety concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to present the full phase&nbsp;2 data in rGBM to the FDA and discuss the status of the VB-111 program with the agency during the first half of 2016.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, based on observations from early clinical trials, we have advanced VB-111 into tumor specific, repeat-dose trials. In thyroid cancer, we
are conducting an exploratory Phase 2 clinical trial to evaluate safety and efficacy of VB-111. According to the National Cancer Institute, there are an estimated 535,000 people currently living with thyroid cancer in the United States, with an
estimated 60,000 new cases of thyroid cancer each year and an estimated 1,850 annual deaths as a result of the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;21, 2015,&nbsp;we
announced positive results from our multi-cohort Phase 2 trial of VB-111 in advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). The pre-specified primary trial endpoint of <FONT STYLE="white-space:nowrap">6-month</FONT>
progression free survival, or PFS, for at least 25% of enrolled patients was met, showing a dose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
response for VB-111. VB-111 also demonstrated favorable safety and survival data, and a potential for dose-dependent disease stabilization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patients in this open-label, dose-escalating trial, were treated in two cohorts. In the first cohort, 12 patients received a single intravenous infusion
of VB-111 at a low dose of 3x10e12&nbsp;viral particles, or VPs. The second cohort included 17 patients who received VB-111 at a high dose of 10e13&nbsp;VPs every two months, until disease progression. Six patients (35%)&nbsp;in the high-dose cohort
met the primary endpoint of six-month PFS using Response Evaluation Criteria in Solid Tumors (RECIST), compared to three patients (25%)&nbsp;in the low-dose cohort. PFS at 12 months was 25% in the VB-111 high-dose cohort, versus 0% in the low-dose
cohort, potentially indicating dose-dependent disease stabilization. Several patients also had lesional objective responses, such as complete or partially resolved metastatic lesion or metastatic lymph node. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to observe the enrolled patients and expect to provide a full Phase 2 report by the end of 2016. Due to our current focus on rGBM, we intend
to pursue further clinical development of VB-111 for thyroid cancer with a strategic partner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ovarian cancer was diagnosed in approximately 22,000
American women in 2013, according to the National Cancer Institute. In ovarian cancer, clinical trials of bevacizumab, which, like VB-111, is an anti-angiogenic agent, demonstrated some improvement in progression free survival in women with
high-risk advanced ovarian cancer. Therefore, we are conducting an additional Phase 1/2 clinical trial in ovarian cancer, which combines VB-111 therapy with paclitaxel, a common chemotherapeutic agent used to treat ovarian cancer, to evaluate safety
and efficacy in this indication. The trial is currently enrolling patients for the Phase&nbsp;2 phase, as the combination therapy merits further development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of May&nbsp;30, 2015, 16 patients were enrolled in the trial, four of whom received low dose of VB-111 (3x10e12&nbsp;VP) together with paclitaxel at a
lower (40mg)&nbsp;or full dose, whereas 12 patients received a full dose of both paclitaxel (80mg)&nbsp;and VB-111 (1x10e13 VP). Tumor response data were available for the four patients who received the low dose of VB-111, and ten out of
12&nbsp;patients who received the higher dose of VB-111. Six out of the ten patients evaluated for tumor response at the high dose level (60%)&nbsp;met the Gynecological Cancer Intergroup criteria of at least 50% reduction in CA-125, three of whom
were post-Avastin&#153; failure. None of the four patients treated with low dose VB-111 showed reduction in CA-125. As reference, the AURELIA trial reported CA-125 response in 11.6% of patients treated with chemotherapy and 31.8% CA-125 response in
ovarian cancer patients treated with a combination of chemotherapy and Avastin&#153; (J Clin Oncol. 2014;32(13):1302-8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of May&nbsp;30, 2015, all
four patients treated with low dose VB-111 had died and the group had median OS of 6&nbsp;months, whereas eight of 12 patients who received high dose VB-111 were alive. As of February&nbsp;29, 2016, 20&nbsp;patients were enrolled in the trial. We
have been following the patients for tumor response and survival data and expect to provide updated results from this Phase 2 study in the second quarter of 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe these data are another proof-of-concept for the safety of VB-111 in combination therapy, and are encouraged by the positive results in another type
of solid tumor. We are considering launching a randomized controlled trial for VB-111 in ovarian cancer, subject to securing the required funding. We intend to discuss the data from this Phase&nbsp;2 trial with the FDA during the first half of 2016.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional VTS Pipeline candidates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our VTS
platform technology enables systemic administration of gene therapy to either destroy or promote angiogenic blood vessels. Beyond VB-111, we have generated additional product candidates which utilize the same vector and promoter as in VB-111, yet
comprise alternative functional transgenes. VB-511 is an anti-angiogenic candidate, while VB-211 and VB-411 are pro-angiogenic candidates that may be employed for ischemic conditions like peripheral vascular disease. All three candidates have
demonstrated pre-clinical efficacy and are ready for toxicology. We may pursue further development of VB-511 internally, but we aim to partner-out the pro-angiogenic candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the status of our VTS platform: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160947g34h96.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g160947g12b69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Lecinoxoid Platform Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body&#146;s inflammatory
response. Lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids, which possess immune modulating anti-inflammatory properties, modified to enhance stability and
activity. We believe that Lecinoxoids hold significant promise in their ability to treat a range of chronic immune-based inflammatory diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inflammatory response is a complex physiologic process balancing both pro- and anti- inflammatory components
that interact intimately with the body&#146;s immune system. Oxidized phospholipids are instrumental in the interplay of these components that maintain equilibrium. When the inflammatory response is not adequately balanced, excess inflammation
results and may cause both acute and chronic disease states. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g160947g83a57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lecinoxoid platform seeks to harness the ability of oxidized phospholipids to regulate and attenuate key
immune-inflammatory signaling. We believe that our approach&#151;identifying naturally occurring anti-inflammatory compounds and modifying them to enhance stability and activity&#151;may lead to more physiologically balanced responses than other
available anti-inflammatory therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VB-201 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead Lecinoxoid-based compound, VB-201, was designed as an oral agent for the control of chronic inflammatory disorders. It was clinically developed for
psoriasis and ulcerative colitis, however, our recent Phase 2 data do not support further development for these indications. We believe that VB-201 may still have potential in other disorders in which TLR-2 and TLR-4 or monocytes play a role. In
this regard, in March 2015 we presented preclinical findings at a Keystone scientific conference demonstrating that VB-201 can inhibit Non-Alcoholic Steatohepatitis, or NASH, and liver fibrosis in a murine NASH model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-alcoholic fatty liver disease is the most common liver disease in the western world. This pathological condition is characterized by lipid accumulation in
hepatocytes and ranges from the non-progressive form termed steatosis to NASH, the progressive form that is prone to the development of cirrhosis, liver cancer, and liver failure. NASH is characterized by fatty liver inflammation. Several studies
have implicated TLR4 and its co-receptor CD14 in NASH and fibrosis. In addition, studies have emphasized the crucial role of infiltrating monocytes/macrophages for the progression of liver inflammation and fibrosis in experimental mouse models and
in patients with liver cirrhosis. It has become clear that the macrophage compartment of the liver, traditionally called Kupffer cells, is greatly augmented by an overwhelming number of infiltrating monocytes upon acute or chronic liver injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VB-201 inhibits the CD-14/TLR4 and TLR2 pathways as well as monocyte migration. Using an external CRO, we studied VB-201 in a mouse model of NASH and found
that while treatment with VB-201 did not reduce steatosis, it significantly decreased liver lobular inflammation and liver fibrosis compared to vehicle treated mice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beyond VB-201, we have developed second and third generations of Lecinoxoid product candidates. Our results highlight the potential of some of these
molecules, such as VB-703, a third generation candidate whose IP life-cycle can extend to the mid-2030s. In May 2015 at the DDW conference, we presented that VB-703 inhibits liver fibrosis by blocking TLR4 signaling pathways. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recent preclinical studies which we performed also demonstrate efficacy of VB-201 and VB-703 in a rat model of
renal fibrosis. Renal fibrosis is a direct consequence of the kidney&#146;s limited capacity to regenerate after injury. Renal scarring results in a progressive loss of renal function, ultimately leading to end-stage renal failure and a requirement
for dialysis or kidney transplantation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead Lecinoxoid molecule, VB-201, is a Phase-2 ready oral molecule which has demonstrated safety in
&gt;&nbsp;600 patients and proof-of-concept in a Phase 2 study for vascular inflammation. Our next-generation molecule VB-703, offers long IP lifecycle with demonstrated efficacy in liver and renal fibrosis models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the status of the Lecinoxoid platform: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g160947g56q48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that Lecinoxoids have therapeutic potential in disorders in which TLR-2 and TLR-4 or monocytes play a role, such
as atherosclerosis, NASH/Liver fibrosis and renal fibrosis. In spite of that potential, we have decided strategically to focus our efforts and resources on development of novel anti-cancer therapies, such as VB-111, and therefore we intend to seek
strategic partner/s that would promote development of our Lecinoxoid assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expanding our Oncology Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to continue RnD activities in the oncology field to strengthen the pipeline of our anti-cancer drug candidates. In this regard, we believe that we
have identified a novel tumor-specific target that may be used as a marker for specific targeting of several types of tumors. We intend to continue pre-clinical development of potential therapies leveraging this novel target, while securing our
intellectual property around this undisclosed target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends, at least in part, on our ability to protect our proprietary technology and intellectual property, and to operate without infringing or
violating the proprietary rights of others. We rely on a combination of patent, trademark, trade secret and copyright laws, know- how, intellectual property licenses and other contractual rights, including confidentiality and invention assignment
agreements to protect our intellectual property rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;22, 2016, we had 143 granted patents and 65 applications pending worldwide for our oncology program and VTS platform technology and 122
granted patents and 70 patent applications pending worldwide for our anti-inflammatory program and Lecinoxoid family of compounds. Our lead VTS asset, VB-111, is covered by US granted patent extending to 2033 before any extensions. Our lead
Lecinoxoid, VB-201, is protected by US granted composition-of-matter patent extending to 2027 before any extensions. In addition, we have pending patent applications covering use of VB-201, VB-703 and additional Lecinoxoid for NASH and fibrosis
indications that may extend, if granted, to the 2030s. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on trade names, trademarks and service marks to protect our name brands. Our registered trademarks in several countries include the following:
&#147;VTS,&#148; &#147;VASCULAR TARGETING SYSTEMS,&#148; &#147;VBL,&#148; &#147;VASCULAR BIOGENICS&#148; and &#147;VASCULAR THERAPEUTICS.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets and Confidential Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patented technology, we rely on our unpatented proprietary technology, trade secrets, processes and know-how. We rely on, among other things,
confidentiality and invention assignment agreements to protect our proprietary know-how and other intellectual property that may not be patentable, or that we believe is best protected by means that do not require public disclosure. For example, we
require our employees to execute confidentiality agreements in connection with their employment relationships with us, and to disclose and assign to us inventions conceived in connection with their services to us. However, there can be no assurance
that these agreements will be enforceable or that they will provide us with adequate protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be unable to obtain, maintain and protect the
intellectual property rights necessary to conduct our business, and may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For a more comprehensive summary
of the risks related to our intellectual property, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet established sales, marketing or product distribution operations because our lead candidates are still in early clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally perform process development
for our drug substance candidates and manufacture quantities of our drug candidates necessary to conduct pre-clinical studies and clinical trials of our drug candidates. We rely on third-party manufacturers to produce bulk drug substance required
for our clinical trials and expect to continue to rely on third parties to manufacture clinical trial drug supplies for the foreseeable future. We also contract with additional third parties for the formulating, labeling, packaging, storage and
distribution of the final drug products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>VB-111 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We manufacture the active pharmaceutical ingredient and the formulated drug product of VB-111 for the clinical development at our small-scale cGMP-compliant
production facility in Israel and pursuant to an arrangement with a third party in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to obtaining additional financing, we
intend to establish a facility to manufacture VB-111 in Israel, which would serve as a second manufacturing site for the supply of VB-111 and enable us to comply with the restrictions of the Research Law and our undertaking to the OCS that an
essential portion of our VB-111 production, and in any event not less than the majority of VB-111 production, will remain in Israel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2016, we employed 27 employees, including 21 in research and development, and 6 in general and administrative positions, and of
which 11 employees have either MDs or PhDs. All of our employees are located in Israel. We believe our employee relations are good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli labor laws
govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and anti-
discrimination laws and other conditions of employment. Subject to specified exceptions, Israeli law generally requires severance pay upon the retirement, death or dismissal of an employee, and requires us and our employees to make payments to the
National Insurance Institute, which is similar to the U.S. Social Security Administration. Our employees have defined benefit pension plans that comply with the applicable Israeli legal requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our employees currently work under any collective bargaining agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate headquarters and research facilities are located in Or Yehuda, Israel, where we lease an aggregate of approximately 9,000 square feet of office
and laboratory space, pursuant to lease agreements that expire in October 2017. This facility additionally houses our clinical development, clinical operations, regulatory and management functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our existing facilities are adequate for our near-term needs. When our leases expire, we may exercise our renewal option or look for
additional or alternate space for our operations. We believe that suitable additional or alternative space would be available if required in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Organizational Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any
subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not a party
to any legal proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_6"></A>Item&nbsp;4A. Unresolved Staff Comments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_7"></A>Item&nbsp;5.
Operating and Financial Review and Prospects </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion of our financial condition and results of operations should
be read in conjunction with &#147;Item 3. Key Information&#151;Selected Financial Data&#148; and our financial statements and the related notes to those statements included elsewhere in this Annual Report. In addition to historical financial
information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these
forward-looking statements as a result of many factors, including those discussed under &#147;Item 3. Key Information&#151;D. Risk Factors&#148; and elsewhere in this Annual Report. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The audited financial statements for the years ended December&nbsp;31, 2015, 2014 and 2013 in this Annual Report have been prepared in
accordance with IFRS as issued by the IASB. None of the financial information in this Annual Report has been prepared in accordance with U.S. GAAP. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization of first-in-class treatments for cancer. Our program is based on our proprietary Vascular Targeting System, or VTS, platform technology, which utilizes genetically targeted therapy
to destroy newly formed, or angiogenic, blood vessels, and which we believe will allow us to develop product candidates for multiple oncology indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that we are developing for solid tumor indications, with an advanced
program for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. We have obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following treatment
with standard chemotherapy and radiation. We have also received orphan drug designation in both the United States and Europe. Our pivotal Phase 3 GLOBE study in rGBM began in August 2015. The study is being conducted under a special protocol
assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA, with full endorsement by the&nbsp;Canadian Brain Tumor Consortium (CBTC) and is planned to recruit approximately 252 patients in the US, Canada and Israel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have been conducting a program targeting anti-inflammatory diseases based on the use of our Lecinoxoid
platform technology. Lecinoxoids are a novel class of small molecules we developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. As we reported in February 2015, the lead product
candidate from this program, VB-201, failed to meet the primary endpoint in Phase 2 clinical trials for psoriasis and for ulcerative colitis. As a result, we have terminated our development of VB-201 in those indications. Nevertheless, based on
recent pre-clinical studies, we believe that VB-201 and some second generation molecules such as VB-703 may be applicable for NASH and renal fibrosis. Since the Company intends to focus substantially all of our efforts and resources on advancing our
oncology program, we will seek to monetize our Lecinoxoid assets via strategic deals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing our lead oncology product candidate, VB-111, for
solid tumor indications, with current clinical programs in rGBM, thyroid cancer and ovarian cancer. In interim analyses of data from our ongoing open-label Phase 2 clinical trial of VB-111 in rGBM, we observed dose-dependent attenuation of tumor
growth and an increase in median overall survival, which is the time interval from initiation of treatment to the patient&#146;s death. The U.S. FDA has granted VB-111 fast track designation for prolongation of survival in patients with glioblastoma
that has recurred following treatment with temozolomide, a chemotherapeutic agent commonly used to treat newly diagnosed glioblastoma, and radiation. On July&nbsp;1, 2014, the FDA concurred with the design and planned analyses of our Phase 3 pivotal
trial of VB-111 in rGBM pursuant to an SPA. At the time, commencement of the trial was subject to our providing the agency with more information regarding our potency release assay for the trial. We developed this assay and submitted initial
information to the FDA on May&nbsp;26, 2014. On February&nbsp;5, 2015, the FDA found our data satisfactory and removed the partial hold. We began our Phase 3 pivotal trial of VB-111 in rGBM in August 2015. According to the study protocol, an interim
analysis will take place when 91 mortality events will occur in the trial. The timing of the interim analysis, which depends both on enrollment and on VB-111 activity, is expected in the first half of 2017. Full data will be available when 151
events will occur in the trial. Based on interactions with the FDA, we believe the current trial, if successful, will support a Biologics License Application (BLA) in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VB-111 is also being studied in a Phase 2 trial for recurrent platinum-resistant Ovarian Cancer and in a Phase 2 study in recurrent, iodine-resistant
differentiated Thyroid Cancer. An interim analysis of the ovarian cancer study showed evidence of clinical benefit, and the Thyroid Cancer study met its primary endpoint of 6 month Progression Free Survival (PFS) with disease stabilization and
safety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, we had studied VB-111 in over 170 patients and have observed it to be well-tolerated. In December 2015, we have
been granted a US composition of matter patents that provides intellectual property protection for VB-111 in the US until October 2033 before any patent term extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced operations in 2000, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital,
developing our VTS and Lecinoxoid platform technologies and developing our product candidates, including conducting pre-clinical studies and clinical trials of VB-111 and VB-201. To date, we have funded our operations through private sales of
preferred shares, a convertible loan, public offering and grants from the Israeli Office of Chief Scientist, or OCS, under the Israel Encouragement of Research and Development in Industry, or the Research Law. We have no products that have received
regulatory approval and accordingly have never generated revenue. Since our inception and through December&nbsp;31, 2015, we had raised an aggregate of $187.0 million to fund our operations, of which $113.4 million was from sales of our equity
securities, $40.5 from our initial public offering, or IPO, $15 million from a November&nbsp;3, 2015 underwritten offering, and $18.1 million from OCS grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred significant losses. For the years ended December&nbsp;31, 2015, 2014 and 2013, our loss was $14.9 million, $17.4 million,
and $17.4 million, respectively. We expect to continue to incur significant expenses and losses for at least the next several years. As of December&nbsp;31, 2015, we had an accumulated deficit of $142.0 million. Our losses may fluctuate
significantly from quarter to quarter and year to year, depending on the timing of our clinical trials, the receipt of payments under any future collaborations we may enter into, and our expenditures on other research and development activities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, we had cash, cash equivalents and short-term bank deposits of $37.1 million. To
fund further operations, we will need to raise additional capital. The Company may seek to raise more capital to pursue additional activities. The Company may seek these funds through a combination of private and public equity offerings, government
grants, strategic collaborations and licensing arrangements. Additional financing may not be available when the Company specifically needs it or may not be available on terms that are favorable to the Company. As of February&nbsp;1, 2016, we had 27
employees. Our operations are located in a single facility in Or Yehuda, Israel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not generated any
revenue. We do not expect to receive any revenue from any product candidates that we develop unless and until we obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses consist of costs incurred for the development of both of our platform technologies and our product candidates. Those expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">employee-related expenses, including salaries and share-based compensation expenses for employees in research and development functions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred in operating our laboratories and small-scale manufacturing facility; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses relating to outsourced and contracted services, such as external laboratories, consulting and advisory services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">supply, development and manufacturing costs relating to clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintenance of facilities, depreciation and other expenses, which include direct and allocated expenses for rent and insurance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs associated with pre-clinical and clinical activities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development activities are the
primary focus of our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage
clinical trials. Our research and development expenses may increase in absolute dollars in future periods as we continue to invest in research and development activities related to the development of our platform technologies and product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are recognized as incurred. An intangible asset arising from the development of our product candidates is recognized if certain
capitalization conditions are met. As of December&nbsp;31, 2015, we did not have any capitalized development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain development
activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and clinical sites. Nonrefundable advance payments for goods or services to be received in
future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and the services are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received grants from the OCS as part of the research and development programs for our VTS and Lecinoxoid platform technologies. The requirements and
restrictions for such grants are found in the Research Law. These grants are subject to repayment through future royalty payments on any products resulting from these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development programs, including VB-111 and VB-201. Under the Research Law, royalties of 3% to 3.5% on the revenues derived from sales of products or services developed in whole or in
part using these OCS grants are payable to the Israeli government. The maximum aggregate royalties paid generally cannot exceed 100% of the grants made to us, plus annual interest generally equal to the 12-month LIBOR applicable to dollar deposits,
as published on the first business day of each calendar year. The total gross amount of grants actually received by us from the OCS, including accrued LIBOR interest as of December&nbsp;31, 2015 and 2014, totaled $21.7 million and $19.2 million,
respectively. As of December&nbsp;31, 2015, we had not paid any royalties to the OCS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Research Law is targeted at maintaining the intellectual
property and manufacturing rights relating to OCS-funded projects in Israel. Under certain circumstances, where the above is not followed, the royalty rate might be higher and accordingly calculated to a formula based on the ratio of the
participation by the State in the project to the total project costs incurred us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to paying any royalty due, we must abide by other
restrictions associated with receiving such grants under the Research Law that continue to apply following repayment to the OCS. These restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or
otherwise transfer our know-how outside of Israel, and may require us to obtain the approval of the OCS for certain actions and transactions and pay additional royalties and other amounts to the OCS. In addition, any change of control and any change
of ownership of our ordinary shares that would make a non-Israeli citizen or resident an &#147;interested party,&#148; as defined in the Research Law, requires prior written notice to the OCS. If we fail to comply with the Research Law, we may be
subject to criminal charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable accounting rules, the grants from the OCS have been accounted for as an off-set against the related
research and development expenses in our financial statements. As a result, our research and development expenses are shown on our financial statements net of the OCS grants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist principally of salaries and related costs for personnel in executive and finance functions such as salaries, benefits and share-based compensation. Other general and administrative expenses include facility costs not
otherwise included in research and development expenses, communication expenses, and professional fees for legal services, patent counseling and portfolio maintenance, consulting, auditing and accounting services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Expenses (Income), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial income
is comprised of interest income generated from interest earned on our cash, cash equivalents and short-term bank deposits and gains and losses due to fluctuations in foreign currency exchange rates mainly in the appreciation and depreciation of the
NIS exchange rate against the U.S. dollar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial expenses primarily consist of fluctuations in foreign currency exchange rates and gains and losses
resulting from the re-measurement of our convertible loan liability between July 2013 and May 2014. We continued to record adjustments to the estimated fair value of the convertible loan liability until it was converted into our Series E preferred
shares in May 2014, after which we no longer record any related periodic fair value adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxes on Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated taxable income since our inception, and had carry forward tax losses as of December&nbsp;31, 2015 of $121.0 million. We anticipate that
we will be able to carry forward these tax losses indefinitely to future tax years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize deferred tax assets on losses for tax purposes carried forward to subsequent years if utilization of
the related tax benefit against a future taxable income is expected. We have not created deferred taxes on our tax loss carry forward since their utilization is not expected in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with IFRS. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the
date of the financial statements, as well as the reported expenses incurred during the reporting periods. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future
events that are believed to be reasonable under the circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We make estimates and assumptions concerning the future. The resulting accounting
estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are
discussed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
operate a number of equity-settled, share-based compensation plans for employees (as defined in IFRS 2 &#147;Share-Based Payments&#148;), directors and service providers. As part of the plans, we grant employees, directors and service providers,
from time to time and at our discretion, options to purchase our ordinary shares. The fair value of the services received in exchange for the grant of the options is recognized as an expense in our statements of comprehensive loss and is carried to
additional paid in capital in our statements of financial position. The total amount is recognized as an expense ratably over the vesting period of the options, which is the period during which all vesting conditions are expected to be met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate the fair value of our share-based awards to employees, directors and service providers using the Black-Scholes option pricing model, which
requires the input of highly subjective assumptions, including (a)&nbsp;the expected volatility of our shares, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate, and (d)&nbsp;expected dividends. Due to the lack of a
public market for the trading of our shares until October 2014 and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historic volatility of a group of similar companies that
are publicly traded. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own share price becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from the
estimates. Vesting conditions are included in assumptions about the number of options that are expected to vest. At the end of each reporting period, we revise our estimates of the number of options that are expected to vest based on the nonmarket
vesting conditions. We recognize the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to additional paid in capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted average assumptions we have used in our Black-Scholes calculations for the years ended December&nbsp;31, 2015,
2014 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2015&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2014&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee share options:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of our share compensation expense: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The decrease in share-based compensation expense by $1,576 thousand to $1,041 thousand in 2015 is mainly due to additional
options granted to the Chief Executive Officer Prof. Dror Harats of $2,249 thousand in 2014, offset by an increase in stock based compensation expenses granted and recognized in 2015 mainly to two external directors of the Company and new options
granted to the employees and officers of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Loan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2013, we closed a Convertible Bridge Loan Agreement, or the CLA, with some of our shareholders and related parties. The CLA provided for the
infusion of an aggregate amount of $10.0&nbsp;million in the form of a convertible bridge loan, or the Convertible Loan, to bridge our cash needs until a financing opportunity is achieved. The Convertible Loan was denominated in U.S. dollars and
bore an annual interest rate of 10%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2014, or the Conversion Date, the Convertible Loan was converted into 1,082,235 Preferred E Shares.
Following such conversion, the entire balance of the Convertible Loan was reflected in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change in the fair value from January&nbsp;1, 2014
until the Conversion Date and from July&nbsp;1, 2013 to December&nbsp;31, 2013 amounting to $2.3 million and $1.6 million, respectively, were charged to financial expenses in the statement of comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended
December&nbsp;31, 2015, 2014 and 2013 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended <BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015 Increase <BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014 Increase <BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;%&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expense (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development expenses, net</I>.&nbsp;Research and development expenses are shown net of OCS grants. Research
and development expenses for the year ended December&nbsp;31, 2015 were $11.2 million, compared to $11.0 million for the year ended December&nbsp;31, 2014 and $13.5 million for the year ended December&nbsp;31, 2013, an increase of $0.2 million or 2%
and a decrease of $2.5 million, or 19%, respectively. The increase in research and development expenses in 2015 was mainly due to increased expenses for the VB-111 subcontractors and consultants in 2015 of $3.6 million as the Phase 3 pivotal trial
of VB-111 in rGBM commenced in August 2015, offset by lower expenses for VB-201 and Psoriasis subcontractors and consultants of $2.8 million in 2015 as the clinical trials were completed by 2014 and payroll related expenses of $0.6 million due to an
overall reduction of share based compensation expense and favorable currency exchange rates. The decrease in research and development expenses in 2014 was largely due to a $1.0&nbsp;million increase in the amounts of OCS grants received
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in 2014 in support of the Company&#146;s Lecinoxoid project, which totaled $1.6 million as compared to $0.6 million received in 2013, a reduction in VB-111 clinical expenses of $0.5 million,
lower expenses in VB-111 manufacturing process scale-up development of $0.8 million (the project was completed), and savings of other development expenses that amounted to $0.4 million offset by an increase in VB-201 clinical expenses of
$0.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and administrative expenses. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the year ended December&nbsp;31, 2015 was $3.7 million, compared to $3.8&nbsp;million for the year ended
December&nbsp;31, 2014 and $2.5 million for the year ended December&nbsp;31, 2013, a decrease of $130 thousand or 3%, and an increase of $1.3 million or 55%, respectively. The decrease in 2015 is related to the share-based compensation of $1.7
million for options granted to the Chief Executive Officer Prof. Dror Harats in 2014, offset by an increase to share-based compensation expense for options granted to 2 external directors of the Company and additional costs associated with being a
public company such as increased legal, insurance, investor and public relations, accounting and compliance fees for a total of $1.6 million. The increase in 2014 was attributed to payroll related costs associated with the share-based compensation
expense for additional options granted to the Chief Executive Officer Prof. Dror Harats of $1.7 million, offset by bonuses and other payroll related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial expense (income), net.&nbsp;</I>Financial expense (income), net for the year ended December&nbsp;31, 2015 was $17&nbsp;thousand, compared to $2.6
million for the year ended December&nbsp;31, 2014, and $1.4 million for the year ended December&nbsp;31, 2013, a decrease of $2.6 million or 99%, and an increase of $1.2 million or 86%, respectively. The decrease in 2015 was primarily attributable
to the change in the fair value of the convertible loan in 2014 with no additional impact 2015 since its conversion to Preferred E Shares on May&nbsp;15, 2014, and the increase in 2014 was primarily attributable to the change in the fair value of
the convertible loan since its closing on July&nbsp;1, 2013 and its conversion to Preferred E Shares on May&nbsp;15, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital
Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception and through December&nbsp;31, 2014, we have raised a total of $113.4 million from sales of our equity securities before
the initial public offering, $40.5 million gross in the public offering ($34.9 million net) and $18.1 million from OCS grants. Our primary uses of cash have been to fund working capital requirements and research and development, and we expect these
will continue to represent our primary uses of cash. On November&nbsp;6, 2015, the Company closed on an underwritten offering with gross proceeds to the Company of $15.0 million ($13.6 million net after deducting the underwriting discounts and
commissions and offering expenses payable by the Company). The Company intends to use the proceeds from the offering to advance clinical programs, working capital, and other general corporate purposes, and expects that such proceeds, together with
its cash, cash equivalents and short-term bank deposits as of December&nbsp;31, 2015 would provide sufficient funding for its operations for approximately 30 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2015,
we had cash, cash equivalents and short-term bank deposits of $37.1 million and working capital of $34.4 million. We expect that our cash and cash equivalents and short-term bank deposits will enable us to fund our operating expenses and capital
expenditure requirements for approximately 30 months and is expected to be sufficient to enable us to complete our on-going Phase 3 clinical trial of VB-111 in rGBM, to complete our Phase 2 clinical trial of VB-111 in thyroid cancer and to complete
our Phase 1/2 clinical trial for VB-111 in ovarian cancer. We are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of VB-111 and our other product candidates. Our future
capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of regulatory review of VB-111 and any other product candidates we may pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of future development activities, including clinical trials, for VB-111 and any other product candidates we may pursue; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or in-license other products and technologies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish any future collaboration arrangements on favorable terms, if at all. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such
time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any
committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as a holder of our ordinary shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit,
reduce or terminate our product development or future commercialization efforts or grant rights to develop and market <FONT STYLE="white-space:nowrap">VB-111</FONT> and any other product candidates that we would otherwise prefer to develop and
market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table sets forth the primary sources and uses of cash for each of the periods set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for December&nbsp;31, 2015 was $13.2 million and consisted of primarily net loss of $14.9 million arising primarily from
research and development activities, partially offset by a net reduction of working capital of $0.5 million and net aggregate non-cash charges of $1.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&nbsp;31, 2014 was $13.7 million and consisted primarily of net loss of $17.4 million arising
primarily from research and development activities in addition to net increase in working capital of $1.8 million, partially offset by net aggregate non-cash charges of $5.5 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating activities for the year ended December&nbsp;31, 2013 was $13.1 million and consisted primarily of net loss of $17.4 million arising
primarily from research and development activities, partially offset by net aggregate non-cash charges of $2.2 million and a net reduction of working capital of $2.0 million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing
activities was $30.1 million for the year ended December&nbsp;31, 2015. This was primarily due to the purchases of short-term bank deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash
provided by investing activities was $1.4 million for the year ended December&nbsp;31, 2014. This was primarily due to maturation of short-term bank deposits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities was $6.5 million for the year ended December&nbsp;31, 2013. This was
primarily due to maturation of short-term bank deposits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $13.7 million for the year ended December&nbsp;31, 2015 was the result of the net receipt of $13.6 million from
the issuance of ordinary shares per the closing of the November&nbsp;6, 2015 underwritten offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities of $40.1
million for the year ended December&nbsp;31, 2014 was the result of the net receipt of $34.9 million from issuance of ordinary shares in our IPO, and the receipt of $4.9 million from the issuance of preferred E shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&nbsp;31, 2013 was the result of the receipt of $10.0 million from the convertible loan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following tables summarize our contractual obligations and commitments as of December&nbsp;31, 2015 that will affect our future liquidity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less <BR>than&nbsp;1<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3 <BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5 <BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More <BR>than&nbsp;5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have obligations to make future payments to third parties that become due and payable on the achievement of certain
development, regulatory and commercial milestones, such as the start of a clinical trial, filing of an NDA, approval by the FDA or product launch, or royalties upon sale of products. We have not included these commitments on our statement of
financial position or in the table above because the achievement and timing of these milestones is not fixed and determinable. These potential future commitments include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Agreement with the Contact Research Organization (&#147;CRO&#148;). </I>In January 2015, the Company entered into an agreement with a CRO according to which it will receive project management, clinical development
and other related services from the CRO for the execution of the Phase 3 rGBM clinical trial study in consideration for up to $18.7 million. Through December&nbsp;31, 2015, expenses in the total amount of $3.6 million were incurred.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Agreement with Tel Hashomer.</I>&nbsp;On February&nbsp;3, 2013, we entered into an agreement with Tel
Hashomer&#151;Medical Research, Infrastructure and Services Ltd., or Tel Hashomer, a private company whose purpose is to promote the welfare of the Sheba Medical Center, or the Hospital, and Prof. Dror Harats, our chief executive officer. The
agreement with Tel Hashomer resolved claims of the Hospital regarding the ownership of certain inventions and patent rights owned by us and developed in part by Prof. Harats and other inventors who were engaged by us and by the Hospital in parallel.
The agreement provided us with a waiver of rights by the Hospital and Tel Hashomer in connection with intellectual property developed by these inventors prior to the date of the agreement. In consideration for the waiver, we undertook to pay 1% of
any net sales of any product covered by the intellectual property covered under the agreement, which includes all of our current product candidates, and 2% of any consideration that we receive for granting a license or similar rights to this
intellectual property. Such amounts will be recorded as part of our cost of revenues. In addition, upon the occurrence of an exit event such as a merger, sale of all shares or assets or the closing of an initial public offering, we are required to
pay to Tel Hashomer 1% of the proceeds received by us or our shareholders as the case may be. In November 2014, following the completion of our IPO, we paid to Tel Hashomer the amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
of $0.4 million. Royalty and all other payment obligations under this agreement will expire once we have paid an aggregate sum of NIS 100&nbsp;million (approximately $26 million) to Tel Hashomer
by way of pay out, exit proceeds and licensing consideration. Amounts previously paid as royalties on any net sales will not be taken into account when calculating this aggregate sum. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Agreement with Crucell.</I>&nbsp;On April&nbsp;15, 2011, we entered into a Commercial License Agreement with Crucell Holland B.V., or Crucell, for incorporating the adenovirus 5 in VB- 111 and other drug candidates
for cancer for consideration including the following potential future payments: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual license fee of &#128;100,000 ($109,000), continuing until the termination of the agreement, which will occur upon (i)&nbsp;the later of the expiration date of the last related patent or 10 years from the first
commercial sale of VB-111 or (ii)&nbsp;the termination of the agreement by us, which is permitted, upon three months&#146; written advance notice to Crucell; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a milestone payment of &#128;400,000 ($436,000) upon receipt of the first regulatory approval for the marketing of the first indication for each product covered under the agreement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">royalties of 0.5%-2.0% on net sales </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no limits or caps on the amount of potential royalties.
Pursuant to the agreement, the Company has the right to terminate the agreement by giving Crucell three months&#146; written notice. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Participation by the OCS.</I>&nbsp;We receive grants from the OCS, as part of the oncology and anti-inflammatory research and development programs. The requirements and restrictions for such grants are set forth in
the Research Law. These grants are subject to repayment through future royalty payments on sales of any products resulting from these research and development programs, including VB-111 and VB-201. Under the Research Law, we are obligated to pay
royalties of 3% to 3.5%. The maximum aggregate royalties paid generally cannot exceed 100% of the grants made to us, plus annual interest generally equal to the 12-month LIBOR applicable to dollar deposits, as published on the first business day of
each calendar year. The total gross amount of grants actually received by us from the OCS as of December&nbsp;31, 2015 totaled approximately $18.1 million, and the balance of the principal and interest in respect of our commitments for future
payments to the OCS totaled approximately $21.7&nbsp;million. As of December&nbsp;31, 2015, we had not paid any royalties to the OCS. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Off-Balance Sheet Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our
inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance
or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our statement of financial positions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of
IFRS 9 was issued in July 2014. It replaces the guidance in IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement
categories for financial assets: amortized cost, fair value through OCI and fair value through P&amp;L. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities, there
were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income for liabilities designated at fair value through profit or loss. The standard is effective for accounting
periods beginning on or after January&nbsp;1, 2018. Early adoption is permitted. We have yet to assess IFRS 9&#146;s full impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the
IASB issued IFRS 16&#151;Leases which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract and replaces the previous leases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standard, IAS 17&#151;Leases. IFRS 16 eliminates the classification of leases for the lessee as either operating leases or finance leases as required by IAS 17 and instead introduces a single
lessee accounting model whereby a lessee is required to recognize assets and liabilities for all leases with a term that is greater than 12 months, unless the underlying asset is of low value, and to recognize depreciation of leases assets
separately from interest on lease liabilities in the income statement. As IFRS 16 substantially carries forward the lessor accounting requirements in IAS 17, a lessor will continue to classify its leases as operating leases or finance leases and to
account for those two types of leases differently. IFRS 16 is effective from January&nbsp;1, 2019 with early adoption allowed only if IFRS 15&#151;Revenue from Contracts with Customers is also applied. The Company is currently evaluating the impact
of adoption on its Financial Statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for
an &#147;emerging growth company.&#148; As an &#147;emerging growth company,&#148; we are electing to not take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards, and as
a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Section&nbsp;107 of the JOBS Act provides that our decision to not take
advantage of the extended transition period for complying with new or revised accounting standards is irrevocable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Cautionary Note Regarding Forward-Looking Statements&#148; in the introduction to this Annual Report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_8"></A>Item&nbsp;6. Directors, Senior Management and Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets
forth certain information relating to our executive officers and directors, including their ages as of February&nbsp;1, 2016. Unless otherwise stated, the address for our directors and executive officers is c/o Vascular Biogenics Ltd., 6 Jonathan
Netanyahu St. Or Yehuda, Israel. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers and Director</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dror Harats</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amos Ron</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erez Feige</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Business Operations</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yael Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Clinical Development</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eyal Breitbart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Research and Operations</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Naamit Sher</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Drug Development</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ayelet Horn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel and Company Secretary</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Non-Executive Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bennett M. Shapiro (3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ruth Arnon (3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jide J. Zeitlin (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jecheskiel Gonczarowski (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dan J. Gelvan (2)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ruth Alon (3)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ron Cohen (1)(2)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip A. Serlin (1)(2)(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Independent director under the rules of the NASDAQ Stock Market. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prof. Dror Harats</I> founded our company in 2000 and has served as our chief executive officer since our inception. He has been a member of our board of
directors since January 2001. Prof. Harats is the Chairman of the Bert W. Strassburger Lipid Center at the Chaim Sheba Medical Center at Tel Hashomer and chairman of its Institute Review Board. Prof. Harats received his M.D. from Hadassah Medical
School at the Hebrew University of Jerusalem, Israel, following which he conducted post-doctoral work at the University of California, San Francisco. Prof. Harats is also a Professor of Medicine in the Departments of Internal Medicine and
Biochemistry at the Sackler Faculty of Medicine of Tel-Aviv University, Israel. Prof. Harats has also served as a visiting scientist at Syntax Discovery Research. Prof. Harats currently serves as an observer on the board of directors of Art
Healthcare Ltd. We believe Prof. Harats is qualified to serve on our board of directors because of his extensive technical and industry experience, as well as his knowledge of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amos Ron</I> has served as our chief financial officer since May 2011. Prior to joining our company, from July 2008 to April 2011, Mr.&nbsp;Ron was the
chief financial officer of Atlantium Technologies Ltd., a privately held start-up in the field of clean-tech. Prior to that, Mr.&nbsp;Ron served as the chief financial officer and chief operating officer of Medical Compression Systems, and prior to
that, Mr.&nbsp;Ron served as the chief financial officer of Interpharm Laboratories Group, a wholly owned subsidiary of Serono S.A. Mr.&nbsp;Ron holds an M.Sc. (Honors) in Chemical Technology Management from the Hebrew University of Jerusalem, a
B.Sc. in Business Administration, Empire State College (SUNY) (Jerusalem Branch) and a B.Sc. in Chemistry from the Hebrew University of Jerusalem. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Erez Feige</I> has served as our vice president of business operations since January 2014. Prior to that, from 2012 to 2014, Dr.&nbsp;Feige served
as our director of business development and, from 2006 to 2012, Dr.&nbsp;Feige served as our head of biochemistry. Dr.&nbsp;Feige holds a B.Sc., and M.B.A. and a Ph.D. from Bar-Ilan University, Israel and completed a post-doctoral fellowship at the
Dana- Farber Cancer Institute and Harvard Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Yael Cohen</I> has served as our vice president of clinical development since 2008.
Prior to joining our company, Dr.&nbsp;Cohen served in various positions in Gamida Cell Ltd., Merck&nbsp;&amp; Co. and Merck Research Labs, from 2000 to 2008. Dr.&nbsp;Cohen holds an M.D. from the Sackler Medical School at Tel Aviv University,
Israel, and completed her residency in internal medicine at the Chaim Sheba Medical Center at Tel Hashomer, Israel, and a fellowship in hematology at the Rabin Medical Center, Petach Tikva, Israel. Dr.&nbsp;Cohen is a senior physician at the
Hematology Department at the Sourasky Medical Center, Tel Aviv, Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Eyal Breitbart</I> has served as our vice president, research and
operations since January 2014. Prior to that, from 2006 to 2013, Dr.&nbsp;Breitbart served as our vice president, research. Prior to that, Dr.&nbsp;Breitbart served as head of research from 2002 to 2006 and prior to that as project manager from 2001
to 2002. Dr.&nbsp;Breitbart holds a B.Sc., M.Sc. and Ph.D. from Bar-Ilan University, Israel, and completed a post-doctoral fellowship at Tufts University School of Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Naamit Sher</I> has served as our vice president of drug development and regulatory affairs since 2006. Prior to joining our company, from 2005 to
2006, Dr.&nbsp;Sher was head of QC laboratories, operations division at Teva Pharmaceutical Industries Ltd. From 1992 to 2005, Dr.&nbsp;Sher acted as quality control/quality assurance director at InterPharm, a subsidiary of Ares- Serono.
Dr.&nbsp;Sher holds a B.Sc., M.Sc. and Ph.D. from the Hebrew University of Jerusalem, Israel. She completed post-doctoral fellowships at each of the Hebrew University, Jerusalem, Israel, and Rutgers University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adv. Ayelet Horn</I> has served as our general counsel since our inception in 2000, and has served as our company secretary since 2007. Adv. Horn holds an
LL.B from Tel-Aviv University, Israel, and an M.B.A. from Herriot Watt University, Edinburgh, Scotland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Bennett&nbsp;M. Shapiro, M.D.</I>&nbsp;has served on our board of directors since September 2004 and as Chairman since 2007. In addition to serving
on our board of directors, Dr.&nbsp;Shapiro has been a senior partner at Puretech Ventures, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an innovation enterprise, since 2004, and as chairman from 2009-2015; he now continues as a Non-Executive Director of PureTech HealthPLC-PRTC. From 1990 to 2003, Dr.&nbsp;Shapiro served as
executive vice president, Merck Research Laboratories. Prior to that, from 1970 to 1990, Dr.&nbsp;Shapiro was a professor of the Department of Biochemistry at the University of Washington and served as chairman from 1985 to 1990. Prior to joining
the University of Washington, from 1965 to 1970 Dr.&nbsp;Shapiro served as a research associate, then section head, in the Laboratory of Biochemistry of the National Heart Institute of the U.S. National Institutes of Health. Dr.&nbsp;Shapiro also
currently serves as an external director on the board of directors of Momenta Pharmaceuticals, various private companies and the Drugs for Neglected Diseases Initiative, an independent, non-profit drug development partnership. Dr.&nbsp;Shapiro
previously served on the board of directors of Celera Corporation prior to its acquisition by Quest Diagnostics Inc. Dr.&nbsp;Shapiro received his B.S. in chemistry from Dickinson College and his M.D. from Jefferson Medical College. Dr.&nbsp;Shapiro
has been a Guggenheim Fellow, a fellow of the Japan Society for the Promotion of Science and a visiting professor at the University of Nice. We believe Dr.&nbsp;Shapiro is qualified to serve on our board of directors because of his extensive
technical and industry background, and his experience serving on boards of directors of companies in our industry, including public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prof.
Ruth Arnon</I>&nbsp;has served on our board of directors since August 2007. Prof. Arnon is an immunologist with the Weizmann Institute of Science in Israel. Prof. Arnon joined the staff of the Weizmann Institute in 1960, and served as vice president
of the Institute from 1988 to 1997. Prof. Arnon is a member of the Israel Academy of Sciences, and from&nbsp;2010 until 2015 served as its president. Prof. Arnon is also an elected member of the European Molecular Biology Organization. She has
served as president of the European Federation of Immunological Societies, and as secretary-general of the International Union of Immunological Societies. Her awards and honors include the Robert Koch Prize in Medical Sciences, Spain&#146;s Jimenez
Diaz Memorial Award, France&#146;s Legion of Honor, the Hadassah World Organization&#146;s Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology, and the Israel Prize. Prof. Arnon earned her M.Sc. in Chemistry
from the Hebrew University, Jerusalem, Israel, and her Ph.D. from the Hebrew University. We believe Prof. Arnon is qualified to serve on our board of directors because of her extensive technical and industry background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jide J. Zeitlin</I> has served on our board of directors since March 2008. Mr.&nbsp;Zeitlin is the president of The Keffi Group Ltd., an investment firm.
Mr.&nbsp;Zeitlin is also Chairman of Coach, Inc., a designer and marketer of premium handbags and accessories. Prior to 2006, Mr.&nbsp;Zeitlin was a partner at the Goldman Sachs Group, Inc., where he held senior management positions in the
investment banking division, including that of global chief operating officer. He also served in the firm&#146;s executive office. Mr.&nbsp;Zeitlin is Chairman Emeritus of Amherst College. He is Chairman of the Investment Committee of the Nigeria
Sovereign Investment Authority and is, or has been, a member of the boards of Affiliated Managers Group, Inc., Milton Academy, the Harvard Business School Board of Dean&#146;s Advisors, Teach for America, Doris Duke Charitable Foundation, Montefiore
Medical Center, Playwrights Horizons, Saint Ann&#146;s School, and Common Ground Community. Mr.&nbsp;Zeitlin holds an A.B. degree<I>, magna cum laude</I>, in Economics and English from Amherst College and an M.B.A. from Harvard University. We
believe Mr.&nbsp;Zeitlin is qualified to serve on our board of directors because of his broad business and investment background and service on boards of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jecheskiel Gonczarowski</I> has served on our board of directors since March 2001. Since 2010, Mr.&nbsp;Gonczarowski has served as the chairman and chief
executive officer of D.S.N.I. Investments Ltd., an Israeli based private family office, managing various local and international investments. Prior to that, Mr.&nbsp;Gonczarowski founded and co-managed Getter Group Ltd, a publicly traded company in
Israel specializing in exclusive representation of leading international suppliers and brands, from 1982 to 2010. Mr.&nbsp;Gonczarowski also served on the board of directors of Rotshtein Realestate Ltd., a publicly traded company in Israel
performing private and public construction in Israel. Mr.&nbsp;Gonczarowski studied economics, mathematics and business administration at the Hebrew University of Jerusalem, Israel. We believe Mr.&nbsp;Gonczarowski is qualified to serve on our board
of directors because of his broad business background and experience with public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Dan&nbsp;J. Gelvan</I> has served on our board of
directors since July 2005. Since 2005, Dr.&nbsp;Gelvan has served as the managing director-life sciences of Aurum Ventures M.K.I Ltd. Before joining Aurum Ventures, Dr.&nbsp;Gelvan was the chief executive and president of GammaCan International,
Inc., a development-stage pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, from 2004 to 2005. From 2004 to 2008, Dr.&nbsp;Gelvan served as a member of the Israel National Committee on Biotechnology and, from 1997 to 2004, Dr.&nbsp;Gelvan served as the chief
executive officer and president of Zetiq Technologies. From 1995 to 1997, Dr.&nbsp;Gelvan held a senior position in Clal (Israel) Ltd., an investment firm. Dr.&nbsp;Gelvan holds a B.A. and an M.A. in Economics from the Hebrew University of
Jerusalem, Israel and a Ph.D. in Business Economics from Roskilde University in Denmark. We believe Dr.&nbsp;Gelvan is qualified to serve on our board of directors because of his business and industry background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ruth Alon</I> has served on our board of directors since March 2010. Since 1997, Ms.&nbsp;Alon has served as a general partner in Pitango Venture Capital.
Prior to her tenure at Pitango, Ms.&nbsp;Alon held senior positions with Montgomery Securities from 1981 to 1987, Genesis Securities, LLC from 1993 to 1996, and Kidder Peabody&nbsp;&amp; Co. from 1987 to 1993, and managed her own independent
consulting business in San Francisco in the medical devices industry from 1995 to 1996. Ms.&nbsp;Alon is the chairperson of Israel Life Science Industry, a not-for-profit organization representing the mutual goals of approximately 700 Israeli life
science companies. Ms.&nbsp;Alon has a B.A. in Economics from the Hebrew University of Jerusalem, Israel, an M.B.A. from Boston University, and an M.S. from the Columbia University School of Physicians and Surgeons. We believe Ms.&nbsp;Alon is
qualified to serve on our board of directors because of her extensive business and industry background, as well as her experience as a seasoned investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Ron Cohen, M.D</I>.&nbsp;joined our board in February 2015. In addition to serving on our board of directors, Dr.&nbsp;Cohen has served as
President, Chief Executive Officer and founder of Acorda Therapeutics, Inc., since 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ
tissues for transplantation, from 1986 to 1992. Dr.&nbsp;Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians&nbsp;&amp; Surgeons. He completed his residency in Internal
Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr.&nbsp;Cohen is Chair of the Board of the Biotechnology Innovation Organization (BIO). He previously served as Director and Chair of the New York
Biotechnology Association. He&nbsp;is a recipient of the NY CEO Lifetime Achievement Award and the Ernst&nbsp;&amp; Young Entrepreneur of the Year Award for the New York Metropolitan Region, and has been recognized by PharmaVOICE Magazine as one of
the 100 Most Inspirational People in the Biopharmaceutical Industry.&nbsp;We believe Dr.&nbsp;Cohen is qualified to serve on our board of directors because of his extensive business and industry background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Philip A. Serlin</I> joined our board in February 2015. In addition to serving on our board of directors, Mr.&nbsp;Serlin is the Chief Financial&nbsp;&amp;
Operating Officer of BioLineRx since 2009. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. accounting department at the National Office in Tel Aviv, as well as seven years
at the SEC at its Washington, D.C., headquarters. Mr.&nbsp;Serlin also serves on the Board of Directors of Kitov Pharmaceuticals Ltd. He previously served on the Board of Directors of Vringo, Inc. from 2010 to 2012. Mr.&nbsp;Serlin is a CPA and
holds a Master&#146;s degree in Economics and Public Policy from The George Washington University. We believe Dr.&nbsp;Serlin is qualified to serve on our board of directors because of his experience servicing public companies and his accounting
background. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Arrangements Concerning Election of Directors; Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current board of directors consists of nine directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among our executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advisory Boards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We established an advisory board with
specific expertise in oncology. In addition we have an advisory board comprised of industry experts with significant experience in the pharmaceutical industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Oncology </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernest Borden, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deborah Blumenthal, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Penson, M.D., MRCP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick Wen, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Keith Bible, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Cloughesy, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nicholas Butowski, M.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Brenner, M.D. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Industry Experts </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ian Wilding, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bonnie Goldman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James S. MacDonald, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John G. Aunins, Ph.D. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Executive Officers and
Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate compensation paid by us to our current directors and executive officers, including share based compensation, for the year
ended December&nbsp;31, 2015, was $2.7 million. This amount includes any amounts set aside or accrued to provide pension, severance, retirement, annual leave and recuperation or similar benefits or expenses. It does not include any business travel,
relocation, professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in Israel. The above also includes the provision for bonuses for the year ended
December&nbsp;31, 2015 in the amount of $0.3&nbsp;million. As of December&nbsp;31, 2015, options to purchase an aggregate of 1,799,878 ordinary shares granted to our directors and executive officers were outstanding under the Employee Share
Ownership and Option Plan (2000), or the 2000 Plan, and the Employee Share Ownership and Option Plan (2011), or the 2011 Plan, and the Employee Share Ownership and Option Plan (2014), or the 2014 Plan at a weighted average exercise price of $2.78
per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Israeli
Companies Law, 5759-1999, or the Companies Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to
management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our chief executive officer is appointed by, and serves at the discretion of, our board of
directors, subject to the employment agreement that we have entered into with him. All other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable employment agreements that we may enter into
with them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of association, our board of directors must consist of at least three and not more than nine
directors, including at least two external directors. Our board of directors consists of nine directors, including two external directors. The external directors were nominated by our board of directors and elected at a meeting of our shareholders.
Other than external directors, for whom special election requirements apply under the Companies Law, as detailed below, and our amended and restated articles of association provide that directors (other than external directors) are elected annually
at the general meeting of our shareholders by a vote of the holders of a majority of the voting power present and voting, in person or by proxy, at that meeting. We have only one class of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following of our directors were elected in accordance with the terms of our articles of association in effect prior to the initial public offering of our
shares and are nominated for re-election by our shareholders at the next annual general meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Shapiro was appointed as an industry expert by a majority of the other directors, a majority that included representatives of our major shareholders. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prof. Harats was entitled to be a board member for so long as Prof. Harats is either (i)&nbsp;the chief executive officer of our company; or (ii)&nbsp;a holder of 3% or more of our issued and outstanding share capital;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Gonczarowski was appointed by J.J.D. Holdings G.P., A.J.J.G. Technology Investments 2003 and Inspe Aktiengesellschaft on behalf of the holders of the Series A preferred shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Gelvan was appointed by Aurum Ventures M.K.I. Ltd.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;Alon was appointed by persons affiliated with Pitango Venture Capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Zeitlin was appointed by the Keffi Group VI LLC on behalf of the holders of the Series D preferred shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Prof. Ruth Arnon was appointed by a majority of the other directors, which included representatives of our major shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the adoption of our amended and restated articles of association upon the closing of our initial public offering, the rights set forth in the previous
articles were terminated and no additional agreements exist with respect to the nomination of our board members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2015, at a general
meeting of our shareholders, each of Dr.&nbsp;Ron Cohen and Mr.&nbsp;Phil Serlin was appointed as an external director by a majority of the shareholders who have no personal interest in his nomination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We comply with NASDAQ rules that a majority of our directors are independent. Our board of directors has determined that with the exception of Prof. Harats,
all of our directors are independent under such rules. The definition of &#147;independent director&#148; under NASDAQ rules and &#147;external director&#148; under the Companies Law overlap to a significant degree such that we would generally
expect the two directors serving as external directors to satisfy the requirements to be independent under NASDAQ rules. However, it is possible for a director to qualify as an &#147;external director&#148; under the Companies Law without qualifying
as an &#147;independent director&#148; under NASDAQ rules, or vice-versa. The definition of external director under the Companies Law includes a set of statutory criteria that must be satisfied, including criteria whose aim is to ensure that there
is no factor that would impair the ability of the external director to exercise independent judgment. The definition of independent director under NASDAQ rules specifies similar, if slightly less stringent, requirements in addition to the
requirement that the board of directors consider any factor which would impair the ability of the independent director to exercise independent judgment. In addition, external directors serve for a period of three years pursuant to the requirements
of the Companies Law. However, external directors must be elected by a special majority of shareholders while independent directors may be elected by an ordinary majority. See &#147;&#151;External Directors&#148; for a description of the
requirements under the Companies Law for a director to serve as an external director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the exemption available to foreign private
issuers under NASDAQ rules, we do not intend to follow the requirements of NASDAQ rules with regard to the process of nominating directors, and instead, will follow Israeli law and practice, in accordance with which our board of directors (or a
committee thereof) is authorized to recommend to our shareholders director nominees for election. See &#147;Item 16G. Corporate Governance&#148; for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law and our amended and restated articles of association, nominees for directors may also be proposed by any shareholder holding at least
1% of our outstanding voting power. However, any such shareholder may propose a nominee only if a written notice of such shareholder&#146;s intent to propose a nominee has been given to our company secretary (or, if we have no such company
secretary, our chief executive officer). Any such notice must include certain information, including, among other things, a description of all arrangements between the nominating shareholder and the proposed director nominee(s) and any other person
pursuant to which the nomination(s) are to be made by the nominating shareholder, the consent of the proposed director nominee(s) to serve as our director(s) if elected and a declaration signed by the nominee(s) declaring that there is no limitation
under the Companies Law preventing their election, and that all of the information that is required under the Companies Law to be provided to us in connection with such election has been provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our amended and restated articles of association allow our board of directors to appoint directors
to fill vacancies on our board of directors, for a term of office equal to the remaining period of the term of office of the director(s) whose office(s) have been vacated. External directors are elected for an initial term of three years and may be
elected for additional three-year terms under the circumstances described below. External directors may be removed from office only under the limited circumstances set forth in the Companies Law. See &#147;&#151;External Directors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial expertise.
See &#147;&#151;External Directors&#148; below. In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its
operations. Our board of directors has determined that the minimum number of directors who are required to have accounting and financial expertise is one. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>External Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, we are
required to have at least two directors who qualify as external directors. The appointment of two new external directors was made by a resolution of the general meeting of our shareholders on February&nbsp;11, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law provides that external directors must be elected by a majority vote of the shares present and voting at a shareholders meeting, provided
that either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in the election of the external director (other than a personal
interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested majority; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total number of shares voted against the election of the external director by non- controlling shareholders and by shareholders who do not have a personal interest in the election of the external director (other
than a personal interest not deriving from a relationship with a controlling shareholder does not exceed 2% of the aggregate voting rights in the company). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;controlling shareholder&#148; is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other
than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or
its general manager. With respect to certain matters, a controlling shareholder is deemed to include any shareholder that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the voting rights in
the company, but excludes a shareholder whose power derives solely from his or her position as a director of the company or from any other position with the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial term of an external director is three years. Thereafter, an external director may be reelected to serve in that capacity for additional three year
terms, provided that either (i)&nbsp;his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company&#146;s voting rights and is approved at a shareholders meeting by a disinterested
majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company, provided that the nominating shareholder, the external director and
certain of their related parties meet additional independence requirements; or (ii)&nbsp;his or her service for each such additional term is recommended by the board of directors and is approved at a shareholders meeting by the same majority
required for the initial election of an external director (as described above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of office for external directors for companies traded on certain
foreign stock exchanges, including The NASDAQ Global Market, may be further extended, indefinitely, in increments of additional three-year terms, in each case provided that, in addition to reelection in such manner described above, (i)&nbsp;the
audit committee and subsequently the board of directors of the company confirm that, in light of the external director&#146;s expertise and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
special contribution to the work of the board of directors and its committees, the reelection for such additional period is beneficial to the company, and provided that (ii)&nbsp;the external
director is reelected subject to the same shareholder vote requirements as if elected for the first time (as described above). Prior to the approval of the reelection of the external director at a general shareholders meeting, the company&#146;s
shareholders must be informed of the term previously served by him or her and of the reasons why the board of directors and audit committee recommended the extension of his or her term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">External directors may be removed from office by a special general meeting of shareholders called by the board of directors, which approves such dismissal by
the same shareholder vote percentage required for their election or by a court, in each case, only under limited circumstances, including ceasing to meet the statutory qualifications for appointment, or violating their duty of loyalty to the
company. If an external directorship becomes vacant and there are fewer than two external directors on the board of directors at the time, then the board of directors is required under the Companies Law to call a shareholders meeting as soon as
possible to appoint a replacement external director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each committee of the board of directors that exercises the powers of the board of directors must
include at least one external director, except that the audit committee and the compensation committee must include all external directors then serving on the board of directors. Under the Companies Law, external directors of a company are
prohibited from receiving, directly or indirectly, any compensation for their services as external directors, other than for their services as external directors pursuant to the Companies Law and the regulations promulgated thereunder. Compensation
of an external director is determined prior to his or her appointment and may not be changed during his or her term subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Companies Law provides that a person is not qualified to serve as an external director if (i)&nbsp;the person is a relative of a controlling shareholder of the company, or (ii)&nbsp;if that person or his or her relative, partner, employer, another
person to whom he or she was directly or indirectly subject, or any entity under the person&#146;s control, has or had, during the two years preceding the date of appointment as an external director: (a)&nbsp;any affiliation or other disqualifying
relationship with the company, with any person or entity controlling the company or a relative of such person, or with any entity controlled by or under common control with the company; or (b)&nbsp;in the case of a company with no shareholder
holding 25% or more of its voting rights, had at the date of appointment as external director, any affiliation or other disqualifying relationship with a person then serving as chairman of the board or chief executive officer, a holder of 5% or more
of the issued share capital or voting power in the company or the most senior financial officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;relative&#148; is defined under the
Companies Law as a spouse, sibling, parent, grandparent or descendant; spouse&#146;s sibling, parent or descendant; and the spouse of each of the foregoing persons. Under the Companies Law, the term &#147;affiliation&#148; and the similar types of
prohibited relationships include (subject to certain exceptions): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an employment relationship; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">control; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">service as an office holder, excluding service as a director in a private company prior to the initial public offering of its shares if such director were appointed as a director of the private company in order to serve
as an external director following the initial public offering. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term office holder is defined under the Companies Law as the general
manager, chief executive officer, chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&#146;s title, a director, or a manager
directly subordinate to the general manager. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, no person may serve as an external director if that person&#146;s position or professional or
other activities create, or may create, a conflict of interest with that person&#146;s responsibilities as a director or otherwise interfere </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with that person&#146;s ability to serve as an external director or if the person is an employee of the Israel Securities Authority or of an Israeli stock exchange. A person may furthermore not
continue to serve as an external director if he or she received direct or indirect compensation from the company including amounts paid pursuant to indemnification or exculpation contracts or commitments and insurance coverage for his or her service
as an external director, other than as permitted by the Companies Law and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the termination of an
external director&#146;s service on a board of directors, such former external director and his or her spouse and children may not be provided with a direct or indirect benefit by the company, its controlling shareholder or any entity under its
controlling shareholder&#146;s control. This includes engagement as an office holder or director of the company or a company controlled by its controlling shareholder or employment by, or provision of services to, any such company for consideration,
either directly or indirectly, including through a corporation controlled by the former external director. This restriction extends for a period of two years with regard to the former external director and his or her spouse or child, and for one
year with respect to other relatives of the former external director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, at the time at which an external director is appointed, all members of the
board of directors, who are not controlling shareholders or relatives of controlling shareholders of the company are of the same gender, the external director to be appointed must be of the other gender. A director of one company may not be
appointed as an external director of another company if a director of the other company is acting as an external director of the first company at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to regulations promulgated under the Companies Law, a person may be appointed as an external director only if he or she has professional
qualifications or if he or she has accounting and financial expertise (each, as defined below). In addition, at least one of the external directors must be determined by our board of directors to have accounting and financial expertise. However, if
at least one of our other directors (i)&nbsp;meets the independence requirements under the Exchange Act, (ii)&nbsp;meets the standards of the NASDAQ listing rules for membership on the audit committee, and (iii)&nbsp;has accounting and financial
expertise as defined under Israeli law, then neither of our external directors is required to possess accounting and financial expertise as long as each possesses the requisite professional qualifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A director with accounting and financial expertise is a director who, due to his or her education, experience and skills, possesses an expertise in, and an
understanding of, financial and accounting matters and financial statements, such that he or she is able to understand the financial statements of the company and initiate a discussion about the presentation of financial data. A director is deemed
to have professional qualifications if he or she has: (i)&nbsp;an academic degree in economics, business management, accounting, law or public administration, (ii)&nbsp;an academic degree or has completed other higher education, in the primary field
of business of the company or a field which is relevant to his or her position in the company, or (iii)&nbsp;at least five years of experience serving in one of the following capacities, or at least five years cumulative experience serving in two or
more of the following capacities: (a)&nbsp;a senior business management position in a company with a significant volume of business, (b)&nbsp;a senior position in a company&#146;s primary field of business, or (c)&nbsp;a senior position in public
administration or service. The board of directors is charged with determining whether a director possesses financial and accounting expertise or professional qualifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that Dr.&nbsp;Gelvan and Mr.&nbsp;Serlin have accounting and financial expertise and possess professional qualifications
as required under the Companies Law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages management to promote a
culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and review
sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management
to mitigate or eliminate such risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to
serve as chairman of the board of directors. Our board of directors has appointed Dr.&nbsp;Shapiro to serve as chairman of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an audit
committee, a compensation committee and a nominating and corporate governance committee. We have adopted a charter for each of these committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, we are
required to appoint an audit committee. The audit committee must be comprised of at least three directors, including all of the external directors, one of whom must serve as chairman of the committee. The audit committee may not include the chairman
of the board, any director employed by or otherwise providing services on a regular basis to the company, to a controlling shareholder or to any entity controlled by a controlling shareholder, any director who derives most of his or her income from
a controlling shareholder, nor a controlling shareholder or a relative thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the Companies Law, the audit committee of a publicly
traded company must consist of a majority of unaffiliated directors. In general, an &#147;unaffiliated director&#148; under the Companies Law is defined as either an external director or as a director who meets the following criteria: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">he or she meets the qualifications for being appointed as an external director, except for the requirement (i)&nbsp;that the director be an Israeli resident (which does not apply to companies such as ours whose
securities have been offered outside of Israel or are listed outside of Israel) and (ii)&nbsp;for accounting and financial expertise or professional qualifications; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">he or she has not served as a director of the company for a period exceeding nine consecutive years. For this purpose, a break of less than two years in the service shall not be deemed to interrupt the continuation of
the service. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the NASDAQ listing requirements, we are required to maintain an audit committee consisting of at least three independent
directors, all of whom are financially literate and at least one of whom has accounting or related financial management expertise. Our audit committee consists of our two external directors Mr.&nbsp;Serlin and Dr.&nbsp;Cohen, and of Dr.&nbsp;Gelvan
and is chaired by Mr.&nbsp;Serlin. Mr.&nbsp;Serlin and Dr.&nbsp;Gelvan are audit committee financial experts as defined by the Securities and Exchange Commission rules and all of the members of our audit committee have the requisite financial
literacy as defined by the NASDAQ Stock Market rules. All the members of our audit committee are &#147;independent&#148; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and under the listing standards of NASDAQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules of the
Securities and Exchange Commission and NASDAQ rules as well as the requirements for such committee under the Companies Law, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in
accordance with Israeli law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the engagement or termination of the person filling the office of our internal auditor; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary
obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our
accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants
are independent of management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, our audit committee is responsible for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether there are deficiencies in our business management practices, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to
improve such practices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest) and whether such transaction is extraordinary or material under the Companies
Law (see &#147;&#151;Approval of Related Party Transactions Under Israeli Law&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the board of directors approves the work plan of the internal auditor, to examine such work plan before its submission to the board and propose amendments thereto; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">examining our internal controls and internal auditor&#146;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">examining the scope of our auditor&#146;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment
of our auditor; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for the handling of employees&#146; complaints as to deficiencies in the management of our business and the protection to be provided to such employees. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee may not approve any actions requiring its approval (see &#147;&#151;Approval of Related Party Transactions Under Israeli Law&#148;),
unless at the time of approval a majority of the committee&#146;s members are present, which majority consists of unaffiliated directors including at least one external director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation committee
consists of Mr.&nbsp;Serlin and Dr.&nbsp;Cohen, our two external directors, and of Mr.&nbsp;Zeitlin. Mr.&nbsp;Serlin serves as the chairman of the compensation committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We chose to rely upon the exemption available to foreign private issuers under the listing requirements of the NASDAQ Stock Market with respect to the
determination of the compensation of our chief executive officer and other executive officers, and, in lieu of forming a compensation committee consisting entirely of independent directors (or the determination of such compensation solely by the
independent members of our board of directors), we have a compensation committee in compliance with the Israeli Companies Law. See &#147;Item 16G. Corporate Governance.&#148; However, all of the current members of our compensation committee are
independent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, the board of directors of a public company must appoint a compensation committee. The compensation committee must
be comprised of at least three directors, including all of the external directors, which shall be a majority of the members of the compensation committee and one of whom must serve as chairman of the committee. However, subject to certain
exceptions, Israeli companies whose securities are traded on stock exchanges such as NASDAQ, and who do not have a controlling shareholder, do not have to meet this majority requirement; provided, however, that the compensation committee meets other
Companies Law composition requirements, as well as the requirements of the jurisdiction where the company&#146;s securities are traded. We do not have a controlling shareholder and therefore our external directors will not comprise the majority of
the members appointed to our compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each compensation committee member who is not an external director must be a director whose compensation does not
exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions as the audit committee as to who may not be a member of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duties of the compensation committee include the recommendation to the company&#146;s board of directors of a policy regarding the terms of engagement of
office holders, to which we refer as a compensation policy. That policy must be adopted by the company&#146;s board of directors, after considering the recommendations of the compensation committee, and will need to be brought for approval by the
company&#146;s shareholders, which approval requires what we refer to as a Special Majority. A Special Majority approval requires shareholder approval by a majority vote of the shares present and voting at a meeting of shareholders called for such
purpose, provided that either: (a)&nbsp;such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement; or (b)&nbsp;the
total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#146;s aggregate voting rights. On
May&nbsp;27, 2015 our shareholders approved our compensation policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation policy must serve as the basis for decisions concerning the
financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain
factors, including advancement of the company&#146;s objectives, the company&#146;s business plan and its long term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#146;s
risk management, size and nature of its operations. The compensation policy must furthermore consider the following additional factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the knowledge, skills, expertise, and accomplishments of the relevant office holder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the office holder&#146;s roles and responsibilities and prior compensation agreements with him or her; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between the terms offered and the average compensation of the other employees of the company, including those employed through manpower companies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of disparities in salary upon work relationships in the company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of reducing variable compensation at the discretion of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#146;s performance during that period of service, the person&#146;s
contributions towards the company&#146;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation policy must also include the following principles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the link between variable compensation and long term performance and measurable criteria; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be
restated in the company&#146;s financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum holding or vesting period for variable, equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maximum limits for severance compensation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee is responsible for
(a)&nbsp;recommending the compensation policy to a company&#146;s board of directors for its approval (and subsequent approval by its shareholders) and (b)&nbsp;duties related to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation policy and to the compensation of a company&#146;s office holders as well as functions previously fulfilled by a company&#146;s audit committee with respect to matters related to
approval of the terms of engagement of office holders, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending whether a compensation policy should continue in effect, if the then- current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing
compensation policy must in any case occur every three years); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to the board of directors periodic updates to the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing implementation of the compensation policy; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether the compensation terms of the chief executive officer of the company need not be brought to approval of the shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a compensation committee charter setting forth the responsibilities of the committee, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the responsibilities set forth in the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
nominating and corporate governance committee consists of Dr.&nbsp;Shapiro, Mr.&nbsp;Gonczarowski, Ms.&nbsp;Alon and Dr.&nbsp;Arnon, and is chaired by Dr.&nbsp;Shapiro. Each of the members of our nominating and corporate governance committee are
independent under the listing requirements of The NASDAQ Global Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a nominating and governance committee charter
sets forth the responsibilities of the nominating and governance committee which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing and assisting our board in reviewing and recommending nominees for election as directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing the performance of the members of our board; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing and maintaining effective corporate governance policies and practices, including, but not limited to, developing and recommending to our board a set of corporate governance guidelines applicable to our
company. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Auditor </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role of the internal auditor is to examine, among other things, our compliance with applicable law and
orderly business procedures. The audit committee is required to oversee the activities and to assess the performance of the internal auditor as well as to review the internal auditor&#146;s work plan. We intend to appoint an internal auditor within
the time limits set by the Companies Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An internal auditor may not be: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who holds more than 5% of the company&#146;s outstanding shares or voting rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an office holder or director of the company; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a member of the company&#146;s independent accounting firm, or anyone on its behalf. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approval of Related Party Transactions Under Israeli Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fiduciary Duties of Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#147;Management&#151;Executive
Officers and Directors&#148; is an office holder under the Companies Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An office holder&#146;s fiduciary duties consist of a duty of care and a duty
of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an office holder act in
good faith and in the best interests of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duty of care includes a duty to use reasonable means to obtain: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other important information pertaining to these actions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duty of loyalty includes a duty to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any activity that is competitive with the company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disclose to the company any information or documents relating to the company&#146;s affairs which the office holder received as a result of his or her position as an office holder. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may be aware of and all related material
information or documents concerning any existing or proposed transaction by the company. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the
transaction is considered. An office holder is not obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered as an extraordinary transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;personal interest&#148; is defined under the Companies Law to include a personal interest of any person in an act or transaction of a company,
including the personal interest of such person&#146;s relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at
least one director or the general manager, but excluding a personal interest stemming from one&#146;s ownership of shares in the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A personal
interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even
if such shareholder has no personal interest in the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an
extraordinary transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, an extraordinary transaction is defined as any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction other than in the ordinary course of business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that is not on market terms; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that may have a material impact on the company&#146;s profitability, assets or liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If it is determined that an office holder has a personal interest in a transaction, approval by the board of
directors is required for the transaction, unless the company&#146;s articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of
directors may approve an action by the office holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is adverse to the company&#146;s interest or that is not performed by
the office holder in good faith. An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#146;s audit committee and subsequently by the board of directors. The compensation of, or an
undertaking to indemnify or insure, an office holder who is not a director requires approval first by the company&#146;s compensation committee, then by the company&#146;s board of directors, and, if such compensation arrangement or an undertaking
to indemnify or insure is inconsistent with the company&#146;s stated compensation policy or if the office holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is subject to a Special Majority
approval. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by ordinary majority, in that order, and under certain
circumstances, a Special Majority approval. If shareholders of a company do not approve the compensation terms of office holders, other than directors, but including the chief executive officer, the compensation committee and board of directors may
override the shareholders&#146; decision, subject to certain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, a person who has a personal interest in a matter which is considered
at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless the chairman of the relevant committee or board of directors (as applicable) determines that he or she should be present
in order to present the transaction that is subject to approval. If a majority of the members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may
participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling
shareholder of a public company. See &#147;&#151;External Directors&#148; for a definition of controlling shareholder. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who
holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be
aggregated. The approval of the audit committee, the board of directors and a Special Majority, in that order, is required for (a)&nbsp;extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal
interest, (b)&nbsp;the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (c)&nbsp;the terms of engagement and compensation of a controlling shareholder or his or
her relative who is not an office holder or (d)&nbsp;the employment of a controlling shareholder or his or her relative by the company, other than as an office holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three
years, unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require the
approval of the compensation committee, board of directors and shareholders by a Special Majority and the terms thereof may not be inconsistent with the company&#146;s stated compensation policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors,
that would otherwise require approval of a company&#146;s shareholders may be exempt from shareholder approval upon certain determinations of the audit committee and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors. Under these regulations, a shareholder holding at least 1% of the issued share capital of the company may require, within 14 days of the publication of such determinations,
that despite such determinations by the audit committee and the board of directors, such transaction will require shareholder approval under the same majority requirements that would otherwise apply to such transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements with Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into written employment agreements with each of Dror Harats, Erez Feige, Amos Ron, Yael&nbsp;Cohen, Eyal Breitbart and Naamit Sher. All such
agreements contain provisions regarding non-competition, confidentiality of information and assignment of inventions. The non-competition provisions apply for a period of 24 months following termination of the respective officer&#146;s employment.
In addition, we are required to provide notice of between three and six months prior to terminating the employment of such executive officers other than in the case of a termination for cause. Other than with respect to Prof. Harats, these
agreements do not provide for benefits upon the termination of these executives&#146; respective employment with us, other than payment of salary and benefits during the required notice period for termination of these agreements, which varies under
these individual agreements. Prof. Harats&#146;s agreement provides for six months of severance in the event Prof. Harats&#146;s employment is terminated by us without cause or terminated by Prof. Harats for good reason. Pursuant to his employment
agreement, &#147;Cause&#148; means Prof. Harats&#146;s conviction of any felony related to our business, a serious breach of trust by Prof. Harats, including theft, embezzlement of our funds, self-dealing, prohibited disclosure of confidential or
proprietary information and Prof. Harats&#146;s engagement in any prohibited business competitive to our own, Prof. Harats&#146;s disregard of lawful instructions of our board of directors with respect to his duties to us following notice, or Prof.
Harats&#146;s willful failure to perform any of his fundamental functions or duties. Pursuant to his employment agreement, &#147;Good reason&#148; means a material reduction in Prof. Harats&#146;s status, title, position or responsibilities, a
reduction in Prof. Harats&#146;s salary which is not part of a general reduction in salary applicable to all of our employees, a failure by us to continue any material compensation or benefit plan, program or practice in which Prof. Harats is
participating, or a material breach by us of any provision of Prof. Harats&#146;s employment agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2016, Professor Jacob George
notified the Company of his resignation from the role of the Company&#146;s Chief Scientific Officer, effectively immediately, for personal reasons which are unrelated to the Company, its operations, policies or practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have entered into compensation agreements with certain of our directors. The amounts payable pursuant to these arrangements have been approved
by our board of directors and shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors do not receive compensation for their service as our directors or otherwise, unless such
compensation is approved by our compensation committee, and then by the board of directors followed by the shareholders. The compensation of our directors may be fixed, as an all-inclusive payment or as payment for participation in meetings, or as a
combination thereof. In addition, such compensation may include: (i)&nbsp;in the case of a director who is also an officer, a salary or other compensation in respect of his or her work as an officer, as may be agreed upon by the director and us; and
(ii)&nbsp;reimbursement of expenses, including travel expenses, expended in connection with his or her duties as a member of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;1, 2016, we employed 27
employees, including 21 in research and development, and 6 in general and administrative positions, and of which 11 employees have either MDs or PhDs. All of our employees are located in Israel. We believe our employee relations are good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli labor laws govern the length of the workday, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance
pay, annual leave, sick days, advance notice of termination of employment, equal opportunity and anti- discrimination laws and other conditions of employment. Subject to specified exceptions, Israeli law generally requires severance pay upon the
retirement, death or dismissal of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee, and requires us and our employees to make payments to the National Insurance Institute, which is similar to the U.S. Social Security Administration. Our employees have defined benefit
pension plans that comply with the applicable Israeli legal requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our employees currently work under any collective bargaining
agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Ownership </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information
regarding the share ownership of our directors and executive officers, please refer to &#147;&#151;Equity Compensation Plans&#148; below and &#147;Item 7. Major Shareholders and Related Party Transactions&#151;Major Shareholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of February&nbsp;11, 2016, our directors and executive officers hold, in the aggregate, options exercisable for 1,699,878 ordinary shares. These options
have an exercise price of $2.78 per share and have expiration dates generally twenty years after the grant date of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1,681,523 options are
vested as of February&nbsp;11, 2016 and have a weighted average exercise price of $2.05 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2000 Plan, the 2011 Plan and the 2014 Plan, allow us to grant options to purchase our ordinary shares to our directors, officers, employees, consultants,
advisers and service providers. The option plans are intended to enhance our ability to attract and retain desirable individuals by increasing their ownership interests in us. We no longer intend to grant options under the 2000 Plan or the 2011
Plan, and the remaining shares reserved for future grants under the option plans will constitute the initial share reserve for the 2014 Plan. Additionally, upon the expiration of options granted under the 2000 Plan or the 2011 Plan, the ordinary
shares underlying such expired options will increase the pool reserved for allocation under the 2014 Plan. As of February&nbsp;11, 2016, we had reserved an aggregate of 2,931,106 ordinary shares under the option plans. As of February&nbsp;11, 2016,
options to purchase an aggregate of 2,316,929 ordinary shares were outstanding, options to purchase 246,317 ordinary shares had been exercised, of which 4,384 had been transferred to the beneficiary holders, and options to purchase 417,585 ordinary
shares were reserved for future grant under the plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plans are designed to reflect the provisions of the Israeli Income Tax Ordinance [New
Version]&#151;1961, as amended, mainly Sections 102 and 3(i), of the Ordinance, which affords certain tax advantages to Israeli employees, officers and directors that are granted options in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the Ordinance allows employees, directors and officers, who are not controlling shareholders and who are Israeli residents, to receive
favorable tax treatment for compensation in the form of shares or options. Section&nbsp;102 of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and
also includes an additional alternative for the issuance of options or shares directly to the grantee. Section&nbsp;102(b)(2) of the Ordinance, which provides the most favorable tax treatment for grantees, permits the issuance to a trustee under the
&#147;capital gains track.&#148; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section&nbsp;102 of the Ordinance, as well as the shares issued upon exercise
of such options and other shares received following any realization of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust
for the benefit of the relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of the registration of the options in the name of the trustee. However, under
this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares. Section&nbsp;3(i) does not provide for a similar tax benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plans may be administered by our board of directors either directly or upon the recommendation of a committee appointed by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation committee recommends to the board of directors, and the board of directors determines or
approves the eligible individuals who receive options under the plans, the number of ordinary shares covered by those options, the terms under which such options may be exercised, and other terms and conditions of the options, all in accordance with
the provisions of the plans. Option holders may not transfer their options except in the event of death or if the compensation committee determines otherwise. Our compensation committee or board of directors may at any time amend or terminate each
of the plans; however, any amendment or termination may not adversely affect any options or shares granted under such plan prior to such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
option exercise price is determined by the compensation committee and specified in each option award agreement. In general, the option exercise price is the fair market value of the shares on the date of grant as determined in good faith by our
board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Share Ownership and Option Plan (2014) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, we adopted and obtained shareholder approval for our 2014 Plan and the U.S. Appendix thereto, which will become effective upon the closing of
this offering. The 2014 Plan provides for the grant of options, restricted shares, restricted share units and other share- based awards to our directors, employees, officers, consultants, advisors and service providers, among others and to any other
person whose services are considered valuable to us. Following the approval of the 2014 Plan by the Israeli tax authorities, we will only grant options or other equity incentive awards under the 2014 Plan, although previously-granted options and
awards will continue to be governed by our 2000 Plan and 2011 Plan. The initial reserved pool under the 2014 Plan will be 928,288 ordinary shares, subject to adjustments as set forth in the 2014 Plan, including an automatic annual increase on
January&nbsp;1 of each year such that the number of shares issuable under the 2014 Plan will equal 4% of our issued and outstanding share capital on a fully diluted basis on each such January&nbsp;1, or a lesser number of shares determined by the
board of directors. The Board determined not to increase the number of shares reserved under the 2014 Plan during 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2014 Plan will be
administered by our board of directors or by a committee designated by the board of directors, which shall determine, subject to Israeli law, the grantees of awards and the terms of the grant, including, exercise prices, vesting schedules,
acceleration of vesting and the other matters necessary in the administration of the 2014 Plan. The 2014 Plan will enable us to issue awards under various tax regimes including, without limitation, pursuant to Sections 102 and 3(i) of the Ordinance,
and under Section&nbsp;422 of the Code. Options granted under the 2014 Plan to U.S. residents may qualify as &#147;incentive stock options&#148; within the meaning of Section&nbsp;422 of the Code, or may be non-qualified. The exercise price for
&#147;incentive stock options&#148; must not be less than the fair market value on the date on which an option is granted, or 110% of the fair market value if the option holder holds more than 10% of our share capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to grant awards under the 2014 Plan only to our employees, directors and officers who are not controlling shareholders and are considered
Israeli residents, under the capital gains track of Section&nbsp;102(b)2 of the Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards under the 2014 Plan may be granted until June&nbsp;8,
2034, 20 years from the date on which the 2014 Plan was approved by our board of directors, provided that awards granted to any U.S. participants may be granted until June&nbsp;8, 2024, 10 years from the date on which the 2014 Plan was approved by
our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that options granted under the 2014 Plan will generally vest over four years commencing on the date of grant such that
50% vest on the second anniversary of the date of grant and an additional 6.25% vest at the end of each subsequent three-month period thereafter for 24 months. Options, other than certain incentive share options, that are not exercised within 20
years from the grant date expire, unless otherwise determined by our board of directors or its designated committee, as applicable. Share options that qualify as &#147;incentive stock options&#148; granted to a person holding more than 10% of our
voting power under the U.S. appendix to the 2014 Plan will expire within five years from the date of the grant and any other options granted under the U.S. appendix to the 2014 Plan will expire within 10 years from the date of grant. Except as
otherwise determined by the board of directors or as set forth in an individual&#146;s award agreement, in the event of termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment or services for reasons of disability or death, or retirement, the grantee, or in the case of death, his or her legal successor, may exercise options that have vested prior to
termination within a period of one year from the date of disability or death, or within 180 days following retirement. If we terminate a grantee&#146;s employment or service for cause, all of the grantee&#146;s vested and unvested options will
expire on the date of termination. If a grantee&#146;s employment or service is terminated for any other reason, the grantee may exercise his or her vested options within 90 days of the date of termination. Any expired or unvested options return to
the pool for reissuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a merger or consolidation of our company, or a sale of all, or substantially all, of our shares or assets or
other transaction having a similar effect on us, then without the consent of the option holder, our board of directors may determine, at its absolute discretion, whether outstanding awards held by or for the benefit of any grantee and which have not
yet vested, is to be assumed or substituted and whether acceleration of such awards will be available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Share Ownership and Option Plan
(2011) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, we adopted the 2011 Plan. The term of the 2011 Plan is twenty years. Each option granted under the 2011 Plan entitles the
grantee to purchase our ordinary shares. The options granted under the 2011 Plan generally vest during a four-year period following the date of the grant in 13 installments: 25% of the options vest one year following the grant date, and additional
1/16 of the options vest at the end of each subsequent quarter over the course of the following three years. The options expire twenty years after the date of grant if not exercised earlier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of certain changes in our share capital structure, such as a consolidation or share split or dividend, appropriate adjustments will be made to the
numbers of shares and exercise prices under outstanding options. Unless otherwise determined by the board of directors, upon the consummation of certain kinds of transactions, such as a liquidation, a merger, reorganization or sale of all or
substantially all of our assets, any unexercised outstanding options shall expire, provided that in case of merger or consolidation or the sale, transfer or exchange of all or substantially all our assets or shares, the surviving corporation does
not assume the options or substitute them with appropriate options in the surviving corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, when an option holder&#146;s employment or
service with us terminates, his or her option will no longer continue to vest following termination, and the holder may exercise any vested options for a period of 90 days following termination without cause. If an option holder&#146;s employment
with us terminates due to disability (as determined by the board of directors) or if the termination of employment results from his or her death then the option holder or his or her estate (as applicable) has twelve months to exercise the option. If
an option holder retires from our company, then, with the approval of the board of directors, the option holder or his or her estate (as applicable) has six months to exercise the option. If termination of employment results from cause, his or her
outstanding options will expire upon termination. No option may be exercised after its scheduled expiration date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Share Ownership and
Option Plan (2000) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2000, we adopted the 2000 Plan, which was amended and restated in 2003 due to changes in applicable tax law. The
original term of the 2000 Plan was ten years. In 2013, the terms of outstanding options were extended by 10 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each option granted under the 2000
Plan entitles the grantee to purchase one of our ordinary shares. The options granted under the 2000 Plan generally vest during a four-year period following the date of the grant in three installments: 50% of the options vest two years following the
grant date, 25% of the options vest three years following the grant date and the remaining 25% of the options vest four years following the grant date. The options under the plan expire ten years after the date of grant if not exercised earlier.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of certain changes in our share capital structure, such as a consolidation or share split or dividend, appropriate adjustments will be made
to the numbers of shares and exercise prices under outstanding options. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the event of certain transactions, such as an acquisition, or a merger or reorganization or a sale of all or substantially all of our assets, there shall be an acceleration of exercise of
unvested options, immediate or otherwise, which depends on, among other things, the nature of such transaction, and provided that in case of merger or consolidation the surviving corporation does not assume the options or substitute them with
appropriate options in the surviving corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, when an option holder&#146;s employment or service with us terminates, his or her option
will no longer continue to vest following termination, and the holder may exercise any vested options for a period of 90 days following termination without cause. If an option holder&#146;s employment with us terminates due to disability (as
determined by the board of directors) or if the termination of employment results from his or her death or due to retirement after age 60, then with the approval of the board of directors, the option holder or his or her estate (as applicable) has
twelve months to exercise the option; however, the option may not be exercised after its scheduled expiration date. If termination of employment results from cause, his or her outstanding options will expire upon termination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_9"></A>Item&nbsp;7. Major Shareholders and Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Major Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
sets forth information with respect to the beneficial ownership of our ordinary shares as of February&nbsp;11, 2016: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or entity known by us to own beneficially more than 5% of our outstanding ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our executive officers and directors individually; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our
ordinary shares is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes
of the table below, we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of February&nbsp;11, 2016 to be outstanding and to be beneficially owned by the person holding the options for the
purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of ordinary shares beneficially owned is based on
22,477,571 ordinary shares outstanding as of February&nbsp;11, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to our transfer agent, as of February&nbsp;16, 2016, there
were 21 record holders of our ordinary shares. None of our shareholders has different voting rights from other shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in the footnotes below, we believe each shareholder has voting and investment
power with respect to the ordinary shares indicated in the table as beneficially owned. Unless otherwise indicated, the address of each beneficial owner is c/o Vascular Biogenics Ltd., 6 Jonathan Netanyahu St., Or Yehuda, Israel 60376. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Ordinary&nbsp;Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Keffi Group VI LLC (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,858,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aurum Ventures M.K.I. Ltd (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,254,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Persons affiliated with Pitango Ventures (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,658,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jecheskiel Gonczarowski (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,208,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bennett&nbsp;M. Shapiro (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prof. Dror Harats (6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,618,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Erez Feige</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jecheskiel Gonczarowski (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,208,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Dan&nbsp;J. Gelvan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jide&nbsp;J. Zeitlin (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,858,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prof. Ruth Arnon</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Ruth Alon</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Ron Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Philip Serlin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Amos Ron</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Yael Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Eyal Breitbart</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Naamit Sher</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adv. Ayelet Horn</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group&nbsp;(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,272,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">These shares may be deemed to be beneficially owned by Jide Zeitlin, our director and president of The Keffi Group VI LLC. The address of The Keffi Group VI LLC is 500 Fifth Avenue, New York, New York 10110.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,254,778 shares held by Aurum Ventures M.K.I. Ltd. Voting and investment power over such shares are vested with Mr.&nbsp;Morris Kahn, who controls Aurum Ventures M.K.I. Ltd. As such, Mr.&nbsp;Kahn may be
deemed to have beneficial ownership over our shares held by Aurum Ventures M.K.I. Ltd. The address of Aurum Ventures M.K.I. Ltd. is 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,623,570 shares held by Pitango Venture Capital Fund IV L.P. and 35,060 shares held by Pitango Venture Capital Principals Fund IV L.P. (collectively, the &#147;Pitango Funds&#148;). The Pitango Funds are
managed by their sole general partner, Pitango V.C. Fund IV, L.P., the sole general partner of which is Pitango G.P. Capital Holdings Ltd., an Israeli company owned indirectly (through personal holding entities) by each of the following individuals:
Rami Kalish, Chemi J. Peres, Aaron Mankovski, Isaac Hillel, Rami Beracha and Zeev Binman, none of whom has sole voting or investment power of our shares and each of whom has shared voting and investment power of such shares. Ms.&nbsp;Alon is a
General Partner of Pitango Ventures IV L.P., but does not have sole or shared voting or investment power over the shares held by the Pitango Funds. The address of the Pitango Funds is 11 HaMenofim Street, Building B, Herzliya, Israel 46725.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,471,115 shares held directly by Mr.&nbsp;Jecheskiel Gonczarowski, 583,333 shares held by D.S.N.I. Investments Ltd. and 153,569 shares held by Inspe Aktiengesellschaft (collectively, the &#147;J.J.D.
Funds&#148;). The shares held by D.S.N.I. Investments Ltd. and Inspe Aktiengesellschaft may be deemed to be beneficially owned by Jecheskiel Gonczarowski, our shareholder and director. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">Consists of (a)&nbsp;24,440 outstanding shares held by Puretech Ventures LLC, which may be deemed to be beneficially owned by Bennett M. Shapiro, our
chairman and a senior partner and chairman of Puretech Ventures LLC; (b)&nbsp;26,141 outstanding shares held by Bennett M. Shapiro and Fredericka F. Shapiro, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
JTWROS; and (c)&nbsp;options to purchase 183,890 shares exercisable within 60 days of February&nbsp;11, 2016 held by Bennett M. Shapiro. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;666,742 outstanding shares held by or for Prof. Harats; (b)&nbsp;options to purchase 920,174 shares exercisable within 60 days of February&nbsp;11, 2016; and (c)&nbsp;warrants exercisable for 31,932
shares within 60 days of February&nbsp;11, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 736,902 shares held by D.S.N.I. Investments Ltd. and Inspe Aktiengesellschaft. These shares may be deemed to be beneficially owned by Jecheskiel Gonczarowski, our shareholder and director. In addition, this
number consists of 1,471,115 shares held directly by Mr.&nbsp;Jecheskiel Gonczarowski. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;options to purchase 1,391,026 shares exercisable within 60 days of February&nbsp;11, 2016; (b)&nbsp;warrants exercisable for 49,725 shares within 60 days of February&nbsp;11, 2016; and (c)&nbsp;7,
831,501 outstanding shares. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the material terms of those transactions with related parties to which we are party since January&nbsp;1, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a written policy which provides that the approval of the audit committee is required to effect specified actions and transactions with our
directors, executive officers and controlling shareholders, or in which such persons have an interest. See &#147;Item 6. Directors, Senior Management and Employees&#151;Approval of Related Party Transactions Under Israeli Law.&#148; The term
&#147;controlling shareholder&#148; means a shareholder with the ability to direct the activities of our company, other than by virtue of being an executive officer or director. A shareholder is presumed to be a controlling shareholder if the
shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or its general manager. For the purpose of approving transactions with controlling shareholders, as well as
corporate approval of executive compensation, the term also includes any shareholder (or two or more shareholders having a personal interest in the same matter being brought for approval) that holds 25% or more of the voting rights of a company if
the company has no shareholder that owns more than 50% of its voting rights. The transactions described below were entered into prior to the effectiveness of this policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuances of Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Series E Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, we issued and sold an aggregate of 1,495,331 Series E preferred shares under a subscription agreement, all of which converted into ordinary shares
immediately prior to the closing of our initial public offering, consisting of 413,096 Series E preferred shares purchased for an aggregate purchase price of approximately $4.9 million, and 1,082,235 Series E preferred shares issued upon conversion
of the convertible loan described above which we refer to as our Series E financing. The table below sets forth the number of the Series E preferred shares issued to our executive officers, directors and entities that, as of the date of this Annual
Report on Form 20-F, beneficially own more than 5% of our outstanding ordinary shares, through purchase of shares in the Series E financing or through conversion of the convertible loan, and the number of ordinary shares resulted from the conversion
of such preferred shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.30pt; font-size:8pt; font-family:Times New Roman"><B>Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series E <BR>Preferred<BR>Purchase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of<BR>Series&nbsp;E&nbsp;Preferred<BR>Resulting from<BR>Conversion&nbsp;of&nbsp;Loan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Ordinary<BR>Shares Resulted <BR>from&nbsp;the&nbsp;Conversion<BR>of Series E <BR>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jecheskiel Gonczarowski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inspe Aktiengesellschaft</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aurum Ventures M.K.I Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pitango Venture Capital Fund IV L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pitango Venture Capital Principals Fund IV&nbsp;L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Keffi Group VI LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bennett M. Shapiro and Fredericka F. Shapiro, JTWROS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bennett&nbsp;M. Shapiro, Mr.&nbsp;Gonczarowski, who is affiliated with Inspe Aktiengesellschaft,
Mr.&nbsp;Zeitlin, who is affiliated with The Keffi Group V LLC and The Keffi Group VI LLC, Dr.&nbsp;Gelvan, who manages the life science holdings of Aurum Ventures M.K.I. Ltd., and Ms.&nbsp;Ruth Alon, who is affiliated with Pitango Venture Capital
Fund IV LP and Pitango Venture Capital Principals Fund IV LP, are each members of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Our Initial Public Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our shareholders who owned shares prior to our initial public offering, including certain 5% shareholders, directors and their affiliates,
purchased an aggregate of 3,833,333 ordinary shares in our initial public offering in October 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:94.15pt; font-size:8pt; font-family:Times New Roman"><B>Shareholders and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;or&nbsp;Ordinary&nbsp;Shares<BR>Purchased in the IPO</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Keffi Group VI LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aurum Ventures M.K.I. Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">D.S.N.I. Investments Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pitango Venture Capital Fund IV L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bennett M. Shapiro and Fredericka F. Shapiro, JTWROS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prof. Dror Harats</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prof. Ruth Arnon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bennett&nbsp;M. Shapiro, D.S.N.I. Investments Ltd. who is affiliated with Mr.&nbsp;Gonczarowski, Mr.&nbsp;Zeitlin,
who is affiliated with The Keffi Group V LLC and The Keffi Group VI LLC, Dr.&nbsp;Gelvan, who manages the life science holdings of Aurum Ventures M.K.I. Ltd., Prof. Ruth Arnon and Prof. Dror Harats are each members of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights of Appointment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current board of directors
consists of nine directors. Pursuant to our articles of association in effect prior to the initial public offering, certain of our shareholders had rights to appoint members of our board of directors. All rights to appoint directors terminated,
although previously serving directors that were appointed prior to the offering will continue to serve pursuant to their appointment until the first annual meeting of shareholders held after our initial public offering. We are not a party to, and
are not aware of, any voting agreements among our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have in place indemnification agreements with each of our executive officers exculpating them from a breach of their duty of care to us to the fullest
extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by Israeli law, subject to limited exceptions, including with respect to liabilities resulting from the initial public offering
to the extent such liabilities are not covered by insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our executive officers and key employees. The employment agreements contain standard provisions, including
assignment of invention provisions and non-competition clauses. See &#147;Item 6. Directors, Senior Management and Employees&#151;Employment Agreements with Executive Officers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our investor rights
agreement entitles our preferred shareholders to certain registration rights following the closing of our initial public offering. In accordance with this agreement, and subject to conditions described
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
below, the following executives, directors and entities, which as of the date of this prospectus beneficially own more than 5% of our ordinary shares, assuming the conversion of all of
outstanding preferred shares into ordinary shares, are entitled to registration rights: Jecheskiel Gonczarowski and entity affiliated therewith, The Keffi Group VI LLC, Aurum Ventures and Pitango Ventures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form F-1 Demand Rights</I>. Upon the request of the holders of more than 50% of the shares held by our former preferred shareholders given more than 180
days after the effective date of the registration statement related to our initial public offering, we are required to file a registration statement on Form F-1 in respect of the ordinary shares held by our former preferred shareholders. Following a
request to effect such a registration, we are required to give notice of the request to the other holders of registrable securities and offer them an opportunity to include their shares in the registration statement. We are not required to effect
more than two registrations on Form F-1 in the aggregate and not more than one registration in any 12 month period and we are only required to do so if the aggregate proceeds from any such registration are estimated in good faith to be in excess of
$6.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form F-3 Demand Rights</I>. After we become eligible under applicable securities laws to file a registration statement on Form F-3,
which will not be until at least 12 months after the date of this prospectus, upon the request of the holders of more than 20% of the shares held by our former preferred shareholders, we are required to file a registration statement on Form F-3 in
respect of the ordinary shares held by our former preferred shareholders<I>.</I> Following a request to effect such a registration, we are required to give notice of the request to the other holders of registrable securities and offer them an
opportunity to include their shares in the registration statement. We are not required to effect a registration on Form F-3 more than twice in any 12 month period and are only required to do so if the aggregate proceeds from any such registration
are estimated in good faith to be in excess of $2.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights</I>. Following our initial public offering, shareholders
holding registrable securities also have the right to request that we include their registrable securities in any registration statement filed by us in the future for the purposes of a public offering for cash, subject to specified exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cutback</I>. In the event that the managing underwriter advises the registering shareholders that marketing factors require a limitation on the number of
shares that can be included in a registered offering, the shares will be included in the registration statement in an agreed order of preference among the holders of registration rights. The same preference also applies in the case of a piggyback
registration, but we have first preference and the number of shares of shareholders that are included may not be less than 30% of the total number of shares included in the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination</I>. All registration rights granted to holders of registrable securities terminate on the fifth anniversary of the closing of our initial
public offering and, with respect to any of our holders of registrable securities when the shares held by such shareholder can be sold within a 90 day period under Rule 144<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses</I>. We will pay all expenses in carrying out the foregoing registrations other than selling shareholders&#146; underwriting discounts and
transfer taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_10"></A>Item&nbsp;8. Financial Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial statements are set forth under Item&nbsp;18. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
never declared or paid any cash dividends to our shareholders. We currently anticipate that we will retain all of our future earnings, if any, for use in the operation of our business. Additionally, our ability to pay dividends on our ordinary
shares is limited by restrictions under the terms of the agreements governing our indebtedness and under Israeli law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_11"></A>Item&nbsp;9. The Offer and Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares are quoted on the Nasdaq Global Market under the symbol &#147;VBLT.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated since October&nbsp;1, 2014, which was the date on which our ordinary shares began trading on the
Nasdaq Global Market under the symbol &#147;VBLT,&#148; the high and low sales prices of our ordinary shares as reported by the Nasdaq Global Market. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price&nbsp;Per&nbsp;Ordinary&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;High&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Low&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Quarterly:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Most Recent Six Months:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 28, 2016, the last reported sale price of our ordinary shares on the Nasdaq Global Market was
$3.48&nbsp;per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_12"></A>Item&nbsp;10. Additional Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Memorandum and Articles of Association </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary
Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All ordinary shares will have
identical voting and other rights in all respects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer of Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the
transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any
way by our amended and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares do not
have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements
for external directors described under &#147;Item 6. Directors, Senior Management and Employees&#151;Board of Directors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of association, our board of directors must consist of not less than
three, not including two external directors, but no more than nine directors, including two external directors, as required by the Companies Law. Pursuant to our amended and restated articles of association, other than the external directors, for
whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote of holders of our voting shares, participating and voting at the relevant meeting. Each director will serve until his
or her successor is duly elected and qualified or until his or her earlier death, resignation or removal by a vote of the majority voting power of our shareholders at a general meeting of our shareholders or until his or her office expires by
operation of law, in accordance with the Companies Law. In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on the board of directors to serve for a term of office equal
to the remaining period of the term of office of the directors(s) whose office(s) have been vacated. External directors are elected for an initial term of three years, may be elected for additional terms of three years each under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. See &#147;Item 6. Directors, Senior Management and Employees&#151;Board of Directors.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend and Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may declare a
dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders
of a company unless the company&#146;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be
determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings
generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of the distribution, or we may otherwise
only distribute dividends that do not meet such criteria only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern
that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our
liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the
grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Israeli law, we are
required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the&nbsp;previous annual general meeting. All meetings other than the annual general meeting of
shareholders are referred to in our amended and restated articles of association as extraordinary general meetings. Our board of directors may call extraordinary general meetings whenever it sees fit, at such time and place, within or outside of
Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene an extraordinary general meeting upon the written request of (i)&nbsp;any two of our directors or one- quarter of the members of
our board of directors or (ii)&nbsp;one or more shareholders holding, in the aggregate, either (a)&nbsp;5% or more of our outstanding issued shares and 1% of our outstanding voting power or (b)&nbsp;5% or more of our outstanding voting power. One or
more shareholders, holding 1% or more of the outstanding voting power, may ask the board to add an item to the agenda of a prospective meeting, if the proposal merits discussion at the general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of our shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amendments to our articles of association; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment or termination of our auditors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment of external directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of certain related party transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increases or reductions of our authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of our board of director&#146;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law and our amended and restated articles of association require that a notice of any annual general meeting or extraordinary
general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties,
or an approval of a merger, notice must be provided at least 35 days prior to the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law and our amended and restated articles
of association, shareholders are not permitted to take action via written consent in lieu of a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters
submitted to a vote before the shareholders at a general meeting. As a foreign private issuer, the quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold
or represent between them at least 25% of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time or date if so. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vote Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our amended and restated articles of association. Under the Companies Law, each of
(i)&nbsp;the approval of an extraordinary transaction with a controlling shareholder and (ii)&nbsp;the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#146;s relative (even if not
extraordinary) requires, the approval described above under &#147;Management&#151;Approval of Related Party Transactions Under Israeli Law&#151;Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions.&#148;
Under our amended and restated articles of association, the alteration of the rights, privileges, preferences or obligations of any class of our shares requires a simple majority vote of the class so affected (or such other percentage of the
relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. An exception to the simple
majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section&nbsp;350 of the Companies Law, which requires the approval of holders of 75% of
the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Access to Corporate Records
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and principal
shareholders register, articles of association and financial statements; and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any
document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary
to protect our interest or protect a trade secret or patent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions Under Israeli Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Full Tender Offer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A person wishing to acquire shares of
an Israeli public company and who would as a result hold over 90% of the target company&#146;s issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&#146;s shareholders for the purchase of
all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to
make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and
outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be
transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as
determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If (a)&nbsp;the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of
the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b)&nbsp;the shareholders who did not accept the tender
offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#146;s issued and
outstanding share capital or of the applicable class from shareholders who accepted the tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Tender Offer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the
acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law
provides that an acquisition of shares in a public company must be made by means of a special tender offer if, as a result of the acquisition, the purchaser would become a holder of more than 45% of the voting rights in the company, provided that
there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A special tender
offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#146;s outstanding shares, regardless of how many shares are tendered by
shareholders. A special tender offer may be consummated only if (i)&nbsp;outstanding shares representing at least 5% of the voting power of the company will be acquired by the offeror </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and (ii)&nbsp;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, controlling shareholders, holders of 25% or
more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with
the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer,
unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Merger </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law permits merger transactions if approved by each party&#146;s board of directors and, unless certain requirements described under the
Companies Law are met, by a majority vote of each party&#146;s shareholders, and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented
at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint
25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#146;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the
merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#147;Item 6. Directors, Senior Management and Employees&#151;Disclosure of Personal
Interests of Controlling Shareholders and Approval of Certain Transactions&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the transaction would have been approved by the shareholders of a
merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company,
if the court holds that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders of the target company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a
reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by
each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover Measures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Companies Law allow us
to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. No
preferred shares are currently authorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that
may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of
preferred shares will require an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting.
The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies
Law as described above in &#147;&#151;Voting Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli tax law treats some acquisitions, such as stock-for-stock swaps between an Israeli company and a foreign company, less favorably than U.S. tax law. For
example, Israeli tax law may subject a shareholder who exchanges ordinary shares in an Israeli company for shares in a non-Israeli corporation to immediate taxation unless such shareholder receives authorization from the Israeli Tax Authority for
different tax treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of Class Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and
dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in
our amended and restated articles of association. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Establishment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registration number with the Israeli Registrar of Companies is 51-289976-6. Our purpose as set forth in our amended and restated articles of association is
to engage in any lawful activity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our ordinary shares is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C. Material Contracts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not entered into any
material contracts other than in the ordinary course of business and other than those described in &#147;Item 4. Information on the Company,&#148; &#147;Item 6. Directors, Senior Management and Employees&#148; or elsewhere in this Annual Report.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D. Exchange Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non- residents of Israel, except for shareholders who are subjects of countries that are, or have
been, in a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 1998, Israeli currency control regulations were liberalized significantly, so that Israeli residents generally
may freely deal in foreign currency and foreign assets, and non-residents may freely deal in Israeli currency and Israeli assets. There are currently no Israeli currency control restrictions on remittances of dividends on the ordinary shares or the
proceeds from the sale of the shares provided that all taxes were paid or withheld; however, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-residents of Israel may freely hold and trade our securities. Neither our articles of association nor the laws of the State of Israel restrict in any way
the ownership or voting of ordinary shares by non-residents, except that such restrictions may exist with respect to citizens of countries which are in a state of war with Israel. Israeli residents are allowed to purchase our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E. Taxation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description is not intended to
constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ordinary shares. You should consult your own tax advisor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israeli Tax Considerations and Government Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following is a brief summary of the material Israeli tax laws applicable to us, and certain Israeli Government programs that may benefit us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and
disposition of our ordinary shares purchased by investors. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of
investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. Because parts of this discussion are
based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion below
is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Corporate Tax Structure in Israel </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli
companies are generally subject to corporate tax, currently at the rate of 26.5% of a company&#146;s taxable income. However, the effective tax rate payable by a company that derives income from an Approved Enterprise, a Benefited Enterprise or a
Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company are subject to tax at the prevailing corporate tax rate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Law for the Encouragement of Industry (Taxes), 5729-1969 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for
&#147;Industrial Companies.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Industry Encouragement Law defines an &#147;Industrial Company&#148; as a company resident in Israel, of which 90%
or more of its income in any tax year, other than income from defense loans, is derived from an &#147;Industrial Enterprise&#148; owned by it. An &#147;Industrial Enterprise&#148; is defined as an enterprise whose principal activity in a given tax
year is industrial production. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following corporate tax benefits, among others, are available to Industrial Companies: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amortization over an eight-year period of the cost of patents and rights to use patents and know-how which were purchased in good faith and are used for the development or advancement of the Industrial Enterprise;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">under certain conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses related to a public offering are deductible in equal amounts over three years. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we have not
generated income yet, there is no assurance that we qualify as an Industrial Company or that the benefits described above will be available to us in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Law for the Encouragement of Capital Investments, 5719-1959 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital
investments in productive assets, such as production facilities, by &#147;Industrial Enterprises&#148; (as defined under the Investment Law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Investment Law was significantly amended effective April&nbsp;1, 2005 (the &#147;2005 Amendment&#148;), and further amended as of January&nbsp;1, 2011 (the &#147;2011 Amendment&#148;). Pursuant to the 2005 Amendment, tax benefits granted
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in accordance with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently are subject to the provisions of the 2005
Amendment. Similarly, the 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits under the Investment Law
as in effect prior to January&nbsp;1, 2011 were entitled to choose to continue to enjoy such benefits, provided that certain conditions are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment
apply. We have examined the possible effect, if any, of these provisions of the 2011 Amendment on our financial statements and have decided, at this time, not to opt to apply the new benefits under the 2011 Amendment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Benefits Prior to the 2005 Amendment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An
investment program that is implemented in accordance with the provisions of the Investment Law prior to the 2005 Amendment, referred to as an &#147;Approved Enterprise,&#148; is entitled to certain benefits. A company that wished to receive benefits
as an Approved Enterprise must have received approval from the Investment Center of the Israeli Ministry of the Economy (formerly the Ministry of Industry, Trade and Labor), or the Investment Center. Each certificate of approval for an Approved
Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, an Approved Enterprise is entitled to receive a grant from the Government of Israel or an alternative package of tax benefits, known as the
alternative benefits track. The tax benefits from any certificate of approval relate only to taxable income attributable to the specific Approved Enterprise. Income derived from activity that is not integral to the activity of the Approved
Enterprise does not enjoy tax benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a company that has an Approved Enterprise program is eligible for further tax benefits if it
qualifies as a Foreign Investors&#146; Company (&#147;FIC&#148;), which is a company with a level of foreign investment, as defined in the Investment Law, of more than 25%. The level of foreign investment is measured as the percentage of rights in
the company (in terms of shares, rights to profits, voting and appointment of directors), and of combined share capital and loans, that are owned, directly or indirectly, by persons who are not residents of Israel. The determination as to whether a
company qualifies as an FIC is made on an annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a company elects the alternative benefits track and distributes a dividend out of income
derived by its Approved Enterprise during the tax exemption period it will be subject to corporate tax in respect of the amount of the dividend (grossed-up to reflect the pre-tax income that it would have had to earn in order to distribute the
dividend) at the corporate tax rate which would have been applicable without the tax exemption under the alternative benefits track. In addition, dividends paid out of income attributed to an Approved Enterprise are generally subject to withholding
tax at source at the rate of 15% or such lower rate as may be provided in an applicable tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Investment Law also provides that an Approved
Enterprise is entitled to accelerated depreciation on its property and equipment that are included in an Approved Enterprise program during the first five years in which the equipment is used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefits available to an Approved Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations and the
criteria in the specific certificate of approval. If a company does not meet these conditions, it would be required to repay the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have Approved Enterprise programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax
Benefits Subsequent to the 2005 Amendment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2005 Amendment applies to new investment programs commencing after 2004, but does not apply to
investment programs approved prior to April&nbsp;1, 2005. The 2005 Amendment provides that terms and benefits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included in any certificate of approval that was granted before the 2005 Amendment became effective (April 1, 2005) will remain subject to the provisions of the Investment Law as in effect on the
date of such approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2005 Amendment provides that a certificate of approval from the Investment Center will only be necessary for receiving cash
grants. As a result, it was no longer necessary for a company to obtain an Approved Enterprise certificate of approval in order to receive the tax benefits previously available under the alternative benefits track. Rather, a company may claim the
tax benefits offered by the alternative benefits track directly in its tax returns, provided that it meets the criteria for tax benefits set forth in the amendment. In order to receive the tax benefits, the 2005 Amendment states that a company must
make an investment which meets all of the conditions, including a minimum qualifying investment in certain productive assets as specified in the Investment Law. Such investment allows a company to receive &#147;Benefited Enterprise&#148; status, and
may be made over a period of no more than three years culminating with the end of the Benefited Enterprise election year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The extent of the tax benefits
available under the 2005 Amendment to qualifying income of a Benefited Enterprise depends on, among other things, the geographic location in Israel of the Benefited Enterprise. The location will also determine the period for which tax benefits are
available. Such tax benefits include an exemption from corporate tax on undistributed income generated by the Benefited Enterprise for a period of between two to ten years, depending on the geographic location of the Benefited Enterprise in Israel,
and a reduced corporate tax rate of between 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in the company in each year. The benefits period is limited to 12 or 14 years from the beginning of the
Benefited Enterprise election year, depending on the location of the Benefited Enterprise. We informed the Israeli Tax Authority of our choice of 2012 as a Benefited Enterprise election year. A company qualifying for tax benefits under the 2005
Amendment which pays a dividend out of income derived by its Benefited Enterprise during the tax exemption period will be subject to corporate tax in respect of the amount of the dividend (grossed-up to reflect the pre-tax income that it would have
had to earn in order to distribute the dividend) at the corporate tax rate which would have otherwise been applicable. Dividends paid out of income attributed to a Benefited Enterprise are generally subject to withholding tax at source at the rate
of 15%-20% or such lower rate as may be provided in an applicable tax treaty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The benefits available to a Benefited Enterprise are subject to the
fulfillment of conditions stipulated in the Investment Law and its regulations. If a company does not meet these conditions, in a given tax year during the benefits period, it would generally not be eligible for tax benefits during such tax year;
however, the company&#146;s eligibility for tax benefits in prior and future years should not be impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have one Benefited Enterprise
program under the Investments Law, which, we believe, may entitle us to certain tax benefits. The tax benefit period for this program has not yet commenced but is expected to end no later than the end of tax year 2023 or tax year 2025. During the
benefits period, which shall commence with the year we will first earn taxable income relating to such enterprise, subject to the 12 or 14 year limitation described above, and shall run for a period of up to 10 years (assuming FIC status), a
corporate tax exemption is expected to apply with respect to the taxable income from our Benefited Enterprise program (once generated) generated during the first two years of the benefits period (so long as it remains undistributed) and reduced
corporate tax rates are expected to apply to such taxable income generated in the remaining years of the benefits period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no assurance that our
future taxable income will qualify as Benefited Enterprise income or that the benefits described above will be available to us in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax
Benefits Under the 2011 Amendment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2011 Amendment canceled the availability of the benefits granted to companies under the Investment Law prior
to 2011 and, instead, introduced new benefits for income generated by a &#147;Preferred Company&#148; through its &#147;Preferred Enterprise&#148; (as such terms are defined in the Investment Law) as of January&nbsp;1, 2011. The definition of a
Preferred Company includes a company incorporated in Israel that is not wholly-owned by a governmental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entity, and that has, among other things, Preferred Enterprise status and is controlled and managed from Israel. Pursuant to the 2011 Amendment, in 2014 and thereafter a Preferred Company is
entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise unless the Preferred Enterprise is located in development zone A, in which case the rate will be 9%. It should be noted, that the
classification of income generated from the provision of usage rights in know-how or software that were developed in the Preferred Enterprise, as well as royalty income received with respect to such usage, as Preferred Enterprise income is subject
to the issuance of a pre-ruling from the Israel Tax Authority stipulating that such income is associated with the productive activity of the Preferred Enterprise in Israel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such lower rate as
may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding
tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2011 Amendment also provided transitional
provisions to address companies that may be eligible for tax benefits under the Approved Enterprise or Benefited Enterprise regimes. These transitional provisions provide, among other things, that unless an irrevocable request is made to apply the
provisions of the Investment Law as amended in 2011 with respect to income to be derived as of January&nbsp;1, 2011: (1)&nbsp;the terms and benefits included in any certificate of approval that was granted to an Approved Enterprise which chose to
receive grants before the 2011 Amendment became effective will remain subject to the provisions of the Investment Law as in effect on the date of such approval, and subject to certain other conditions, (2)&nbsp;terms and benefits included in any
certificate of approval that was granted to an Approved Enterprise which had participated in an alternative benefits track before the 2011 Amendment became effective will remain subject to the provisions of the Investment Law as in effect on the
date of such approval, provided that certain conditions are met, and (3)&nbsp;a Benefited Enterprise can elect to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain conditions are
met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined the potential Israeli tax implications associated with the adoption and implementation of the provisions of the 2011 Amendment and
have decided, at this time, not to apply the new benefits under the 2011 Amendment. There is no assurance that our future taxable income will qualify as Preferred Enterprise income or that the benefits described above will be available to us in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of Our Shareholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does
not address the tax consequences applicable to shareholders that own, or have owned at any time, directly or indirectly, 10% or more of our shares (&#147;Controlling Shareholders&#148;), and such shareholders should consult their tax advisers as to
the tax consequences of owning or disposing of our shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Gains Taxes Applicable to Non-Israeli Resident Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident company that were purchased after the Company was listed for
trading on a stock exchange outside of Israel will be exempt from Israeli tax so long as such capital gains were not attributable to a permanent establishment that the non-resident maintains in Israel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, non-Israeli resident corporations will not be entitled to the foregoing exemption if the Israeli residents: (i)&nbsp;have a controlling interest,
directly or indirectly, alone, together with another (i.e., together with a relative, or together with someone who is not a relative but with whom, according to an agreement, there is regular cooperation in material matters of the company, directly
or indirectly), or together with another Israeli resident, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of more than 25% in one or more of the means of control in such non-Israeli resident corporation, or (ii)&nbsp;Israeli residents are the beneficiaries of, or are entitled to, 25% or more of the
revenues or profits of such non-Israeli resident corporation, whether directly or indirectly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, a sale of securities by a non-Israeli
resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under the United States- Israel Tax Treaty, the disposition of shares by a shareholder who (1)&nbsp;is a U.S. resident (for purposes
of the treaty), (2)&nbsp;holds the shares as a capital asset, and (3)&nbsp;is entitled to claim the benefits afforded to such person by the treaty, is generally exempt from Israeli capital gains tax. Such exemption will not apply if: (1)&nbsp;the
capital gain arising from the disposition can be attributed to a permanent establishment in Israel, (2)&nbsp;the shareholder holds, directly or indirectly, shares </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">representing 10% or more of the voting power of the company during any part of the 12-month period preceding the disposition, subject to certain conditions, or
(3)&nbsp;such U.S. resident is an individual and was present in Israel for 183 days or more during the relevant taxable year. In such case, the sale, exchange or disposition of our ordinary shares would be subject to Israeli tax, to the extent
applicable; however, under the United States-Israel Tax Treaty, the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange or disposition, subject to the
limitations under U.S. law applicable to foreign tax credits. The United States-Israel Tax Treaty does not relate to U.S. state or local taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some
instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they
are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Non-Israeli Shareholders on
Receipt of Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary
shares at the rate of 25%, unless relief is provided in a treaty between Israel and the shareholder&#146;s country of residence, subject to receipt of a valid certificate from the Israeli Tax Authority allowing for such reduced rate. With respect to
a person who is a &#147;substantial shareholder&#148; at the time of receiving the dividend or at any time during the preceding twelve months, the applicable withholding tax rate is 30%. Furthermore, an additional 2% tax might be applicable to
individual shareholders if certain conditions are met. A &#147;substantial shareholder&#148; is generally a person who alone or together with such person&#146;s relative or another person who collaborates with such person on a permanent basis,
holds, directly or indirectly, at least 10% of any of the &#147;means of control&#148; of the corporation. &#147;Means of control&#148; generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets
upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. Notwithstanding the above, dividends paid to a non-Israeli resident &#147;substantial shareholder&#148; on publicly traded
shares, like our ordinary shares, which are held via a &#147;nominee company&#148; (as defined under the Securities Law, 1968), are generally subject to Israeli withholding tax at a rate of 25%, unless a different rate is provided under an
applicable tax treaty, provided that a certificate from the Israeli Tax Authority allowing for a reduced withholding tax rate is obtained in advance. Under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on
dividends paid to a holder of our ordinary shares who is a U.S. resident (for purposes of the United States- Israel Tax Treaty) is 25%. Unless a reduced tax rate is provided under an applicable tax treaty, a distribution of dividends to non-Israeli
residents is subject to withholding tax at source at a rate of 15% if the dividend is distributed from income attributed to an Approved Enterprise or a Benefited Enterprise, while a 20% rate applies if the dividend is distributed from income
attributed to a Preferred Enterprise. We cannot assure you that in the event we declare a dividend we will designate the income out of which the dividend is paid in a manner that will reduce shareholders&#146; tax liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the dividend is attributable partly to income derived from an Approved Enterprise, Benefited Enterprise or Preferred Enterprise, and partly to other
sources of income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. U.S. residents who are subject to Israeli withholding tax on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend may be entitled to a credit or deduction for Untied States federal income tax purposes in the amount of the taxes withheld, subject to detailed rules contained in U.S. tax legislation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estate and Gift Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israeli law presently does not
impose estate or gift taxes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Material U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax considerations relating to the ownership and disposition of our ordinary shares by a
U.S. Holder (as defined below). This description addresses only the U.S. federal income tax considerations to U.S. Holders that will hold such ordinary shares as capital assets. This description does not address tax considerations applicable to U.S.
Holders that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, financial institutions or insurance companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts, regulated investment companies or grantor trusts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers or traders in securities, commodities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax exempt entities or organizations, including an &#147;individual retirement account&#148; or &#147;Roth IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that received our shares as compensation for the performance of services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that will hold our shares as part of a &#147;hedging,&#148; &#147;integrated&#148; or &#147;conversion&#148; transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships (including entities classified as partnerships for U.S. federal income tax purposes) or other pass-through entities, or holders that will hold our shares through such an entity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">S corporations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that acquire ordinary shares as a result of holding or owning our preferred shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons whose &#147;functional currency&#148; is not the U.S. dollar; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own directly, indirectly or through attribution 10% or more of the voting power or value of our shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, this description does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local or non-U.S. tax
considerations of the ownership and disposition of our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This description is based on the U.S. Internal Revenue Code of 1986, as amended,
or the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to
change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a
different position concerning the tax consequences of the ownership and disposition of our ordinary shares or that such a position would not be sustained. Holders should consult their own tax advisers concerning the U.S. federal, state, local and
foreign tax consequences of owning and disposing of our ordinary shares in their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this description, the term
&#147;U.S. Holder&#148; means a beneficial owner of our ordinary shares that, for U.S. federal income tax purposes, is (i)&nbsp;a citizen or resident of the United States, (ii)&nbsp;a corporation (or entity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii)&nbsp;an estate
the income of which is subject to U.S. federal income tax regardless of its source, or (iv)&nbsp;a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one or more U.S.
persons have the authority to control all of its substantial decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity treated as a partnership for U.S. federal
income tax purposes) holds our ordinary shares, the U.S. federal income tax consequences relating to an investment in our ordinary shares will depend in part upon the status of the partner and the activities of the partnership. Such a partner or
partnership should consult its tax advisor regarding the U.S. federal income tax considerations of acquiring, owning and disposing of our ordinary shares in its particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated below, this discussion is subject to U.S. federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Persons considering an investment in our ordinary shares should consult their own tax advisors as to the particular tax consequences applicable to
them relating to the ownership and disposition of our ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion under
&#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, if you are a U.S. Holder, the gross amount of any distribution made to you with respect to our ordinary shares before reduction for any Israeli taxes withheld therefrom,
other than certain distributions, if any, of our ordinary shares distributed pro rata to all our shareholders, generally will be includible in your income as dividend income to the extent such distribution is paid out of our current or accumulated
earnings and profits as determined under U.S. federal income tax principles. To the extent that the amount of any distribution by us exceeds our current and accumulated earnings and profits as determined under U.S. federal income tax principles, it
will generally be treated first as a return of your adjusted tax basis in our ordinary shares and thereafter as either long-term or short-term capital gain depending upon whether the U.S. Holder has held our ordinary shares for more than one year as
of the time such distribution is received. We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles. Therefore, U.S. Holders should expect that the entire amount of any distribution generally
will be reported as dividend income. Non-corporate U.S. Holders may qualify for the preferential rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held
for more than one year) applicable to qualified dividend income (as discussed below). The Company, which is incorporated under the laws of the State of Israel, believes that it qualifies as a resident of Israel for purposes of, and is eligible for
the benefits of, the Convention between the Government of the United States of America and the Government of the State of Israel with Respect to Taxes on Income, signed on November&nbsp;20, 1975, as amended and currently in force, or the U.S.-Israel
Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Israel Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program.
Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; below, if the U.S.-Israel Tax Treaty is applicable, such dividends will generally be &#147;qualified dividend income&#148; in the hands
of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements are met. The dividends will not be eligible for the dividends received deduction
generally allowed to corporate U.S. Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders generally may claim the amount of Israel withholding tax withheld either as a deduction from
gross income or as a credit against U.S. federal income tax liability. However, the foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed the
proportionate share of a U.S. Holder&#146;s U.S. federal income tax liability that such U.S. Holder&#146;s &#147;foreign source&#148; taxable income bears to such U.S. Holder&#146;s worldwide taxable income. In applying this limitation, a U.S.
Holder&#146;s various items of income and deduction must be classified, under complex rules, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
either &#147;foreign source&#148; or &#147;U.S. source.&#148; In addition, this limitation is calculated separately with respect to specific categories of income. The amount of a distribution
with respect to the ordinary shares that is treated as a &#147;dividend&#148; may be lower for U.S. federal income tax purposes than it is for Israeli income tax purposes, potentially resulting in a reduced foreign tax credit for the U.S. Holder.
Each U.S. Holder should consult its own tax advisors regarding the foreign tax credit rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, the amount of a distribution paid to a U.S.
Holder in a foreign currency will be the dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the U.S. Holder receives the distribution, regardless of whether the foreign currency is converted into U.S.
dollars at that time. Any foreign currency gain or loss a U.S. Holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in foreign currency are converted into
U.S. dollars on the day they are received, a U.S. Holder generally should not be required to recognize foreign currency gain or loss in respect of the dividend. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange or Other Taxable Disposition of Our Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; if you are a U.S. Holder, you generally will
recognize gain or loss on the sale, exchange or other taxable disposition of our ordinary shares equal to the difference between the amount realized on such sale, exchange or other taxable disposition and your adjusted tax basis in our ordinary
shares, and such gain or loss will be capital gain or loss. The adjusted tax basis in an ordinary share generally will be equal to the cost of such ordinary share. If you are a non-corporate U.S. Holder, capital gain from the sale, exchange or other
taxable disposition of ordinary shares is generally eligible for a preferential rate of taxation applicable to capital gains, if your holding period determined at the time of such sale, exchange or other taxable disposition for such ordinary shares
exceeds one year (i.e., such gain is long-term capital gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Any such gain or loss that a U.S. Holder recognizes generally will be
treated as U.S. source income or loss for foreign tax credit limitation purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received
are translated into U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a
purchase or sale. An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our ordinary shares that are traded on an established securities market, provided the election
is applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or received are translated into U.S. dollars at
the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S.
Holder realizes will be U.S. source ordinary income or loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any taxable year, a U.S. Holder would be subject to special rules generally intended to reduce or eliminate any benefits from
the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A non-U.S. corporation is classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules
with respect to the income and assets of subsidiaries, either (i)&nbsp;at least 75% of its gross income is &#147;passive income&#148; or (ii)&nbsp;at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a
CFC for the year being tested, would be measured by fair market value of the assets, and for which purpose the total value of our assets may be determined in part by the market value of our ordinary shares, which is subject to change) is
attributable to assets that produce &#147;passive income&#148; or are held for the production of passive income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities
and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares. If a
non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation
and as receiving directly its proportionate share of the other corporation&#146;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares, we will continue to be treated as a PFIC with respect
to such U.S. Holder in all succeeding years during which the U.S. Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must determine our PFIC status annually based on tests which are factual in nature, and our status will depend on our income, assets and activities each
year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, because we had no revenue-producing operations, we believe that we were a PFIC for our 2015 taxable year. In addition, unless and until we
generate sufficient revenue from active licensing and other non-passive sources and otherwise satisfy the asset test above, we expect to be treated as a PFIC in future taxable years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will apply to both (a)&nbsp;any
&#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your holding
period for our ordinary shares) and (b)&nbsp;any gain realized on the sale or other disposition of the ordinary shares. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if
(a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year
(other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#146;s regular ordinary income rate for the current year and would not be subject to the interest
charge discussed below), and (c)&nbsp;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the
lower rates of taxation applicable to long-term capital gains discussed above under &#147;Distributions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain elections exist that may alleviate
some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market treatment) of our ordinary shares. If a U.S. Holder makes the mark-to-market election, the U.S. Holder generally will recognize as
ordinary income any excess of the fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares
over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in
the ordinary shares will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an
ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our ordinary shares are &#147;regularly
traded&#148; on a &#147;qualified exchange.&#148; Our ordinary shares will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of the ordinary shares are traded on a qualified exchange on at least
15 days during each calendar quarter (subject to the rule that trades that have as one of their principle purposes the meeting of the trading requirement as disregarded). The NASDAQ Global Market is a qualified exchange for this purpose and,
consequently, if the ordinary shares are regularly traded, the mark-to-market election will be available to a U.S. Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently intend to
provide the information necessary for U.S. Holders to make qualified electing fund elections. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the
alternative treatments would be in their particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section would
apply to indirect distributions and gains deemed to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns ordinary shares during any year in which we are a PFIC and the U.S. Holder recognizes gain on a disposition of our ordinary shares or
receives distributions with respect to our ordinary shares, the U.S. Holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to
the company, generally with the U.S. Holder&#146;s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the
ownership and disposition of our ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares and the IRS information reporting obligations with respect to the ownership and
disposition of our ordinary shares. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which
may include all or a portion of their dividend income and net gains from the disposition of ordinary shares. Each U.S. Holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax
to its income and gains in respect of its investment in our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding Tax and Information Reporting Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. backup withholding tax and information reporting requirements may apply to certain payments to certain shareholders. Information reporting
generally will apply to payments of dividends on, and to proceeds from the sale or redemption of, our ordinary shares made within the United States, or by a U.S. payor or U.S. middleman, to a holder of our ordinary shares, other than an exempt
recipient (including a payee that is not a U.S. person that provides an appropriate certification and certain other persons). A payor will be required to withhold backup withholding tax from any payments of dividends on, or the proceeds from the
sale or redemption of, ordinary shares within the United States, or by a U.S. payor or U.S. middleman, to a holder, other than an exempt recipient, if such holder fails to furnish its correct taxpayer identification number or otherwise fails to
comply with, or establish an exemption from, such backup withholding tax requirements. Any amounts withheld under the backup withholding rules will be allowed as a credit against the beneficial owner&#146;s U.S. federal income tax liability, if any,
and any excess amounts withheld under the backup withholding rules may be refunded, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Asset Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who
are individuals are required to report information relating to an interest in our ordinary shares, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938
(Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition
of our ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE
INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES.</I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F. Dividends and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G. Statement by Experts
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>H. Documents on
Display </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may inspect our securities filings, including this Annual Report and the exhibits and schedules thereto, without charge at the offices of
the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of the Annual Report from the Public Reference Section&nbsp;of the SEC, 100 F Street, NE, Washington, D.C. 20549 upon the payment of the prescribed fees.
You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding
registrants like us that file electronically with the SEC. You can also inspect the Annual Report on this website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of each document (or a
translation thereof to the extent not in English) concerning our company that is referred to in this Annual Report is available for public view (subject to confidential treatment of certain agreements pursuant to applicable law) at our principal
executive offices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I. Subsidiary Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;
11. <A NAME="toc160947_13"></A>Quantitative and Qualitative Disclosures About Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our
business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates. Approximately
25% of our expenses in 2015 were denominated in New Israeli Shekels and 3% in Euros. Changes of 5% and 10% in the US$/NIS or the US$/Euro exchange rate will increase or decrease the operation expenses by up to 1% and 0.2%, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fluctuations in exchange
rates, especially the NIS against the U.S. dollar, may affect our results, as some of our assets are linked to NIS, as are some of our liabilities. In addition, the fluctuation in the NIS exchange rate against the U.S. dollar may impact our results,
as a portion of our operating cost is NIS denominated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the changes in the exchange rates of the NIS
against the U.S.&nbsp;dollar at year end: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:22.65pt; font-size:8pt; font-family:Times New Roman"><B>Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ended December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inflation Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
do not believe that inflation had a material effect on our business, financial condition or results of operations in the last two fiscal years. If our costs were to become subject to significant inflationary pressures, we may not be able to fully
offset such higher costs through hedging transactions. Our inability or failure to do so could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;12. <A NAME="toc160947_14"></A>Description of Securities Other Than Equity Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc160947_15"></A>PART II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. <A NAME="toc160947_16"></A>Defaults, Dividend Arrearages and Delinquencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;
14. <A NAME="toc160947_17"></A>Material Modifications to the Rights of Security Holders and Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds from Initial Public
Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;6, 2014, we completed an initial public offering in the United States on the NASDAQ Global Market of our ordinary shares,
par value NIS 0.01&nbsp;per share. Pursuant to the initial public offering, we sold a total of 6,760,418 ordinary shares (including the shares sold pursuant to the over-allotment option) at a price of $6.00 per share.&nbsp;The aggregate offering
price of the shares sold (including the over-allotment option) was approximately $40.5 million.&nbsp;The net proceeds we received from the offering (including the over-allotment option) were approximately $34.9 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, we had used approximately $10.9 million of the net proceeds of our initial public offering. We intend to continue to use the
balance of the proceeds from the initial public offering as disclosed in our Registration Statement. None of proceeds from our initial public offering were used for direct or indirect payments to our directors, officers or their associates, or to
persons owning 10% or more of our equity securities, or to our affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. <A NAME="toc160947_18"></A>Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have performed an
evaluation of the effectiveness of our disclosure controls and procedures that are designed to ensure that the material financial and non-financial information required to be disclosed to the SEC is recorded, processed, summarized and reported
timely. Based on our evaluation, our management, including the Chief Executive Officer, or CEO and the Chief Financial Officer, or CFO, has concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the
Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report are effective. Notwithstanding the foregoing, there can be no assurance that our disclosure controls and procedures will detect or uncover all failures
of persons within the Company to disclose material information otherwise required to be set forth in our reports. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Annual Report on
Internal Control Over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial
reporting, as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial
reporting and the preparation and fair presentation of published financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent
limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation and may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our CEO and CFO, conducted an evaluation, pursuant to Rule 13a-15(c) promulgated under the Exchange Act, of the effectiveness, as of
the end of the period covered by this Annual Report, of its internal control over financial reporting based on the framework in Internal Control&#151;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
(2013). Based on the results of this evaluation, management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Independent Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This annual report does not include an attestation report of the Company&#146;s registered public accounting firm because management&#146;s report was not
subject to attestation by our independent registered public accounting firm as emerging growth companies are exempt from this requirement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in
Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our
disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent
limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of
two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent
limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no changes in our internal
control over financial reporting (as defined in Rules 13a-15(f) and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> under the Exchange Act) that occurred during the year ended December&nbsp;31, 2015 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. [<A NAME="toc160947_19"></A>Reserved] </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16A. <A NAME="toc160947_20"></A>Audit committee financial expert </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the Securities and Exchange
Commission and the NASDAQ corporate governance rules. Our board of directors has determined that Mr.&nbsp;Philip&nbsp;A. Serlin and Mr.&nbsp;Dan&nbsp;J. Gelvan are audit committee financial experts as defined by the Securities and Exchange
Commission rules, have the requisite financial experience and are independent as defined by the NASDAQ corporate governance rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;
16B. <A NAME="toc160947_21"></A>Code of Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees,
including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#147;code of ethics&#148; as defined in this Item&nbsp;16B of Form 20-F
promulgated by the SEC. The full text of the Code of Business Conduct and Ethics is posted on our website at<I> www.vblrx.com</I> Information contained on, or that can be accessed through, our website does not constitute a part of this Form 20-F and
is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16C. <A NAME="toc160947_22"></A>Principal Accountant Fees and Services </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth, for each of the years indicated, the fees billed by Kesselman&nbsp;&amp; Kesselman, a member firm of PricewaterhouseCoopers
International Ltd., our independent registered public accounting firm: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Service rendered</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>95</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit fees consist of services that would normally be provided in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant can reasonably
provide, including work regarding the public listing or offering during 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Audit related services relate to reports to the OCS. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Tax fees relate to tax compliance, planning and advice. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors reviews and pre-approves all
audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent auditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;
16D. <A NAME="toc160947_23"></A>Exemptions from the Listing Standards for Audit Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16E. <A NAME="toc160947_24"></A>Purchase of Equity Securities by the Issuer and Affiliated Purchasers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the year ended December&nbsp;31, 2015, neither we nor any affiliated purchaser (as defined in the Exchange Act) purchased any of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16F. <A NAME="toc160947_25"></A>Change in Registrant&#146;s Certifying Accountant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16G.
<A NAME="toc160947_26"></A>Corporate Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a foreign private issuer whose shares are listed on the NASDAQ Global Market, we have the option to
follow certain Israeli corporate governance practices rather than those of NASDAQ, except to the extent that such laws would be contrary to U.S. securities laws and provided that we disclose the practices we are not following and describe the home
country practices we follow instead. We rely on this &#147;foreign private issuer exemption&#148; with respect to the following NASDAQ requirements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Quorum requirement</I>. Under our articles of association and as permitted under the Companies Law, a quorum for any meeting of shareholders shall be the presence of at least two shareholders present in person, by
proxy or by a voting instrument, who hold at least 25% of the voting power of our shares instead of 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the issued share capital required under Nasdaq
requirements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as stated above, we comply with the rules generally applicable to U.S. domestic companies listed on NASDAQ, subject to
certain exemptions the JOBS Act provides to emerging growth companies. We may in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future elect to follow home country practices in Israel with regard to other matters, including the formation of compensation, nominating and corporate governance committees, separate executive
sessions of independent directors and non-management directors and the requirement to obtain shareholder approval for certain dilutive events (such as for the establishment or amendment of certain equity-based compensation plans, issuances that will
result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company and certain acquisitions of the stock or assets of another company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following our home country governance practices, as opposed to the requirements that would otherwise apply to a company listed on NASDAQ, may provide less
protection than is accorded to investors under NASDAQ listing requirements applicable to domestic issuers. For more information, see &#147;Item 3. Risk Factors&#151;We are an &#145;emerging growth company&#146; and a &#145;foreign private
issuer,&#146; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and foreign private issuers will make our ordinary shares less attractive to investors&#148; and &#147;Risk Factors&#151;We are a
&#145;foreign private issuer&#146; and intend to follow certain home country corporate governance practices, and our shareholders may not have the same protections afforded to shareholders of companies that are subject to all NASDAQ corporate
governance requirements.&#148; We will also be required to comply with Israeli corporate governance requirements under the Companies Law applicable to Israeli public companies such as us whose shares are also listed for trade on an exchange outside
Israel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16H. <A NAME="toc160947_27"></A>Mine Safety Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc160947_28"></A>PART III </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_29"></A>Item&nbsp;17. Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial Statements are set forth under Item&nbsp;18. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_30"></A>Item&nbsp;18. Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Consolidated Financial Statements beginning on pages F-1 through F-7, as set forth in the following index, are incorporated herein by
reference. These Consolidated Financial Statements are filed as part of this Annual Report. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_1">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_2">STATEMENTS OF FINANCIAL POSITION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_3">STATEMENTS OF COMPREHENSIVE LOSS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_4">STATEMENTS OF CHANGES IN EQUITY (CAPITAL DEFICIENCY)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_5">STATEMENTS OF CASH FLOWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin160947_6">NOTES TO THE FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160947g83d02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin160947_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">To the shareholders of </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion,
the accompanying balance sheets and the related statements of comprehensive loss, changes in equity (capital deficiency) and cash flows present fairly, in all material respects, the financial position of Vascular Biogenics Ltd<B>. </B>at
December&nbsp;31, 2015 and 2014, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2015 in conformity with International Financial Reporting Standards as issued by the
International Accounting Standards Board. These financial statements are the responsibility of the Company&#146;s board of directors and management. Our responsibility is to express an opinion on these financial statements based on our audits. We
conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates
made by the board of directors and management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion<B>.</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tel-Aviv,&nbsp;Israel</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certified Public Accountants (lsr.)</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A member firm of PricewaterhouseCoopers International Limited</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px dotted #000000; BORDER-TOP:1px dotted #000000; padding-left:8pt; padding-right:8pt">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:1.00em; font-size:10pt; font-family:Times New Roman"><I>Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; text-indent:1.00em; font-size:10pt; font-family:Times New Roman"><I>P.O. Box 50005 Tel-Aviv 6150001 Telephone: +972 -3-7954555, Fax: +972 -3- 7954556, www.pwc.com/il</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin160947_2"></A>STATEMENTS OF FINANCIAL POSITION </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Note</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>U.S. dollars <BR>in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5a</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term bank deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5b</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12a</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NON-CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL NON-CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Liabilities and equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CURRENT LIABILITIES&#151;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12b</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NON-CURRENT LIABILITIES&#151;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance pay obligations, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMMITMENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, NIS 0.01 par value; Authorized as of December&nbsp;31, 2015 and 2014, 70,000,000 and 49,200,000 shares, respectively;
issued and outstanding as of December&nbsp;31, 2015 and 2014, 22,470,321 and 19,898,674 shares, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(142,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL LIABILITIES AND EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The accompanying notes are an integral part of the financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin160947_3"></A>STATEMENTS OF COMPREHENSIVE LOSS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman"><B>Note</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>U.S.&nbsp;dollars&nbsp;in&nbsp;thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RESEARCH AND DEVELOPMENT EXPENSES,</B> net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12c</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12d</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OPERATING LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL INCOME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL EXPENSES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value of convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8,14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">_</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL EXPENSES,</B> net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LOSS FOR THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER COMPREHENSIVE INCOME&#151;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Items that will not be reclassified to profit or loss&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Re-measurements of post-employment benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPREHENSIVE LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>U.S. dollars</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LOSS PER ORDINARY SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>WEIGHTED AVERAGE ORDINARY SHARES OUTSTANDING&#151;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,309,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The accompanying notes are an
integral part of the financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(Continued)&#151;1 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin160947_4">
</A>STATEMENTS OF CHANGES IN EQUITY (CAPITAL DEFICIENCY) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary</B><br><B>Shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred</B><br><B>shares</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>paid&nbsp;in&nbsp;capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>U.S. dollars in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>BALANCE AT JANUARY&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,069,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(92,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>CHANGES DURING THE YEAR ENDED DECEMBER 31, 2013:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Excess of fair value of convertible loan, at date of inception, over the amount received</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Share based payments to employees and non-employees services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>BALANCE AT DECEMBER&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,069,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(109,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>CHANGES DURING THE YEAR ENDED DECEMBER&nbsp;31, 2014:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of convertible loan into preferred E&nbsp;shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,082,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of preferred E&nbsp;shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Employee stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Conversion of preferred shares into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,564,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,564,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of ordinary shares, net of issuance costs in amount of $5,684 thousand</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,760,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Share based payments to employees and non-employees services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>BALANCE AT DECEMBER&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,898,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(127,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(Concluded)&#151;2 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">STATEMENTS OF CHANGES IN EQUITY (CAPITAL DEFICIENCY) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>ordinary<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Ordinary<BR>shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Other<BR>comprehensive<BR>income</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Additional<BR>paid in<BR>capital</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Warrants</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Accumulated<BR>deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>U.S.&nbsp;dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in&nbsp;thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>BALANCE AT DECEMBER 31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,898,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">162,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>CHANGES DURING THE YEAR ENDED DECEMBER 31, 2015:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,882</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Employee stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Issuance of ordinary shares and warrants, net of issuance costs in amount of $1,349 thousand</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Share based payments to employees and non-employees services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>BALANCE AT DECEMBER 31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,470,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">174,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(142,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Amount less than $1 thousand </TD></TR></TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The accompanying notes are an integral part of the financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin160947_5"></A>STATEMENTS OF CASH FLOWS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>U.S.&nbsp;dollars&nbsp;in&nbsp;thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,407</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments required to reflect net cash used in operating activities (see Appendix A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity of short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash generated from (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,090</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of employees stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of preferred E shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares and warrants, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash generated from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,547</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>EXCHANGE GAINS (LOSSES) ON CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH AND CASH EQUIVALENTS AT END OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>APPENDIX A:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments required to reflect net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value of convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange losses on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net changes in severance pay obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease(increase) in long term prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) accounts payable:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>APPENDIX B:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non cash activity&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible loan into preferred E shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The accompanying notes are an integral part of the financial statements. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><A NAME="fin160947_6"></A>NOTES TO THE FINANCIAL STATEMENTS<B> </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 1&#151;GENERAL INFORMATION: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Vascular Biogenics Ltd. (the &#147;Company&#148; or VBL) was incorporated on
January&nbsp;27, 2000. The Company is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL has also developed a proprietary platform of small
molecules, Lecinoxoids, for the treatment of chronic immune-related indications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In October 2014, the Company raised $ 34.9&nbsp;million
in an Initial Public Offering (&#147;IPO&#148;) on the NASDAQ Stock Market (see note 10d), net of issuance costs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">VB-111 is the
Company&#146;s lead product candidate in the company&#146;s cancer program, and VB-201 is the company&#146;s lead Lecinoxoid-based product candidate. In February 2015, VB-201 did not meet the preset endpoints in Phase 2 clinical trials for psoriasis
and for ulcerative colitis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In 2015, the Company launched its Phase 3 clinical trial of VB-111 in rGBM, the first patient in which was
randomized in August 2015. The Company is conducting its Phase 3 clinical trial of VB-111 in rGBM under a special protocol assessment concurred by the FDA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has incurred significant losses, and it expects to continue to incur significant expenses and losses for at least
the next several years. As of December&nbsp;31, 2015, the Company had an accumulated deficit of $142.0 million. The Company&#146;s losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of its clinical
trials, the receipt of payments under any future collaboration agreements it may enter into, and its expenditures on other research and development activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2015, the Company entered into an underwritten offering of 2,500,000 ordinary shares together with accompanying warrants to
purchase an aggregate of 1,250,000 ordinary shares. The combined offering price of each ordinary share and accompanying warrant was $6.00. The net proceeds from this offering, which closed on November&nbsp;6, 2015 were $13.6 million after deducting
the underwriting discounts and commissions and offering expenses payable by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the Company had
cash, cash equivalents and short-term bank deposits of $37.1 million. The Company may seek to raise more capital to pursue additional activities. The Company may seek these funds through a combination of private and public equity offerings,
government grants, strategic collaborations and licensing arrangements. Additional financing may not be available when the Company need it or may not be available on terms that are favorable to the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Approval of financial statements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">These financial statements were approved by the Board
of Directors on March&nbsp;28, 2016. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation of the financial statements</B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The financial statements of the
Company have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board (&#147;IASB&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise
stated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared under the historical cost convention, subject to
adjustments in respect of revaluation of financial liabilities at fair value through profit or loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company&#146;s accounting policies. The areas involving a higher degree
of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note&nbsp;3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Actual results could differ from those estimates and assumptions. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Functional and presentation currency: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Functional and presentation currency </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Items included in the financial statements of the
Company are measured using the currency of the primary economic environment in which the entity operates (the &#147;functional currency&#148;). The financial statements are presented in U.S. dollar ($), which is the Company&#146;s functional and
presentation currency. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Transactions and balances </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Foreign currency transactions are translated into the functional
currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities
denominated in foreign currencies are recognized in the income statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">All foreign exchange gains and losses are presented in the
statements of comprehensive loss within financial income or expenses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cash and cash equivalents </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and short-term
bank deposits (with original maturities of three months or less) that are not restricted as to withdrawal or use, and are therefore considered to be cash equivalents. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property and equipment: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">All property and equipment (including leasehold improvements) are stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditures that are directly attributable to the
acquisition of the items. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Repairs and maintenance are charged to the income statement during the period in which they are
incurred. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Annual rates of depreciation are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">9-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">25-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">An asset&#146;s carrying amount is written down immediately to its recoverable amount if the
carrying amount is greater than its estimated recoverable amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Leasehold improvements in buildings under operating leases are
depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful life of the improvements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Gains and losses on disposals are determined by comparing proceeds with the associated carrying amount. These are included in the statements of comprehensive loss. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Impairment of non-financial assets </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Assets that are subject to depreciation are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset carrying amount exceeds its recoverable amount. The recoverable
amount is the higher of an asset fair value less costs to dispose and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Non-financial assets that suffered from impairment are reviewed for possible reversal of the impairment at each reporting date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2015, no impairment has been recognized. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>f.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial assets: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Classification </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company classifies its financial assets as &#147;Loans and
Receivables.&#148; The classification depends on the purpose for which each financial asset was acquired. The Company&#146;s management determines the classification of financial assets at initial recognition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. The
Company&#146;s receivables include &#147;other accounts receivable,&#148; &#147;cash and cash equivalents,&#148; and &#147;short-term bank deposits.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Recognition and measurement </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Ordinary purchases and sales of financial assets are carried at
the settlement date, the date on which the asset is delivered to or by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Financial assets are derecognized when the rights to
receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership of the assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Loans and Receivables are initially recognized at fair value. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Impairment of financial assets </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company assesses at the end of each reporting period
whether there is objective evidence that a financial asset or group of financial assets is impaired. The amount of the loss is measured as the difference between the asset&#146;s carrying amount and the present value of estimated future cash flows
(excluding future credit losses that have not been incurred) discounted at the financial asset&#146;s original effective interest rate. The asset&#146;s carrying amount is reduced and the amount of the loss is recognized in the statements of
comprehensive loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the Company has not recognized any impairment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>g.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial liabilities: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Financial liabilities at fair value through profit or loss </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">This category includes the
Company&#146;s convertible loan, which was designated by management to be recorded at fair value through profit or loss (see note 8). The loan was convertible into a variable number of Preferred Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gains or losses arising from changes in the fair value of financial liabilities at fair value through profit or loss are presented in the
statements of comprehensive loss under &#147;financial income or expenses.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Other financial liabilities </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Other financial liabilities are initially measured at fair value.
In subsequent periods, the other financial liabilities are presented at amortized cost. Any difference between the consideration and the redemption value is accreted to profit or loss over the term of the liability, using the effective interest
method. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Financial liabilities are classified as current liabilities, unless the Company has an unconditional right to defer settlement of
the liability for at least 12 months after the end of the reporting period, in which case they are classified as noncurrent liabilities. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>h.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share capital </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Ordinary Shares are classified as equity. Incremental costs directly
attributable to the issue of new shares or options are included in equity as a deduction from the proceeds. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Preferred
Shares were converted into Ordinary Shares following the completion of an IPO by the company in 2014 in a ratio of 1:1 (see also note 10). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2014, the Company executed a 1-to-4.5 share split of the Company&#146;s shares by way of an issuance of bonus shares for each
share. Upon the effectiveness of the share split, (i)&nbsp;3.5 bonus shares were issued for each outstanding share, (ii)&nbsp;the number of ordinary shares into which each outstanding option to purchase ordinary shares is exercisable was
proportionally increased, and (iii)&nbsp;the exercise price of each outstanding option to purchase ordinary shares was proportionately decreased. Unless otherwise indicated, and except for authorized capital, all of the share numbers, loss per share
amounts, share prices and option exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-to-4.5 share split. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>i.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Deferred income tax </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Deferred taxes are recognized using the liability method on
temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Deferred income tax assets are recognized only to the extent that it is probable that future taxable income will be available against which the
temporary differences can be utilized. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is
realized or the deferred income tax liability is settled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the absence of expectation of taxable income in the future, no deferred tax
assets have been recorded in the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>j.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Employee benefits: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Post employment benefit obligation </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Israeli labor laws and the Company&#146;s agreements
require the Company to pay retirement benefits to employees terminated or leaving their employment in certain other circumstances. Most of the Company&#146;s employees are covered by a defined contribution plan under Section&nbsp;14 of the Israel
Severance Pay Law from the beginning of their employment with the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With respect to the remaining employees, which are not covered
by a defined contribution plan under Section&nbsp;14 of the Israel Severance Pay Law only from January&nbsp;1, 2010, the Company records a liability in its statement of financial position for defined benefit plans that represents the present value
of the defined benefit obligation as of the statement of financial position date, net of the fair value of plan assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The defined
benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of
highly rated corporate bonds that are denominated in the currency in which the benefits will be paid (NIS) and that have terms to maturity approximating the terms of the related liability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Remeasurement gains and losses arising from adjustments to reflect actual experience and changes in actuarial assumptions are charged or
credited to equity in other comprehensive income in the period in which they arise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Vacation and recreation pay </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Under Israeli law, each employee is entitled to vacation days and
recreation pay, both computed on an annual basis. The entitlement is based on the length of the employment period. The Company recognizes a liability and an expense for vacation and recreation pay based on the entitlement of each employee. <B></B>
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>k.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share-based payments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company operates a number of equity-settled, share-based
compensation plans to employees (as defined in IFRS 2 &#147;Share-Based Payments&#148;), directors and service providers. As part of the plans, the Company grants employees, directors and service providers, from time to time and at its discretion,
options to purchase Company shares. The fair value of the employee and service provider services received in exchange for the grant of the options is recognized as an expense in profit or loss and is recorded to Additional paid in capital within
equity. The total amount recognized as an expense over the vesting period of the options (the period during which all vesting conditions are expected to be met) was determined as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Share based payments to employees and directors by reference to the fair value of the options granted at date of grant. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Share based payments to service providers by reference to the fair value of the service provided. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vesting conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognized over the
vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">At the end of each reporting
period, the Company revises its estimates of the number of options that are expected to vest based on the vesting conditions. The Company recognizes the impact of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to additional paid in capital. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">When options are exercised, the Company issues new shares, with proceeds less directly attributable transaction costs recognized as share
capital (par value) and additional paid in capital. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>l.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Provisions </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Company has a present legal or
constructive obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation. Provisions are measured by discounting the future cash outflow at a pretax interest rate that reflects
current market assessments of the time value of money and the risks specific to the obligation. The carrying amount of the provision is adjusted in each reporting period in order to reflect the passage of time and the changes in the carrying amounts
are carried to the statement of comprehensive loss. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>m.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Research and development expenses </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Research expenses are charged to profit or loss as
incurred. An intangible asset arising from development of the Company&#146;s products is recognized if all of the following conditions are met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It is technically feasible to complete the intangible asset so that it will be available for use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Management intends to complete the intangible asset and use it or sell it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There is an ability to use or sell the intangible asset; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It can be demonstrated how the intangible asset will generate probable future economic benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs associated with the intangible asset during development can be measured reliably. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Other
development costs that do not meet the above criteria are recognized as expenses as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015 and 2014, the Company has not yet capitalized any development costs. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>n</B>.</TD>
<TD ALIGN="left" VALIGN="top"><B>Government grants </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Government grants, which are received from the Israeli Office of
Chief Scientist (the &#147;OCS&#148;) by way of participation in research and development that is conducted by the Company, fall within the scope of &#147;forgivable loans,&#148; as set forth in International Accounting Standard&nbsp;20
&#147;Accounting for Government Grants and Disclosure of Government Assistance&#148; (&#147;IAS&nbsp;20&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As approved by the OCS,
the grants are received in installments as the program progresses. The Company recognizes each forgivable loan on a systematic basis at the same time the Company records, as an expense, the related research and development costs for which the grant
is received, provided that there is reasonable assurance that (a)&nbsp;the Company complies with the conditions attached to the grant, and (b)&nbsp;it is probable that the grant will be received (usually upon receipt of approval notice). The amount
of the forgivable loan is recognized based on the participation rate approved by the OCS; thus, a forgivable loan is recognized as a receivable when approved research and development costs have been incurred before grant funds are received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Since at the time of grant approval there is reasonable assurance that the Company will
comply with the forgivable loan conditions attached to the grant, and it is not probable that the related research and development will generate revenue, grant income is recorded against the related research and development expenses in the
statements of comprehensive loss. If in subsequent periods it becomes probable that royalties will be owed to the OCS, then a liability is recorded at that time. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>o.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Operating lease </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Leases in which a significant portion of the risks and rewards of
ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to the statements of comprehensive loss on a straight-line basis over the period of the lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>p.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Segment reporting </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Operating segments are reported in a manner consistent with the
internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>q.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Loss per Ordinary Share </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Basic loss per share is calculated by dividing the loss
attributable to equity holders of the Company by the weighted average number of Ordinary Shares issued and outstanding during the year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The diluted loss per share is calculated by adjusting the weighted average number of outstanding Ordinary Shares, assuming conversion of all
dilutive potential shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s dilutive potential shares consist of Preferred Shares, convertible loan, and options granted
to employees and service providers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The dilutive potential shares were not taken into account in computing loss per share in 2015, 2014,
and 2013 as their effect would not have been dilutive. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>r.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>The following new standard has been issued, but is not effective for the financial periods beginning January&nbsp;1, 2015, and has not been early adopted: </B></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">IFRS 9, Financial Instruments, addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in
IAS 39 that relates to the classification and measurement of financial instruments. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortized cost, fair value
through other comprehensive income and fair value through profit or loss. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities, there were no changes to
classification and measurement except for the recognition of changes in own credit risk in other comprehensive income for liabilities designated at fair value through profit or loss. The standard is effective for accounting periods beginning on or
after January&nbsp;1, 2018. Early adoption is permitted. IFRS 9 is to be applied retrospectively. The Company is yet to assess IFRS 9&#146;s full impact. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">In January 2016, the IASB issued IFRS 16&#151;Leases which sets out the principles for the recognition, measurement, presentation and disclosure of
leases for both parties to a contract and replaces the previous leases standard, IAS 17&#151;Leases. IFRS 16 eliminates the classification of leases for the lessee as either operating leases or finance leases as required by IAS 17 and instead
introduces a single lessee accounting model whereby a lessee is required to recognize assets and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 2&#151;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
liabilities for all leases with a term that is greater than 12 months, unless the underlying asset is of low value, and to recognize depreciation of leases assets separately from interest on
lease liabilities in the statements of comprehensive loss. As IFRS 16 substantially carries forward the lessor accounting requirements in IAS 17, a lessor will continue to classify its leases as operating leases or finance leases and to account for
those two types of leases differently. IFRS 16 is effective from January&nbsp;1, 2019 with early adoption allowed only if IFRS 15&#151;Revenue from Contracts with Customers is also applied. The Company is currently evaluating the impact of adoption
on its Financial Statements. </TD></TR></TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 3&#151;CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Estimates and judgments are continually evaluated and are based on historical experience and other factors, including
expectations of future events that are believed to be reasonable under the circumstances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company makes estimates and assumptions
concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and
liabilities within the next financial year are discussed below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Share-based payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">With respect to grants to employees, the value of the labor services received from them in return is measured on the date of grant based on the
fair value of the equity instruments granted to the employees. For options granted prior to the Company&#146;s IPO in order to measure the fair value of the labor service received, the Company first measured the share value by using the income
approach method which is an analysis that involves forecasting the appropriate cash flow stream over an appropriate period and then discounting it back to a present value at an appropriate discount rate. This discount rate should consider the time
value of money, inflation, and the risk inherent in ownership of the asset or security interest being valued. Once the share value was estimated, the Company used the Black-Scholes model to value the equity instrument. Since the Company was not
publicly traded, it looked for comparable companies in the healthcare sector to set the volatility assumption and estimated the equity instrument&#146;s life. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management estimates the fair value of the options granted to consultants based on the value of services receivable over the
vesting period of the applicable options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The value of the transactions, measured as aforesaid, is expensed over the period during which
the right of the employees and non-employees to exercise or receive the underlying equity instruments vests; commensurate with every periodic recognition of the expense, a corresponding increase is recorded to additional paid in capital, included
under the Company&#146;s equity (see also note 10). </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4&#151;FINANCIAL RISK MANAGEMENT: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial risk management: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Financial risk factors </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities expose it to a variety of financial
risks: market risk (including foreign exchange risk and price risk), credit and interest risks and liquidity risk. The Company&#146;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize
potential adverse effects on the Company&#146;s financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4&#151;FINANCIAL RISK MANAGEMENT</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Risk management is performed by the Chief Financial Officer of the Company, who identifies
and evaluates financial risks in close cooperation with the Company&#146;s Chief Executive Officer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company&#146;s finance department
is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. The Board of Directors provides guidelines for overall risk management, as well as policies dealing with specific areas such
as exchange rate risk, interest rate risk, credit risk, use of financial instruments, and investment of excess cash. In order to minimize exposure to market risk and credit risk, the Company invested the majority of its cash balances in highly-rated
banks. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Credit and interest risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Credit and interest risk arises from cash and cash equivalents and
deposits with banks. A substantial portion of the liquid instruments of the Company are invested in short-term deposits in a leading Israeli bank. The Company estimates that since the liquid instruments are mainly invested for the short-term and
with a highly-rated institution, the credit and interest risk associated with these balances is immaterial. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">Liquidity risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Prudent liquidity risk management implies maintaining sufficient cash and the
availability of funding through an adequate amount of committed credit facilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Management monitors rolling forecasts of the
Company&#146;s liquidity reserve (comprising cash and cash equivalents and deposits). This is generally carried out based on the expected cash flows in accordance with practice and limits set by the management of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company is in a research stage and has not yet generated revenues. It is therefore exposed to liquidity risk, taking into consideration
the forecasts of cash flows required to finance its investments and other activities. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">Market risk&#151;Foreign exchange risk </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Company might be exposed to foreign exchange risk
as a result of making payments to employees or service providers and investment of some liquidity in currencies other than the U.S. dollar (the functional currency of the Company). The Company manages the foreign exchange risk by aligning the
currencies for holding liquidity with the currencies of expected expenses, based on the expected cash flows of the Company. Had the dollar been stronger by 5% against the New Israeli Shekel (&#147;NIS&#148;), assuming all other variables remained
constant, the Company would have recognized an additional expense of $100 thousand, $87 thousand and $82 thousand in profit or loss for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Capital risk management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s objectives when managing capital are to
safeguard the Company&#146;s ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. It should be noted that the Company is in the research and
development stage and has not yet generated revenues. (See also note&nbsp;1a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4&#151;FINANCIAL RISK MANAGEMENT</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Fair value of financial instruments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The different levels of valuation of financial
instruments are defined as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Quoted prices (unadjusted) in active markets for identical assets or liabilities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Level&nbsp;3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Inputs for the asset or liability that are not based on observable market data (unobservable inputs).</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The fair value of financial instruments traded in active markets is based on quoted market prices at the dates
of the statements of financial position. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">A market is regarded as active if quoted prices are readily and regularly available from an
exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm&#146;s length basis. These instruments are included in level 1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation
techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in
level 2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015 and 2014, the fair value of financial instruments (cash and cash equivalents, short term bank deposits, accounts
receivable and accounts payable) are assumed to approximate their carrying value. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Classification of financial instruments by groups: </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Loans and<BR>receivables</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S.&nbsp;dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in&nbsp;thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2015:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term bank deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (except for prepaid expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2014</B>:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (except for prepaid expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 4&#151;FINANCIAL RISK MANAGEMENT</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Financial<BR>liabilities at</B><br><B>amortized&nbsp;cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>U.S. dollars in<BR>thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2015 -</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2014</B> -<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Composition of monetary balances </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The composition of financial instruments by currency:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NIS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pound<BR>sterling</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro&nbsp;&amp;</B><br><B>SEK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>U.S. dollars in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short term bank deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (except for prepaid expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NIS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pound<BR>sterling</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro&nbsp;&amp;</B><br><B>SEK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>U.S. dollars in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (except for prepaid expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 5&#151;CASH AND CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cash and cash equivalents: </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S.&nbsp;dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in&nbsp;thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash in bank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Short-term bank deposits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The bank deposits in 2015 of $30,056 thousand are for terms of
six months to one year and carry interest at annual rates of 0.49%-1.25%. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 6&#151;PROPERTY AND EQUIPMENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Composition of assets, grouped by major classifications, and changes therein is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated depreciation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;at<BR>beginning<BR>of year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additions<BR>during<BR>the year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance<BR>at end<BR>of year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;at<BR>beginning<BR>of year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additions<BR>during<BR>the year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance<BR>at end<BR>of year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;book<BR>value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><B>U.S. dollars in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2015:</B></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="13" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2014:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="13" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2013:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="13" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7&#151;SEVERANCE PAY OBLIGATIONS, </B>net<B>: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Company has both defined benefit and defined contribution plans. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Company has no obligation relating to the defined contribution plans. The obligation under the defined benefit plans is covered partly by regular deposits with severance pay funds and by the purchase of insurance
policies. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 7&#151;SEVERANCE PAY OBLIGATIONS, </B>net&nbsp;&nbsp;(continued): <B></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Company&#146;s obligation to make pension payments is covered by regular deposits with defined contribution plans. The amounts deposited are not reflected in the statements of financial position.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The amounts recognized in the statements of financial position were as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance pay obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liability in the statements of financial position</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Amounts credited to other comprehensive income for the years ended December&nbsp;31, 2015, 2014 and 2013 were
$6 thousand, $10 thousand and $22 thousand, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The principal actuarial assumptions used for December&nbsp;31, 2015 and 2014
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Future salary increases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The amounts recorded as an employee benefit expense in respect of defined contribution plans for the years ended December&nbsp;31, 2015, 2014 and 2013 were $254 thousand, $268 thousand and $270 thousand,
respectively. </TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8&#151;CONVERTIBLE LOAN </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2013, the Company closed a Convertible Bridge Loan Agreement (&#147;CLA&#148;) with some of its shareholders
and related parties. The CLA provided for the infusion of an aggregate amount of $10.0&nbsp;million in the form of a convertible bridge loan (the &#147;Convertible Loan&#148;), to bridge for the Company&#146;s cash needs until a financing
opportunity was achieved. The Convertible Loan is denominated in U.S. dollars and bore an annual interest rate of 10%. The principal shall automatically convert upon the earlier of: (i)&nbsp;a financing round for investment in preferred convertible
shares of the Company superior to the Preferred D Shares in liquidation preference, in which case the conversion will automatically be into the new round Preferred Shares at an average discount of 22.7%, (ii)&nbsp;immediately prior to an IPO, in
which case the conversion will automatically be into 1,153,773 Preferred D-1 shares or (iii)&nbsp;on April&nbsp;30, 2014, in which case the conversion will automatically be into 1,153,773 Preferred D-1 Shares. The lenders had the right to demand
repayment of the principal amount plus interest only on the occurrence of the earlier of the following events: (i)&nbsp;an event of acceleration as defined in the CLA, (ii)&nbsp;any of the distribution events described in the Articles of Association
or (iii)&nbsp;the consummation by the Company of a transaction generating proceeds to the Company of at least $20.0 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As
aforementioned, the convertible loan was designated by management to be recorded at fair value through profit or loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At initial
recognition, the difference between the fair value of the CLA and the consideration received was $19.4 million, which was charged to additional paid in capital within equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 8&#151;CONVERTIBLE LOAN</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The change in the fair value from January&nbsp;1, 2014 until the Conversion date and from
July&nbsp;1, 2013 to December&nbsp;31, 2013 amounting to $2.3 million and $1.6 million, respectively, were charged to financial expenses in the statement of comprehensive loss. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2014 (hereafter&#151;&#147;Conversion date&#148;), upon the closing of a financing round (see note&nbsp;10c), the Convertible
Loan was converted into 1,082,235 Preferred E Shares. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9&#151;COMMITMENTS: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In April 2011, the Company executed a Commercial License Agreement with Crucell Holland B.V. (&#147;Crucell&#148;), for incorporating the adenovirus 5 in VB-111 and other drug candidates for cancer for
consideration including the following potential future payments: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual license fee of &#128;100&nbsp;thousand ($109 thousand), continuing until the termination of the agreement, which will occur upon (i)&nbsp;the later of the expiration date of the last related patent or
10&nbsp;years from the first commercial sale of VB-111 or (ii)&nbsp;the termination of the agreement by the Company, which is permitted, upon three months&#146; written advance notice to Crucell; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a milestone payment of &#128;400&nbsp;thousand ($436 thousand) upon receipt of the first regulatory approval for the marketing of the first indication for each product covered under the agreement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">royalties of 0.5%-2.0% on net sales. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">There are no limits or caps on the amount of potential
royalties. Pursuant to the agreement, the Company has the right to terminate the agreement by giving Crucell three months&#146; written notice. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2012, the Company signed a lease agreement for the building it uses in consideration of $203 thousand per year. As of September&nbsp;30, 2015, the lease was extended for two years through
September&nbsp;30, 2017. The future minimum lease payments required in each of the next two years under the operating leases for such premises are approximately as follows: 2016&#151;$171 thousand, 2017&#151;$128 thousand. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company entered into operating lease agreements for vehicles it uses. The leases will expire in 2018. The expected lease payments for the
years ending December&nbsp;31, 2016, 2017 and 2018 are approximately $167 thousand, $118 thousand and $32 thousand, respectively. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In February 2013, the Company entered into an agreement with Tel Hashomer&#151;Medical Research, Infrastructure and Services Ltd. (&#147;Tel Hashomer&#148;). The agreement with Tel Hashomer provides that the
Company will pay 1% of any net sales of any product covered by the intellectual property covered under the agreement and 2% of any consideration received by the Company for granting a license or similar rights to such intellectual property. Such
amounts will be recorded as part of the Company&#146;s cost of revenues. In addition, upon the occurrence of an exit event such as a merger, sale of all shares or assets or the closing of an initial public offering such as the IPO, the Company is
required to pay to Tel Hashomer 1% of the proceeds received by the Company or its shareholders as the case may be. Royalty and all other payment obligations under this agreement will expire once the Company has paid an aggregate sum of NIS
100&nbsp;million (approximately $26 million) to Tel Hashomer by way of pay out, exit proceeds and licensing consideration. Amounts previously paid as royalties on any net sales will not be taken into account when calculating this aggregate sum.
Amounts payable upon occurrence of an exit event is not considered to be probable until actual occurrence. Upon occurrence of such event, as such event does not represent a substantive milestone with regard to the Company&#146;s intellectual
property, the amount to be paid is recorded in the Statement of Comprehensive Loss under research and development costs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 9&#151;COMMITMENTS</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In November 2014, following the completion of an IPO the Company paid to Tel Hashomer amount of $0.4 million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In January 2015, the Company entered into an agreement with a Contact Research Organization (&#147;CRO&#148;) according to which it will receive project management, clinical development and other related services
from the CRO for the execution of the Phase 3 rGBM clinical trial study in consideration for up to $18.7 million. Through December&nbsp;31, 2015, expenses in the total amount of $3.6 million were incurred. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants. At time the grants
were received, successful development of the related project was not assumed. In the case of failure of the project that was partly financed by the Government of Israel, the Company is not obligated to pay any such royalties. Under the terms of the
Company&#146;s funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from projects so funded up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of an annual
interest based on Libor. As of December&nbsp;31, 2015, the total royalty amount payable by the Company, before the additional Libor interest, is approximately $18.1 million ($21.7 million including interest). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In addition, under the Research Law, we are prohibited from transferring, including by way of license, the OCS-financed technologies and related intellectual property rights and know-how outside of the State of Israel,
except under limited circumstances and only with the approval of the OCS Research Committee. We may not receive the required approvals for any proposed transfer and, even if received, we may be required to pay the OCS a portion of the consideration
that we receive upon any sale of such technology to a non-Israeli entity up to 600% of the grant amounts plus interest. </TD></TR></TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Composed of shares of NIS&nbsp;0.01 par value, as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred A Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred B Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred C Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred D Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred E Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary Shares (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,470,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,898,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Ordinary Shares confer upon their holders the following rights: (i)&nbsp;the right to vote in any general meeting of the Company; (ii)&nbsp;the right to receive dividends; and (iii)&nbsp;the right to receive upon
liquidation of the Company a sum equal to the nominal value of the share, and if a surplus remains, to receive such surplus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2014, the Company increased its authorized capital to 70,000,000 shares,
NIS&nbsp;0.01 par value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;10, 2014, the Company executed a 1-to-4.5 share split of the Company&#146;s shares by way of an
issuance of bonus shares for each share. Upon the effectiveness of the share split, (i)&nbsp;3.5 bonus shares were issued for each outstanding share, (ii)&nbsp;the number of ordinary shares into which each outstanding option to purchase ordinary
shares is exercisable was proportionally increased, and (iii)&nbsp;the exercise price of each outstanding option to purchase ordinary shares was proportionately decreased. Unless otherwise indicated, and except for authorized capital, all of the
share numbers, loss per share amounts, share prices and option exercise prices in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-to-4.5 share split. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Following the completion of an IPO and the decision of the holders of all outstanding Preferred Shares from March 2014 to waive their
preferential conversion rights with respect to the currently contemplated public offering, the Company converted all outstanding Preferred Shares into Ordinary Shares in a ratio of 1:1. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In January 2014 and May 2014, two former employees exercised options to purchase an aggregate of 132,134&nbsp;Ordinary Shares. The total cash exercise price received by the Company in those transactions was $267
thousand. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>On May&nbsp;15, 2014, the Company closed a round of financing, selling an aggregate of 413,096 Preferred E Shares in consideration of $4,938 thousand. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>On October&nbsp;6, 2014, the Company completed its IPO on the NASDAQ Stock Market in a public offering according to which it issued 6,760,418 Ordinary Shares in consideration for $40.6 million, before issuance
costs. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>On October 2014, immediately prior to the IPO, the Company gave effect to an anti-dilution right held by the Company&#146;s Chief Executive Officer and issued him 342,977 ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>f.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>On November&nbsp;3, 2015, the Company entered into an underwritten offering of 2,500,000 ordinary shares together with accompanying warrants to purchase an aggregate of 1,250,000 ordinary shares. The ordinary
shares and warrants were sold in combination, with one warrant for each ordinary share sold, and represented the right to purchase 0.50 of an ordinary share. The combined offering price of each ordinary share and accompanying warrant was $6.00. The
net proceeds from this offering, which closed on November&nbsp;6, 2015 were $13.6 million after deducting the underwriting discounts and commissions and offering expenses payable by the Company. The warrants will be exercisable beginning on
May&nbsp;6, 2016 and will expire on May&nbsp;6, 2021 at an exercise price of $7.50 per one ordinary share. The ordinary shares and warrants were immediately separable and were issued separately. The fair value of the separable warrants on the date
of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the warrants are mainly as follows: ordinary share price based on the share&#146;s price at the stock market on November&nbsp;3, 2015:
$6.01; expected volatility based on comparable companies in the healthcare sector: 69.0%; risk-free interest rate: 1.59% (the risk-free interest rate is determined based on rates of return on maturity of unlinked treasury bonds with time to maturity
that equals the average life of the warrants); expected dividend: zero; and expected life to exercise of 5.5 years. The consideration was allocated between ordinary shares and warrants based on the ratio of the warrants&#146; fair value and the
ordinary share price. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>g.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share based compensation plans </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In February 2000, the Company&#146;s board of directors
approved an option plan (the &#147;Plan&#148;) as amended through 2008. Under the Plan, the Company reserved up to 1,423,606 Ordinary Shares of NIS&nbsp;0.01 par value of the Company for allocation to employees and non-employees. Each option is
exercisable to acquire one Ordinary Share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In April 2011, the Company&#146;s board of directors approved a new option plan (the &#147;New
Plan&#148;). Under the New Plan, the Company reserved up to 766,958 Ordinary Shares (of which 159,458 Ordinary Shares shall be taken from the unallocated pool reserved under the Plan) for allocation to employees and non-employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2014, the Company&#146;s shareholders approved the adoption of the Employee Share Ownership and Option Plan
(2014)&nbsp;(&#147;2014 Plan&#148;) effective as of the closing of the public offering. Under the 2014 Plan, the Company reserved up to 928,000 Ordinary Shares (of which 28,000 Ordinary Shares shall be taken from the unallocated pool reserved under
the New Plan). The Ordinary Shares to be issued upon exercise of the options confer the same rights as the other Ordinary Shares of the Company, immediately upon allotment. Any option granted under the Plan that is not exercised within ten years
from the date upon which it becomes exercisable, will expire. Any option which was granted under the New Plan, and was not exercised within twenty years from the date when it becomes exercisable, will expire. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In April 2013, the Company&#146;s shareholders approved the extension of the exercise period of options granted to employees and officers
during 2003-2005 by an additional ten years. As a result of such extension, the Company recorded during 2013 additional expense of $115 thousand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Option exercise prices and vesting periods shall be as determined by the board of directors of the Company on the date of the grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The options granted to employees through December&nbsp;31, 2002 are subject to the terms stipulated by section 102 of the Israeli Income Tax
Ordinance (the &#147;Ordinance&#148;). Among other things, the Ordinance provides that the Company will be allowed to claim as an expense for tax purposes the amounts credited to the employees as a benefit upon sale of the shares allotted under the
plans at a price exceeding the exercise price, when the related tax is payable by the employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The options granted to employees after
December&nbsp;31, 2002, are subject to the terms stipulated by section&nbsp;102(b)(2) of the Ordinance. According to these provisions, the Company will not be allowed to claim as an&nbsp;expense for tax purposes the amounts credited to the employees
as a&nbsp;capital gain benefit in respect of the options granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Options granted to related parties or non-employees of the Company are
governed by Section&nbsp;3(i) of the Ordinance. The Company will be allowed to claim as an expense for tax purposes the amounts equal to the expenses it recorded in the financial statements in the year in which the related parties or non-employees
exercised the options into shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In October 2015, the Company&#146;s board of directors approved the granting of 432,470 options under
its 2014 Plan to its employees and officers at an exercise price of $7.52 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Options granted in 2013: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of options granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>price&nbsp;per<BR>ordinary<BR>share&nbsp;($)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>The&nbsp;fair&nbsp;value</B><br><B>of options</B><br><B>on&nbsp;date<BR>of grant (in<BR>thousands)&nbsp;(2)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>according&nbsp;to&nbsp;option&nbsp;plan of the<BR>Company (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.30pt; font-size:8pt; font-family:Times New Roman"><B>Date of grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;than<BR>directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>To<BR>directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*116,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">45,000 options were allocated to an officer who also serves as a director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">The options will vest as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">125,331 options over 4 years from the date of grant; 1/16 of the options at the end of each quarter in the course of the 4 years. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">13,500 options over 1 year from the date of grant; 1/2 of the options vested on the date of grant and 1/2 will vest within a year from date of grant. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are mainly as follows: Ordinary Share price, based on a
valuation prepared by the Company with the assistance of an external independent expert: $4.15; expected volatility based on comparable companies in the healthcare sector: 69.0%; risk-free interest rate: 2.62% (the risk-free interest rate is
determined based on rates of return on maturity of unlinked treasury bonds with time to maturity that equals the average life of the options); expected dividend: zero; and expected life to exercise: 9 years. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Options granted in 2014: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Number of options granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>according&nbsp;to&nbsp;option&nbsp;plan of the<BR>Company (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.30pt; font-size:8pt; font-family:Times New Roman"><B>Date of grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;than<BR>directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>price&nbsp;per<BR>ordinary<BR>share ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>The&nbsp;fair&nbsp;value</B><br><B>of options</B><br><B>on&nbsp;date<BR>of grant (in<BR>thousands)&nbsp;(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*374,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">was allocated to an officer who also serves as a director. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">The options are fully vested. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are mainly as follows: Ordinary Share price, based on a
market price : $6; expected volatility based on comparable companies in the healthcare sector: 85.0%; risk-free interest rate: 2.42% (the risk-free interest rate is determined based on rates of return on maturity of unlinked treasury bonds with time
to maturity that equals the average life of the options); expected dividend: zero; and expected life to exercise: 10 years. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Options granted in 2015: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other&nbsp;than<BR>directors</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;options&nbsp;granted<BR>according&nbsp;to&nbsp;option&nbsp;plan<BR>of the Company (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>price per<BR>Ordinary<BR>Share&nbsp;<BR>($)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>The&nbsp;fair</B><br><B>value&nbsp;of<BR>options&nbsp;on&nbsp;date<BR>of grant&nbsp;(in<BR>thousands) (2)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:45.30pt; font-size:8pt; font-family:Times New Roman"><B>Date of grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>To<BR>directors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1)&nbsp;February 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2)&nbsp;November 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">60,000 options were allocated to two external directors of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">The options will vest over 3 years from the date of grant; 1/12 of the options at the end of each quarter in the course of the 3 years. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are mainly as follows: an exercise price equal to
$6.03, fair value of these options was estimated at $722 thousand with expected volatility based on comparable companies in the healthcare sector: 69.0%; risk-free interest rate: 1.99% (the risk-free interest rate is determined based on rates of
return on maturity of unlinked treasury bonds with time to maturity that equals the average life of the options); expected dividend: zero; and the contractual term. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">432,470 options were allocated to employees and officers of the Company: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">The options will vest by 4 years with 50% on the second year anniversary; the remaining 50% at 1/8 of the options at the end of each quarter over the course of the last 2 years. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data used for computing the fair value of the options are mainly as follows: an exercise price equal to
$7.52, fair value of these options was estimated at $1,916 thousand with expected volatility based on comparable companies in the healthcare sector: 86.0%; risk-free interest rate: 2.28% (the risk-free interest rate is determined based on rates of
return on maturity of unlinked treasury bonds with time to maturity that equals the average life of the options); expected dividend: zero; and the contractual term. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>h.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Changes in the number of options and weighted average exercise prices are as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,885,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,543,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,647</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,134</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,304,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,885,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,688,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 10&#151;SHARE CAPITAL</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>i.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>The following is information about exercise price and remaining contractual life of outstanding options at year-end: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December 31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of<BR>options<BR>outstanding<BR>at end
of<BR>year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average of<BR>remaining<BR>contractual<BR>life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>options<BR>outstanding<BR>at end of<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average of<BR>remaining<BR>contractual<BR>life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>options<BR>outstanding<BR>at end of<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise</B><br><B>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average of<BR>remaining<BR>contractual<BR>life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">406,841</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">171,990</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">721,632</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">729,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">511,246</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">60,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">432,470</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">2,304,179</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,885,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>j.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>Expenses for share based compensation recognized in statements of comprehensive loss were as follows: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in&nbsp;thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative and general expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The remaining unrecognized compensation expenses as of December&nbsp;31, 2015 are $1,822 thousand; this amount
will be expensed in full by July 2019. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11&#151;TAXES ON INCOME </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is taxed according to Israeli tax laws: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Measurement of results for tax purposes </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company measures its results for tax
purposes in nominal terms in NIS based on financial reporting under Israeli accounting principles, while (as detailed in note 2) the functional currency of the Company is the dollar and the Company&#146;s financial statements are measured in dollars
and in accordance with IFRS. Therefore, there are differences between the Company&#146;s taxable income (loss) and income (loss) reflected in these financial statements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Tax rates </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The income of the Company, other than income from Benefitted Enterprises (see
c below), is subject to the normal corporate tax rate. The corporate tax rate for 2015, 2014 and 2013 were 26.5%, 26.5% and 25%, respectively. In January 2016, the Law for the Amendment of the Income Tax Ordinance (No.&nbsp;216) was published,
enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from 26.5% to 25%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11&#151;TAXES ON INCOME</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Tax benefits under the Law for the Encouragement of Capital Investments, 1959 </B>(the &#147;Investment Law&#148;) <B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the Investment Law, including Amendment No.&nbsp;60 to the Investment Law that was published in April 2005, by virtue of the Benefited
Enterprise program for certain of its production facilities, the Company may be entitled to various tax benefits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The main benefit arising
from such status is the reduction in tax rates on income derived from a Benefited Enterprise. The extent of such benefits depends on the location of the enterprise. Since the Company&#146;s facilities are not located in &#147;national development
zone A,&#148; income derived from Benefited Enterprises will be tax exempt for a period of two years and then have a reduced tax rate for a period of up to an additional eight years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The period of tax benefits, as described above, is limited to 12 years from the beginning of the Benefited Enterprise election year (2012). As
of December&nbsp;31, 2015, the period of benefits has not yet commenced. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the event of distribution of cash dividends from income which
was tax exempt as above, the amount distributed will be subject to the tax rate it was exempted from. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company is entitled to claim
accelerated depreciation in respect of equipment used by the approved enterprises during five tax years. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Entitlement to the above benefits
is conditioned upon the Company fulfilling the conditions stipulated by the Investment Law and regulations published thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In the
event of failure to comply with these conditions, the benefits may be canceled and the Company may be required to refund the amount of the benefits, in whole or in part, with the addition of linkage differences to the Israeli consumer price index
and interest. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Investment Law was amended as part of the Economic Policy Law for the years 2011&#151;2012 (the &#147;Amendment&#148;),
which became effective on January&nbsp;1, 2011. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Amendment sets alternative benefit tracks to the ones currently in place under the
provisions of the Investment Law, including a reduced corporate tax rate. Tax rate for &#147;Preferred Enterprise&#148; income of companies not located in national development zone A is 16% for fiscal year 2014 and thereafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The benefits are granted to companies that qualify under criteria set forth in the Investment Law; for the most part, those criteria are
similar to the criteria that have existed in the Investment Law prior to its amendment and the benefit period is unlimited in time. However, in accordance with the Amendment, the classification of licensing income as Preferred income is subject to
the issuance of a pre-ruling by the Israel Tax Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under the transitional provisions of the Investment Law, a company is allowed to
continue to enjoy the tax benefits available under the Investment Law prior to its amendment until the end of the period of benefits, as defined in the Investment Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In each year during the period of benefits of its Benefitted Enterprise, the Company will be able to opt for application of the Amendment,
thereby making available to itself the tax rate described above. The Company&#146;s election to apply the Amendment is irrevocable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2015, the Company&#146;s management decided not to adopt the application of the Amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 11&#151;TAXES ON INCOME</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">There is no assurance that future taxable income of the Company will qualify as Benefited or
Preferred income or that the benefits described above will be available to the Company in the future. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Losses for tax purposes carried forward to future years </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The balance of carry forward
losses as of December&nbsp;31, 2015 and 2014 are $121 million and $102 respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Under Israeli tax laws, carryforward tax losses have
no expiration date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Deferred tax assets on losses for tax purposes carried forward to subsequent years are recognized if utilization of
the related tax benefit against a future taxable income is expected. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company has not created deferred taxes on its carry forward
losses since their utilization is not expected in the foreseeable future. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Tax assessments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The Company has tax assessments that are considered to be final through
tax year 2010. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 12&#151;SUPPLEMENTARY FINANCIAL INFORMATION: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>a. Other current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Institutions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government grants receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>b. Accounts payable&#151;</B>other:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee&#151;related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sundry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 12&#151;SUPPLEMENTARY FINANCIAL INFORMATION</B>&nbsp;&nbsp;(continued):<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>c. Research and development expenses, </B>net:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subcontractors and consultation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office rent and maintenance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government grants (see note 9e)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>d. Administrative and general expenses</B>:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign travel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 13&#151;LOSS PER SHARE </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted loss per share: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Basic </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic loss per
share is calculated by dividing the result attributable to equity holders of the Company by the weighted average number of Ordinary Shares in issue during the year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Diluted </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All Ordinary
Shares underlying Preferred Shares and outstanding options have been excluded from the calculation of the diluted loss per share for the years ended December&nbsp;31, 2015, 2014 and 2013 since their effect was anti-dilutive. The total number of
options excluded from the calculations of diluted loss per share were &#150; 2,304,179, 1,885,123, and 1,642,348 for the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 13&#151;LOSS PER SHARE</B>&nbsp;&nbsp;(continued):<B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S. dollars in thousands,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>except per share data</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted</B>:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to equity holders of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of ordinary shares in issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,309,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,627,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 14&#151;FINANCIAL INCOME, </B>net<B>: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>U.S.&nbsp;dollars</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>in&nbsp;thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest from deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value of convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other financial expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TOTAL FINANCIAL EXPENSES, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VASCULAR BIOGENICS LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>NOTES TO THE FINANCIAL STATEMENTS&nbsp;&nbsp;(continued)<B> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 15&#151;RELATED PARTIES&#151;TRANSACTIONS AND BALANCES: </B></P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Transactions with related parties </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Key management personnel include members of the Board
of Directors, the Chief Executive Officer and all Vice Presidents of the Company and companies controlled by them<B>. </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>U.S. dollars in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1) Expenses&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Administrative and general expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value of convertible loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2) Key management compensation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Labor cost and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Balances with related parties: </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>U.S. dollars in<BR>thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management&#151;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payables and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Severance pay obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTE 16&#151;SUBSEQUENT EVENT </B></P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2016, the Company granted 114,129 restricted stock units (&#147;RSUs&#148;) to its officers with a milestone vesting period
dependent on the achievement of certain milestones. This grant was for the October&nbsp;25, 2015 RSUs approved by the Board.&nbsp;The fair value of these RSUs on the date of grant was approximately $412 thousand.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc160947_31"></A>Item&nbsp;19. Exhibits </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Articles of Association of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on September&nbsp;30,
2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Memorandum of Association of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.4 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on September&nbsp;30,
2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, dated as of March&nbsp;13, 2008, by and among the Registrant and the other parties thereto, as amended. (incorporated by reference to Exhibit 4.1 of the Registration Statement
on Form F-1 filed with the Securities and Exchange Commission on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.2 of Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July&nbsp;29, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase ordinary shares, dated May&nbsp;8, 2014, issued to S.R. Horn Assets Ltd. (incorporated by reference to Exhibit 4.3 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on
June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase ordinary shares, dated April&nbsp;1, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.4 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission
on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase ordinary shares, dated May&nbsp;14, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.5 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on
June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to purchase ordinary shares, dated December&nbsp;28, 2001, issued to Dror Harats, as amended (incorporated by reference to Exhibit 4.6 of the Registration Statement on Form F-1 filed with the Securities and Exchange
Commission on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employee Ownership and Share Option Plan (2011) of the Registrant, and form of agreement thereunder (incorporated by reference to Exhibit 10.1 of the Registration Statement on Form F-1 filed with the Securities and Exchange
Commission on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Release and Indemnification Agreement to be entered into between the Registrant and its officers and directors (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form F-1 filed with the Securities
and Exchange Commission on June&nbsp;25, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Commercial Gene Therapy License Agreement, dated April&nbsp;15, 2011, between the Registrant and Crucell Holland B.V. (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form F-1 filed with the Securities and
Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement, dated February&nbsp;3, 2013, between the Registrant and Tel Hashomer&#151;Medical Research, Infrastructure and Services Ltd. (incorporated by reference to Exhibit 10.4 of the Registration Statement on Form F-1 filed with
the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Manufacturing Services Agreement, dated January&nbsp;5, 2012, between the Registrant and Lonza Houston, Inc. (incorporated by reference to Exhibit 10.5 of the Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;F-1</FONT> filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement, dated May&nbsp;14, 2008, between the Registrant and Genzyme Pharmaceuticals (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form F-1 filed with the Securities and Exchange
Commission on June&nbsp;6, 2014).</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Technical Agreement on the Manufacture of Capsules, dated April&nbsp;29, 2008, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order (incorporated by reference to Exhibit 10.7 of the
Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Technical Agreement on the Manufacture of Capsules, dated August&nbsp;3, 2012, between the Registrant and Encap Drug Delivery and standard terms and conditions of purchase order (incorporated by reference to Exhibit 10.8 of the
Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Material Transfer and Confidentiality Agreement, effective as of September&nbsp;19, 2005, among the Registrant, Crucell Holland B.V. and BioReliance Ltd. (incorporated by reference to Exhibit 10.9 of the Registration Statement on
Form F-1 filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Services Agreement, dated September&nbsp;24, 2012, between the Registrant and BioClinica, Inc., and Addendum dated November&nbsp;19, 2012 and August&nbsp;29, 2013 (incorporated by reference to Exhibit 10.10 of the
Registration Statement on Form F-1 filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clinical Trial Agreement, dated September&nbsp;9, 2012, between the Registrant and SCIderm GmbH (incorporated by reference to Exhibit 10.11 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission
on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Service Agreement, dated November&nbsp;8, 2012, between the Registrant and KCR S.A. (incorporated by reference to Exhibit 10.12 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on
July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Service Agreement, dated December&nbsp;16, 2013, between the Registrant and KCR S.A. (incorporated by reference to Exhibit 10.13 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission on
July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.14#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement, dated January 2013, between the Registrant and Matzlawi Building Company Ltd. (incorporated by reference to Exhibit 10.14 of the Registration Statement on Form F-1 filed with the Securities and Exchange Commission
on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Material Transfer and Confidentiality Agreement, effective February&nbsp;6, 2012 between the Registrant, Crucell Holland B.V. and Lonza Houston, Inc. (incorporated by reference to Exhibit&nbsp;10.15 of the Registration Statement on
Form F-1 filed with the Securities and Exchange Commission on July&nbsp;18, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement between the Registrant and Prof. Jacob George, dated January&nbsp;24, 2010, as amended on August&nbsp;1, 2012 (incorporated by reference to Exhibit 10.16 of the Registration Statement on Form F-1 filed with the Securities
and Exchange Commission on June&nbsp;6, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employee Share Ownership and Option Plan (2014) of the Registrant, and form of Capital Gains Option Agreement thereunder (incorporated by reference to Exhibit 10.17 of the Registration Statement on Form F-1 filed with the Securities
and Exchange Commission on June&nbsp;25, 2014).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Services Agreement, effective as of January&nbsp;30, 2015, by and between PPD Development, L.P. and the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>12.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>13.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>15.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, Independent Registered Public Accounting Firm.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit have been omitted pursuant to a grant of confidential treatment by the Securities and Exchange Commission and the non-public information has been filed separately with the Securities and
Exchange Commission. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top">English summary of original Hebrew document. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">The certifications furnished in Exhibit 13.1 hereto are deemed to accompany this Annual Report on Form&nbsp;20-F and will not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of
1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant
specifically incorporates it by reference. </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to
sign this annual report on its behalf. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VASCULAR BIOGENICS LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dror Harats</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dror Harats</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 29, 2016 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>d160947dex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 12.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Dror Harats, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 20-F of Vascular Biogenics Ltd.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
company as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the company&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#146;s auditors and the audit committee of the
company&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;March&nbsp;29, 2016 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dror Harats</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dror Harats</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>d160947dex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-12.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 12.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Amos Ron, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 20-F of Vascular Biogenics Ltd.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
company as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The company&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the company&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the company&#146;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to
materially affect, the company&#146;s internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The company&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#146;s auditors and the audit committee of the
company&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#146;s ability to record, process,
summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 29, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amos Ron</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amos Ron</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>d160947dex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-13.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 13.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO 18 U.S.C. SECTION&nbsp;1350, AS ADOPTED PURSUANT TO SECTION&nbsp;906 OF THE SARBANES- </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OXLEY ACT OF 2002 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the Annual Report of Vascular Biogenics Ltd. (the &#147;Company&#148;) on Form 20-F for the period ended December&nbsp;31, 2015 as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Dror Harats, Chief
Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) the Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March 29, 2016 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dror Harats</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dror Harats</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Vascular Biogenics Ltd. (the &#147;Company&#148;) on Form 20-F for the
period ended December&nbsp;31, 2015 as filed with the Securities and Exchange Commission (the &#147;Report&#148;), I, Amos Ron, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) the Report fully complies with the requirements of section
13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;March&nbsp;29, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Amos Ron</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amos Ron</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>5
<FILENAME>d160947dex151.htm
<DESCRIPTION>EX-15.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-15.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 15.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-202463) and Form F-3 (No. 333-207250)
of Vascular Biogenics Ltd. of our report dated March&nbsp;28, 2016 relating to the financial statements, which appears in this Form 20-F. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="63%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tel-Aviv, Israel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;28, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certified Public Accountants (Isr.)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A member firm of PricewaterhouseCoopers International Limited</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g160947g12b69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g12b69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1PH4&AO=&]S:&]P(#,N,  X0DE-! 0
M     '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$W
M-#8U-AP"!0! 36EC<F]S;V9T(%=O<F0@+2!60DQ4("T@1F]R;2 R,"U&(%]7
M;W)K:6YG($=R;W5P($-U;75L871I=F4@0V]M;0 X0DE-!"4      ! /I3Q:
M$R'8\4VQ\UV%?I,'.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             "S0  !DT          0
M       !              9-   "S0                     !
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M;&]N9P   LT     4F=H=&QO;F<   9-     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    &.$))300,     !&'     0   *
M  !'   !X   A2   !%K !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !' * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MC=^/:/;/^%;NVM_>V_ZLB*Z27>^@%KG18ZE\$-:UP<UN_P!7=:[VUO\ YO\
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MM8WTV* ZS2&Q[M>3]EIDSIK^G_U_ZVJ_J8G_ '"Q_P#P;_WH2]3$_P"X6/\
M^#?^]"C_ -%<QWQ_XV3_ +UUA\<^&C08\_\ X7R__?M[H]O2<GK]%^2^RNPN
M;Z+2QM-7JM#:J 74676-^C_UVW^<7HGHY'@S[S_Y%>??5W)KKZQCG'P*W6/)
M9-(>;&!WT[V?:+;J6^FWZ>[_  ?^$7H$W?Z5WW-_\@I(<MDP7&?!<M?29%H<
M_P [BYN<)8O=X(1X*R\ JOW(XU>C?X,_SC_Y%/Z.1X,_SC_Y%--W^D=]S?\
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MT![=_O(9^;_*7SLDG8^#CC7'N/F^7_"6S]SA/\WL=KM]>^S_ %B_[L?]N?\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C(U(#$Q.C0Q.C,R ')R,3<T
M-C4V       #H $  P    '__P  H ( !     $   9-H , !     $   +-
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!2$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M 0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,38Z,#,Z,C4@,3$Z-#$Z,S( <G(Q-S0V-38       .@
M 0 #     ?__  "@ @ $     0  !DV@ P $     0   LT         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
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M 0$! 0$! 0$!_\  $0@ Y0($ P$1  (1 0,1 ?_$ !\  0 ! P4! 0
M       !!@<( @0%"0H#"__$ 'L0   $! ,#!0D%$ H*#@@""P$#! 4"!@<1
M "$Q"$%1$A-A<? )%!46%QB!D:%7L<'1X1DB)"8G,C9&4E9FE):7UO$C)34W
M0D=5=M/5,S135%AB=Y*UUR@X0T1%2&1E9W*%AI.5<W1U@H2'I;8*IV.FM+?"
MQ,7&Q]3B_\0 '@$! 0 !!0$! 0            $& @,$!0<("0K_Q " $0
M! ,#!@8)"0T/#0P)! ,! @,$  41!B$Q!Q)!46'P$Q06<8&1"!4B5J&QP='5
M%U15DY66U.'Q&",F,C5%4E-79764T@D9)"4S-#9"1$98A9*TUB<H-T-'8F-D
M<H*7T^(X2&9T=G>#A(:DL\5SAXB8HK*UML1GIL;E>,+#_]H # ,!  (1 Q$
M/P"CJFST5)/CA,KTX.L#0T.JZ-7WI$>H4A >] A) D@#R^4'.JB0MR@"& 1B
MO:&P_JO,IO*K-6:[>31(W$F3-F=?B[8'"YN%!!$@$2 ,XYA45*% ':(XQ^&$
MML].K9VY4LQ)%2=LIG-YJDT*Z=BU;%% SMVH*BYA$J1"H('$#"%PYH10\N5A
M99C/<TD+L],#BS@EC<&N;RU4M+B"5I41Z13"2XFP!&G.*+,C+C@,$>3",<4
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MI.$277[CYTB<@@8BBF:0Q1SBF$,?H9,L)2F%$;,4):R(20!&8[EE*XA/'DD
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M@$/M*7\@OFOWU1C'&' _NA<!_P#2*8W;<.JH5VP%R<<K."T=?]\G:Y6"PQ\
MMQ'HM;#@$/M*=U/VA?-UU\4!<N-#A6H_X0^@<![KG#KI?%LILK4U2:\',CH9
M.*Q6E9(9B71L;6N=TR!EB4GI17KSDYH"F().3&<^9$7S98# (QB,5@P2T-O+
M.V:F1Y6]835RY1EH3=R,MDR\P2:R\5E$1=.3MRFX)(ATCYQC!0I::Z1ZA9')
M=:VV<F3GLLFDB9,EYT:SS,)U:)K*5W\W!NBY*R9)NS%!==1-=,4R%, G,)@P
M*(QR\L588IN5+TK),R@TQ":W%0]\*HTG?XNC84ZI(FTLY1 >MA[S.@C.AA*@
M-(,$2S"X>3CM)-:FS,^7<MY<X04.W,T(45$R(E<\>8(3) S,%*&7#BKA,Y\T
ME4Q$2F *1TMHK"VRLNU9NYRS=(INRS$YBI**.#,>UDU<R5T28"EGD:F"8-%D
MTQ.IFK  '3,8HQ4\,SP1QK"X9C*C,;X8Q7EP/!442 "Q$(XET *8HD80" \J
M)2!07N VM;'=@ZE)CN"%<2\QV@"+H@*MQ,V /IA<% U4@#3P@% *#&,G8STB
M;14S2:E3F @5@<S=V4CTQJ9@-3F)FN#&$0 ."$U:A0,(#-1((REXS*0" V,"
MBG 7LD$1QHQ#"!12P5?>YAH\B.T$!L48Q0#8+PB 3C<GXN1WQF7<64.!$W'#
M-^ .H(B4"%5S@(8PB @!0-41"E*QJ"7S_C:DN!E-A?(IBHLRXN[XTFD4 $ZB
MB EX5,A2F QCF*4  0$34K$NLS> V]4ZO#[$VMJ(H3UBY8O,(2IB@B@AY1AL
M<?)Y4<8PEP0!<PTZ,LHJ",R." :_<2N6,W$QF"C1FR:IBJX<KBFDBFF%U3'-
M0H5$0*6_.,82E+41 !T2MG.9U,&DIE"+^93)\L5!FR9@LLX75&H@1--/.$<T
MH',<UQ4R 8YQ*0IC%XV5)YAG&7VV9V5Q=(FMV+4&HQ51G)SHBTRQ0CCBC) ^
M/FQB.2'"7")EQ@Y$<0011##C@V>F\HM/)V<[E:>>P?%4,W.LAP*IBI+*(&$R
M9@SBU.F82@(U$M!$ PCM+66?GUB[0S&S,[4X.:RLZ*;Q-NZ%=$AUFR+HI2K$
M$"*"":Q ,)1S0-4 $0"IN?\ "3D _P!OK,@S^B3K9[LH]_'T=..ZX!#[2EC]
M@7S?%&.<9<5_7"UU?[8I310!OZ<=D3X3<<_VP5\?[9/"VH7^ORSXW] 9X<70
M^TI_R"^;1KQNB\9<?;U?;5,*\^C3JTT@#FXB ?1RZ]P$1!4>.5]UC+]8C"-[
M!D.0XO (_:4O:R^:)QEP-W#K>VG'GI?MU7AS@,47.-34\DQ,A;H;-"Y5,2U0
MWM*)A2+'A>J5)B 4FP0)"3831$"XPB (88XH@A&P6A$<8M::TTFLL$N!^R>N
MEIJZ49L6TKEQW[I9=)NHY.4J"(9X@"*2AZ@ T HC0+QC-[&6+M#;@TX&63&6
M,&\B8)S"9OIY.$Y2Q:M5G:+)(YW+@02 3.'":8 80J)BA6M 'A9?KI*<RK$B
M!#,;BF4*F]P<#/"HG-,*$6MR):EB!QB6J"^]'.%4>3R4D<,0FDF0F01_/PPC
MULHM]9"<KMVS54457#5XZ$'[0S'BHR]ZE+W35YQDI!;NTW2Z9 0.&<?. 2B(
M"6O<S_)3E LXU>/'K8'"#1_+F)3RM^$SX\$VEKB;L'TOXF*P.Y<LQ;*JB[3-
MFD$HE.4I@-FW#BF*(M; W&/O(<#8.=);XW6"!<<4 #RHRD@GPJ3"P"&,><@*
MB+Y,$8\JT,5LP,O*RN",Q69%=*$SR-A.@#@Y*".>5$1X0Q:%'N@*-*#?'GI6
MTY.S5F!4)D:7I* DH]!)R+1)2I0!,[@ X,B@B<M"F. ]T4:1\RIG@.+4G$3(
M4:4ABB!>82\DFEHN2$0B"R.!3%"D$.1'>$^(H80AB$0^=BMH3=2A4BZB3B7J
M$:B(.3D50,1N)?I@7, B"8A?7/H(:8UK2^?(*-$EFDU2._ #,TU4713O /0"
M&:D,4#+E.(@!>" P#G !;X^XS"8".-Q![,C;X$YJR)<4X&&I!3$01F'* 4%&
MF%QE0%EQQ11P1" !"( (CINY\OXJ+PIFRC4J1EA<)\&HD*12B8QRG3J4Q0*
MC4M<!TWQLBE,P> P.1XF^%8C;BJO"I+@N<X$*B9-42F*<3B!<TX (&$ '$(H
MF3ZNM$\JE"!D<I@*5IF],[P)G9$YM1JYG6&B0F=VX%80@J;3CH>:A40A"/+B
MA"*"'E!C%[-VPLW:EPX:RQ-T1P@V0?E2?RUPP,ZESDZB;>8- <)DX=FL=(Y2
M+$Q$+P"H".:VQR>6PL.U:/9PJQ5:NGCJ6*+2F=-)JFQG#)-)9Y)Y@+-94&DR
M:IK)'5;J!](>I3&S34KX7-P !LX+,M/HDZX7 +#_ &0 STS#/=C, ;H?:4_Y
M!1\81Y_QE<:APZVKZ=2ZN%>ZYJ5IIAX3<=S@L$+ /]M'6WWL(F9YCD(\-]Q'
M#BZ'VE/^04/$$.,. _MRNC^VG"G36^G1@&V'A-QMDN69?\I/ !W#J9?(;YVX
M: (X< A]J3_D%\W/CY I>,N?MZWMI\/Y6CS<P4Y-D]ER7+[E,SVY.H-;3"GB
M5BCB/5*OHM:F;R0*(YXOG8N^%1,,8<L A@$8[C:P]+:&;RFS,H=SJ9I&!DS!
M(5N+MN'6'AEDT$P32* &.85%2A0- Z@C(K)6?G=L[02^S4D7(,RF1ERMQ=O!
M:MR@V;K.E3+.#B)4R$204,(B WTUU&B$M?I94+"VU2X34S.ICVT,$;4_-K@S
MKTBE])/.;%BPA:; !#6<6F.Y2SG(H2@L,< 0&01Q8HTRDV1<+D:*(S"7OC3)
MC*SL9I*5V+I!68H.7+1PNDX*4",U4FC@>,YQBE$E#9M0KG;[(W;UFU5?MW$J
MG$L))9I/4YI(Y^VFS!RA)G3)E,6C99HHH*DP07?M0%GF%44!013SA*(!<HV:
MBB2DRDV94Y29</(1*#7LDLE9%]:$*,Z-2!*J*XA\Z1&8.8!:V,W.[DY$T%3N
M9>1)T-&RIEFY4W!AT(G$P%5'"@$$<0 (\T3E\_46=-TF4V478E$[U$C=V=9H
M4!O,Y2 @F0 *")A4*4 TW8_8)ABB6Q-L+]RW&"$#8V\'6")>64(!%RS$0*!4
MP%\F.",#!+"$8!@$(K"&-T%I:9P9F51D9V4F>9L!T1<%3I].9(!X0"WAW0E
M+\8V!;3@C,LP%&8E8**<$1Z9-P#0RH"8!2*XH")E"B U("@FN$*!&I(_F+H(
MS$3V*Z LV,@V-&Y]\EEGP  QDQQD'F0EFP<H.65'$!D(#"(PA< '4@>7N@,9
MJ9HX*F<4E#("BJ!%"B&<F<29V:<,#%-00OK2(Y2FC$R9'J;]H=9(JR17)7*
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M .F_$=(=8! 7)QN(^$%@!8<^^3Q"^X;\OI <[WTW" . 0I3@DOY!:[1PKO2
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MPB.0]+Y17R4U3(VJR42=,LGF9GID2(30,3)&-Q,2BWD%EP0P%I>1S9L420L
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M4$\YN0QOI+X^H;6Y TY78NQ[R6IS5"U!YC9J66R/,4'!)2@O;,B:TH59'!
M,C*E5D9;,S(F5S72I2#16A1YE;M'L3<A9UCI*<R-T3R@B?DB96H8B#S)9#F(
M"WHD#7,N%6*LXXXI$U)HHG!2"0\T"RR^1R^S<9:92S:2YV\D<U:]LF1IP@@X
M<2E)<9$ ( 29D(I,"@L=<ZIBM9>B91\L5%50J(%S1/U#/L<+03*83B7RZTLA
M?=I9D2SSIVU;3YRU+:DPN15DJIT9.<S5)HD@0SV<.2)2IN=TW1XR8XG E4)J
MV2^JG=MDB!O<>4\FPD-;L*MJ-3J3#&N!W3G1-A*^-W2MZM,9#"E6*DA,)IN0
ME0\DR*#O$LILI4M6SLP#)QG3%3@F3X',M.557B';$ICL$WAYB@V4;@()N5VR
M93JT( 4'.C&5LBT^1L),;;#,F0EE"?#S&6&9SDAD$ FO:<Y$IHK+DY,Z?(O+
MUV+5ZHHBA58QL[N(O(.F899WN.[*P1#81T'3AEGCTSQ[[Z8\:&@>7X^L-5VP
M(BUK6AZ\@$ $! ,] $;7 1OD&07L.(.]]-]^:)37=A6X!NN"^X-%=(  8!IB
M<M<KAPU#(0MTZ[[6M<0UPZ.O7\7R11I7&@AC3$ YO#?=IB0S#E#;CGKI8+WM
MP'AH'7B[[[C +PKHV[.BZGDTXQI  O\ 6VOQ !SN&>[AOS$0ZKSRZM77X?EB
M4 !\%+N>O@'&_IQ7MJ,5NC00"'7+CKEH.5@ +BW#JT^+>D7KII'93GUZ0")
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M/#CK+UVU]O2YP_;ZJP[63&E>U[X:#ZT<:J?:Z8= 7UI>,/%R8[YR^^0VS /
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MT0 +_!SWQH, @HN,PT"2BRX(C###.;@**@@A&.,PPR/DPP%P0@,44<0A##"
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MJ<H)4G2;I80**.-JH]%+\R/+*E.4Q3?-I8J3DS:M2DF*(BBRRQ.C@B,$LN"
M8AA@AY/S-EFF$P:VE9D;/G;<G:9L82(.5DB"87;X!,)4S@43"   C2HT"^X
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M_8CGY*2'K_6%/) *SUA$?WV*F<+^/DU='!U]%L3MU./968_CKG_60]3/)O\
M<^L0/_9.0\U?J?OCMAY9ZP@-QJQ4P?\ O[-.6X1 ?"VF@Z>_B]NIP/UUF/XZ
MYQT?VS'&(&33)Q0 ]3ZQ'39.08[:2\*AX!IS5GRS5AS^JQ4P=/M\FGT?\+9Y
M_#8!M?$[<S?V5F.O]>N-M/[9MZ!AZF>3?[GUB+L/H4D.K8P'FPKC$>6:L-_W
MV*F!K]ODU_UKT6N.';J<>RLQ_'7/^LWZX>IIDW^Y]8>^M?H2D..S]+[^@,-(
M4I#RSUAO;RLU,OP\?)JXVR_;:_6(]5N-[=3CV4F//QUSC[9%]3/)O]SZQ :
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M40)P09H@8V=G"-U,*C01'4 !2X0$(JBZ6:/=%5[H! M*!<-0"MW-41VZ!IV
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M'0-L4H2ZEFM*2*=.$"F;EY@E :<;''SVA1S#*#6IQQ'46ZH4VU"_".O=G 3
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MF^3')UE@L4YF@VFDKLDZF5JY"X825W+VB"O#(RUTH#=/AG9DG":RJP.&R*"
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M&TF\BF&5L,I#PJLH46<RRUDMM"SDR$Q<)'4/.VB_&I:F+0HNR-DRE Z294S
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M5B*DTW<TH2S3M9)DPOC*E9'"4XF-0C=6=E(8X5U0G%?,B-R:R7,OP:EB&$N
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M>T9-NS^N24N7S.^LH-\97BD;-)0/9<UK%*YW9I6%O31J@>(]?&U:D"A1^RP
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M_P#*\?.,/SS7L9M!<I_3DXG0>,V_2(P^9DURN'T]T3RU^FJ;/6 ^(@WSMT<
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M0\X"D_WR*_R6F[^H<.2D^]9I_C\N^%PY<V9]?+^YDU^!1/E_I1]\BS\EIO\
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M_12@,NH3,\QTR]F'"J?9FNVU\OG\,.*M?6R'M*?Y.OSP\(+_ ._EM\A 05J
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MPE>0CGQV=(BD3*W*WQG0E&NA;BZ-+4GCIFZI04H)3E-<% [H1,8HB)M% H&
MFIC0(%<IG$F=4@A>81$,P,THTS<0J.=@(!3"^.T^2Y;@DR3)0DXE5&O*E*59
M=E<I<< PFK2Y>9T306K, ;Q 8JA1@>8 Q7",P0&(1"^.<F7-*4HZ"@ TU[Z:
M=$<(Y@,<PW@ CHTA7?1T5BINV[ANQJWT^&-&JFW"M>GR4\<.(\,7&@;[UWT0
MYOEWZ(=NWM'$AOOJYA\$.KV_K[<+7PNOKT<\.</)2_P[ZH!Z_?T =,L-_'#R
MWX<]P;TUX0]>5] N/J]@>H.&+LUTWWYX;[W5WK#<-O0.NMK;ODMPPW$,.B&G
MQAAOX]&V&[M?Y>H.G7$YH:? .K56_#?# 'PCU]?5G?\ 7AOJ^7?0$-G-71OC
MCSAA'E7[NCEM.4TW!Y%&O(/YXSAVX9WL%K8^6\MO[*&/X$;!79QQ_P";77PQ
M^YGYF-_85MD-:_U2'W_V]9_>^^.OI+6F42=BEYV>XB'GQY<-I%IJT0I!&F&7
M@EA#3=PE,XF-<"P%4+J+FJ+C+2@WQ$"E"(V)5#& %#YP$R0"S@R@2J\:&>)S
M+/S2\""!&*K82B;/S^%%0X"!>#S<RHYX#W(_7RU@IVIE]8Y32JL.3K?)4]L4
M=(5U>V7;=>U#><D.5MP' BS!JB<#*\9!0%J$!$2B)PREFC;6IY,+E5L"1GTQ
MLG78$D'9AE5 J1I0(15%EQ/(T"]6>E%[B3H9;B7,3PH2N9'.K(XU,)T;<5&I
M-&#N#VC:G4=U!V*:UE64C2*8$Q CIL27YYA#AQ*5OPC9<Y#%J<1.!A2 QC4\
M>E&0.U$L:6+,H%G".Y!V2-I,K<X<)+JBHXLO-%;0"V135"7@HXFA6TP8IK-%
M<U I413*Z.5(E<L*S;2S'0D_8K45#;5#;5Y^G*C5<]L-#+SFR3(_JRJ'-Y4A
MT]3JBFUQ%"4[S$R(EDYJ6=6X%FBY')5:@PGGX(HN]F4X1EO)H[DA@?J.I5-;
M0D24166-VH$K1B YJA0!99J11RHDJ<OSU8AS" FJ'C%@\D\PRBIY>4[,.DG=
MB9=(K<Y/<ASB9M)A*I:@?*"Z/:*TJJ)G37C!V<L?N$9$D]0;&(#4BR"1#Y@@
M&#TC[3U+)KE3:-IC62::NR<T5?K@T5K8ZH2 W(9IFSE,+C,41,ES2S.<S2_&
MH:5*)\!R;3"'XXIGF-,6KC2J"@Y0XXVG3)PWFS.9*OFY)C,$)B5XU33<+B9
MSCYPNBJY;%.D<' J%,#@1373*?,. U+]"6AR1VPDTYR76ML+)[%3U[8C)\\L
M#,;(VD=N)1)1"8M9:!Y])WS24S(J3Y%>7BT=D5EY#OI4J9$JR1QS0OA,/='Z
M;.DTN$]I)%F2)Q(VVJ2;039+SA"VF>$Z>TSI6%.C8WMZ+5"7!/SR:G3O!I9:
M)0@*7*(XQ<CH2(8S>S4M@T%P=V5JL8X6BELU224X,04:R]J=L(+*@;.XTMW*
MAC D8O""8V<(@ #Y]+>Q9M4SE#:SBUHI25LID"MIDU=S-J+LG%+3VMMD%IR
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M_/OLAU[^/7NOU=.5\(M_/3?QCUZXC+U_+\M\+]^CXO!#1S>6X?BU1(^]ORZ
M]/K'C;"'1JVUK?K\5!QAV_7A$@/;MZ=;9]-L(O/\>KIYN?"&N$3#??S0"P;\
MO1OUX9YVZ^G/%WTZO-?\47HT;=5WGZ>H/;MVOZ[@YJ[[\W/"[5OLN\\.WO\
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M%BZF$,T.VEMKZW  ?1-?7PTTC6/KGYDG+L!5##^:"]D!FHB)53#(<F6:D8H
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M1M###1\8HAL&<(0CE?(,7U1+&FH 9&;%B.H)I;;Q!::_P1I/V(^7E,ICG_-
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MQX?.95:VT4U?SR?93K8S><31TJ]F,SF#:R+IZ]=KF$RJ[A=6S!CJ'.(Z1H4
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M&668^KMKPMZL->_5#7YM]7CQ"%LM][AO#3?E???ANRTR;[[\]T.K3OKYOC&
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M]I.$ W" IVLXGQ/A . *<+P(*9X ;.SKXX5RV6JQO/C%X7VIJ7N@3@X(G>;
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M8/*BAYQ>8>;:*( BM%$&*3)=:1(RRB64/)TD=P(\8.GE,D!#+UO'AC%F "J
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MHK4%(WMC>D@ LE.027+W#Y\PV,8SCS8XSSS##C(XXOHEK8=PR;HM6KJS:#=
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MW"DAEC0B;683D[2;+,B/ 1%F<[% 5D <H-7+HJW#$742$F<*;15-)10I#"8
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M3N03IJ=G,9:]3!5NY;J4Q"H&352,!545TC$606(FN@=-4A3!["^Y^]T"E+;
ME&"7YAB;I8KI+*"".:Y4@,A)23$D(" HR;)1+-,B,.;CHXH!<VOE&*F-29S9
M@FH3$JLWZVL!;]K:QJ#5T9-M/6Z8"X;AW!'9"TJZ:E$;RZ5D0$3(F&H52$I@
M_GR[*[L4)_V/T^/-I25Y.LF,Y=&+(YX8HJKR==43'+(I^<A0(F[3*!@9/1 B
M,S1(!@ CDBZ!.Q\.(=?RZ9<>UQ]('5I#?7HWU!\>#U[Z[^;JNB1]>[V>][>(
M8D/('EK=J^7FA\G;M[^$08C?KVUZL[@ ;[7'3/%T;\W/MNJ%8U:+^CPASXWW
M"(5T1/#=Z,K96$+?%T]<\>]8GQB.O;X.?2.N)^/+A[=W7A$^/>F_@AZA["&>
M86XX1;\=]'GB-_3O]-];^GX..$+^O#'F'9?#+M>UQ'U='  TW8;]6_3"_?JW
M\,,^V[H]_"&S?STPNZ8=OU^WUX1-N^^N !>VZ]K>GJUU'HQ=F_Q>.+A=S[[,
M-@Z[KH7Z.P9#OWC?MK-^N^&_7>&X_(][CZ^W8<(>7?>\.K%N#I"]^WP!QZ,7
M 1V#A?OY8:Z4NWT[WW8C$Z"/L',.V0]M,2)C&G/T6U[9_'Z,6[PX87<^'FB[
M[CY_DXU[;V]V97EJ=A#P2Z-+BVNG*.[V#P:O1'I%]U 10BG#O0XX!/".&(D/
MV6&*$8.4&DP )1 V @-;Z7:8I3"4P"4.Z 0IIO\ *(_)HIAQ)^P9LS-#7+@I
M$4X3PVLA%,X9(73G4V:)\)E^3Z8.1LQ2%)LK*W1S5DD4]3N:PUT/9"8E"1^Y
MU/ Y*%R%$UD(N,5HC328+J7Z-04PTUZM%(Y0NE:T&A1 ! ;M-<1#8&C"Z/NQ
M[ &S<RKY<7GLTZS.$DC+Z.0$$[U%FV;FN0)4EA:J<&BGDH-[RXJ$[9(,"M3=
M8PG0K(W).C:T#@M4M[0V)4KBB5X#G&"H"%]P &C>F$07:N(9H#00$0"\=%;^
M;#52FF+85#[GC)B:5VTVC"UQAJ+**N3$=.GJK53:M.L=-Y"DY<Y*VZGU)YRE
MN829OI(A1G.1AZ%Y9"WY6I3I29?F)*^R^86E1:#M.Y'@QOJ AGB-  *W ("&
ML-> 75I&XFZ'.#A #-S1KFAB.-1KB.@;PIX]=%NY\TBENG2>6YU?W.:ZIM"I
MPC?9[DJ>YO:WF39I7U>FC:!:(Y6>5;ZX3:V/LKS!/Y\2"8YF<%DS3(R*"SYE
M@5(GM2B-J;0F:('&IZWB41[D<0TB. \XQ%':@&J4*$T9X!W8!<.K$=5X!&4-
M,Z ,])IE0N<IS?/$<M)9,?I?72G,4SOLS%3+.$T3T;/;_529W1Y=E<;M/3BL
M4+4$;GWDG/@0+U2,#Q;"6IM;-Y- $S )3&$ +02X@(ZS5"E<, OPC9.L*A:&
M*6N=G5#]J&@*4O"_379C%_OBS]=L;T;&_@\^CPPPB5AVT^7A8.UL-\=]-^]8
MNSS>:H7U&GRQ@OM/B/CVR:?8:AW!_+TQ\;^_CU"Q TE;J@?7%7$ ']RL]-(\
M8RD_5IC^!T?Y_,HR1H1^\G23_)O)8?\ ZO-^[TYY!ZK8PVU'[))_^&)E_.U=
M/BV;:QZ)9#]BMG/P)+?YHEL#J\6BZX<+WSZQ]%K!?+MJ'0]%-]L9'IU=-,>L
M<-Z0OV] ]OCTPB?'OYKX</7\FG#IT'*PX1=QW\//HA8>WM[;NK#??>^'BOIO
M3?9$Y[^V0=?1\.$2'MN-@OU;NV6_*V$73X=_%$!\?#MKG\N&^^_-#?3JWZL8
M:]&^WK]G;=DB0M?+CEA%J(:PANX6SRW:;^UN@</# .CFOOZM/@APRSZN/Q_J
MPB0OEUVM?+XO5T99XODKO=%IY?!S0[!B;C :XW:]%=&.G3IOB.CT^JWR!B[>
MCKK\8PW\>_36-75OU .@-1Q(F^^J-/#@'8.P=6F+KO\ CW^.+KU[B(^##;&J
MPB&E_1UB'7H/JQ.:'3HIY.JGF'7'EV[N^(!7FBMA /J2+N  'TXNULATRS =
MPA;>./F7+A?/I5I$92 ZZ?HMSXX_;;\R]J.2W*-_R_0OOTV>EU;]87A=I'4$
M8_R/W29TD%/LT2DVM\X.5(J>434T7KQ2U:_=Z2Y4QK>7Z8%;PZL1*);9K>D[
M4[I!9'Z($#LF7M\"8P\&XXZ W"VML56I),V(FZ4E[27*RZ:,!6,1!\DNZ<J+
M&3 APX-4$EB DL( HFJ0+Q)4#>YS_L5&EI%<K,[=N9&TMM::WZ5O,G-KV\NX
M>:63=L9;+4&+29'7;B+Q@J\9K _EP<99JMW)E2IBZ*F).=E#;\I3)%,I9D:7
M&.JS*MHLHJZWT7<VIGHFH<WN6:D.+DY-!<]35.$IS@_R@\,!CHI0O:B1@5)Y
MM;0A(/@;S3A-*J%IVK=B@T12?(GEAID26+))2T55$'JBBB97*SELY4043%0Q
M5N*@8JZ7SNB7ZI'73SL;+9V@M9-[03286-?H6]3L4YMXT>/[?)-)?-K+-FC5
M\:S\GDDZDDMG3&9%9)+R]*T(HJR5V(J)F<E+FGMLU[;LH(WB0G ^5IJ-3REL
M)3-LI*DY:AIAY^;']#,">&9DL J@+AER$]W3&G$1\APL3&,":**&#E<8EI$"
MG:&%NN(-K+N) ( )>Z653=$!8*T^=@*X&,4>Z[DVFD94[['Z>+LK1M4YQ)B*
M3GLB93ED24.F],*<FESB6JFE2P\")AF@ILE$TU" 9M4Y0,J ">EPG;;KH&FH
M?.E*Y#I=.$G^/$@4:8S61$U4T32W+TT4QFV59@?'(9G0H"*B3R$X R+U?A2<
M'LY0SJE)2!*TQIHHE)&\M:*6=J'LN:L%VXO&<L1,4B;0J2;ABY;.5E3*D3!T
MYXT9(YLYPJ)D3'S"D$E#%QAIV.V4=;*!(K7VBM?(YX%GK26ZF"<P7>6K4FLS
ME%K9-.);+VH2EPY4LO9\9)VP;H<3D;!--ZDD=PL\!4I45+"..V8#3MYONV5(
M\KG1H%]27F;2),F50G*4+I<F%K/8GI@<E;?$J)3*%S,O<$L"M**B%*<:4?#"
M=S8EQ\%2T(IVJ4M&T;B("]5<E;KC>9)8#IJ(G,4! HG14.03%SLT39P5H$>D
MMLA/'>QRE^0JT,W(5RWLJQDRD^E22ATF\TECM.8L)DU1<@BHLFV?MVZHH+ D
M*R9#IU3$V<%4I-I#9*HU,<D3QLZT,GUPGICK-*565<QUIFEI5GRNRRPOB<8Z
M:2.3*($)53:ZG1B4LF>9DZMQY@@@8$('@!Q6X2:R*7JM7,HECPSE":-I@*LP
M< ?@4FQ^$!D@5N4A#D4-<HX6**E"$S$B&#.CIE\E>6JW4LG]G\J.4.S;6SS^
MPDZL8A*[!2AZBG.'\V; U+:NT)YT*BJ3IF0H'1E4I51:<(=3.<\&(IFO>;W1
M.ES15NF$V2XR58<I&E:=:N5(F*6WAFHG*H%3)4FGLQ20A2R^V4[E67X7-0TE
MO94+M-LROYS@_HDQ0F-"54F*BC[ UJ6A)@R=()/S-D7$P=*MU$I:@7AGK4[8
MHI$9-41,9,#%!1=94QEBE+\X3$H5\^)V+UKWUB[7R6:3"QC6T$XD%B[*RN:,
M7]OIQG2JRMII9:!PM,G5IYS,A:)/3,#BRDLIEJ;:6N%CYKU5)4X%P,K;6QCJ
MA379FDEJ:'1M74-I<]R&^K5YB2)*[N#I4"99P*7- )C8SH$I:5[(2Q@L@).[
MX)-&& 2^1'%C<QF2;QI)D$TU"'EK)5L<QJ9JAU'[MV!B4OS<QR4HUOSBCHO'
MZ/R?V F-D+596;0/7K-TWRA6OE]HI>@V*L"S)LSLW*I(=![PJ92&6,LP56+P
M!E"<$H4!,!ZE#*":-JS95JHH::PUFH9/DZ;0;/2YJIVNEPN:VE!0J=WN7)5"
M3Y<J%,A:8M+/;<O0MA2%4IEUF6P(5+DVI32UQ(1&"/<+SN2OA2?S&5NW$T(P
M(S.0'!22YTLBW*U0>+YA2NR'*D4ISHHG JBB9!!1,HF*/D4HR-Y8[')O;#V$
MRAV;D.3-]:]Y:=O-3R=ZXRAV?832;]NYI9J5BH=6SSILX=G<I(S-\W%PDV=*
MD,W4', *@EK;;H/*>SX_4JERF,U2U,$Y[,[S1.:BV=HIO$Q*9W5KB'"*I2J<
M%"(*FS #X<F))4RVX/:1CELCE@V('**%+WMO-[12QM*UF:$O717<2927.!3(
MT!-5V94BO'E' I"]5X44R 9 RQ$6X5X(BEU.LFO8_P"4:<Y3)=;&:6MDLVED
MCRKL;?2<[Y]:D)BC9]% [7DHC(TE^24M[7IJG.E-6TO7F$U4S1=N&H"MPW"N
MFW-(4Q;3=:JFS!)DZ**45XH6FH/,[2A<V9+4"7&+Q/D]E->Y:5FQ*V2-<C>9
M5+6$-RR.%(N;E)R5483'&(8T*6F;*SB8O56K@64SE192X(50A722/%FJ(JHB
M)12SRJM"&*4_<G2$R9A 3"8O.9]CQ:.5Y)+ V3EL^D*=L\G.4)7*+*'CAJ^7
MLU-)AV[G;XC":HI@C, 0783@R"CE IEV[I(BJ)5"E"*)CVF:%2G(==J94LD*
MI#?+=1F/9\9I>=)QF="_OBM;2"=XIKF.8IE+!2*!BBF,B+O9IEN6 /9FF,J"
M&&,LLR.*'A]MY>W;39HR:.R)/F\L11.NJ513A&2_#*K+W 4@K5H1)+.(F  6
MIKS#D 9)<HDZM'D[M9;"T=E',TLO,,IC^:-)%*7$MEZ"%MI $GE<LE)N!XQ,
M0E:A>%>36;\&_>E.(B!CD*!KC/G=!6 )^VH*A2[);X:YUDK]0.M,CH'\]NC0
M-26C$S'S <RS2"5289%&Z%=[HDL;6"DLF (ACC@Y$ CS%;4D,]G3U)NH)IC-
M99,&Q5A*8B7$%UU@37 ![K.X4A*$&X &@W ,8O+^QGF8V;R1V9FD^EQ&EALF
MN4BP=H',M3<E<O%K>2DDM(_E'#(E)FM#\(NL#O@C*&$ *4<XU*N;MOF@\A3=
MXQ4TI]5HQ/4;:FI_M,UC)GM_E9U.9SI)=7=\ADNFH-T"8%4"AS?5\<4S3"<B
M7&MY*1L,200":>/))::6M7/#LV;_ #7,]93I^5RJDJ8@,SK* V9B!2U$RCE4
M3.%1(H<A2)B0H9PCTCKL;LHUHY*$LM9::Q15;+9(+2Y)[#'L[+INS(^)/V;*
M7]O;5<:,J*(I,Y<W*64RPCANFY.L[*N)@(G% R!MTR9*2N@BA?*LWJRZ4[8E
M3MI-^@3JFL?###/<#;"W,J'GEL "_((4BD%1ZL"T0PGB!"B((S,<5A:5!J$J
M Z#A09?:!U.5<T254273:D*D3.I\\*+<XB)Z!W0  UK3)+2=CO/IRAE&(VG$
MC1/;+(=9')5+S*)/ XC,K/"Z%T^<9B!J2UP*R0HD0SUZIU42#-+%9[.VW=0.
MBS$PJ#*63>DG=*Z5GAF]REUKILX>/C;4](])&)T<YLF= JG9@/DU&ZDH0E&4
MG)E8GB)/X06.40QJD:S<DUHI9+$$,Z7K [)VP3<K(D:"+LCQ!9%$QEUTC.4N
M+$4S>+MSI)+ 4%%% .)BFZ+*=V.F4BWLQF21+82):0+,K!C)&LT>6K;<G'5D
M5F"\Q9M9-*7",@F2<\7:*.!G<Y:/YBQ!3BR#4"E271ZEKP@-H8L@N$(B( (V
M$;"-ABY-\L@B$,QW9XPH0$1$:#>-<- ]5=MV.F^/M,-%0"NFF@::QH-,:<\5
M))\H3-4":&22Y+9'&99IF1P(:V1B:$\:Q>XKE$7)+)()+N(A#"$1IIL0PE$$
MP&'GF%DEF&0[K9JY>+HM6J"CAPX.5)%%(ACJ*',/<E*4H5$1\ 7X!'36AM!)
M+*R69VBM',FDFD4F:*OIG,WRQ4&C1LD%3J*J&$+Q$0(F0N<HJJ<J29#*G(4W
MK^[GGW/.6-D662YRG INF.O<RMP%/K\792@DQM5P%F&RG*AAD(97AA![?(8"
ME#L<$2<H2VPHLHWZRR>Y/F]E6Y7[X"+SYPF(**!0R;%,X!5LW' 3B%RZX7GO
M2)1+.%3^?SLMNRUG67V='L[9X[N3Y+),[SY7*S#P+JT3M QBISV>$*.HPC+9
M:)CI,4Q!90#O#F.GV;\/7Z_DQZ='Q9$7MH'R6SW<+<.K?:XW[^'S\^BMQT_*
M._- ./K]5K9>KX<2'7LT;;M6-?-C$_)E[/6'#WK81(CIXY[^K/CIV$,7S?'=
MJBCU4NWU1([\[Z>KI]@<.&)#1\GR[TB!S ;]O7B_%OKZKXD,PXCIKUZB =&8
M=8=.%VO7KU8;^:+C\6O1UC\4.P_KR]>)OOC##?PTP'F\,+?)\F6&_/"MV&K<
M0PT?+?"W;Y>GY<77OO0(#S^;R8<T.O/IU'.W5O[<&^]^K?3$AN^#/VY8D(>S
MX?@R]_"+HW\>G?H>]VM\?;)OOO\ &\?CV\_-7P5%F'O]K=>0X1(99Z9_#;T;
M@^*^+?U;^6+X-_'%%5*).44WJ*0G*,///D&<B"2"2XS#3SC9;<RRB2H"P&.,
MPV.("RRX BBCCBAAA"XY[2H52.%*]R/BU=6](W$?U5/8:MXT#R>.^[".@.0*
MY5HIY0B29=D&IM>YGD!)0K9J8JCS._RJV2.;0&LBZ84;&_R DG!QHZY'2!))
M<A(#DTS+89-J0Z27$GE=S0F0.4Z1.D75@HJ4@E*8]*!G!2F::N& B%0Q^ESK
MPJ,=H)$A.!CE)7]K?B !C3N<!NNK2X;AOC921M1;7@.]-54T5#J^[IVB>5\K
M-DA-$N.35.=16<BNSPUIWEK5S7L\(V>NYAU,53 F=VB82:)3 Q2L4@J&E MP
M?5"M'056 2=T?8%!J(5VA2^@AINNO"(*2-#"!2!4! PW#2E=(;*:K[Z5NCF'
M#:-V^X)HJ/::I@;WY.^5,1U3I^PL$PSJ^T;IHT50:F=DG60Y*-V>FZ6I<<F.
MFYJA[E5T555J855!&K5/@-SJZHB4K;>$7SE*F, WU*(#4 TT"E.Y#:&-PXQ.
M#0 I S2"%0H-0O'14<1KY[M$=AW<^($JEPVP'IGG&>ZDRK,&TTE7RC4BHC88
MVO\ .\OIJ 4.:"70%(RW*A+XW(5;<L8D,QIF0B!X):85IQJQ5&>K/Y+2OSX0
MJ:HES1,%*B #=A0-&G3JCCNJ?. $"A3. P%&H %2TT;!YZ#MC J9Z_;7JEHE
M5-)55JU15FFM\5->U+(YE-V8^7MF)0=7VG,K2=%3<IPIQ C10+I<>'QD0D.#
MK.Z6=90C63ZL 8T'A8KC<(MG4 ZF<(]WW-Q1K=3&[14.BZ.3P:-+R$$  ,P:
MAW5 OK2ZM*W#6X.@.UG9.7U'*+V@I'J%-,YSPFI;M$3-(]/IOJ$D;2YM?*?#
M(=-YL;37-T9V*7&V8X4;W-,P-R-\3M18G)$A2$XT\Y!%'CFMQ/0Y3B)LTU $
M0I4*:-D<!QFU(8A0+G%J( -;]NC9<%^F,M METY]>>N['*Y]%WFCC^33Y-0[
M-E=&#KRW\;B/#I'>/OB%L/#Y@\GFT0T>/7=2G1AT\P1@OM0?9XQ_S-0_Z>F/
M'J=A?J4Z_"2O\T91XQE)^K3'\#H_S^91DE0F_D3I)G_%O)=_R>;QRW_(&6_&
M$VH_9)/_ ,,S+^>*[^,1CT6R'[%+.5"_M++1V?K1*ZF-+AU#%U=P6]X?:&7P
M '7CHM-_@$/C\XX[8R/G\=_ET](UK$_#[V7PXD0?%=?X*[Z(>W(.F_HZ^B^F
M_%WW'5TP^.[Y=&&F';MV]N)OOOX(;^?QP'AZ\^WH]_"&W>ZF^D=(A2^&$.CJ
MWI /7T6&^>GJN%_UVM-Z[ZAIY84TZJ=?1S#39$V]'7[VG0/R8D2(]MK!K?AT
MVT]7LQ>??$/'OIBWZO!S^77TW0[='K]&)#?;TW]// ;ZZ^O7A<1MNZ>O7%WK
MLWVP#"FT*\W-LTW]$+;[VX:^OV>CTXD+M(^7HT;]<.W;7"&GY/D\G1#AV[>G
M"'EOOT[[-L.'7;+T:>O(-<(!IT[^3HUUIBWWZQX[[].=]V8VZ!Q=] :]Q'KB
M;[[^&)UW^L>VG#7?;$AAT^*//MW6W:=64@K?3V48*44GGQ.=3(E]+=)ZEPUW
M>$IJ^97U$<A(4PJRH86^ &LH\D@"X1@/4*C(HX^=A"#Q7*+;M>R\\;LD[,V.
MGA5I8@YX>TDC&:N43&<NTQ305XVW!)$03*829AJGJ;.T!^F'89=C*AEIR;S^
MT8Y9LN.3-67VP=R@\NR66V)9:53$A)1)W:;V9-AECTSE^07*B)%Q4* (%(F!
M I4>K5;MM/S; B,<ME^@C? YHBG)NC6T\7)8'!O.CC+)7HHCU98*T1IA9L!2
MM.)A!D99D,!@C#$ 8&?*Z])FYV3O)87/*!R9UC3%SB"(@!BUF5Y1$!"H75 0
MT1]9M^P/EKLRY&O9=]EPZ,S7.T=E;Y96ZQFKDA2F.V< E(S"@N0IB&,BH!5"
M@8HF* "%=AY]RO\ P<-G/._VDG;O_C^.6-'JPNON>Y*O></I/5OICD!V :(T
M_KL>S"U_V7D]7X V^#5B\^Y4(A_L<-G7T20?IO\ ]_Z\/?#.SU8'7W/<E7O/
M'TG%^8#1_A8]F%S>J\GU?4'R^"L//O5AILX[.G1]))P?_P _AZL#K[GN2KWG
MB/\ YG#Y@- ?]]AV8/\ I>(-=MTAZL.:*EEG:\GJ=%:E!)NR-1B;5R-+&N5H
MY9I8\OJI*B+R,5J4[6:J.(2P:1GF00E0WM%$ Y8WD<K,Q<&$J&3?)>L8"YPE
M1L6HH8"@( )A*29"( %0J.&%8ZJ;=A#9R0(I.9]V979625NNL5N@O-LM["7(
M++G^D125>2=$BBHXE3(83CH+%/F[=*].:80?LV;/))Q)D91Y)LBJ"S232QBA
M,*-+C70QEFEQ0Q01EQA#%!$$4,0 ("&-H<L#L!$!R>Y*P$-'(\=?X3CLR=@,
MU5(11/LL^R_434*4Z:A,L"1R'(< ,4Y#ED(E,4P"!BF 1*(4$+J1\O/O5A_Q
M<=G3/6TDG6WZ_1X>][V'JP.ON?9*O>>/I,8U?,!(:>RQ[,$=5<KQ*^"0P';O
M5CKLX[.F^WTDG"(AEI]'W#MOP]6!U]SW)5[SQ"_W3B!V : 8=ECV8-1#[KQ/
M)(::?!#S[E6[9PV=! >$D'6T_P#7^W5B>K Z^Y[DJ]YYO2<7Y@- ?]]CV85P
M_=>)LN^H/7I\$3Y]ZJ]O-QV=.(?20=T!_?\ VMU8>K ZQ]3W)5[SQ])[]</F
M D?X6/9@_P"EY/;]X(>?<JU\W'9TXC]))V7"P^$/9UX>K"Z^Y[DJ]YX^DX?,
M!H7_ -=CV873E>)3_P"@[=,1Y]ZL--G'9U_(DX.G^_QWZ?+AZL#K3D^R5!_V
M/'Q=L[]QA\P$A4/Z[#LP-/\ =>)L#V!WPB?/O5A_Q<=G3?\ :0=EI_R_?[+9
MX>K Z^Y[DJ]YX^DX#V :%+^RP[,'1_=>)?L^H-!YM>&B(\^Y5;_:X[.G4$DG
M<1_YP"W5IGZWJPNON>Y*O>>/DF</F T+_P"NR[,+;_5>3T:?J!N \T!V[U=O
M]KALZB 7^T@[_P#W^GWLKXH98'0_W/LE0?\ 8\?2>^R =@&C_"Q[,+;_ %7B
M>']( 'FT==[S[E8#ELX[.H;_ +"C@Z=SAGJ.O5;$]6%U]SW)5[SQ])[^" ]@
M&AI[+#LP1_\ 6Z0?_(-[M,!V[587 =G#9TZ/I).TTR^C\N/K'#U875W]3W)5
M[SQ])W^"'S :(!4>RQ[,'_2\GZ! .:O3&0&S%W1:2I4K%+*^I](9/I[):T5#
M0\3O1)K"7)ZEDIQAA*!U(/.@<HG%I)$.0\M2:%*L4H8S#4IQIJ>!$K[RSV6L
MC.9H*OK"9/6S<:D.ZE5F.*/6V?W(JD.+Y7.* #11,N:8Y!, &KW)O,\KWYG3
M/)Y86;-;*]DGV15JIXCP3UE9S*%E(+-[-S<[4PJ<342"4MRMGI[C,'JW#(HN
M"E(LF1-0SA'UARM2Z2YWEQEF^4*RU-F.6)C;DKNQ/K//Z5<V.C:M+A.3+$:H
MAKC*.)-+B 0&$?G1O!%##'#$ ?1+>V97:"3EM*;,KMUR HDLG+S&(H0P7"40
M<TIKT@(" T$!"/QAF^3&96?FC^23N=6\E<VE;I9C,9<^F16[MF[0.)%4%T5&
M!3D4(8-.(4$HB40$>>\@C=[I58/RT@_JG&_RK5]@[.>YI_A,==R(+WU6Q]V$
M?@->C")&@K<.?E*J_P"B="_ZI[6##E8K[!V<]S3_  J'(DO?3;'W81^ ^'';
M#R"MWNDU>_+,OUW\$W]N)RK5]@[.^YI_A,.1!:UY56RYNW"-.:G$8!05N#2I
M57\_PS+_ *I[>K%Y5J^P=G/<T_PF'(@O?5;+W92N_P"X[]<1Y!&[W2JO_EH7
M\+3?#E8K[!V<]S3_  F'(@O?5;+W82^ [T"'D$;O=*J_T_3H7GNS_:G?OPY5
MJ^P=G/<T_P )T?+#D07OJMC=7Z\(_ =&BL/((W9?5*J_E^&A=N'\DX<JU?8.
MSGN:?X3#D06_Z*K8W_?A+P?H&'D$;O=*K!^6A?\ 5.'*Q7V#LY[FG^%0Y$%[
MZK9>["7P'X]&$/((W>Z55_\ +0O^J>W7ARK5]@[.>YI_A,.1!;OHJMC=]^$?
M@.GY*0&@C</\957_ ,M"_P"J<3E6K[!V<]S3_"=$.1!;OHJME=]^4O@,3Y!6
M[W2JO\/LT+^!I#3=B\JU?8.SGN:?X3$Y$%[ZK9>["/P&L/(*W>Z35_A]FD']
M4].'*M7V#LY[FG^$]'QQ>1!>^JV/NPC\!AY!6T/XR:O?EI!;U>";>S$Y5J^P
MEG?<TWPF'(@O?5;+W81^ UB/((W9_5)J_G^&A?K_ ')OZ^GCB\K%?8.SGN:?
MX3$Y$%[ZK9>[*7P&)\@K=[I-7_RT@#+ADT@'J^/#E6K[!V<]S3]?ZYQAR(+W
MU6R]V4?@,/(*W>Z35_C;QT+M_HGT]>)RK5]@[.^YI_A,7D07OJMES]N4J\WZ
MQAY!&[W2:OWX^.A?J_<G3HQ>5BOL'9SW--\)^.)R(+WU6R]V$?@-(X&9TQE-
M99F(QL)FB>U$KL;N]I6]6XIUTTS(H1H%#L6S)5RJ%$DC7+C(0;6P#P)(@BC3
M%FF! $<>-M1Z9X4SP6[9N)BC\X9I<"W+P89G<)B=02YV;GF$3#4XF-< A'/;
MR\)>";'CCQZ!!']%3%8KAV?A!$_SU4J:8'S<[,3[@,TA2AHJ.(=0MO"F$CTJ
MI75QN9)KG9KJS2R=JRL;3+\364\-%/Z>TWCJ!-#N_0N"\A.A! H4L4D&E <8
M,,WS"WH!'D0'QP\8SE,"%$ KG@)J  74J%!'"N<'-2M!CFE;*"<P";-S1H!K
MZC4*W:?I=6G1C%*?-!6-E23B74.C51)#F6593I=/Q<NQS+3><BY@DJJU3FBD
MS*[(GV2IN>FM M;IF=RC'-B?(FQQB:RXU;?"M_98"-LKPH_3)T$+RT$!"^HX
MZ!I6NG1HC69F8!N.-+P&H"!JWAAI"HTK?LT!&2]1*_R52.9UC94]4$B22WR<
MVS,9569G!&V2+$^.LT+)<02"G5'FPJE$Y*BT9[VE;4I)YJAI@./*@^AS1#?,
ML0AJ'+0!* Y^NN@0Z "O1S;!43'* E$!'.$N;JI^VU=(:=473EN:)>G5@9YM
ME)_:9JEB86].Z,4Q,3BE=F9X;%<'.)E[8Y(CCTJQ*="(C :0;' -A"X1!%#C
M>*)3% 2TH-X"&^_5&T<#%,(& 0, CB-^O3X!"E=HQS?+BL <J(0 !#ZX;!?(
M0 +Y (7N&6\+#BT#53HZ;]8ZA\401'6.G3HQI30 W:*>0(WL B-@OR;CH&8V
M]>[2X\1OA&G??<,1B/9[W;KPBC\N@.K9X<8GH ;>OU9>FW7Z,(8=7C"[?PQ@
MMM0?9XR?S-0A_P#7ICS#H_7CU"Q%0E;F@_7%4;A'UHSCQC*3]6F/X'1_G\RC
M)&A/[RE)+9?4WDS(/YO-^7#T^P+B 8;:C]DD_P#PS,OYXMLWVQZ+9"ZREG U
MR26[?W(D&D-G7?JI=;.V>MO3\6OHQT6&&]]VJG@&,BWKN'QQJO<<Q[:!V]_$
MA3JIYKNL0"(MH-NKIMG\&=N'1A?OU;\^V'@ZO)?HV]</1;")#MUX1=[]]6^$
M.W;Y/?OA$B1 --=][6MUAZ?>&_%%OWU4IX@B.PVWX0^+XX::_%Z.V_#?SPYK
MZ=.T>BM=D->OW^W3[^$2F^_5N$1U6OIU=N&'R^:+JK77SZ V875\>$:NVN7M
M^/X\(D1\&N$-^C?KA>]^BP;L[=7#ISZ\4?'?IWOB[TW\@]4.';V#VUOB0Z*T
MWT:-OAAP]H='J[9]&&^^^B'FQ\_.%W5HK"]QZ/>Z,QWWOAHW\?1#?54,/EO\
ML>5?NZ5_.<IK_D4;.%LYSG#Y= &W#7'RWEMIRI8_@1KS_KQ_6G3S1^YGYF+_
M &%;8_\ ..^_^WK/Q:C:TH-6ZI-,MBB;Z>TDJ-.\K,VQ13M*[3%*LG/S\RMB
MI"_SNO6$+G%N0J$B4]*@/(5J"CC83"DQI1T0 49"(XQ:"53-XVL\Y:R]XX;I
MV;9%460;+*I%S%WJARF43(8H"4IBF$!$*%$!$*4&/6,BV4;)_92UF7V2VFMI
M9>03=]E[M.LRE<XG<NES]TDO+;/MD%6[5TX265(LY3413.0A@.JF<A1$Q1"+
MDS7L82(V,E:*A)J1NA%,6ON>=,ZM2!.0*9HBE<RM+PAI]',#HV/ACE$D=785
M"N:(UK!$H5MZ"$3!B;$L!:88=P]FVY4GSOB"P,2V3ETQ:N1,XX TQ7)+ 7.1
M43YJA^$4>@9#.,1,:AP90*2F*2;+Q:)V_L'9E6VK12USSLF[5V+M+(Q2E(3<
MM@V#BTA98S=R\K4%F;,$T925"8@FBY<"!<UVJ8RM:FK1LY;+1?G7TZEVD:"G
M:JA4@[-=0&FJ*6<9W='KONI;I3]NG1*YMCT^+Y>\72T$SK%*-+ V@M2JDQBH
M7 P#H"DO+FDGDA M U18 T&4-9(Y2>%<NU%1,]/+DW0*)K+'1%$"O#F3*5,%
M"F('ST2FS ZFP>5/+ /J-VHF=MG%J$LHEI,JMFGED5I'(&<OX&RC2TCJ0JM'
M<O8-YGVT,YE**2ZQG0H+(JD1!L3,,HM\]JG9.I93ZC.U^^M.S1'39'1F:*-R
MW0RK9DW3LZ^5.59DF1*D>)QB3N[ZL8'U0[(8RE$;TPH$[(F+=0:R4I3@WQ&X
M3R0LFC"T"B<F,T3EB[!&5S$73H_'T%E3D.X$IUC(+<,F4BG"($*@4% (4A3%
MK&K([EGMC:6W>1"7O,K 6K7MY*;<S3*'8L))(&?(^<RJ5K+,9("C&7(3*7IL
MG!3I@PF+A1^J=D+PZQVSH"1;BBZ:NKAL$20CV+PGF.IY>TE,IM>R:1FJR*A]
MZQL3-#2E0]> XH7[Q"++A<N3$;'XOEO *HW .5#'$'#EI9H>R[8MF^-"\"<.
M!FI9>*@/,W@6W:XRG T6%H \9 !N0!>HFH< $,KMXKD\:]DA:%?+SR?+9$^2
MN5$R<'MJ1 ]F.&+,7QK8I,>V!32WE&8W%1$I/TR,R%(&HB @4;X4?V9GRIU:
M*L31M84]I?6V:EM?Y!I//LSR4HGI\%H>W274SE,)3;*M$H),EUC4)VZ-/XR5
M)G=Z3M+.]H7!(:V/+EW^8'92^3+/IF_6GC)I,UC3AG+WJ[<[LXD453 RXHH2
MD6R!!S;UW3E4B)%4U X)5451CSVW&5B7V2L)8R49&;3VNL!)F^3:TEL[.2B?
MI6>EP/6#2:K-)8=U.+?C/9I,4E'15.U5E;/L%GKV7N&RY';!IQ<L;61MF79>
MEJ9J"TZF:AR>>%=8ML':0V?7697Z=)Z;'9ADB1IJ;V67%S>D87IJ;S)G:8%I
M$2=Q7)#4D91"TM8WJCU9:E'MLI/)$EY:T<2T'1IA:>;28ZJCIVF9)JW6:H(G
M3*BLF3C!!6$V<8IB&O*=,U2B7=M#E:RNS6591K3RG*"K9]&P^0_)9E*9RF6R
M&SSMG,9_:"4.'\T0<KS%B[<DE#P45.%:MEB+%.= R#E)- R2UHT6R_)370>2
MG"1MF%7M"1SM+-?G6I%9(JB/LHQ47?J=3',32QLWA9,M@I]+43&Q,S;,:Y%.
M[.X*YQ,=8D#;&4)J:$O@A)4$Y0W4;24TU,X;S4[V8@Y<(]K%62RY"%$Y52LT
M>"022=&(\2.9R"X$0$M21FR^5Z?O,HD^;VARMHY,@L_-LF[.RUA0LO+IT%NY
M=:B52M[,'PLE6YK2S4LQF+]W*T'%GWS9&1E9 Y= ?-5$U>U?V2-FZ3-GXAS9
MY#?U\:6E=!IVEFM[(U5+4)9NG"?G&7/&9NFF:7%RAI.=+;G [/#*U,DHMQ$S
M2ZY-:$5IQ@]_C#R)C(Y2VDX*ILUC#VME3E"9HIS Y%7;PR N$G"IS]K^ HHN
MDF1L4'"2B28*B;YZ XY8C+5E4GV4M1J]M'+FQ5[891I!-LG\P>6426DDCLVU
MFG:ES)Y.U:C;).:M#L6,P>/YTZ/*)FU=K@@F6C8!P<[H&RTBD/:-GVC]'*3-
M%-)=I3,[Q+ACBEF.:YB=YO..! M[]=S)D=G!,B@;#3%"-J2M9*8($$98+3ER
MB#O@<=M6E+VDX=R^7,2,T&"ZS<# NY647$IJ"94RZRA0S3 8I 2(G\[H"@J&
M[N/H7L:']M;1Y+K.6XMS;1]:N:6RE+&:$:K2N32QC)")F<-Q19%E;-NJX,[*
M5)=XN\45$7 &%!-ND/!A@_EEPN&7O9#E<..EQRRQC._GZX^@]]Z^75#Y[IUT
MWW#J'=TY[\L\-][H;TZ0V5TZ>FZ%Q 1'VYYZ\!Z^.N&_-O= *#ASW8<]VT=.
MF(S&]_5K?(1O;7(>D=;XO-\FS;73=#97;YQWNV:Y'U96L.>>8[LK:9<>.)#P
M8_+O=76-(#J%PUX#8==<\QZ]+#QRQ=?CZ[NG1S=,7GO^2_?5="X\;]'K#.^_
M@.ZVO";UB4QV[\^]T38,P]X!N(7#7(0MZ+X0PW'XX]5/<&F3:I121-;G,ZF)
M-LKN,*HR1&R9R5@NZN<Q5D@O=*?\Y%"*24HBX%93Y&:)K8N>0@B:285I;NIB
M]ZR3IS\J#@ZPYL@-G<7(N!L\[K. #'9C=1$  Q5S?J9E  " *@*"7\=/S1A_
MD=<6ADS64) KE@;"D6T;N4G0!DC(N!.+9G:4"@;AIT!C(GEX$S7;=B)@>G%
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MT:Q.T^&5J9.YO\2&)]=BBW-R5P!R$2&33*4PU$/+X^?HP (XZQRJ*&,4! -
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MAC&.<YA,8PB(C')^7H[W'*O?B,A_I_C7R4)WR6>]LFWHF.)RV<=Y5L/:;/\
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M?O+M?[59_P#I#$^7D[W'*O?B4A?ZP,_1AR4)WR6>]LFWHF+RV<=Y=K_:K/\
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MFTY4F4.KFMBA%"WDFJMT'AA[O@\TF<!1H-X"-:@'4 !=KPC0+4*B7A*J"41
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MJU8_-4HN1*J6I>=E:M;+[4V'*E$1FL6J(TN&[.TW7WTPP+H\-8VN-K7]T%X
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M64F.@50V5!WOQF]IBD2;M%V7#,@DYY,[2!P9)1=(9@I,4W"2H)FX!9)<R8E
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M(<+)YORTW>.=OCUURP]7*WFNRX[!L18_;I[2<WBA^=L]C>/[JRR?Z:LH0_\
MG&K >BX;HT_-&=H7A*'_ ($W]?WY]M>C <N-O,*V7]X]CP'_ .B;X;8?G;/8
MWX\:RR?Z:LH5;[O9GKV1/S1?:% -)1'+^]YNL%M!RG3XL\@TP'+E;S798/\
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MF22(DLIUA?5K$S5/:?'"6FV*:I,3JVYP)@>&*%0R+%Z%4VB])%9,<..*9XF
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MR<%G,0'K6].R0QQ1%)R1&Q8[#L(1Y"__ ,0#_MKZ7_Y"VFVGWZSIO'HOEO\
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M+OW9DGPN/L95*:CR2R#J'.!J<B(HPDDV;Y!C)*C($(B(RBXW,8((B1 !*B@
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M0NC6[$''7,=V5\3D=)M<SV_IO,>C]T>>'#)>QTHU?4IEAA]JP\%-D//OVB!
M+.4@]'U+I#]7[AV$>-^OC:\CY-H&:>[$Q^$:XO"H>QLHN^]3*G_@P\^_:' +
M^$I#'00^I=(6\1RMX#WY99VSMB<CY-]E-*:NV\Q^$0%9+3+I13;*V6K_ -%O
MX8WC=M\5^1N")6LBIR[I$RQ.>J:EM,I.)1N2<DZ&,Y K.0-B-P)3JRX8B#C$
M2I,J@+CBC(/+-A".'2I8V4'34(16;)'.0Q2JDF[XQTC"40!0I5%3IF,0>Z %
M"'((A0Q3%J$4BZ!3%,:5R90 , F(:5M *< &HE,)$RG I@J B4Q37U 0&/2[
ML=3ULC[85-R9LE*G,J,\W-!:9)/T@*H1,=Y5=S"\XX/V6"-PE]?' 88RO)94
M!2HJ&-.H@3."96D(^8;:$MU8R9"T=SE^NR6$QY?,"B (NT@' W<B";E,! %D
M#"(E$<\@G3,0X^T6;DM@;1,P70L[*TG*5"NVAD:G14$,2]U51$XA\Z5I> 4$
M"G*)0R[\W2A_N9RQ^*&?TV,.Y96H]FWWM@?DQD/(&QG>Y+/:/]J'FZ4/]S.6
M/Q0S^FQ.6-I_9I[_ "R_DPY V-[W)9[2/Y4/-TH?[F<L?BAG]-ARQM/[-/?Y
M9?R8O(*QN')R67?X#_:^6'FZ4/\ <SEC\4,_IL.6-I_9I[_++^3#D#8WO=EO
MM(_E0\W2A_N9RQ^*&?TV+RRM1[-OO;"\WV,3D#8SO<EGM'^U#S=*'^YG+'XH
M9_38<LK4>S;[VPOY,.0-C<.3DL]H_P!J'FZ4/]S.6/Q0S^FQ.6-I_9I][87\
MG9%Y V-[W9;[2/Y4/-TH?[F<L?BAG]-B\LK4>S;Z_P#PA?R8G(&QO>Y+/:/]
MJ'FZ4/\ <TEC\4,_IL3EC:?V:?>V%T?YL.0-C.]R6>TC^5#S=*'^YG+'XH9_
M38<L;3^S3[VPOY,7D#8WO<EGM/\ M0\W2A_N9RQ^*&?TV+RRM1[-OO;"_DPY
M V-[W)9[1_M70\W2A_N9RQ^*&?TV(-L;3C]>WWM@?DQ.0-C>]R6>TC^5#S=*
M'^YG+'XH9_38#;&U XSM][8'Y,.0-C.]R6>TC^5#S=*'^YG+'XH9_38O+*U'
MLV^]L+^3ITQ>0-C>]R6=*%?&:'FZ4/'^+.6/Q0S^FQ.6-J/9M]?_ (0/R=H]
M<.0-C>]V6^TC^5L#JAYNE#_<SEC\4,_IL.6-J/9M][87FPS8<@;&][DLU?J.
MC^5#S=*'^YG+'XH9_38<L;3^S3W^67\F'(*QO>Y+/:/+G0\W2A_N9RQ^*&?T
MV'+&U%WZ=OKL/GA?R8G(&QO>Y+/:=?\ G0\W2A_N9RQ^*&?TV'+&U'LV^_EE
MT?YL.0-C>]R6>T_[4/-TH?[F<L?BAG]-B\LK4>S;[VPOY,.0-C.]R6>T?[4/
M-TH?[F<L?BAG]-B<L;3^S3[VPNC5W-T.0-C>]R6>TC^5#S=*'^YG+'XH9_38
M<L;3^S3W^67\F+R"L;WNRSVD>;[*'FZ4/]S.6/Q0S^FPY8VH]FWNOZ<OY,3D
M#8WO<EGM'^U#S=*'^YG+'XH9_38<L;3W_IT^O_PA?R8<@;&][DL]HIXC0\W2
MA_N9RQ^*&?TV+RRM1CV[?5_RR_DPY V-[W)9?_@?]J'FZ4/]S.6/Q0S^FPY9
M6H]FWW\LO/\ 8ZX<@;&=[DL]I'\J-H;+;#*4<3!+36D9F=%:),WHH!@3DQ*0
M[Y/&"$8HA 33SC#8[B-XHQ$+!EB@]=S .-O5U'+E6XZRHYQS@0>#)4:!]*4H
M%#8$;Q)>RE0 RES9)HU1O3;HES4TQ4'A3YH5'Z8YS&':-=,?/=Z/ATO\-O1B
MQJT[-=/#2&75GZOAPB0OKZO>'"+\OQ7?% ==/DPB0W<!X=OE'UX1<-NH=][N
M> ::>CMZQZ>.^Z<>GS>2 XXX4\&]VN';XO7OX=.)#5Y_'7#JZ]+M[^G8,(:[
M[[NG77?SQ@OM0?9XR?S-0_Z>F/'J-AQ'M4ZI?^F2N&=ZT9W7"$>,92?JTQ_
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M;P84 *XC&$T.Q-3T0^RR=\Q$/[-+V65QM^T.5],K8S/M\_\ L&7M+CX7&/\
M*UL/UK<7??)+8/L9M@.Q)3WY[Z;9WRO_ +M+W !_D'+%[?/[NX97W_J+C6(>
MO(<K6WL6X]TDO1D0&Q-3Z\7TVSQD _[M+]AME_(. 3U^( .8RO-3]1<?#(<K
M6WL6X]TDNKZF0\R:GMQ^FR=\A_NTO6R =W@&W\'M; )Z_']HR]I<:P#UYMB!
M:YL-?TK<7#3ZI)7T_BS;#S)J>\D!\;)WSR_LTO?U!T=A##MZ_K3,98T_47&O
M_CD!M<V"GZ5N+QI]4TM/\6:(UCL2T^S'QMG>^O\ 99>_J'HP"?/Q$ S&5_\
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M1"8 $UXRD Q$QKZ3+HT1U3CLB#'6,8;(%J(%PGPA@%/8<<:!'&!W0*(<PI*
M9!]O8CO&WVG!C?\ 4="G[(AN'V)#3_&6R-D.R&&@_0B%U_U>'6 >PWCK$_-
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;F'&<[@UEW'"<)Q)O2O&<W-S!IF9V<(FH'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g160947g34h96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g34h96.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1B&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$W
M-#8U-AP"!0! 36EC<F]S;V9T(%=O<F0@+2!60DQ4("T@1F]R;2 R,"U&(%]7
M;W)K:6YG($=R;W5P($-U;75L871I=F4@0V]M;0 X0DE-!"4      ! /I3Q:
M$R'8\4VQ\UV%?I,'.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&X%RL         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             ""   !7P          0
M       !              5\   ""                      !
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M;&]N9P   @@     4F=H=&QO;F<   5\     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    %.$))300,      WF     0   *
M   [   !X   ;J    W* !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  [ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MMPMK&XNV;F;?=Z;J]UG_  ?Z+^<5C#ORKFO.3C'$>Q^UK2]K]S=K'>JUU?\
M*<^O_K:1^BG_TEE?TJ__ (U__5.0E;R/0^TW3Z<^H_GUOWG>"'^K_P#!_P#@
MRWP30])V_J_]\\K.$>*7KCN?W_\ O'3;DOIP,<UUU6OV,_1O<RL[8]SPZU)O
M4;R]C3C4L#B YQOI.T3[W[![G[%3RO0WXG] W?9Q'VOUMT2[^:_P>S_P5!_0
M[6_\C_1'^ECE_P!'^1_ZD5:5V?/P;D>$1 )OQ];V.)F74=.J?375:'/L)W6-
MJ; +?<USOY!]17L;-%E<Y#68MLG]$;:WG;^9875G;[UBU[/V/AQ^SHEW]*W>
MG_@OZ)/OV?\ J)#9M]5W_(?;]Z?HM^E_WS^1Z:H9?GEIU+JX/YF']T/3@@@$
M00=01P0LCKW7\CISV8F-4'76U^HVTNT:0[;#JMOO:[;^^M# C[#C?S7\TS^C
MSZ/ _H__  /^C0.M;/L-N_[/M],3ZV[]X?2]+]+Z/[^Q"!B) SCQ1[7PIR1G
M*$ACGP2Z2KB_!O8>5]KQ*LD-=6+FA^Q_(E3NJKOJ=5<T65O$/8[4$>#E(<#C
MY<?).F==-.S+TU-Z:K)TDD$J3)))*4DG224LDDG24I))))3_ /_9.$))300A
M      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    D   "PAVD !     $   "\    Z  DIA(  "<0 "2F
M$@  )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C(U
M(#$R.C(V.C,Y ')R,3<T-C4V       #H $  P    '__P  H ( !     $
M  5\H , !     $   ((          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#,Z,C4@,3(Z,C8Z,SD
M<G(Q-S0V-38       .@ 0 #     ?__  "@ @ $     0  !7R@ P $
M 0   @@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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MUR<U159D<W:"EK74U41&969R=(2'DI.4E;+6*$AG@X:DQ=)CHJ.FI\;'_\0
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M _CMFO?[T%_Z\GV8>^#RH_VN,D_+UK_9W#YQN;;^]EM_^^&)_P!&/V^M[C]
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MU!U(5E"77G%7ETB T@&H]N-84D$@@@B9'*-<79! ,V.G;CZ/+H&H: KI&ND
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M(V_B;_.YQ)62)PR*M2Q\DDI?W)*UL3(T-Y51RUQ<G)686E2I4Y=%51AIIE(
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MR5J:LVE4>157YT*20,JIK"FXEIQ2%N)22AO@"U6]'K"0BTR>(@Q /;BDJ2"
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M6,$(AK$XTET.#+%8\TKJ"C -*I6-K0C1JJ2S0  ,+I/)K"@P  *Z0"H P/'
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M?DU23N?O]1'?X8J^QTQ/ZMO*9-O[-:_^*BU[=AMA]S@A'7Y[^9S]VU]#3O\
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M.A/CT9I>S^Z^N@F;OL=,?CKY3(D#]6M>/&"T-_&</N<$/[=_,WVUO:^AU_\
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M\?6/WP^.0Z<3J.ZYN"9F -Y)'.1MW(D7V.GB>1-SXWL,,9]6@8V$!#3OG(=
MU$0T'IQ$#PTY&1([]- 9)%C>,+1WP-+B/7<:@&^VN YVSG'0<8QW'41T[B.>
M@AJ/#U2)!TB ;6Y#4;CM!Q.O@8\ ;3>?;X1JWQ[L=M\]AU ._AU 0@WU&@TY
M&_<;@3O;O!Q3,WY &-+WGNTMO&E[X .1J\D0S2/DU8$!$*@ !Q4 "(Y\D0J
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M*RD0R_UO$.'@B2D2LJ*0M:)])(!$@24RD&01.FSW(X# U!L&@B/XHCCJ'K
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M?&=!U#4.WA@0_P"+$B+S)WO<ZB1I^8CG:)MK?U Z1V#UZ3,7B<B("/E". $
M$=PR&OCMOWQG7(<2 (,7&EX!'C&W;RD VQ.Q\;G46N? VCOB;#$>'@. $ #
M?JMLAD<"&V=/>WCZ)UV@1-C&\\MX.^D18&Q\/#G<&+ 8G<,^P,]1UQU#V:9
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M=D:WW[HUC8]V!F?F.EKWN;7F-K"\8_7&,AMTP.0UU#QV --,>[2H1X&PUWD
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M4SU,A+BTH#CBETH>:"U%2@VF"H%+9!39X@%((5Q"$GCGB;<#P/#)2.%TI7
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MR_7].NFE/7TNG4M3RZI/T#Y\.HJ#?KJC;6H41X^D8F;Z=W$+OBE[S_KVZ_\
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MS(\14">& T$D)-BYQ DP6TJCXT%2W5W(*B#;9^(9UZ;!VWQX"'?(_F#3X8"
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MP(^O3Z]<:\,,/;KOG/4!$--0Z]1SID=,8X88!U >W?;0.GN#7KMPPQ7A&A)
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M*Q$B9D;S;68)MW X?&)FF0#;]<(Y[=_=MG81UX=0GGKV3O%KR3ZI@ZX><K$
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M !CM_KI&,[?S;:[\<+MO[>?K[O#'T3?;V<O5W^.,:.8"\CI8QZM9+G<]O)M
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M-M-.7>(TI/5W^.-]!:+ Q>--MCZGZ''7)VH]B]=P 1S5TQH'B/3(</3/X/\
M[UR3 ,>'*()MJ,3#9^_Y?<WWD]T QR,1$C#"?(8\]IT\FC3(CC/WPCV'?3/@
M/ =9(LBW]]:3(G^6T]\(;_N[0;A,ZG>2=;Z_/+"?]<>'</)H^G4<AMWWVQQ
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MV'(AZL[!UU\,\53KMOW&2.4=DQ/>+B;@&=>Z #)TM%YN?:1I [9QH&!#ID<
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M_EP^(PV]"-P ;>0.NVV QOKCN/KX>=&9XTSS]>\^%O5 L\T5^#7A\1 .<H3
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M0ZHF.*ICG,Y$U)2ZDZ:,M:I06>E4("2WHY6G4%X=3E[+=/EZZ6H<J7:YVI:
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M0T@!%#B[.2X*/25JHTRE;SKL]8ZXY*BL]8M2Y6H)2I9XB?2*4(25:E*$B82
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M0](HIT.+QZCK#6&M_P M]OTT M^F./,//%UETL<ZBSI).).H*HH72*0K::*
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M#8C0XJ*C%01NNMF WT"NHCB4U#Z0$H>= 2A320EQ:0EHN==U:8( 3UHZTI!
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M+;/7QA:XN\S-"RMR23.L<9#:SF9D<WHA/0O6M;6=776WHU)YI*,:A]&HH
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M%ML>6W@08M,]@N  ;8G33;8 WT$/7J&.^F@AOME;^0F('=,BUQP@"_9+2)Y
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M_3G&>-.I:.-9"DW4H@VYV.AU]47L<= AM? GT%3PIV((A(M,'<$=QOC]P)4
M !Y!@!ZAR'O[^H<>._%!+9UX?H[YG7LT[=<5=6Y '"KU$: 6.N^]^6^)\TH_
M6&=<Z#[.@^[MWQPEOFF.6FFA$#Z[R1.)X'/O5=T$?(#J>W2T8CS*G3[PS'7
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MP'KP(!XB&=M^'&C[X3SGY]3,:FXD=N(ZI?WBO4>P1;8CU#03.'HYP?UJL?\
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M1RWB^ID&<=_O?'.,;!^;K@1[<-MB(F_( 6'*^L7%IPU'/LUM&@B!K&FXG>,
MP&NGK["'3(@.1UZ=LZZAP%M.WLTU^^YC2UA<WQ,=TR/DBTSH3;3EAC :XP.V
M<!C<?#OMTR.H;BT\=-!&\<]])L"8-IPVL#[/5.Q@]D F)Q'0,Z>..HCV]F,8
M#KKC&1TOZR.9W'8!ZQ!MK$:"P$C03)D]D;:1;NL>0=>GKQC.<@ :=!TT\1#
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MT=9PTV:TX6O*LU0@%VF>(/H+,A3M*Z0 _3J(XA"V^!U"%CZCY)_*MT@\D_2
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M@BXX@8QW'09UUJJS'JG5MDT]/)0M2"8<=@'A(D#:=+\\9ZBXN&PKUNG96?\
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M,:\^T12/$Z<Q-XW,;Z>.FD@(]1JR'4,_4(9'4==!U$!]54#E[.SM%^VQU'<
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MCBGN[;=OL.)SM[?)QD/=D! -?'PU# "&V^L'L[ ;#Y=-M0]>L'YAL-#I.NA
MDMQ]>H]>X8Z"';4!#.G?+4C:;G>(D1I/9>TV .!U'+4G>TC2Q[+S>!V%W -^
MN<COMKOIX^O37ASYW[9FXC>>_:]C.!Y#4"".<WMS-MQVXGKIO@?>.H9\<!ZO
M5MQ(C:UCZS?ER&LQRP!Y6L=HN=+::#73NQ&-\AN(^K.@AG Z!N..WJXB-1$R
M>?RGUF+D;\\.8[2-R/&-];>),WQ.O41#7L/3PW'.F^G@&F9OOKSOM(F!<[7-
MNSG-R)O(T,'NTW_/AGKMCZAP ". UVVR&V0R'"=](^0P 3 OII(TD2,/"/J
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M+WY6.L2/4'8;=O=>9O:VA [L VQIJ.FP@(Z]@Z!X9'(!IMQ/+2^DF9,D#0:
M=@V&V)CNUWO<GEXS-B>P: QG\N,^K ^\!$=>_7$ B9[?C1X]P[9OS[ CF/E/
MKVB3J+^O$YZ[8R'4,ACIMC4,Z!G38.J;6T@CV;&/$QRF)L8D^$'<\MC>>^-M
M 9EZM<!U =1TU =]?#KKG;,D':\"+@ZZDCM/9WSI+M%^^R9YCZ^/.,!Z]P'
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M<8=/ XPTZMYQE:7(+F:J<4EE-0M'HM4(2$!:PZH(4AQH*<*I5*5*2I.BU)2
M1HGS<)E9:2HRI\JD#T1*5!?"E*+AW/\ A!EMI5D.:9-:F/.#XH=6=JN>TPV[
M*B=5P@YZO*JLNE.:5L.MH^(%2<'A M=##;K*K)T@"57&0\N9-CVPM5MC+/.
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MH\D-,--J*\THR5*2@ VZX0 >>^L8\>AY(_*2BHK%N^3WI8_UE2^MLIRFO;'
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M-,!TKZ2TR33L.) 5DV2.0XS2A*KMU-8D-NU&A;:#+!X5!\+VP[AGQUP.V/'
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M>0 ?DO?2_.+Q< '?KKJ/VJV]@!CW<0-]^9]>\^HV';M@!WW-SSW!F=.Z/FQ
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M-+'N$$8B=]MIORG2;:3;L$'#L 8$,B&@!CV[=.P_5K/<=2= #^:8[M^7I3V
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M/&XFD6NF"SZ1:5P?%,8^^KD[3UJY>OJY9C!77 IHHG"P+2*:54MH+4EK::)
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A[;=PM$QN1!D8E*'.(2E7QA]SMZKW/9S'+%7<:[&WQ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g160947g45z76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g45z76.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2-$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-S0V-38< @4
M0$UI8W)O<V]F="!7;W)D("T@5D),5" M($9O<FT@,C M1B!?5V]R:VEN9R!'
M<F]U<"!#=6UU;&%T:79E($-O;6T .$))300E       0<O>_KLRM#6CGQG9P
M2N;1XSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!N!3=         "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              /P   %P          !
M                          $             !<    /P
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   /P     %)G:'1L
M;VYG   %P     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #\     !29VAT;&]N9P  !<     #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     8X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MAEK=7;=_MLK^E_UM-33F5-8UV!0+6,>\O<6AS@#MMW?F5[?M+/\ 1[$^L/\
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M@Q66-MW-_,_G&^DW\])3OI+"P^MTUVDY74:;Z75@UEC'-=N!(L.T-/L_M?\
M4+8QLJC*J];'?ZE<N;N ($M.Q_/[KV[4E)4DDDE/"_605GZQW-LJ-X=2P-8
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M(9N_1V?];M_?K=@IP<9K;KW.:#'JY#RY[W'W1+Y<[^356H)@;WK9]/9MXR2
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M@^EZ;]WYGO7+#IOUFZ9&0&D?9B'V6NL8ZK8/IO'N;<_V_F;-Z:;^C+BR#AD
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H "2E7@
M)Q  )*5>   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z
M,#,Z,C4@,3$Z,S<Z,#, <G(Q-S0V-38       .@ 0 #     ?__  "@ @ $
M     0  !<"@ P $     0   _          !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,SHR-2 Q,3HS
M-SHP,P!R<C$W-#8U-@       Z !  ,    !__\  * "  0    !   %P* #
M  0    !   #\          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M 0$! 0$! 0$! ?_  !$( 9,"3 ,!$0 "$0$#$0'_Q  >  $   8# 0
M        ! 4&!P@) 0,* O_$ 'D0   & 0," P0$!0D-#A$&#P$" P0%!@<
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M+NCB._;GJ4SM=BR1E&=NC8$:6RB&DRSKZ+=D[F+C$1[YRD,1#QRIU#QKEP@
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M6NS"V..NAY+A<;",!'!@!7%DDJ5W<L;9K:+$)G1BXY)0HE.FR:D.4?,IBHD
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M(^@_14@#*< 9XT=@_AI]]O8>59C>S?X##F00X#_3MM7S#_K5HOR$-?"/2O\
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M&N6R5ID9)W!:I;I*S6XF2;OJO-8JR7792[2?@L4ZW&I2+(YU*E;WVE^:9?\
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MFGW.EVND7I>T%;HUSN,:W3=0A4V!'FR684LBWRQQ2HC;J6)"@&T *=;6<(0
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MR6F-P>.JSCQ@M((Q=,J;Z8>U]C)V::A4&JIYYW$-W#9S6XD10C"R93NY#Q/
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MW(!8+<-@/)5_P2PM:%;;V1++6-#?YXX[N@L&1XZ0B9)-)V>/DX/X<Y,HV51
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M$4B)*+$.JB*H(KKIJX=NZ+K/#O%LO<Z]:JU%+LRG';6WJ*\FX18,AQ 09+#
MCL)#Z4@<"E%020E03Q(21L+STWZAN6G[SIJUZ:T)H^!J%#;%\=TAIL6F=<XC
M3G6"%)E+F2E&,M>>L0A*%+25HXPA:TJPW4<N%NCQEUE_#'D@+*J*@7RYZ>LQ
MNGG@.>..> UZ0EM"<\"$HXN?"D)SSYX&^,G&>^O&U.+5CB6M6.7$HJQZ 20*
MO/E;/ETS!F N;+0U@&UN*M3UP;0[)VUA>JE1T3&1 "T<R#UUPHWAFHO0]^Y6
M5,L9+P ,4I.:L&DK9IS3GQ8@N2W+<4W%)7)=;<DD7-Z0_(_"(9;1LN2X&OP7
MFI"<\1&3V>JM>WK6&L#K6Z,P&[L5VASJH;#S,(&RQH<2(.J=D//84W"9+WX?
MSUEQ2.K"@D1D]N*O=AW%!N<?-*Z3(07Z#R,#)NP>DK'QZON(YRR1^''DE'_P
MXZD8W]X0^*^,H4RP$<I=1>BW%T;:H>C?B.TY,-G^"95FZU;K1G>2RTO)=5UP
M82UUP#Z^!74<(PG*%8.;T[I$OMPZ1#TFOM6X:A-^A:BZEN.\FU^70%1E,H\F
M,E4CR8F*WUB/*^L5E?"ZG(X;;W2]3EXR#:LF21F["S6ZX3=Y?GB"K-&K.<G)
MES/.3Q9%5W+AJ@V?NCF9%.Y750(1,#+J'**AMU;;5$M=G@61D+=@V^VQK6T)
M!2XMR+%C(B(#Y2A"%J6T@!PA"4J)5A(!Q7-WF^3KYJ"ZZEDJ0Q<[O>9U]?5#
M"V6V)\^<[<7%1 IQQQIMJ0\HQPIU:VTI1EQ2AQ'+^?\ :$Y>L49D!!U2,,M;
M%EO&DCC#*E]C:(HQNU]BGT4A#)R\W,(S)2$FV+)$10,P:LXI=RIX[^*>>ZQQ
M&7G,3H?T[#>M"D734CD/3]Z8OEAM+]T2[;+2^R^J2J/%CJC$F*\ZKSPZXX^A
M X67V^L>+OL$_P"Z$UA<(VH$.V31;5PU;IN3IG5-^C6%;%[OT61%1"3+G36Y
MP G,,();,=IF(MU?62(CW51DL6=L&Z7)\_D[#N6Q_!^*N&#JKCNH4I:+C5RL
M31N,U5U8!689OG[[WYVZ!PJE+F35:MW:)A(BV:\B.NDAZ#L42QZDT^/*W[=J
MF?>+C=$OOIZWK[V$B6F,XTTUU3:.!)CA0<6V1YRW.5<;/Z4M43M2Z,U9F!$O
M&A;1IZRV-<6,X&#%TTITP%S6GWWS(>=#RT3"E;3;R"0VVR=ZN5=M\-]OD'9Z
M:-+QCC:J7O)%5RC:CXJJCF!L'X:5Z;&:<6V.DWTZ_45GY%R8BR@R9W;%%5DS
M+'(1H&>*.M);.BVTVJ7!N0N=[O4^UV:?8H*;]/1*A_!DR,(R+<\RU%:"8C+8
M*4^3I;=4'72\I[\&E'2WOIOU!?X-SLZK-IG35JOFI+3JFZ*TG:7+=<!>[=.\
MM=O$:4_.DE=PDN\+BS*+S*%L,".B,"^7LYLM[Q<**XOW$K164JAD:W9UQ6QH
M*#*L[?7^,,B34\[)'H.KCF2X.5G,+*/*]'(O6K1G6G1(Y\N\563CR'%)1#RS
M3_1QJ87S1R9%BN-G@:5OSMV6[.U:U?+/%B-EY;=NTW;D)1)8:F/*:<<<FME]
MI+24E[Y07[CJSIAT6K2W2(N)JBSZBNVN])M:?:8M?1](TQJ*;/>0PV[>=9W=
MQQV'(>MT=+[3+-M=3&?6\M:8^>!3>L;!&Y2[[?6>18ZIP=(L,9E.!CJO<8J]
M5\]CBY&OL7RCU>+%@+]FW%O*IK+L9$5B+*^Z+&,R49/"(NT_<M5Z*MFKW+,]
M<)5TAOV&6].MS]KEB&^U+=:#2'^MZIQ86P4I=9X2E/6)'6I=;*FS\RZ$Z2;W
MT?-:BCVF#9+A&U3 BVR\1;[;U7&+(M\>0M]<4Q_*&&RW+2XY'D\86KJ5DL*8
M>"'D9"8[W,)Y2W$84O>6+[5=N]!V]MH5Y0(/'M!G7U9B8FNV&-DG],KT!%KR
MTB23N+520(_FIER\;+$1%!Z/ABW0-Q]XT0;#H[4UJT_:9^L;OJ]R2W=I5WNT
M5J:_(F0WF&;E+EOICLF/;G$LEJ-&0VM/%Q-^=QKKT'3W24G572)HN_:KOUIZ
M.[#T?-PGK!!T]I^<];(D2W7"-)D6:W0(RYDA$J\M&0F1,F.OM+2@MNCA+;9L
M%NTSD.XO<#D7*S=)PT@9J6)'TZ.<D*BK%TJ!;I0]99F;)F,DT5-&M$WSMJB8
MR2,@]>%(<X?3-UO1]I;XFZ1LUA6I#DN-'+UR>02I+]SEK5)G.!9 4XD/N*:;
M<4 I3+;9(!VK@>EC7!Z1>D#46JT(<9@S98CV>.XD(7&LL!M,2V,J;22EI:HS
M27WFD$I1(>>"2?E&X-&WOY%QY7X-G6J#AUI>*O2W^/JWETE*6:Y$BZO(-73,
M[=5Q'3#*MS,BW;/'*369G:W)R)?&5467<+JJJJ:BZ=%]FN\N4Y,NVHUVN=<V
MKQ-T\;DERSOSV5H<"TH>C.S8S*UMMJ<C1)C#)*0$I0D)2GH;'TW:CT] @M6V
MP:.:OEKLCVGK=J\61QK4<6UOMN,EM3D::Q;)DAIIU:&9D^V2I*>)2G''5K6I
M4#7MY]^A:#5J5*T##=ZD\?UN:I^.LA7ZB)V>\4>L3GCBXAXER\D @WK9B+IR
M:&^.P4J,7XQR(]28]&KDSHSM$F[3[FQ=M26IB[S8URO%GM-U,&UW.=%X B1(
M0VR93:G@VCRH193 ?X4E6",U8MO3/J"#8;599-@T;?96GK;,L^G-0W^PIN=]
ML=LG=9UD.(Z[)$%YMCK5^1&= EF,E2DI*DJQ4;C/?%E+&E)I]-3J6*;HOC(U
MA/B:X7VF?A!;\8C9A44E$ZK(A(M&@-Q<K*NVK:6CY1!JX,02$,W0;MTK=[Z+
M;%>KG<;D;A?K8B]B(+_;K3<O([=>_(L!@SV>I<<X^!(;6MAUE2T Y(6I2S?T
MSTX:ITS9+/9DVC2=Z7IDW Z2O%_LIN%XTN;GQ&2FTR?*F6>KZQ:W66I<>4AI
M92 "TVVTFTETW"Y#O5*Q'2)A>-0;87D;G,5*<C6[IK85Y6\V5M;)B1F'IWJS
M=PZ1F6J:\>HS9, ;@)@.58W2<O06S1UFM5SU#<XR'E+U*S;8]PBO+0N&ABU0
MEV^.S':#25H;5&64.I<<=XCN"D9!Y"]](.H;_9=(V6:Y&2WHR3>IEIG1VW6[
MBY+OMS:N\R3,?+ZVG'D364.1U,L1^K&0H+.%"X>7MX5US-7+!$V#'>&(:QW9
MU /LA9*K- ;L<A7E[6DTR1KF5G'CZ01C%5#)$5D3UIC"'D5 ,1P86JR[933Z
M>Z.;9IN9#D1+QJ63#M:);5GLLV[*=L]K;FDEY#$5MIE3Z4A12P)KLD,I.4#K
M E8Z/5W3#?-96VX0[AI_1D*XWMRWO:BU):[ B/J&^O6L($5V5.>D26XJBIM+
MDCX-CPO*%<27/P2W&EU1:-^65;5:K+>'5/Q6PMUUPO.8/NL_%5J5:/K57)UA
M#Q:\W+B%B.DI9F+"$:-8MVBFE'-$3K)C%JIBF5+!@]$]@@0(5K1<;\];[9J6
M-JBVQ)$YAQJ!,BNR'TQ8P,,%,%UV2MQ]M14\XH)5UZ3Q<6SNG3QJJZW6Y7QV
MSZ4CWB]Z*GZ&O=PB6R6R_=;;<(\.*Y-F'X24E5S8CP66HCR4HC,H+B?)%)*
MBCX'>'E*O7?;U?F,=3C36VFF!1: DXBY)1@]AP;3;7QK,B2:36D'XISSTPK,
M7$6CUE0$&_20Q5-A*Z.+#+MFL;4Z]<A&UO<OA2[J0^P'FI''&7PPE&,I+368
MK8X74/JP5>?D@C4PNF+5,"]='=]9C68S.C*SFR:>2Y$E%AZ(6)D?CNB$SDJD
M/<$UT\4=<1'$$?@\ A69FUW<WBZ&Q=1(C(^9JC6YF@Y;E\@H5_(F '^3'U0:
MRL\:=EG."K?#JNB04E84Q%)PUM+!R,5-+N))@X3!%DH'F^NM#WV3?;K(LNFK
MA,C7;3\>SJF6?5S5D:N3C$018Z-4VZ0ELR6(:MT.07D!^*A##R3Q."O8^C#I
M-TQ$TO8HNI-9VBW3;%JZ9J%%OU%H"3J5ZSM2IZITI[0MWB..I@R;BA7"XS=8
M[IB35O2H[@"6%5KMW%Y'B\O9WRYD^#:NV4+>K]8['$MGQ2$>I1DA(+*,/?")
MG432=':^$HX2(JH1)8YTRJJ 4#F]BT;97].:4T]8I+C;LFUVF'#D+:)+:GVF
M4A[JR0"IL.<00HI!4D!1 )P/GCI%U)%U?KS5VJ(+3S,*^WZX7"&U(X0^F*\\
M1'ZY*24H=4RE"W$!2@VM10%*">(V8UTU<932E-*5"O?Z5<?6D</OZ1X[^GE]
M?V#J#R/H-!S&^/.1\RTGZO7R[:S%]G!VPYD'_AMM7F #_P!:E%^8:^$>E?\
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M]C4%M^R3E2G85S#AZ5O$MDFZMXJ*ND=DF?J1:M&GBU#G;'K\2U,C-'%TT6<
MNL_:* #@$0'H2*(T=*<O5UDL-QU-IW4<>UQ[+;5OOVUZRQ+@9S_E"0E8ER'
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MJY7[#BUS6H^M0<M84XIH11V[1>23BP(?"7CD[JQ,2*5^@-D'2*,K83/$7?A
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MT([$O'2+*E2(_P &ZUCVV'&:BET2HD:+9WK7(#W6-I;2H]<5,=6X[YH'&I)
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MR(L1I3RTJ2RVM\.O%#G5H4&UE.1V,-CF0KI";F8B?K]Q@\R8)C\>+1&-T6+
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MG-[_ /C3Z#[-Q[:S%]G!_I.9"_X;;5_>I1?+7PCTK?W82OYLS_MO5^KG0/\
MO=V[^=2?]EFMU_M(]O;3)(7*0888G<MS4V^:LP+57E/"R59TM1W$%'6Z,@+X
MHVJUG,Q<';1+IG(NTEXAE*N++&E4?PJ'3R&F]0/MZ;M]K<=;\F95*4AIQ'&E
M*ERY*N()42CB!=6M!6D@*QWBO5;KIF"-:7#4"%*BSY"(B'9#:WFB^TS'@#R=
M;T8"0VVM,5"5EI04OAZI1X%*!B,?8;6Q3@"OIS$$QK]S2K>$8&U,XI\K)L6D
MQ'SU43E6+2475<.7[=N_;JI)NUG+H[DI?%%RXZO&/KM=W^5=K=;XSSW6-1Y1
M4VC*CPX84V-U$D^:<>=YQYG>LC0FEK78[W>KA C]6Y/;<#CG"A"EI<F==DH;
M2E""3A2DH 0DY"0D>:-U4)_TGB__ ">T_P#P!->75ZL-_G^FM<^<[-!8+WQT
M;/N9FLLEAF3VWSN+:G>T*S.VN"QODT,@-;+-M9HL!&2[FK*9 K QC2.GEFJ#
M665K:L(N[*JFT165-8%;@LH7"4<4.RXMH]DVR[7+O-9_M)9M_*YMP\GD_* S
M57+7,ES9<*522R+77=S8!8I_'E2M45%Q=K=-EY.4;2+E2(CE53CLQ[^_SU![
M:(G,DGN+PU9LKQMIE+D]W+X_F+?99*H35?/(.3>SA)'N)N58OH]H>+=.'GA-
MY<CI%I[O.J.62B+9QPU(Y?.?G_70X[.[W\?;]&*RR]I=?K9%7/%-%AG^1:]'
M3%$R1.MIB)O67:%1Y:WLWM99U^#;#@BI360KSE5J51V^I](>6*L5)VU<OG$@
MG,._=_AJHK7_ (KS?EJY1DPYD<O[C)/>&P4V3!A['I)3(R5,DY2?Q9AM]F9"
MSU)BV"@.F\@1Q;9#)Y+>W2&OLQ"=:!&O9 SQXJ<8[#X]GJ]_94ZRWES-$#C.
M?G:YD_<4SW8(,]U2VZRI.I/(;>B8VQW!4K*KNF3=>C7K5M0*2WA)ICC <162
MDN&$K:$9!R=5]-&>2@)*<S[CLY]OI/?V5,+XN6\1[*8JE[W(W_:_2+]LAOM]
MN-SL&:EYRK9@7RC*-<RN8F0> RN2",-1G5>G+9$PB"U?H-I&/D(!O!RR:Q6Z
MHJLK%D+,ZGQ$U8R=N<8;P'N4-PL5F"F0,9?KA3Z'M[:P>4_P-ME-QU*-VN-U
MF\!"ML8SV+9BNOFMFNEN=_"QFI-S*RJ2"FWOVGW]N/&H7;SDG,[NT8;K<78\
MIVJMM-T^.$IR^5Z\9AR!C:RQDGMYW .K#$QR>::_'7ZNR;>>AZO+WZDS5FMM
M-B;&]KI8Q]&.EG+514X]_?Z_#G5^_9N7O)#[-%OJ5JM>3LFM5\9O9RR7.=L.
M6DXV)N#.XL&I(C*N*\LPKMGB?,SML^D4_@.)[V^HB\3$R?17D6S6%D 5!Y^_
MJYU,M\U@RTSS#F:/KV0,BT"DML'[77QI>%C\ANZ2W6=9TRLC<6]EDL<O6%QI
M]>G8-I%1-ZN]$7/:J[!&9O%$5HQ-<FE*O?MENM[LNP[*,LZ3R$A8X*+SU%U"
M;GK;9[T[GVL6RFUZU8<;W&U5FIY GZ0=98C2BR%NBE;4+:/(DM+3::3.6=JG
MM]?OW5@/6U-PDEBJZ9<>Y%W%M[YB:G>SM>X^@V]KO32OK3-SQ[B8,OJ3=+ _
MPJY*3IWLBC;F,Y'R*#)PI(NC(,I)X^=**8W]9]@[<<]O?E5+65:]7').(%'U
MJW!2N[Z(S/O '(M(=+9%4HF/Q-@C<=#X=D:6R78IT:IM!CG-4:8UFZFZ;.;0
MQEY-X\<2S]N=:/5!\.\>SB%59/;D<QY&B:0&+;?GA2&J^RC"\9N#EH>!R(SG
M:[94LX8FBMP4C#?$X=-:2S14L;.K8>5DH-O)6B*:N7+N.7._*CTJ5QF6_6EC
M#T5K@[*.=G^T97*V2T)W(^8+IG6 @_CK/'E'=4VNP&6,?PLYG][B\L\XNZT6
M\L?$/)9&8N( TPXB6,.Q=O1[^XI^WEZ_?PJP&3IW+=TVZY0@MSU^W$/\J.\2
M8H#:_7H2*RO#UO*=+--N'%IE[94F\ S86BTK T3)?GV2XUM8HRO,H&T)L:^Y
MD2'T.,;\J<^6_OO\];Q-]%GR1C+#=6SAC,MLDY+"&0ZC>+32JJ>15<7_ !\]
M1?4NY5Q["L3<3B3&.M);8T9N$%@0DZTS=I>"HCXI8'(>BE:?9V*W<VW FXG$
MV:9W+,XZV]XX@(-Q.JJSKD,G7?/N6<:Y'BY=N0Q'!;(YQ#4&#^O1I5TI!"O?
M%! ")^&4$YJ=NWQQ[#5U-PZFX3#=FREBNA7S+3G ,1F';_(7"TY"R%F*2<UN
MJW3$EW>V5LXRM5&%ERO 4":R5#5,]J=5-?HK[Q][D9S 0,Q*"13U>X_5]IWW
MJA\=I;CLG1&3SW++VX(U?Q]M"S'DO"SZD6[,E2:2]BK64+PCBV57F)]A6K?D
M5Q&1R"K.O.K?%^^7FK(UZ1L$;-"BV='5&/;W=M;1-PMMS&?8A7[=6WURC[Q+
M5/!,EDZ<ID>[3R'"4>;F*0IG&?JL='M%))I:HJDN[8_9EC&)Y2-7147C6Y7S
M5N!%2<9/=G]G.M=.4;W8XV&<GVMY(W4VO&+.F[Y'=8LUQD+K,-#ST/M.AI6L
MH8[MDX!K]9J_!7X72U<D+:N[<,[Z:=CJH\7;,$B(*>KNJI+'&/\ %LXPK68\
MU;T6,.[VZ8WOF 9.CW+)%DNE[W%VB4G7N5&H FFY@+%=FCTE*8UC&5[Z:)&P
M$O)G2@VS->4?(JCU>_OWU"V3-N6E9)/"$A8<S*9,1W[9W?6FN/8F[&,3;=.8
MWRK(X_;R\NT8'JZE!?K255)!1+647B3R34&K!L*D6L5NJ1S'ZQCYNP^JL3KI
ME?--0Q9BZ&IS[,-'N.)MLVU*4I4:M:\T1 R2H5B)E;C)8UQ#CFF%I=PBH]F:
M0CLI3V9[/)H1'P]S'MH)@T9( ^5'OC]OUU<]=UD7&6/KW5\43V;(:R0$K[4-
M];&+>:R@\>Q=A(DRG<22J"TJX<@+V0A'\=9J_*1*ZOQ>5DW<T#ES-OGZZBI'
M;MGNY\_5ZZOQDIMF'$MJFJ.QR3N0D<&3T/LZN^>+$XME_M]^KU>MU@RW'YDE
MZ#/-TW]OK0S#FOT8MVB*&9 ]?K)IB0A8R%2*HLDJ*S+]G%<QN-=W,ECKQDN^
M4FL;H[;5\;2>5Y*TR=I845CC[&;N)B06NA4[,6);KOWJ\4:82)(O&;I.3?&<
M/'R[MPI6QO2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E>+'VE']7+N(_WU07
M]XM3U^E_0K^]9H[^82__ %:X>_;]5?C!]TI^_ITB_P#>=K_]MV2L(O!6\$7'
MA*> "@)"OT&\(%1#J!,5..@#B7N!.>KCOQQKT_C1Q<'$GCQQ<'$.+AY9X<YQ
MGMQBO$>K7P%W@5U84$%SA/!QXX@CBQCBQOPYSC?%=J;!\JLBW29/%7#E,%6Z
M";9<ZSA(0$P*()%(*BR8E*8P'3*8HE*80'@!XI+S*4J6IUL(0KA6LN)"4*R!
MPJ43A*LD#!(.2*J3&?6XVVAEY;KJ0IIM+:RMQ)!/$V@#*TD))"@", G.!L09
M/'3CW1JT<N7?)R^[-T%5W'4GR!R^"D4ZG43@0.'3R7@0$ XT6ZTVCK''&VV]
MO/6M*$;\O.40G?LWW[*-L/NN=2TRZX]E0ZIMM2W,IR5#@2"K*0#D8VP:),7J
M[KW%!FZ6>]9T_<T6ZRKKQ$^?$3]V(0RWB$Z1ZR='47@>0#C13K26^M4ZVEK
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M"@N*RD4]1<=.+L^MD>XLU5I*]2I=@N2P7>0<POQ@8 C4XUB%*1DZ4<VF6!T
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M]S@-65LS#+3T&G(QTDZBSP\$S3=+1;M)\T!16/BVCCI3<HIJ@0JI2"8H=13
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M6<#?:$S\38L]).&T5 QUE8X[IL3D%U W*OWLTY=F+1V20F;'/56 KM>6N:[
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M-Q%+4X@XO;N+X>(]IK:KY1[2U0]UR=BMS&6F"D&:S-- ].HD?(.&L@DHLT\
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M8#CT67<+<XRX$K(4$6"T,G&$X.%MK&Q.X/<16! 9MIO^RE?J_6%/+G_<_/\
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MNU,P/5Y$PME6Z;"2.^CHWKE'"SPRWPUK0MQ+;:W7#PH;2I:U'?A2D$J4<9V
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M_P"1<_W[U4&'(\ ''GS]?Y_EY\:U2@O.%')Y@\6=@KW[>?IKHJ^?T\_7]/\
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M5*#G""3E//Y6>?TGZ-Z#&3@;CGMBN._8>./K[^?R]?,?F ]^1#GMS;J:&^L
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M?356@7$I>)I,"67*%UE']URA:1_9&^.WJQ+OYY=J)^3HQ#9TT@V//AQT6S1
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M"<A5.DGB%*;DH'Z"=0!U=)>> 4K[TI6'V^G(6;,0;<,B9AP=/T"&F\45FR9
ML#/(%1E[:QL==K5>E)%:!BR1%GK!XB4>/4F8IRKE21;HH$7(9@<RA3E4K#F
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M:L>!_!I3NK/K2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5@[E#_1[9/\
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M-4.^1^0"PM@I<U7&35^_M4LF"WQQT<K-!Y)-5(YF3RFX=-'2AT:P]&:RU_\
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M /-?O&VOKXI=I/HMDHHHB*CB-6*EXS9=HDNJ*)2K?LO&33 A2_K764IVP&X
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M/\S<V(?VJ^(/^32?^%TI3_,W-B']JOB#_DTG_A=*4_S-S8A_:KX@^7^AE/\
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M52)J"T;H2+MAR>I-.0]/]2AK45NO$ETKXH\&-.;4PA"UMJ4^J6RP$'K$E(;
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MVEZ2ZK[]VWDF*P(F37()A,( 40\9, $P@FKX?("/)>"@!N@0.F&ICWAV.PY
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M*9/L!1+MD$E"U)XCP)(X.8\TA1.1@8VWQW;=E=6U,8EMO-+1YSBU>>HX4$.
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M:O'K^WGV^..7J.:Z$N) R>7>2!CTYY>GE7V"0F#GCZ(^1@#D#<^H"'U<ZJ(
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MTF:=AX-V^7'/IQ]7U_=^><CN^?'V_75P2.]/L/M^JN@S?H XE+U";@1+Y?2
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M8?R#VY\_77-;<N[8^!KM"O(VP/7N/K'L\*[ * \!P'G\M*IXCWGVFNP$1'R
MOY/\6HX@.W?D>?OCQJDD#F:[R(\AQP'(!]7I^GS^[5/>2I0W('=[,&J2L#EO
M\WO[*B$T2AQR4.KGY!\^W?5)5V GT[YY;^^/';:K2UX/,[]GJ[LU].EVD<R>
M2+]PDR8L&SAZ]=KG(DV:M&J1EG+EPJ80*DBBD0YSJ'$"E*41$0X$=4+4$I*U
MJPE(XB3V#F3ZANKM2GSCM5M"79#[+#"%.//.H99:;!4XZZZH(;;0D9*EJ40
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M#;NY=N-MOJP=^T'%192  =P[_;_%]7&K2E9Y>KWY\_1V5:)[S[\_UUV ''8
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MFRC%)1!FF2138IIL4'"K-R9,43'*&O-HZ57^]2IKC76AA9?3DA+@;02MEM(
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MZY[P;6,YTU>M3)C1DPR.L^JUG;(IKOZ[+'3%,ZQ$U.$WT8_2#W2;AW ^Z2K
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M3,]!(:DH;*TJ*.+A&^#C?;O!VVW^;Y6^(B!C).G2)@#GZ*ZY#<E]  .2\CZ
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MFM++)JRM*N+)%$9VK2Q2<""[!=4BK-R)$TY.*<,)1N4$'B8 I63(B!0$QA
M !$1$>   [B(B/8  .XB/EI2K,3F8FAWZM>QY"NLA6)/DBQHQ4B%:C#@/ C*
MV(Q5&P= \]2+$CPX&**:QFYA =9"(ZE#B60VCO5S/+8)YD[[=]8RY*$G@0"Z
MO^"C<#?&5'L [>X9/96/V0[G'L2*?CFRBLJL8#".,\7JG:MBD-R;W26D$EC.
MG("'ZTN#]WX1@Y,FF4!$NLIME(_<V\[?NCV<;_C);Y^C/#ZQ6&X\M6RW<?X#
M.#RSLISEZ>'BW&*QEE]S9:\D>.Q)1:W1F90%-.469HRE@4#_ +*=TN44TU3?
MLAX\40-W W&LCJ_^L4I?A\E [O-3@'T'/CS%6./'R$I1X_*7GOXE9(_\(2/"
ML:[;DN\V]95:RVN;EA4,(BDYD%_=@YY'I3;$.1N0OR*5,"@'IY $C   2 .8
M"1@ ';.!MZ.W/+_"MDD[DDGO))/M.35J7CX"B(<_7Y]_M'[O+[_74C)W^K//
M<#?NSVX'+F-Z>_O]-<Q#*-DV-KF9VPA7(.GP"-@EI L-)S[D6[BPP5:;H-8N
M)*+QPLI(V!B)A+]%% BZIOHI\:VMDL\[4%UAV6U(:=G35/)80](:C-$LL/2G
M.-]TAM'"TPX1Q'SE<*0<D5H]3:DM.D+#<-1WQV0S:K8F.J4N+$?FO@2ID>$R
M&XT9"WG29$EH'A2>!)4M6$I4:M%:<T;6J@NT;6O<:SKCB0*)V3>6QE=F:SA(
M#BF*J:2P%/X/B )!7$H(@<IB"<!*(!V<WHGU?;BTFX*T_$4]LTF3J2UM%>"
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M$*(.4@A*L1KK%%4;D2,KERIG,HD90X)+.5.CA-54B9P!,.A17I(1/D>@3J$
MYR?2,2ZNW-QT@NO- [D\/6'&0>9X<<NX\R.1S6N3K":\7 BV3AP.);)5Y,GY
M92GB'X<Y",DJP <(44A1X0>YQB3'+=9'C-%:<IJ'4,<R"$@444TW'AE\0#I
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MUU12I0X I9_&.05 (J":WB[%W"(IM-H*0*)$<E0<)W([)0AUQ-R BSC4"*I
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M?I!R(_/CC\VJ5EEG\(E>Z<A*>$X"L#)V3G?8>@8[#FA+4EU(;6E339/$7/-
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MU^.Z%UDZ3L%2-88YLY$R"QG3B0K)I>(A6BJ2C0\>9W&Q;<43':,T^B &QME
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MU5';QY(.UW3ER\=.GTB[5?/WCIV[57<N'#ITNJNLLLL<YCG$>0+T@%6
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M-<R[!!\K6K0W9/8UO/Q KE.#.5;L9%\V0>I "R*;E7PC%,;J!2K27#:/M@R
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M0?DTJ1S/I^H?;50(148U  ;1[)  \@2;(I\?9TD#2F >RHX"E*'!0 H?(
M_-I4USI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
'FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g160947g56q48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g56q48.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[11.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-S0V-38< @4
M0$UI8W)O<V]F="!7;W)D("T@5D),5" M($9O<FT@,C M1B!?5V]R:VEN9R!'
M<F]U<"!#=6UU;&%T:79E($-O;6T .$))300E       0<O>_KLRM#6CGQG9P
M2N;1XSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              &V   &P@         !
M                          $             !L(   &V
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   &V     %)G:'1L
M;VYG   &P@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !M@    !29VAT;&]N9P  !L(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MN_EV?SMO^$L6MZ-O\G[S_<L\=:Z:8)R:V S!?N8##C5[2YO[[7?YB6BM4)Z
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @    D   "PAVD !     $   "\    Z  PKZP  "<0 #"O
MK   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C(U
M(#$Q.C,S.C$R ')R,3<T-C4V       #H $  P    '__P  H ( !     $
M  ;"H , !     $   &V          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    "0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#,Z,C4@,3$Z,S,Z,3(
M<G(Q-S0V-38       .@ 0 #     ?__  "@ @ $     0  !L*@ P $
M 0   ;8         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M!]DW&?Y5L70(VLNG: A*0?\ Y(E"BR0;:=..^#3_ /(N$TX+;W_VC44%S_\
M!5KT1\G'RPJ#HJ0#DPG<JPV9'ELFBN90K*5X00,XXTO*%8RE6$KSE*L9QGLS
MCE3;K3P(XRXVZV6>1MF+@+DN2Y$*J*Y+N7)>FJ'676#5MYIQEP<M3;H$V:9I
MFF8&B$F:*BIFF]-]5_6=PT&XWNW:ZK$\U-62C!@%69(*5/QT>L\DL1 'E)&<
MBOR0KX3S4@(PM:P7<>+DY;)0\RU&Q+Y;)UQFVN))&1+MS;9RT;34TTKIF"-[
M5/$)T";)'6Q55;+Q3R-"%)698+K;[9 NTV,4>'<G'6X:NKI>=1H&W%=V*^.+
M)BX*M.$B(ZGC!F"B2V;VY_?GZ<\EJAJ=N?WY^G/%*=N?WY^G/%*QDU,!P$/+
M3LDXXW'0L8?+'N-H6ZXV%&BNF%+0TCM6ZM+#+BDMHQE2U8PE..W..6GWFXS#
MTAU51IAIQYQ4125&V@4S5$3>JH(JJ(F]>A*O1H[DJ0Q%91%>DO-1VD54%%<>
M,6P127<**1(BJNY$WK6N@75YIXJ()G"7[I"1[=++V#'/V&B6F$;L=1 4!@V7
MJ[Y\<R+/M#)E(YY;<>0Z]D<MHEMM;&%N(U9O&]B-@Y!E.CM);SNC12K=,CI*
M@M[/:/PR<:0)* CS1*+1$2@:&@J*$J;:[@/$#;X1@&WR'5N+=J=&)<X<E8D]
MW:[-B:+3I'%(U9=%"=$10P4%5"4478+-HKB0"I55BA$Q81"@S9+,N!@ 0M"T
MMK%*,R1XN.0EQ:$*8=<0ZE:TIRG"E8QG9N-Q4;-Y9,=&6R4''=LWLVS1410,
M]6D2151%$E14543+>E:KQ*8KH,<4D[9T=;;.P=VK@*BJA@WHUF.2*NH45,D5
M<]U?TNRUYIR-:<L$,V[,I0N':7*@H<E4.=WP:XU"G\*.2OO)[BA<.X5WD]F<
M]N.>K*BHK0K)80GT16$5YM%>1<LE:12S<1<TRT9]*5XD.6J/$D60HQU5)!(P
MZJ,*F>:/+IR:5,ES0].62^:O6U+1KYQ,6Q)@O20;;;ID<T8PX<*T[_V3A(B'
M,D,-N?\ RUNMI2O_ .'.>5H\T3A,BZV3H(A&TABK@"7Q5($74*+Y%5$1?)5!
M,O"T#Q-.BRXJBVZ39HT9#\80<5-)*GE1%54\M51?M_:VUG.)@;;)S A+045)
M2QH-8L<M"UR-G9;R%#'V2;C(PJ,A1Y*7_P!Q&R82ASPG8Z\VT.I+V86Y8DM-
MID)&FNO@:-LNO.-PY;\>*U)?XM'<E2&6398%Y_\ -!K-%SWD@@J$LY:\+WB\
MQEE06HY@KC[+#;LV(Q)EO1F.,R&H<9YX'I!,L?G3V8*F68BI&BBES=N?WY^G
M/)ZM>IVY_?GZ<\4IVY_?GZ<\4IVY_?GZ<\4K7B?ZH=75FSV2L3"[@RJG3<-7
M[781Z593JA7).P, $13<U9@0"(N.:)1)!_[P4\VRVIW_ &BTX2K.-8DXNL\2
M9*AOK.'B,AB-,E#;Y;D&*])%HV1?EMM&TTAH\WXQJ@HI)J5$S6MLB8+O<V'#
MF1T@%RA'D2H,0[C#:GRV8I.B^L>&XZ#SI K+GB *DJ#XJ+T59%*VA2]@-%N5
MJ;9(>"E)Z(? *5@*3P16I4B%EGD1SZTF+!9D17F&SDM9&>[N%(<SC..2L"[0
M+DA\5?$B;>DL$T>0/:XCQ1WB1HE0U;%T"%'$'266:+4/<;-<;43:3(Y +C,5
M\7017&=,Q@)+ J\**VCI-&)*WJUCT*FZL^W;:NZ$9)-6: <CH]WP!\@W-1RP
M@7NWL\"84DG+ SO;^KP;SB%]OZNSMYDI,AJV;R2HRM-+I<=1]I6VRZ-)FA:0
M7/=D2HM8JP9HNMLE#E(\Z.III8[R.N#^LVVH:C'YQ14KU+L$&VB.<<FXI#<P
MM#40M<D&E$JXYC&6VXY2GL).6O&<90@;+JE8SCNXSRM9,=$:57V41]41A5=#
M)Y5Z$:75DXJYID@9YYU0D62JO(D9]5CHJOHC+F;")TJ\FG\VB>53THE82\7R
M#U]#LS4\F9?9+DP88 & @I>R3$C*R3BFP@@8J$$--><=RA><K\$EAI*%*>=;
MQV=N/<+C'MC R)*/D)NML-MQHS\I]UYU51MMMF.VXX2EDJYZ4$415(D3?63;
M;9*NL@H\78"3;+DAUR5)8B1V6&417'77Y#C;8B.:;M2D2KD(K7UHUYK6R*I#
MW:G2696N3K+[L>;D<L-Q>1#"(\UA\0YD<L4H*0$*"+'(9;=9)'=;4G]GMS[;
MKA$NL)BX07=M%DB1-.:#;5=!DT8DVX(. ;;@&V8&*$)B2*FZJ;E;9EHG2+=<
M&=A+C$(NMZP<1-;8.MD+C9&V8.-. X!@2B0&*HN^I9VY_?GZ<\S:P:=N?WY^
MG/%*=N?WY^G/%*J;:.YJOJ$8,ZV1MU?C2\M(5*5NG3UDC 7B3Q(L(:3/BA"!
MH\J0/.%%CQRG&W3'G4ML)6K]7(6\7Z'8Q;<FLSR:<TIMHD"3+:;(W09;!UQD
M"%LW77 !H35%<(D045:G;+AZ=?S<;@O6\7F]2[&7<(T1YP0:-YPV6GS$W0::
M;-QTP11;$5(E1-]2NNWB%L0<20E1\$=-M%/@URUA$5FUJ9$((&><=K4O@:79
M1VC./(4L7"7!LMD)SEIQ*LYL6X1Y3;!IM([D@3)J+,;*),40,P)2B/:7Q3Q%
M),PWAD70M8,NVR8CCX+LY+<=0%V7!<&9!0G  Q1)C&M@ER-!5$/-#S!?&14K
MQ6[9E,I-?M-DFYT7(%+!S(V1B-=1)R<8+WTMX4_&!K=,0I2UXPA"VDJ5^ONX
MSV9Y;FW6!;XTR7(D!LX#:NRA:5'76@1<LR:!5-%SZ$5$5?)5R!9[C<94*)'C
M.(Y<'-E$-X299>/)2R%YQ$;5,DWJA*B;LZD2+) .#J+1/PZQ4%N@+)1*!*'0
M<RVMYX)3V'\MI+:9;<==&RK#S;;:UJ1A*59QE)*C**FDAA00U;4T>;44<%%(
M@4M62&@HI*.>I$155,DK$6)*0D!8TA#5M'4!67$)6B5!%Q!4<]F1*@H>6E55
M$1<U2OQZS5X<(*3?L$,Q&R2VVHZ0>E@6PCW'>WP381:R$L%+<[JO!H8<6I?=
MSW<9[,\\*5%%MMTI,<6G51&G">;1MQ5SR1LU+2:KDN2"JJN2T&'+)UQD8L@G
MFD4G6A8=5UH1^,KC:#J!$S3-21$3/?6%&V%5B9ZYUW,H@0^@LU\BSNG]H,>
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MWPNOVH2#@J=%6.4Z8MG:PMI@!+ BIZ_6>P5N1KQ4J<R$AZ5$&# E&_*9GA7
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M._?\RU0D!TA;9&T=,PAFHV_EN-T'YTS7<OKJS\P+;@-F7[$340I94BXL98M
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M8*?^SHO[WQ^6OP#?+<0=F7#[JI^19C;K6'_LO?:>@EI3_F"G_LZ+^]\?EK\
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M8]41?R\9L.EEUR&L/6_U!W/;[86LT;8<+M>N>I%(4$QJ.Q0A^U3,4:.QKZQ
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MP@:CRF&45Q69AED(( H>RD$0HTJY.JK7Q.E.,]N,9_?^O]>,XS_^^,]F<?\
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M-13<I%EFO6+1;+Z=IMA-W6T@!6^$0"=DF&8@L9I1$C&_MH9(BHA$C8(2HJH
MHN22WS?;#^?5,^S><_-'F!RG9^K+EVS%^XZD.2K_ -;6?L*;^(:>;[8?SZIG
MV;SGYH\<IV?JRY=LQ?N.G)5_ZVL_84W\0T\WVP_GU3/LWG/S1XY3L_5ER[9B
M_<=.2K_UM9^PIOXAIYOMA_/JF?9O.?FCQRG9^K+EVS%^XZ<E7_K:S]A3?Q#3
MS?;#^?5,^S><_-'CE.S]67+MF+]QTY*O_6UG["F_B&GF^V'\^J9]F\Y^:/'*
M=GZLN7;,7[CIR5?^MK/V%-_$-/-]L/Y]4S[-YS\T>.4[/U9<NV8OW'3DJ_\
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MVQX7_:K?_P KZ<;X?_D7!]V3<OQY3Y':V]M6?LGG?Q=QR!\"[]L>%_VJW_\
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MU[7:(B*6T4=.[1GOJ/>4H[^WA?6F/YG-8\#_  M?T7<(O\$XE^[*E?")P?\
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MXUECN&@-I=8PE<"$_$DR0VPIH1!$F&"%5:55,U5Q41N_O.UJSVD43WM@?O\
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MZGG:U9[2*)[VP/W_ (Y!OG4]T]@E>ZISDP]U[9^TH?OJ>=K5GM(HGO; _?\
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A^>AMWJ'^]52/CCW[T_X>;'H3Y_\ 5_A4!QQ[SC]6O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g160947g71z06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g71z06.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2-.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  M*97-S
M92!38V]T=!P"!0 C1F]R;7,@07-S:7-T86YT(#(P,#<@0FQA;FL@1&]C=6UE
M;G0 .$))300E       0 B;EIQ0J#TJ!>#0!23 0NSA"24T$.@      Y0
M !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !)
M;G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O
M;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U
M<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T
M=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--
M64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO
M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  $#P     $  3A"24T$)@      #@             _@   .$))
M300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          3A"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #-0    8              ^<   6(
M      $                          0             %B    ^<
M                 0                         0     0       &YU
M;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^<
M4F=H=&QO;F<   6(    !G-L:6-E<U9L3',    !3V)J8P    $       5S
M;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M      9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A
M=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   /G     %)G:'1L;VYG   %B
M  -U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB
M;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M  ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E
M96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E
M=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S
M971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
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M7;_\V.@_Z%W_ &\__P DG_YK]"_T#_\ MU_]ZF/.82*X9_8/^^:(^'\T#?'
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MP8T&X;K+/S/Y:W/J'EL??DUT8;:I:'.RJI< .U%CLAUKO=].MM;O["R?V?\
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M4XW?7[5H K8?8[7IX7B/\X_^269Z_6MSF_9Z(8X[7>L8<P:M;_.;J7N^CO\
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MTE\\))*?_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    P   "PAVD !     $   "\
M    Z  DGP   "<0 "2?    )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$V.C S.C(U(#$Q.C,Q.C4T $IE<W-E(%-C;W1T   #H $  P
M  '__P  H ( !     $   6(H , !     $   /G          8! P #
M 0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M     0   48" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!2$U- "H    (  @!$@ #     0     !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    #    +"':0 $     0   +P   #H   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z
M,#,Z,C4@,3$Z,S$Z-30 2F5S<V4@4V-O='0   .@ 0 #     ?__  "@ @ $
M     0  !8B@ P $     0   ^<         !@$#  ,    !  8   $:  4
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M 0$! 0$!_\  $0@!D (V P$1  (1 0,1 ?_$ !\  0 !! (# 0
M   '!08("00* 0(#"__$ &D0   & @$  PL%"P8)!PH #P$" P0%!@ '"!$2
M$PD4%187&"%65Y;6&967U-4B,3)455B1DI33UR-!47*QTB0U-U-A=':3M!I"
M4G&RT>0E,S0V.&9U=X&S"B=#M29BH;8Y1D=CAJ*E_\0 '@$!   ' 0$!
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MFHG:GQR*$. &(<ARJB4Q#%$#%,41 P" @(@.3AA?AT8 ,6D)"(" " @S3$!
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M(E34!%R[34%,XE,!3@7JB)3  ^@>BR<4!A4S.5)W3U*M53 !BIN"-$#F*(B
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M':;YVEV/>YD9)=6E9.7LWUF>/$V;REYU,6:TR9HN#RJ8M)@DBU!PBPE)=AJ
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MF8X$,?6!*8VN%$<@2B.4%H] ZGV?S"6U!/V9)PY8R\:+JYT5OLT[=L,P)*C
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M)#+]M8M[!E?ULV?AO B229E#)I))F5'K*F(F0AE3 '1TJ&*4!4'H]'2<1]&
M(0HF$I"E$XW.(% !,/&80"YA^.\#*JG @'44,"863 QS& @:;$ 1')#X"V"/
M*:::10(DFFD0!,($2(5,@"81,8>J0 +TF,(B8>CI$1Z1]."E*0,DA2E+G&Q0
M H7'.(V"P9QSCQQ*<YU!RE#F.:P!E',)AL   !<PB-@    X   AV20*"L"2
M?;"3LQ6[,G:BF B($%3HZ_4 1$>KUNCI$?1Z<9!,K+R2Y=K9>2&5;BRK7M\%
M[1'7%,@$\L^M@;*!/*'( PA;* E\G*MFO:]H]\FB2&(0Q"&(1ZF*4X=!BE,
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M3J',8<XQI%2U'-ZMG<PJ&>.=ES.9+ JY5 A4R!D)D12222( $210033113(
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MQ[1CWPVB]5K'BIU*0;*-EVZ#6U-TW-E>MTVZ/633;H)G3 RB8ZJ58RFL%*(
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M.48-9(KU0[-9!%5!?J5#4:^0&:"]>,6:,I%B+A=8S@4U$I@&4W50!- RB@&
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MB@&DD2/'T69 I%2)IMP<]05!/=*U8+DTS!S+2J(S*5,9<9(KA0ADSR\I-CN
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MR:A@.91=P*AQRLHPF,8YJ59N=]3CJ5NVMZ,XN1&I)_D*Q6A=F6]U=[A=WCV
M?2#F1E8^*C)LI8Z+6D%G;D@O4DQ4;$6$R!0.FB9.1Q534K69H2J0I2Y6;EUM
M\Y%XZ='.D*FNG(F16Q"99A&YK"( (VSB A>2C4YSIS/L/YIB'B^\K26X8N"3
M"DI&C3\CI]!O,F[9)JS<O'<O$73M-L1%(P(',!%1)8XV,?*O2:[J3?)"&Y#0
M[#4K*.3WW%ZSB5G RKYTO6&M%JT/4)<K$QXTO? 6N&B02=?^CBU,J40%<$2
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M'BT?1'N@/)5PLDW;S,>LNNH1%%%)*QJ*JJJF B:29"V03'44.8"D(4!,8P@
M (CD0Q[KH1  :4>(CF  HFFA$1'0 !M;$BGV-/4U)$.JI,L9TTTR&444/C;7
MY2$(0!,<YC#-P I2E 1,81   !$<T<^9YW<IZ[*/H2>=HPTQ&.#M)&+DV5H9
M/V+E,>A1N[:.+$FN@L0?0=-4A3E'T" 9,ICQ7J1SIJL:134(82G34H>FR'(8
M!L)3%-+0,40'2 A%NP^QOZF":,V\PEL[Q@?L7:95FKQICE7CALX2-[51%9*<
M&34(;@,0P@/ ,4SY0?DA^7HO]6Q?$F2;_=<^:T=ZE4SX;%W]K0U-OG^-/Y;,
M0/%H^B7= N2JZJ:"$S'K++'(DDBDE9%%55#F I$TTR6,3G.<P@4A"@)C&$
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M-R"?.K$3\HE8^,160XP:Y* %+,;4*4H 4I2[>V,4I2E#H I2EL0 4H
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M',0MS.7*P$3M:YC&C27^+E0I84X0,I95LVE%6S3#.85>Z0DH4-2TK<(L2H(
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MT9PCPZ;5N_42Z"&RTSIQBUDSLRTO0;3"7N90FH9KMB8MG1RIK)K.W)]CNS'
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M$DDDDTSJ*F,0B9"E$ * !35P%QB74,LM2KQ58X@)U59BP.H80   3',[$PB
M   (CF  #0$7\N^R8:A>3L$97*L1FLMEC<ATT)>QHVH6K-$BAC'.1)LC)R(D
M*<YSF,4I  QC&$;B(Q==KXC<Z+W$15?NNQ&MM@H($PA8>R;YBIJ,B@1("2/>
M#&0L+ALU%), (F**9!(0.J40#T9<.,#\:W2::+JG)DX22MK2:\U9JD3L%@R"
MG>&*6P9@L&B,-)OLAOV/>G7SV9R"JJ?DLQF.5L]]*\/9NP=O,LPG/LEPVD2:
MJP',(F,!S& PYQN,<F7XI<\Y^.3B)W9Q)B*281L4G&R>_HU\Q)&PSM%_$L2M
M'-C40!K&OFS=VQ0 G9M7*"2R)2*)E,$5<$<;5B FM3TT53 A$@34FS0Y 32,
M!TR9)GHER2& #$"UBF !"PA%%E]D&^QXRUR9[+ZEIMB\,Y=/#.FF'4U;N#.W
MR"C9ZX%9*0D4%9VW540<*964LDH=-03%,(#;SOA)S)?JVE=[:J^[6O (!<U7
M.Z8!=2U@U=$?-@L1U)PQICO=ZFF[1\("X[-P0JQ.A0H&RD; G&8XKB>F'QA=
M6V2)IDQ$7%C@<->$7=U+' #!EWL8 '2$91'[)#J"6Q).FWKJ6()T]K@R$B5#
M3U,LEUY$S=7:LI9* ,==0.9%38VMY:1C$-<HB$5&=X><W[/6H2FV.^1T]4JT
M*8UZLR^](>1@804DP12&*BG<^JR8BDD ))"V13%-/[@G5+Z,F5P-QJ702;+4
MW,56Z']"@I-&9TDK!8-;3,\$I+!F#) +!F#-%K+OLB?V/R43683V55?(Y=.I
MME!,YLQH"<-9C, .?+.#QXC(R.' '.(G."JA@,;RC7'/'/G.*'/&S>*XV+9B
M4X-(.W5IPRV_8R0&K*M!3%JK =]6)7P2JV%)(4%&78G2[,G9F+U0Z)U<$<;5
M]CZ]3TS5V)DBVUR;-#['$MA**.4\'6Q*(!826$+!8<T6\O\ LA'V/*5;;[65
M/3DOW0%5)/-A8=S9MMP1;*!8DRUF0DV817+/KA7&N%/E&R@&XQ'\GW/GE%-2
M+Z7F'%%E)63=KOY*2D-K51X^?O72AEG+MXZ<2RB[ERX5.=5998YU%%#&.<PF
M$1RT/@%B^H<ZBE).CJ*&,<YSOY>8YSF$3&,8PNA$QC&$1,(B(B(B(YXV5I]D
MZU$$O:MV+'$Y-FS:(IMVK1M252(-VS=$H$21013E!4TDDR% B:9"E*0H 4H
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M&P'=K,W\JRCEHY)9V=,[<5DRF ;% 1S!8 X 'AMFS /#P< !"ZABF 1&P9Q
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MH!M)#SR4H6%5[+%C(+MUBD*(*&0451= GE'%  *;)Q97M.V6O>7?-AV$V\)
M4T=V\K8T>_RGZO4,R[1<O?0&ZY.J*': ;K%Z.GK!TX(7TU+DY3R8!EVR+N'(
M9=]&3<_E7X+7CL*=-X?K;(UF0T>KL01!UK<LDQ]C"6^4#C)1'61+DFOKF3:P
MWT#'R<W#:3)%%R\L]]:-W)UDVZ[F9L""*ZC<XIKD155<$(J=!0!(L4AC&3.
ME.!1#HR OYH4 $SU^4#7 !%RX !L-AL(GL-AS#;0.F)T:7H-PHHDWIZDEU4B
MD,JFC*I0JHF50N4F90A$#&(50H@8@F  .4;EN$'5QVBQ3:K/;1?6:3Y/MF2K
MJ:L#=-XCZ/Y5J=5R0KA/TA]VD)R^D/3Z<&?S0H%$SU^4#!<HF<N  P<91$^<
M/A#-$4:6H-R=9-O3U)KG;GUMP1&52A4Z!\_D+%(@84CYA\DX%',.:/9>V[4:
MN$&CFRW]N[<ID6;-5YBPI.'"2H"*:J"*C@JBJ:@ (D.F4Q3@ B41 ,"_FA1
MHO'X&$ $"BX< (@.@0 3W$!X+:>")4Z8H%5)1PE(*1502,8BJR<KDYTDCD$
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M)$S& 3B7/K8F$ '0/K;'*BJCJW!F5L*>8F?SNFW]$U4$@,.0I.RTNX:O7DD
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M@I5O!Z!DS+.W0E13?OU5G*+5NF( ?V'0E,NJ5D99>]=BZ<J+G<J$*83-FHG
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M#$(8A#$(8A#$(8A#$(8A'1Z[H>;J\W>1IA#I NRY0P@'\_01L/1GBVO,U8U
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M0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"+5N7^)%/]8;_ /;'+IG_ $P?\)HMG?\
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M;NXR$5J\-"/%&K!PHU[>1=HF/U1,V29)2CE6XM(_[I0T_" !QVSA\$3"<P@
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M9Y+DB6$,IPW +'3'LSDX_:'4*4Y-0ZT.0Y0.0Y*= &*<I@ 2F*8&(@8I@$!
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MH$$1#3DY-[#8+B&?2/'H#A"V>XQF#QOY863>LQIQM*T5E3VFS^-:^\';;O\
M7D'D?)H; +3D&T>Y$J23FN3,<);#%+.6R,F#)\R3>IHN"KHEJ$4RLD!+:X#G
MS\ \7YOW13.D4N5GO8?@#@O8>#T9OCCCR',]AJZ\R6K]WU.T#>5[-8)R+;:F
MITO>(RIZ*>6YQ5=:[#V<Y8O'*L(K9'#)Z9ZA$)3"[)%(KMW'1R97":,!5L?(
M$+^5FM>X%TW&P"&8+".C_(".47**-LP9AX3<(:;AGOP9^",Z@$! ! 0$! !
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MI*L0$6CLDN,JJDR:HE(4R*(%2,5,A KU=U4A>-^Z=:<K^.W'#4M5;;5VS#4
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M='!1TY%NB1$7+E0 *"CA?J=JN<"E ZISF  Z>C*X!8 "][!:X\/PQ;B-Q$;
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M,NN"U02501;#5)WO=%%8.JLBDCXT=FFDJ4 *JF0H$4 .@P"&0WF$K6WT\,K
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M)UT7ZD/MOF'_ +P>,_5J7=X?(Y[+]=+;] E[^TL>QMGG/6A.NB_4A]M\P_\
M>#QGZM2[O&U_N>7$C5G"=22O%DH^[-F;EEVJD8%H)IV580M:ASKD6.QK3%V\
M<.DG#PR+8TA)N%0<*]B5% B"/7!3H-&X($ID3/'-34@]F9RB0%@G;<J+9,1S
ME0*8HFRS@ 9:HB V\DH%"]_&.J=^R!3W'P&M/2K#S$>E:%8K$=[4C3[QR^FS
MXJ9DRN9JX2UE(R2 **E:M$T];)EBHH*BELG:[YRD1[*=[_1A)_6<Z#N-6YPT
MEU\W^I'C7?%2YFX@^JCSZ\/.4B/93O?Z,)/ZSC<:MSAI+KYO]2&^*ES-Q!]5
M'GUX><I$>RG>_P!&$G]9QN-6YPTEU\W^I#?%2YFX@^JCSZ\/.4B/93O?Z,)/
MZSC<:MSAI+KYO]2&^*ES-Q!]5'GUX><I$>RG>_T82?UG&XU;G#277S?ZD-\5
M+F;B#ZJ//KP\Y2(]E.]_HPD_K.-QJW.&DNOF_P!2&^*ES-Q!]5'GUX><I$>R
MG>_T82?UG&XU;G#277S?ZD-\5+F;B#ZJ//KP\Y2(]E.]_HPD_K.-QJW.&DNO
MF_U(;XJ7,W$'U4>?7AYRD1[*=[_1A)_6<;C5N<-)=?-_J0WQ4N9N(/JH\^O#
MSE(CV4[W^C"3^LXW&K<X:2Z^;_4AOBI<S<0?51Y]>'G*1'LIWO\ 1A)_6<;C
M5N<-)=?-_J0WQ4N9N(/JH\^O#SE(CV4[W^C"3^LXW&K<X:2Z^;_4AOBI<S<0
M?51Y]>'G*1'LIWO]&$G]9QN-6YPTEU\W^I#?%2YFX@^JCSZ\/.4B/93O?Z,)
M/ZSC<:MSAI+KYO\ 4AOBI<S<0?51Y]>'G*1'LIWO]&$G]9QN-6YPTEU\W^I#
M?%2YFX@^JCSZ\/.4B/93O?Z,)/ZSC<:MSAI+KYO]2&^*ES-Q!]5'GUX><I$>
MRG>_T82?UG&XU;G#277S?ZD-\5+F;B#ZJ//KP\Y2(]E.]_HPD_K.-QJW.&DN
MOF_U(;XJ7,W$'U4>?7AYRD1[*=[_ $82?UG&XU;G#277S?ZD-\5+F;B#ZJ//
MKQ[$W-'W<W@%M1-I5]54!<A(VRD/H*&(#4.T,BI(KK'3(X6#[END)>LLI]P7
MH^^%):G%9:071IO('@%$":Q+YJB[<CEYLHJ)"@82ETG-?R0SQ>L*P3G*^P0I
MVK98)B&4!U.)"XE[(-:L82&<J&$A5#Z$R:3FS!PB&$7(;DUMS7&WXK4&H-0U
M/8TL.D;=OB?D+;?GU+:M*S2+"TA9."BB,:U/F>6"6!XGX'.Z,TCTEP.+Y4J)
M0 ^.44,00 H -P$1OFL :>'BS_);BC/IIE,41,.>X %OA+<./A$/WB 1CTCW
M2NVS3C84S4M"-9:A5J1T51:;)O\ 8)(RQW7;7(ZI4*T:ZJIH@:^LRAX*-2M[
MXUOL:DBN=DSB"'C8Y\[>$;$E%;.:Q0&P%L&>XF-D@%AT9LKA'..BX7B<$ L4
M1'C$W    FSC?/G  T!;/ICRGS^Y O\ ?#[B-#<:J2_Y)U6&L5@O+97;KYKJ
MYC7XNOU>V05@@+(-+/.R;:T1=B)#-XQW!LGT;9!:$>*C&'<NVTH+'$<DI $^
M>X .;,8 OIMPVS#I"^@8"BD "<3B!+@(#;@S\7Q7 ;?!F&\6_;>Z";-V3K:P
M7/4.JE*_KB"U'K[8%ZV$YO[*,O=0FKU99RKHU&IP"U0L$-.R</:*K(14O(OE
MF[!:'<F?L0!?LB#-KHCDC;R1+<PA:X".4%@N A_5TV'X!X8 B6]A-Y658H"&
M;-8;B%P$=-LWRA'O>NZ37=VYVJRU5KNHOX*'7V]0*+9Y*S6-6TM+[K&M6=TM
M<;C5&5(?03'7+^QU>0A8QRA8W$B5<\4[F6;%F_63:!5,)C@    !["(YQ,7*
MOF"^;-IMI$,^FS62Y)37$3>2)LV:PB73>V<0'1>^GY>+:.Z-[0U+JW5MBM^O
M]8V66;:!UKN+;:RNU"P]AGDK@ET.FVLZ9$U:3DC/VC--.:D'EO:5:M N\&'B
MGSP&YWH2:\<"E')+:PB81,%[!?-:]P'-FO<39AM;*$LVL$$3!<0\H"AF'3IX
M0L/PAF !S!P ,C1//_8[QO<]G2>BX&(XVT#D<CQ^L^Q5=B+K6Q@@-P;U*0V2
MM4B5H&+>JP;B<JXRI5)P5DU'<D8BG>K+MQFUX0$WD^24PE$= VN( (AP?GT#
MF#->362V* &\LQ0$ X+V ;<>?/G^+XHS/X[[I/O^D36QV=>"#ISC85ZK>N9'
MO\[U2[TBG3B]99WX4CM6W@]K9I>,F5XMF07)#1*#)Z5TJ1X40K$-E (VL%Q
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MB1PS?,G)$UV[A(X=4Z:A ,'_ %98+(+-E5$'"2B"Z)S)JHJD,FHF<HV,0Y#
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MTME 4M3F*YYNT>U$2?LY)/:R;.E)0T665;LU)B@J\63-,",6FQ$5#N2)&41
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MJ ,V/\B119QZJPYH$M,(;9S$,N=NT<@Q &Z;% ]C"@6V8RYK%%92X@ AD$S
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M?%V-M*-Y,J+K27^'0VHQ,Y<HKU?G'CD/)KR#]=]2>Y-J^+L;:4;R9476DO\
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MV>IG AA#VI?@C]'NI5FDL1U/&$Z:TQ8)*$I-F!DU'C<ARCKBV8Q3* 8H\8"
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M[?#?1HCTX%<;E=K<#><.I6>W-CZ_AZ7R!V))S$M3Y--I,WV$IE,DB*5.SO!
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M-.'\&6)D(.UT>FZI</9J@5>4;.72#>$N<K).WK8PJD.9PQ67R)%CB< &XE,
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ME_=%=#2;X@_7&*>G=MT&+U?2HU]+O47C&&!LZ2+7+.N5-9)VZ*<H+-H99!4
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MIJ&(FLN9-,<1/*T3;RY8TB1+,9F;R&Z2RJ+=!,3 -UUC*K)Y9$[?T28Y9Q$
MN4N48,A+#2A5V0)F^59LRAEJJ$8OE5#  A]S2*FU5 #FX#G#)* "-C#8H]C.
MF7G2.O:K!4JG*J059K<<VBX>+9U*U)(MFK9,J91-U( O:N%>KVKIR<!5<N#J
M+JF,H<PYYI?R&J)F\</WR17#MTH9594[]@(F,8;V"[H<DA?:D('DD* %+8 C
ML3:NJ+9MTFK9ZLD@@0I$R%E,UL %"UQ_T,,HYASF,.<PB(C<1BYO+5K?\N/O
M=>V_866FY.>^:)=.8=ZBMOA4ERBXZJFO<X>6K6_Y<?>Z]M^PL;DY[YHETYAW
MJ&^%27*+CJJ:]SAY:M;_ )<?>Z]M^PL;DY[YHETYAWJ&^%27*+CJJ:]SAY:M
M;_EQ][KVW["QN3GOFB73F'>H;X5)<HN.JIKW.'EJUO\ EQ][KVW["QN3GOFB
M73F'>H;X5)<HN.JIKW.'EJUO^7'WNO;?L+&Y.>^:)=.8=ZAOA4ERBXZJFO<X
M>6K6_P"7'WNO;?L+&Y.>^:)=.8=ZAOA4ERBXZJFO<X>6K6_Y<?>Z]M^PL;DY
M[YHETYAWJ&^%27*+CJJ:]SAY:M;_ )<?>Z]M^PL;DY[YHETYAWJ&^%27*+CJ
MJ:]SAY:M;_EQ][KVW["QN3GOFB73F'>H;X5)<HN.JIKW.'EJUO\ EQ][KVW[
M"QN3GOFB73F'>H;X5)<HN.JIKW.'EJUO^7'WNO;?L+&Y.>^:)=.8=ZAOA4ER
MBXZJFO<X>6K6_P"7'WNO;?L+&Y.>^:)=.8=ZAOA4ERBXZJFO<X>6K6_Y<?>Z
M]M^PL;DY[YHETYAWJ&^%27*+CJJ:]SAY:M;_ )<?>Z]M^PL;DY[YHETYAWJ&
M^%27*+CJJ:]SAY:M;_EQ][KVW["QN3GOFB73F'>H;X5)<HN.JIKW.'EJUO\
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M<HN.JIKW.*U ;)IUHD21,))NG;\Z*RY4E8.?8$[) O75,+B1BVC8!*7[Q16
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MGX@'BXOAB'M\=T=VG;KAJ8>++&QQ.LK'QJVKR'F+3,:V@)]V]<4"0=U]U5;
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MQQ%1T983G/1;TF*+84=EI$O-FDSUI(AP;I U*<HHHE44.<NN96481,( (6
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ME)B)1Z ?$7 -1*=HJ5M19TJB5UZ<)GGS4Q7BN3D@<P&<CK8@&<-:R+&L8+&
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MD-XK9+6'G(%#L$XFR.6KN9:!)P E>N&2QUVIS*"\%5/LE3F.!4CD*81Z#@8
M ,Y\UU/FJ[9R2H:=;81XF)R:JG3)Y/V04HY$DP<RY=1RS544,T%9,4EE3GL@
MHD4PC8Y3   &P*XJX'K/I=,E*^H\SV4HK(,%MOV@"@DX(":Q0*#@"&RR% MS
ME,(6N6PYXMWR?VO\0;?.\-]H9K/L2]4O[R&(_JS,>RC*[]^$/OC4AUXQ[:'D
M_M?X@V^=X;[0Q[$O5+^\AB/ZLS'LH;]^$/OC4AUXQ[:'D_M?X@V^=X;[0Q[$
MO5+^\AB/ZLS'LH;]^$/OC4AUXQ[:'D_M?X@V^=X;[0Q[$O5+^\AB/ZLS'LH;
M]^$/OC4AUXQ[:)>TYI!G:+,D?8=AK]3JL<)%WW?ME@VSZ6,!P$L<Q)X0$Y"J
M@!N^'G1U44PZI.E4Y>KW+ ?4'XM5I5R)L3:(JNBZ,E9DW,R&8RMRTF,Y,!RB
M25RY(Y-=(5< -LE]DY#=(HE3REU"9.CUUJBZ E$I.2F:MIR;SAS=- 49JR4;
ML@$,[E<VO 4QBW#6D;W.;.:Q S[9X6X:FKT6QA(6WT6.BXUNFU9,VUD@TT4$
M$B@4I2E![]_T=)C#TF,81,81$1'/MC(*'"EI-+J?I^FG,JDTI:I,Y>P:2UPD
M@V;HE A"$*5+.-@N8YKG4.(G.8QS"(^-'U82F9.W#Y]4LJ=.W2AEEUU9LR,H
MHH<;B(B*_P @!H      "*GY2==^OM,]YX3Z]F8VFG')4RZ"Z[*+3='3W+LF
MZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>\\)]>
MQM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#='3W+L
MFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>\\)]
M>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#='3W+
MLFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>\\)
M]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#='3W
M+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>\\
M)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#='3
MW+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>\
M\)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#='
M3W+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF>
M\\)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#=
M'3W+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7VF
M>\\)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E#
M='3W+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7V
MF>\\)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==E
M#='3W+LFZT8]O#RDZ[]?:9[SPGU[&TTXY*F707790W1T]R[)NM&/;P\I.N_7
MVF>\\)]>QM-..2IET%UV4-T=/<NR;K1CV\/*3KOU]IGO/"?7L;33CDJ9=!==
ME#='3W+LFZT8]O%&GKE4)N..QAK57)=Z95)4K.,FXQ\Z,FF;I44*W:N551(F
M'I.8""!0])A ,J)2Z8-CZZY8/6Z0 )146:KI)@(Z $YTRE 1T  CG',$0-.)
M0]**#.:2YVN/E BV?-EU1*40$Q@325.<0*&<P@%@#.,6+EU%&&(0Q"&(0Q"&
M(0Q"&(0Q".<Q_#4_JA_;E-3@^7]T5T-)OB#]<0WHW_)#K_\ V?1_XESFS5;]
M\LY_M@_LDXTC#_[RZ=_N\/VRT2MFNQN$,0AB$,0AB$,0AB$,0AB$,0AB$,0A
MB$,0AB$,0AB$,0AB$:T>3#E1+;$J4I4!#P7"^E1LW5-_Z$4?PU$C&'[_ *.D
M1Z ] =  &?%?5J8YXS4-CS/:>HW%*O*6D3:3T^LA*)#4TUE<N25<RU)9PHFT
M:.4D2J+*&$ZIP(!CF$3&$1CV%@]A?AU5-#L9O4=$4Q.YHJ\F"2LPF<F8/7:B
M2#@Q$4SKKH'4,5(@9)"B:Q2Y@S1QXKC]MN9B(B;80]?.TGH]"4ATEI:L-GS]
MHY(51$R#%PNFY,=0#%*"?4Z_7$"" &'HS59(35Z5#(9#44KQ8KY5A4TK;3F1
M)+XPH,YA,F+M,JC<[:7NZA1=G44*<I02UK7 4$$Q #YHNWDAU-C!Z]8.</:6
M*M+G2C1Z<E#HJMVZR1A*H"CA.7&2 I;"(FRK9.<!$(A:0)*13]Y&2+)-F_CW
M"S1ZT7CVI%FSAN<4UDE2"ATE,F<HE, _SAG!IGJC]4_)IB^E,TQIQ<83*6NU
MV+]DYK2H$UVCMLH9%=NL07MR*)*$,0Y1T"48WYK@Q@H];(.VN'%"+-G*1%D%
MB4[*1(JDH4#$.0=C9RF*-P&.'WZO_FVWIZ>C_ FGIZ/O_P#Y#^;^?+'V46J0
M]_3%7UWGW?8K[QV#8:<,Z'#_ /UR5=V@#U<>GH3;#T>D>ADT]'_7_(8]E%JD
M/?TQ5]=Y]WV&\=@V&G#.APOH_P"SDJ[M%SO:Y9&%5A[FZ9L20$Z_?QD:Z!*.
M.HL\C0(+Q,S8J8K) F"A.@ZA"E/T_<"/0.;8_P :]5G+:0D5=/,9\4DZ:J29
M3.4RAZ&(,U.=P]E!43ODS-23(SE$J0.$['62(12_D":PQB$,*L"W,Y?2%+#>
MBS3*7-V[ITD-+RT")H.KZR8%1: F839)O)*(B6UQ +Q:_?RW_0:_L33]SFI^
MRBU2'OZ8J^N\^[[&8WC<'?>RHCU;E7=H=_+?]!K^Q-/W./91:I#W],5?7>?=
M]AO&X.^]E1'JW*N[0[^6_P"@U_8FG[G'LHM4A[^F*OKO/N^PWC<'?>RHCU;E
M7=H=_+?]!K^Q-/W./91:I#W],5?7>?=]AO&X.^]E1'JW*N[1,NG]@56NRIXZ
M]5BOS4#(G( /W<!$O'D0X$Q2@N!UFAE%&(EZ>W1 PF3$ 52 ?NRF]3ZF'5\8
MAT+4:DEQ?KBL*MHR=G3+MM,IP^F<UII\91,A7I%7"YEW$J,EE[,:%.)TQ*1=
ML43 HFIRS$_4S4+.I:5]1]'TQ*YNQ*819H2=@@VF2 %,84<DB $3= :VLJ"
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M@;8ILHH?ZQL4V;R@#7\QLP9PSY@B8=4=70B(CJ;<41$P6$1)(;B'$([9YP^
M8\^)[7[K^4M'W9@,?^7UG]T8/2!C?_C3^Z, ^D!'I$,C["W!VQ@]G#@=8Y@.
M<+S*QC@-P,8-?\HP"(B!AN("-P&(>R-KG-__ $V8H>2&27[G(<P#I /]9Y@^
M ,T>#4YH8.J8]G,'6$W09;60AUA^^;H':?1UAZ Z1^^.0'45X-F"QM6_@:(
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M&BPJCFYL2)J"ZK:,P>61,F<AVH'(8H(1E%B$,0AB$:9.8_\ ETGO_A4%_P
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MF8NUPA%9R IBMV4KM:C(J*:'<LCJ( NN_DF\K(,>\8AFH(B+9,RCQ-(Q4P1
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M%,<H15-?-L<H;T1)7J+]I4#$RZ$E92$NO3=D<HL6!C&0$P <MUA$XZXI>QN
MH1'7BE:O5N=^:7W[C.9[W&(7,:KO5V;]TC:=TU.<O2?K)IVT/%*U>K<[\TOO
MW&-[C$+F-5WJ[-^Z0W34YR])^LFG;0\4K5ZMSOS2^_<8WN,0N8U7>KLW[I#=
M-3G+TGZR:=M#Q2M7JW._-+[]QC>XQ"YC5=ZNS?ND-TU.<O2?K)IVT2UJ;1D_
M>Y@QIMH_@J]'F2._<NFJC=P[$3E'O%B1<$S"JHGUQ.OU3)H% !-TF,4H^D]3
M=J1*RQBJ@QJJETXI"B)*=%6=3&82]PR>3$XG*8LHE*3HB)C.'"0*&5=Y)T6:
M8 )@,HHF4>:XDXOR:CY6!90Y9S>>/2J%9(-W":Z#8H%$!=NS)&.&MD/D@5&X
M'5,(V$"E,,;*XB(CH*.:1,2T18Q[)$B+=L@0I"$(0 #I$"@'64/T=910W2=0
MXB<XB81'/O73-,2&C9#+:9IB6-9/(Y0V3:L&#-(B22221 (!C 0 UQ92V6JL
M>ZBJ@F.<QC"(QX+F4R?3=\XF4R<JNWKI0RJZZQA,<YC"(V"XCDD+>Q"!8I"V
M*4  (J69Z+&&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q
M"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(0Q"&(1SF/X:G]4/Y^C^?\
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MT9+HQ;0;9!4^G2ELAV$JT(JP(XL#YI88.Y)(_P NZ*\G&SD06.MB \-OE_\
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MWB>Q^0SY FPXU_$W1Y$RW(+9LK"2UA8RC=J_3D)J(>,I4ZCENDHY*\(Y$O\
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MWYQ@LW>7C)-5JP>#7 .X[PW3)66[P=!U1!RR[_KKCO5P D*(+(=FH'5+]UZ
MZ&Y2>>:H]/E_>H;KI)[J_P"I9SW"*]YTNA_7U#YCLWV-C<I//-4>GR_O4-UL
MD]U?]2SGN$/.ET/Z^H?,=F^QL;E)YYJCT^7]ZANMDGNK_J6<]PAYTNA_7U#Y
MCLWV-C<I//-4>GR_O4-ULD]U?]2SGN$/.ET/Z^H?,=F^QL;E)YYJCT^7]ZAN
MMDGNK_J6<]PAYTNA_7U#YCLWV-C<I//-4>GR_O4-ULD]U?\ 4LY[A#SI=#^O
MJ'S'9OL;&Y2>>:H]/E_>H;K9)[J_ZEG/<(^J7*#1:QA*G>T#& O6$/ EE#T
I(!T^F&_I$,E-2T[*%Q:I<69]+Q__ )41"K)(;0J^^63S@O\ B8A'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g160947g83a57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g83a57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1?,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-S0V-38< @4
M0$UI8W)O<V]F="!7;W)D("T@5D),5" M($9O<FT@,C M1B!?5V]R:VEN9R!'
M<F]U<"!#=6UU;&%T:79E($-O;6T .$))300E       0<O>_KLRM#6CGQG9P
M2N;1XSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!8GA2         "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _0      !( -0    $ +0
M  8       $X0DE- _<      !P  /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              #Z   !]@         !
M                      $              ?8   #Z
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   #Z     %)G:'1L;VYG
M   !]@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    ^@    !29VAT;&]N9P   ?8    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
M#:@    !    H    %    '@  "6    #8P &  !_]C_[0 ,061O8F5?0TT
M __N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %  H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ /54DDDE*22224I))))2DDEG,ZWC/>UK:[2QSJV"
MZ&BN;6LM8-Y?^[:S<DIT4DD#)S,;%V>L_:ZP[:V %SW'_@ZJPZRS;^?L9[&?
MI$E)U2=9AMR;ADNK:Z6[180#&W\W?^;N29FY;VA[<"UK3&CW5-=!V?F"Q_[[
M_I_Z)4[NON?D#IV+2:NH.+0_[2!Z-.]H>TW74/?3D7[7_HNGT9/VF_\ [KXW
MZW6E(1DY0<*C9TT6&G<QKG#<7C]&^Y^TM_5_5_T=?^C_ .M)]^>-P8[I9@$,
M)<1)_,<X>[:W]_\ ]&+4Z?TZK"#W;WWY-Q!R,JT@V6$3M^CM9757N=Z5%364
MU?F,^FK:2G%]6_[-5MMZ>,B7FX/U:=3Z+*BQS=OM^D]^]"IOS0]YO=TYS))K
M:QT.B):U[R=OTO;]#_/6^DDIQ^DY-=F,Y_4+L"Q^]S6/QG-+(;[7M+WG^<99
MN8_]Q7NFEIQ26&6&V[:1Q'JV;=O\E"R>E-=<[+P;3A9CM7V,&ZNR/^Y>++:[
M_P#C?T67L]E654H5=6--K<7JM?V2]Q#*[A)QK7.,,;1D&-EK_P#N+D^E?ZG]
M'^U5_ITE.DDJ]74,"^STJ<FJVS]QCVN=QN^BT_NJPDI__]#U5)5Z<['?2+'6
M,;&T6 N VO<&_HW;OSMST2S(HJ8;+;&,8T@.<YP !.@:7%)21)1#V$P' GR/
MD#_WY-ZM<QO;.AB1P9C_ *E)3-)0]6J=N]LG2)$SQ_!0.7BBUM1N8+'M]1C2
MX26?OM_DI*3*(K8  &@ &0(X/BAUY>+9Z?IVL=ZP<:@'#W!G\YL_>V?GIKL[
M"H!-U]=<:'<X#7[TE-;,;;T_&LR<,MV5-+W8UA(K(&KO2>UMEE#]O\VQC+*?
M^!_/3].JK]:VZVQMO4'!HR&AP<:6F7U8K&MV[*F3^Y^G_G50ZK]9.A?92T9;
M+6BRES_3#K06"ZKU?YBN[=[5R_0>I4]*ZQE960'O]9UQ+F-@V$FKWEUWI[O4
M]/UOI)*>G^MW6L/I^&,6]MYLR@=C\8N8^O:06W>M6VSTW,?MV?H[&?Z;]$I_
M5^[IG4^CNQ:J'5UU.-5['@M<;/YU^1ZC=KW6W6.^T?:?Y_U_TO\ .KC?KCUY
MO5GFW$MMQSTW&ML;Z5@AS['U5M-CJ"[TF;&6;/7]+>C?5_ZQ6]%=E],JWYEM
MEK+JAD&SU#NIJ=D>UM+W-V/;^>DI[S!?<Q]N'>YUC\>"RYTR^I\^DYYV,K]5
MCF64OV;_ .:]?_#^FKBX9OUNZED98RL/$KOBE["ZEEMA/NK=7O\ 39N:QKO4
M_/\ _,.VI<7TL>[ES03 ($D?NO\ <W^TDIFDD@YESZ,2ZZMNZRMCG,:9@N E
MK?;[DE+Y60S&H?>\%P9$-:)<XD[6,8T?2?8]VQJJ,Z77DM=9U1C,FVUI#Z'?
MI*&-,?H:J[!L?]'])>^OU+_^!9^@KYN_ZU=0LNQ6WX$-;8+"-MD%PKMLK]KZ
M'L=L</5_GO5994KU7UT8YS&6XA:7EHTL!U=_)>UECO;[_H)*=/&Z/TZBNZBT
MC(QR6LKQKCOJIK$>EC55VE^UN_W_ /;=/]'Q\6FF46=,LK >ZS M>VJ+"7OI
M>_;71MM>[U;,>V[]'M?Z]M=V1]/[)_,>2Y]6+FYMN2Y[WU]5^WY3ZR\-:Y]5
MC_L WP^O,]%KOT7YG^"QKEZ'C?6#H]OU;KQLG)VV.P VYUH>!_,_I'/O</3=
M_7]9)3__T>TNQL9^2&_L>Q[<>\5TV%Q:QN]['VWT5-)]*GV;_97_ #G\Y^C]
M2UC9&"!DVVGIHNN-OJ[FNL#2W=<SU1+O2^TM:QC_ -'^D_6?T2Z)))3SW[-Q
M,>A[6=&<65/NHJ9ZFXFF]C'9-P][]K;[/T>S^<]B _!P6V.8WH=CVV-;N!)V
M -->_;_PC?;_ ,=Z7Z+U*UU"22GGK.F=/=BML=TEX=8+!Z0<XEH$[3M&YK7/
M^E5[?95^C_G?3QU)U^17530>E9-GHUQ7%D.V-VL]]E9;7ZVT_I*]_O\ \%ZR
MWTDE.)00;64#I=]%1WU;M\5M;:7NL>RMC]K6^SZ?Z.RKU/\ !*E3]1<<$'(S
M;GF-I%365 B?WMMEO_@JZA))3@O^I70;:GU7UV7M>TM(LL<Z)[C58/UEZ=C4
M=(;AU8C:<FF^HY+ZA!=43[<L/]SFXC[1^L;_ /#?SG^DL[Q!R<6C)8&W-G:2
M6.:2U[20:R^JVLLMI?L>]F^IZ2GS=GU3ZMU=KL9C3C-?8+777BP-;46>F_:/
M^U%E[MM[*-]?_=CT;D9OU.ZW@,8,Q]'I!UKWY(L)K!M]*JIMOJ,9E.L=Z6RK
MT&?SEM=:[:UK<9WIV=5MJ+@7-:\T$@$%HVFR@N]KO=^DWHF)BX-E@S&VG-M8
M2&76.W["=T^BQNVBAVRWTW.IJKLLJ_G?424XOU%Z1G]/Q'V9F.<0V,8QM#G-
M<X;777>YS)^C]IV_]N+J$DDE*22224UNH8]E^/\ H-HR:G"W'<Z(%C>&N=LM
M<RNYN['N?6SU?0MM]-<%]8L?J&9U[)RJ\7(N:[&#6UAA.UK0UUV([T2]U>0V
MUSW6L:[]+3;^B]7UZM_HRJ9N-AN!R+W&AS1M.0QYJ<![FL:^RLLWL:ZUSF5V
M_HO5]Z2GS_#^HG4^J8WV^O*^P/=2RBNM['.#P6LKS+'^ZI[*[',_1^W]-_/6
M?SZZ*WZL]'NKKZ3CUEUM;:Z\[*8YS=K&;;+&/<QVS[3EM]GH;_T5.3]I_P!'
MZVM6W"R+17^T;;RYQ<VIMH9P6OVSC"FW:ST_W_\ 2>HK^/CT8U+:,>MM53!#
M6,$ ?<DI_]+U5))))2DDDDE*22224I))))2DDDR2GAOKGUO,QNM-QL2QE==5
M#/7L?4RP->]UA8/TK-_T&^[W^FQ:_P!2.HWYF!DLRG-=DX]Y:_8UK&EKF5V5
M.:VMK&^Z5S7UJPNIT]5]3,MWFQ@KIR!6T-MK:7/%=M;?9Z]/J/\ ['\A:WU$
MP.I4TFQEGI=-<\O@M:7WO@5RU[A^CQJVL;L_\#24]DDDDDI22222E+%^N&?9
M@="MLIC[1:^NK'!#2"]SVZ.]1KZ]NQK_ *35M+F?KK@]4R,)SJ'^KA#:Z_'#
M ;&%A]1F3CV ;_8YOZ1B2G!^K?7NH/ZUA-R[F/HN>ZEX;376YEA8_P!-C]C-
M_P!-O[__ (&O1%Y9T3"ZAD=7HMP'"S+K&YEKF#TV-(=7]HO:/I[6/?Z7_@2]
M/H9972QEMANL:T!]I ;N/=VQGM:DI__3]522224I))))2DDDDE*22224I#OM
M]&BRXC=Z;7/CQVC="(@9_P#0<C_BG_\ 4E)2'-Q!GXYQLS&JNI<02QSW<C4'
M2O<A_M6BIFV::V5O]':7N: X;F[ WT![?T5G\C]&KOVBC_2,_P X*O;C]+N)
M-@J=/,D1,O=NB?I_I;/?_+24HYT;]QI9Z;O3?NL+8= ?M]]3?S';E%W4V-V^
MZDAS_3!;87 /V^ML<YE3FL_1?I/?^8@=0IPACM%.)7G$7B_T38UL/ .V_P#2
MNV>R&JA7DW##%>+T9K:;'O>*_697#3-;G^G;Z%E+[ZOYMNWV>HDIUV=2:\.+
M74^RWT'381^DGT_2]U7T]_L41U:AU@J%N,;""[:+M8!%9G]'[?TCMBS_ %99
M8YO3*OM%.0T[7/:=Y$O&55<\,:Y_\U9ZW]B[])59Z8;:F65M#^B4OEWZ2LVU
M#]Z_U=WT7-^TVW>SZ?\ A4E.PWJ5;OHV8QD%VEX/M'TG?0^BU2KS3:0*C187
M#<T-NF0?SA%?T52HP^FY>._[?AX]+K'DNJEKI ]C'.<WZ6YC59IPNCT/8^EE
M-;F.WM+2![MIJW?]MO>Q)2V-ALZ>RYV)B54^JXVVACR-SO\ MO\ Z/T%>K>+
M*VV 0'@. /F)0KKZ#2\>HSZ)_.'@I8W]&J_J-_(DI__9.$))300A      !5
M     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!!
M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-
M!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z  /!GP  "<0  \&?   )Q!!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C(U(#$Q.C,T
M.C(U ')R,3<T-C4V       #H $  P    '__P  H ( !     $   'VH ,
M!     $   #Z          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!2$U-
M "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#,Z,C4@,3$Z,S0Z,C4 <G(Q-S0V
M-38       .@ 0 #     ?__  "@ @ $     0   ?:@ P $     0   /H
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              /
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ ] 'I P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            (!08'"0($
M"@,!"__$ %T0   & @(! @,$! 8*"PP+  $" P0%!@ '"!$2$R$)%#$5(D%1
M%A<CD1@9,E9AUR8G-D)59W&!EI<S-41%5&)F=K&UP20W0T97<G>4H;31UB5'
M4E.&AY.CTO#Q_\0 %0$! 0                    '_Q  @$0$  0(' 0$
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M'*H)D OJ>)2@ 2VP& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M.)_Y!O\ S3?] X$1>$@=:6>@/7MM':WT'O\ \=Y8?^W)'[?Y EYE# 8# 8#
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MHY.?V$XF*0-RC=N@T01:M44F[9NF1%!!!,J2**290*FFDF0 (0A"@!2E*
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M\*90E?@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<3?R3?^:/\
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MD\G;%8#H)J+QZ$8R,P6 Z!OG#E4]@[1^ DYL+:%MV%R.Y0;JW'4[*SF(J.T
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M/RP,RZ:YF-'J.KM?<IH&(XW<E=C(RI6>H9BQLI5"1<0[@&ZBM=L*)@82:,B
M@XCF_J%>JI&Z]$1+V(3GP& P& P& P& P& P& P& P& P& P& P& P& P& P
M&!@K:_'NB;769S+P92JW2*,"D->Z>\&$LS%0IBF*19V@7PDF8F*7U&4BFX0,
M3LH 3R$<"#'([F5O?@X>C-MGZLF-_P!3O-T852'NVKH605FX%@H*1%W]T@VJ
M;DJ0HIJ%4,_0,1NJH"@^F4H= '0GGT%\1[;UDTM::+<67'71TI5;7(V SE[
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M/N(B/O@7%@,"A6B=1J]9L5E<)"NA78*7G5D2G!,5D8F/</U$@4$I@(*A&YB
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M8JML"ZVFQS35Q]K0M@ULZJ+6'07CBN42'%><F5S&\P/Z1U$&P.@#S22,GY&
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MY&S-PGH-'9&QH^NR%[<2;JR# ,;"LA%H/%ID DQ(@W*!$ >!ZP)]>?O@<IN
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M;S+.I7UA5XEU%#(,W<= U> B%FKE@DJV.D>4C(UF]>@;Q\Q4=***G P>9A
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M9@/>.3#L[L.Q0 X (X%+8;FU-*.K$RCMD4MXZJ1%U+*@A8HLYX1-J?TW2D@
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M318[6_%F^5NIKC;9"2,@>)C8ROSS1])/3.V;M&-;-9U5=Z[="B@H8IB")3%
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M KAT+_TUFR*BR+DQS)@)^AP-3E.@J_K[1U\@*Q$Q]1CK5+5:;C8"/>SDJHA
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M[B(CE$A,!@,!@,!@,!@,!@,!@,!@,!@,!@6I>8]>5I]CCFS6'>KO(EX@DTL
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MU=5:*U-KMP*@NJE1*[$O05*!3D?I1Z2CY(Q2B(!Z+Q59(.OP(&!F; 8# 8#
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MY$[FT)4VE$U5=9*NU] _DE'LTD%4Q<G'LZHD41./J*'.(F   1$??OVP-_/
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M94Z7RMK4]0J?]^8G92_B(8%OV2!XNTR<5K5LWE.UVP(@B9:$FN0]Q82217
M* J,W%L373!4# *8F*'D @("("&!DH^A]8)18S*ENV2G#ILQD#2A]T["*P(Q
M!+UA=B[&S^B#8$?VGK"?T_#[WET/>!1:?K#2.P(]66HVR;O;8Q!R=FN_KV]+
MW*M4728 *C=19G:52$6(!BB)#"!@ 0'KH<"[/X.E&_P_M;_6_L?_ .8\#B/'
M*BB'7V]M8/H/MM_8WX?_ (CP.BCH36BR[Q!"V[,5<1W0/VZ6Y]A**LQ,43E!
MRF6RBH@(D 3!ZGCV4!'Z8&)T3<2W$XG64.0,@M8E'(-$X1/D9;C2AW1E/2!
M&06_Y@5!4 2 7P[\@$/J X&0G^I-,1E87N<CL.]L:BU:&D7%F=;SOJ,(@Q*/
M1G:LFI:09D;@;[HJF5 H&]O(#8%M4NI<<-C/',?0MR6:XOV;?YIVSKO("Z2K
MI!L8Q"@X609VM50B/DH0OJ"4"=F* CV(8%]O]":SB&_S,G;-E1[45DD </=S
M[";(^LN<$T42J+68A!454,!$R /F<X@!0$1P.$EHG5T*V(]EK?LB,:'70;)N
MGNZ=AM4#N'2A4FR!5%;.1,RJZABII$[$QS" % 1' ^[_ $)K>+8.Y22M>S6,
M:P;+/7K]WN78:#1JT;IF57<N'"EE*DD@DD4RBBIS 0I $PB !@46JZHTO>&!
MY2G;$O5HC4U/04>P6\K[)MDUA3(J"9UF=I4(53TE$U *(@(E,4W0@.!<1N-]
M$,(B,_M?W#KVW!L< ^O?8?V1_7^G Y%XY40H  3VUO;OZ[@V1[]_G_9)[X'+
M^#I1?K]O;5 1_'];^R/^VR#@?-3CS04@**MCVDD!CE3**FXMBD RAQ\2$*)K
M* "<X^Q2A]XP^P (X'T_@Z4;_#^UO];^Q_\ YDP'\'2C?X?VM_K?V/\ _,>!
MQ_@Y44?K/[6'_P#.#8__ &6/\<#]_@Y47_#VUO\ -N#9 ?\ 19,#C_!QHGT^
MW]K"'O[?K?V. >_7L'5C#Z=>W_\ F!AO8U#;ZKOO'Y_4;7L4GZ0;=C:[,LIG
M8-LL$;(PSN*DE%6+EA+R;QNHD"J2:A#'()P.4!$_TP)PX# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&$^2'MH;;0_\A9[_P!S/@7[K[^X
M*D?\T*U_U,RP+OP&!$_FE0ZU=N/FPR35.@[6^908GB_M.OL)QVR4%XT%52/^
M;:N5D#B0HB<6PD,8I>C=A@1Y9DUWIK='%URJQKFNZ\II>8:N5&L0U@8X\HM#
MQABI. 9-44OFSJG5\@6 514.;O[PC@1$W'2-B6G9W-W8NNZGJVYP:;"I>N>V
MZ_&R6)U *UYN28D*3+JI"!9!@P56>-$D>S&61*(#V 8$XD-DZW@^+D9"W6GW
MJQZ(C-/0"LS>G"!VR$NR3:QR1(55DV42F$GSE\9)@JW!,J8 )TU1%$3]A4."
M4'#N&&SMGQ#:H5AKLJ<A'L;KBC@@E$TJNQ,.DR@$I5!LDDD2TR;$2NIX2$*
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M-T8.RG!?S]O8+9Y[SN\=@Q5&>!IG9\91:[:J1-@PBW3 [AW8OTE;% EA:M7
MJ*,V3<H'13(84_4.)E/H&!)SX@ 3#CBBT<1S!]]J(VO6CT&B#<[EXV.C(H+*
M H1$IS%% P!ZQ@#HOB)>_? UB;DD.2,]QQHKN>VQL>50WM6]BPUM@6L,W:DB
M6%8E( D*2+308@X;!(-))XW="Z$P/FY #W(4W8<'5BN/'Z,VCJ[7DA<:M,2U
MK8NJ_+MT&=9AG2=1H,$[<_;DRI&G;M#+(N ,V:1S059%]Z:'LD)NV=I'UKN]
M.8.T=%; VB;9]RJ]HU?H?6%QKT3"P*1V%DN$E:YB)DEI--TP]=^DYC$$C.VK
M<$C%53(MXE 3!@2/E+%R78[H::%9;?NX0%@MFMY)]>%H1JK*Q[*VT5U,V"$8
M.08"R;M$I)'S;"J4RC8PE2.;\,"U!VUR-T@PUSL2U;/V)?8I]M;=6N)^OGK;
M1R8:C4(RPJ5V:(T;,D5SS@NXYHHFL90K9WWX  %-T(1*>[NW[LZ_QE;L>R+[
M&ZY-?M([&"3C)$'4G#-).R*(N6DRLQC&[:**D0Z(2D$*BQ6?8$5.!P P!)JP
M<FN4SY*U(5^U6 LO,.S1TZR+5S$-K4$]EL:S".HDBC0?/[;KZRCKQ='<>L0Q
MG9!*0 -@2U+=-S:ZY#U/C >^V:T_IXO$7Z&N4O',E7[*D5YDN%VCUED&R30
M/)_9J G.GY$^?*FD;RZ' V@8# 8$6N1?]U_&?_TZPO\ U-+X$I<!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#"G)#WT-MH/\ D-/?^YGP
M+]U__<'2?^:-;_ZF98%W8# X*))K)G263(JDH42G34(4Z9RC]2G(8!*8H_B
M@(#@4N1@(*7^7^U8:+DOE0$&OS[!J[^7 0 !!#UTC^D @  ($\0$ # [*$9'
M-B+)MF#-!-P4"+D1;(ID6(4GI@18I" "A03^X!3@8/#[O7C[8'%2(BEH\T2K
M&L%8LZ8)&C5&;<[ R0& P)F:&3% 2 8H& @I^(" " =@&!PC86'AB*)1$5'1
M::I@,JG',FS(BABAT4QRMTTRG,4/8!, B >P8%MR'ZO GA1?IU!6UJIE<%9N
M A#V-R5(G[,Z3=80D%1 A/%(X (    &  ]@_$9NDN&L5]HA"0ZL@@NE'1,^
M,.PD3(F5%)=!%DJN?R*HH  H1N90A_(OEV)NL#N0S^C-'3F(K[VJ-WQ2F<NX
MR'<Q"3L"I_<.NY9,CE6 J?\ ),JJGT7Z"8,"RKGNG6%(:QDT_FX^5-,V:+HK
M0U;5CYM[]N2Z;YQ'1KGY9UVV(J+%UU\PJ0A%>NRAY"(!4X5UJY5.-!%A48.1
MLK-JLW@GR->CYMTDZ*1\@W4C4E3J+J"!B. 22%<HCXJD$P !L"\/M"L/9DK'
MYZ!=V"+[$K/YF/7F(_UDO,P@W\S/6OJH??$0(3S2^][E]\"P]@;BUKK^R4FF
M7F6:QLEL%V\;5TLB1 D:JO&) Z6,[>NU$FK0"%Z%(RAA,93H"AW[X'9-M#7<
MG:YZ@/)%BI(5Z B+1*'D0:!!$B)<ZOV<[)(N%1:*=F0,(C[%3^X(''R# NIR
MXIB3*+5=N*RG'.S$;PJCE:+(R='=@3P0BSJF!!<SD"D$B;03"L %$H&Z# LB
M(NVJ[S8[E6TDX=[+T.RLJU.!+QS$B7Z0OHM)V@TCUG@#\\Z^2 J)P2#U>T#)
M% Y$NP"[&SO7P,98&;JGA&Q:96L[\LO"_)1R3<YSD;RWI']!FFBH*ABI//3*
MF?S$"@/>!0*!L776T'5J7ICEC,J4VQ&K<Q)((-542R[-JFH ,GZ)EB.TD6ZY
M2)N$E/$H"9,O70A@9"5BHM8A$UHU@LF195P0BK-NH0BZX'!98I3IB4JJH'."
MB@ !S@<P&$>QP*:E4JJ@15-&M0*1%Q**Y$XA@0BPE."I?5*5N *>*@ H7R ?
M$X 8.A#O [P0D,!UU B8T%'0I&<G!DV [@R @* KG]+R5%$0 4A4$PIB "7K
MK M!+6E<+LA7:;@'3VTA735:.5=JE5;0T.NZ1>OF\6CX +<9!RV;*.S^0BIZ
M"9?8 'L,A8# 8$6N1?\ =?QG_P#3K"_]32^!*7 8# 8# 8# 8# 8# 8# 8#
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ME(O6%$9MI.%C[8A+.6,-7K,^\FC,SAN@@_F))](/ 627,1)1<2B&4HCAWO\
M)H3?#V2UY-%W4>Q\4G&K7[N?A_M5E'T1AK5Q<CPCXDXJVBFL6JA84Y4HNF8R
M(-W2 >L8? 0K_%-\1GOS05(L-=>SFW("U[R?[ W#!7>K6RG7AI(,YM9H+=S7
MK3,RKPS!1>-9/$IJ(BRUYZT%@8/)R7L);\]]:3-NOO'6WET?<-WU.C3EG7LL
M+2SP:DFQ&2B#LXYR9C-3\$FZ1!R<HG$JJH)% 5/$3% I@ATQXR<E("XQ-UMV
MK[)>:!$L*HZF*!%V""7L+ZO-G+U9*KMT7,VQ:2KZ"360(XCG3U%BL(&33<*$
M[-@7'KC1>ZJ3::Q<=QZ/OFU-5S$-:8ZC:CAY.OR,]JJ=F[?]JQ#JV,G]D91#
M5C]D'0;*2$9*2ZD&+=3TV2I@ IPI6T.+7*U'DSMG<%2KDY+4F[KS5/H=2),U
MYL-%L=BU\QB(7;[95&0]19&%D6AXF0%\N1XP1= [9-U")J]!:M-XV;ZBM?M9
M":IV_P";E]?CKI#;.O)1IJFNPNW8F M;:4LD?1E*@_*ZN;Q5J19=*0MCV.&4
M)XMESMCJ=@&QO@30)&DP.ZWZVI+3IB%N^XYVV5JH7%:)4FPBWK1J3Y]PA#2<
MLS8E=+D4,FR*\4%N0 3 P@7O GS@,!@,!@,!@18Y'' MOXR]_P!]O>$*'WBA
M[C#2_P"!C (_Y"@8?Z,"4^ P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P&!BC>K-)_IO9K-<3@DXI<\0XIF IP#Y%4WW3"4P /8!]2C[8&F*
M,^)AO>!CV,"TJ>I%6D(R9Q+55S W$[E1O'MDFJ)W!TKXBD98R:115,DBBF)Q
M$2)D+T4 [_\ &B[_ /YH:>_T?NG]8. _C1=__P T-/?Z/W3^L' ?QHN__P":
M&GO]'[I_6#@/XT7?_P#-#3W^C]T_K!P'\:+O_P#FAI[_ $?NG]8. _C1=_\
M\T-/?Z/W3^L' %^*+O\ 'K^Q#3WUZ_N?NGY]?^4' ^AOBA;^*<"A4-/]" _[
MP73OV /\8'].!CZ7YO66T7*)V!8]#\9IR]0#<Y82Y2NMIF0L\00@B)4XZ<=7
M-619D ??Q;N$^A$1#H<#(?\ &@;]\R%_1#3_ $8@F_V@NGX=?3^V!]/? ^7\
M:)O_ ,1']$-/=]&_\7[I^'G_ (P?^*'_ +<#]7^*%OTA#"%/T\;]DH?HU?N@
M@(E-X="'ZP/H(#[A^.!CBM\V)^CV^;O=.T%QBJ]VM2(%LMN@-:3$39)XBH_-
M*$EYEA<T'\@0RZ9%1*[75 3E P]F ! ,B_QHN_\ LP?HAI[V'K^Y^Z?T?XP<
M#Z$^*%OXQ!,-0T_V!A#V@+IU["'^,# XG^*)OXJ?D%0T]WV7ZP%TZ]P'_&!_
M1@"_%#W\(+#^B&GOV?CX_P!C]T_OC=#W_; _Z.L 7XHF_A]/NH:>^^/O_P#0
M%T_(1]O[8'_QP/T/BA[^$3!^B&G_ &'_  !=/Z?\8&!P_C1=_P#\T-/?Z/W3
M^L' ?QHN_P#^:&GO]'[I_6#@/XT7?_\ -#3W^C]T_K!P'\:+O_\ FAI[_1^Z
M?U@X#^-%W_\ S0T]_H_=/ZP<!_&B[_\ YH:>_P!'[I_6#@?H?%$W^(@'Z(:>
M^O\ -^Z?U@X%]ZEY6;%Y-;WU%4+W$4Z'C*O<"6YBM3V$['/7,C'Q;\B#=^I+
=V.>06CQ]8QE$$6S=8Q@*(."@ @(;J<!@,!@?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g160947g83d02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160947g83d02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1CX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(Q-S0V-38< @4
M0$UI8W)O<V]F="!7;W)D("T@5D),5" M($9O<FT@,C M1B!?5V]R:VEN9R!'
M<F]U<"!#=6UU;&%T:79E($-O;6T .$))300E       0<O>_KLRM#6CGQG9P
M2N;1XSA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              "R    Z          !
M                          $              .@   "R
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   "R     %)G:'1L
M;VYG    Z     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    L@    !29VAT;&]N9P   .@    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MZ?HA]DCRW.7I>=]:NH?5;ZD='Z8UT=<RL8%KG^XT4_FVO8[_  K*W5T45/\
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M$I\;'VEW_GJLN22^C]3^O_U8Z?D5XC<H9N7;8VMM&+%I!>[9-E@=Z->W\_\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD
M!     $   "\    Z  DQY8  "<0 "3'E@  )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$V.C S.C(U(#$Q.C0T.C W ')R,3<T-C4V
M   #H $  P    '__P  H ( !     $   #HH , !     $   "R
M  8! P #     0 &   !&@ %     0   38!&P %     0   3X!*  #
M 0 "   " 0 $     0   48" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!2$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P
M  #H   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,38Z,#,Z,C4@,3$Z-#0Z,#< <G(Q-S0V-38       .@ 0 #
M ?__  "@ @ $     0   .B@ P $     0   +(         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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MG./OC::EIJZ=.[-,OJ]E1;KE#0C?J2S!SKY9C8N!,T8TBI-T9_9DT"&EZZH
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MI)9:%).08\?^Z,:&_P!;S7W_ )/J_P#Y#EG\I;#_ +5H_P#N_LCL?S-\UO\
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M(   <HB(C]-[ 'Y]Q]OSYX.BX'XQ164BU\,7Q*4U-.I2C;:IDI$U))/]SP
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M)L'B2K1\PE[<Q>-7*2J*R!54E"%ECW?' ^,7DR%JU9/F<_ .7SN!W1\,R/\
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MUXHG)W&TNGTO,RRZ**#R>E7()^#S$TBAN^X.OX,6I"PI4PJ(!/2P) P'P"2
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MNCCS$RDI 0KJ6X<N^&.,>SJVCF+,<B+$.(0XA'YSOQ'&2+_O;M]6X+%^#+A
M1NK;+(N%IB>M=NQB@2[3"%Y.HO/5Z-8W%T[801ACC"R":,UE5TER'=QL<J0Z
M'*DD-J,MW]Q\-B1\-8["3+*4#4NRL, ';^-E]-O*.G/X?;:5?*>F]&UBF\07
M/&UPU!Q=C2AV&?G)ZBSU8O1I MC:MI.JJ56R2TLS!$*^JH_9S\7'>3\XV(S=
MR(E<&1@L^KNYW^X=\<>H04JZW^OMW$ ;[_*+W\B./#B$.(0XA#B$.(0XA#B$
'.(0XA'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
